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Glossary 
Acceptability How acceptable a given intervention is to the target population in 
relation to the effect of the intervention 
Accessibility How accessible a given intervention is to the target population 
(availability of good health services within reasonable reach and 
when needed) [1] 
Correctional facility All institutions where a state holds people deprived of their liberty 
(e.g. prison or jail), excluding migrant centres and police detention 
rooms 
Directly observed therapy (DOT) An approach which seeks to improve treatment adherence by active 
monitoring and recording of the consumption of each and every 
drug dose by an ’observer’ acceptable to the patient and the health 
system [2] 
Feasibility Whether it is feasible to implement an intervention in terms of time, 
money, or other circumstances 
Jail Locally-operated, short-term facilities that hold people awaiting trial 
or sentencing or both, and people sentenced mostly to a term of 
less than one year 
Prevention, care and treatment of HIV 
(macro area 4) 
All public health measures to prevent HIV and minimise HIV 
transmission within the prison environment and in the community, 
including mother-to-child transmission and post-exposure 
prophylaxis 
Prevention, care and treatment of 
viral hepatitis (macro area 5) 
All public health measures to prevent viral hepatitis and minimise 
viral hepatitis transmission within the prison environment and in the 
community, with a focus on hepatitis C treatment 
Prevention and control of injecting-
related infections among PWID 
(macro area 6) 
All public health measures to prevent injecting-related infections 
and minimise transmission of these infections among current or 
former drug users within the prison environment and the 
community 
Prison All institutions where a state holds adults deprived of their liberty 
(e.g. prison or jail), either sentenced or on pre-trail detention 
(remand), excluding migrant centres, and police detention rooms, 
and other facilities such as juvenile prisons or secure training 
centres for children and young people. 
Prison population Adult individuals aged 18 and older detained in prison for custody, 
remand or awaiting trial. In certain instances, the term may include 
individuals visiting correctional facilities, intervening in various 
capacities or prison staff working also in various capacities. This 
population includes vulnerable groups, i.e. men who have sex with 
men (MSM), transgender, people who inject drugs (PWID), foreign-
born persons, homeless people, people with mental health and/or 
substance misuse needs (including alcohol) and others. 
Problem drug use Injecting drug use or long-duration/regular use of opioids, cocaine 
and/or amphetamines 
Service model An operational approach to deliver an intervention, defined by 
descriptors such as time (e.g. at entry, during stay, at release), 
target population (e.g. universal), modality of offer/service delivery 
(e.g. healthcare provider, setting), etc. 
Throughcare It entails continuity of care when transitioning from the community 
to prison settings, as well as from prison settings back into the 
community. The latter covers both interventions starting in prison 
settings aimed at prevention of blood-borne viruses (BBVs) post-
release, as well as interventions starting in prison settings to 
increase linkage to care for BBVs or drug addiction post-release. 
Transition planning It entails the planning for continuity of care when transitioning from 
the community to prison settings, as well as from prison settings 
back into the community. Transition planning may also include a 
broad range of individual needs such as housing, social support and 
re-integration  
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Executive summary 
Compared with the general public, people in prisons have a higher prevalence of infection with blood-borne viruses 
(BBVs) such as human immunodeficiency virus (HIV), hepatitis B virus (HBV) and hepatitis C virus (HCV). This is 
recognised as a major issue for the health of people in prisons, as well as the general population, because the 
majority of people who have been incarcerated will subsequently return to their communities.  
The objective of this report was to systematically review data on prevention and control of BBVs in prison settings, 
with a focus on the countries of the European Union (EU) and the European Economic Area (EEA). 
A systematic literature review was performed in PubMed and Embase from 1990 onwards and in Cochrane Library 
from 1980 onwards (search date 12 January 2017). No language or geographical limits were applied. In addition, 
the following sources were searched through a predefined website list search, including the websites of the main 
international organisations (last search date 8 May 2017) and a call for papers from experts (last call date 7 July 
2017): conference abstracts (2010 or newer), unpublished research reports, protocols and guidelines (2005 or 
newer). A total of 66 primary articles were included from the peer-reviewed literature. In addition, 20 conference 
abstracts/unpublished research reports and 18 guidelines were identified from the grey literature.  
Five peer-reviewed articles (none from the EU/EEA) and one conference abstract were included covering BBV 
prevention through health promotion interventions, condom distribution and safe tattooing programmes in prison 
settings. A range of 11–28% of inmates used condoms through condom provision programmes, but not necessarily 
for sex, and 55–84% supported condom distribution. In a US study condom provision was considered to be cost-
saving, but concerns were raised over a possible increase in sexual activity, including non-consensual intercourse, 
and the inconsistent message of condom availability with the prohibition of sexual activities in prison. Safe 
tattooing in prison was shown to be acceptable for people in detention in one study, however no infection-related 
outcomes were reported to assess the effectiveness in reducing infection transmission. Two randomised controlled 
trials (RCTs) investigated a combination of health promotion and skills-building interventions, and showed 
conflicting results. Five additional peer-reviewed articles (two from the EU/EEA) and one conference abstract were 
included reporting prevention interventions targeting people who inject drugs (PWID) in prison settings. Two 
comparative studies on opioid substitution therapy (OST) found no difference in HIV and HCV seroconversions 
between the OST and control groups. Periods of imprisonment <2 months were significantly associated with 
increased risk of HCV seroconversion, and compared to community settings, OST dropout risk was higher in prison 
during short sentences (≤1 month) and lower during longer (>4 months) sentences. An OST programme in prison 
was no more costly than community-based programmes. HCV seroconversions were reported in one of the three 
studies on a needle and syringe programme (NSP) and were attributed to sharing of injection paraphernalia; no 
HIV or HBV seroconversions were reported. In a country-wide study, a reduction in HCV and HIV prevalence in the 
prison population over a period of more than 15 years was documented, which coincided with the introduction of a 
wide range of harm reduction measures in the community and prison, including a prison needle and syringe 
programme. However, prison staff and, to a lesser extent, people in detention, reported concerns about prison 
security following the distribution of sterile syringes and needles and were not persuaded of the need for such a 
measure. 
Provision of HIV treatment in prison settings was reported in sixteen peer-reviewed articles (seven from the 
EU/EEA) and five conference abstracts. Two comparative studies found no significant difference in adherence and 
viral suppression between self-administered therapy (SAT) and directly observed therapy (DOT), while one study 
showed a higher proportion of viral suppression among individuals receiving DOT for HIV. A sizeable proportion of 
patients voluntarily transitioning from SAT to DOT modality of treatment provision was registered in one study. In 
another, a significant increase in the likelihood of achieving viral suppression was found in a telemedicine group 
compared to conventional care. Overall, all studies reported sufficiently high ranges of treatment adherence and 
levels of viral suppression when treatment was provided in prison settings, and the proportion of HIV treatment 
acceptance among those eligible was reasonably high (73–80%). 
While no study was retrieved reporting on HBV treatment in prison settings, twenty-one peer-reviewed articles 
(seven from the EU/EEA), eleven conference abstracts and two unpublished research reports were included on HCV 
treatment. The majority of the included studies described provision of interferon-based regimens, and focussed on 
implementation modalities. Two comparative studies found no significant difference in treatment completion and 
sustained viral response (SVR) between SAT and DOT models of HCV care provision. Two economic evaluation 
studies from USA concurred that performing a liver biopsy before starting interferon-based treatment is likely to be 
more cost-effective approach than treating all patients. Two comparative studies found no significant difference 
between the main outcomes of HCV treatment completion and SVR in prison versus community, unless patients 
were released or transferred from prison while on treatment. Similarly, release or transfer was reported as a major 
predictor of treatment discontinuation in several studies.  
There have been rapid developments in the management of chronic HCV infection with a new generation of 
medications, called direct-acting antiviral drugs (DAAs), which are now used alone or in combination with PEG-
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IFN/RBV. As a result of the higher effectiveness and reduced side effects of DAAs, the use of interferon-based 
treatment regimes has declined. According to conference abstracts and grey literature reports, the proportion of 
detained patients achieving SVR was much higher with DAA-based than with interferon-based treatment. Finally, 
another US cost-effectiveness study suggests that HCV treatment with DAAs is more cost-effective for incarcerated 
persons than no treatment or treatment with older regimens, provided that it is affordable. 
Many intervention studies among prison populations showed high attrition rates due to prison transfer or release, 
and the improvement of continuity of care between different prisons and upon release from prison – otherwise 
known as ‘throughcare’ – to reduce dropout was identified as an important issue. Thus, nineteen peer-reviewed 
articles (none from EU/EEA) were included reporting on the transitioning of individuals from detention into the 
community (throughcare); no studies were found on the transition from community into prison. Comparative 
studies reported the impact of behavioural and skills-building interventions aimed at improving BBVs prevention 
post-release. In most cases the interventions resulted in greater improvement in relation to several behavioural 
outcomes, such as occurrence of unprotected sexual intercourse, compared to conventional  care. However, this 
was not the case for all measured outcomes, including some specifically relevant ones such as the sharing of used 
drug injecting equipment. In general, interventions were well accepted with low rates of refusal. Linkage to care 
post-release interventions that were investigated ranged from individual education and skills-building programmes 
to active referral to intensified case management. A study describing the latter (being met at the gate by a case 
manager) showed a significantly higher likelihood of participation in drug/alcohol treatment and significantly less 
engagement in sex exchange and street drug use compared to those not being met at the gate. No significant 
difference was reported in access to HIV care or substance abuse services, and adherence to HIV treatment post-
release between intervention and control groups in the other studies. Other observational studies described 
conventional care approaches such as active referral to community healthcare services including provision of drug 
prescription to the patient upon release. For PWID receiving ART, provision of OST before release and retention on 
OST community programme was associated with higher likelihood of viral suppression in one study. Finally, three 
studies showed that initiation of OST during incarceration significantly increases the likelihood of enrolment and 
retention in OST community programmes. 
Overall, there is considerable heterogeneity between studies in the peer-reviewed and grey literature, making 
comparisons difficult. A large proportion of the studies included originate from the USA prison setting, raising 
concerns regarding the generalisability of the findings to the situation in the EU/EEA. Overall, the level of evidence 
derived from the studies included is quite low; most studies had a descriptive and observational design and were 
conducted in single institutions with relatively small sample sizes. Moreover, study characteristics, interventions and 
outcomes were often poorly described. 
Evidence available on interventions for prevention and control of BBVs in correctional facilities is limited, especially 
with regard to prevention interventions targeting PWID. More comparative studies and operational research are 
needed on the effectiveness and impact of interventions in correctional facilities within the EU/EEA.  
In conclusion, the findings from this systematic review reveal a wide variety of interventions that use a range of 
prevention measures, treatment service models and linkage to care interventions directed at the prison setting, as 
well as predictors of intervention uptake and barriers to their implementation. Most notably, release or transfer 
from prison was identified as the main factor hampering adherence and/or completion of treatment for HIV, HCV 
and OST. These findings are crucial to informing and supporting the design of evidence-based public health 
interventions to increase coverage and uptake of BBV prevention measures and to scale up BBV treatment in prison 
settings in the EU/EEA. 
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1. Background 
Worldwide, more than ten million people are held in prison, either as pre-trial detainees/remand prisoners or as 
convicted and sentenced inmates. On 1 September 2015, just over 600 000 persons were being held in prisons 
within the European Union/European Economic Area (EU/EEA), with considerable variation among countries [3]. 
The median imprisonment rate varied from 21.3 prisoners per 100 000 general population in Liechtenstein, to 53 
per 100 000 in the Netherlands and 277.7 per 100 000 in Lithuania. When considering the whole European region, 
the median age of the prison population was 35 years, and the average length of stay seven months [3]. Across 
the Member States of the Council of Europe, on average, 17.3% of inmates were sentenced for drug offences, 
followed by 16.8% who committed theft and 12.9% robbery. The main offence of 14.9% of prisoners was 
attempted or perpetrated homicide, 9.4% were convicted for battery and assault, and 7.6% for sexual crimes [3]. 
Prisons pose particular challenges to reducing the burden of infectious diseases. In part, this is the result of prison 
settings being a high-risk environment, and also because people entering prison settings may already have 
elevated levels of infection. Compared with the general public, people in jails or prisons have a high prevalence of 
infection with human immunodeficiency virus (HIV), hepatitis B, hepatitis C, syphilis, gonorrhoea, chlamydia and 
tuberculosis (TB) [4]. Those who are healthy on entry are at greater risk of exposure to communicable diseases 
such as HIV or viral hepatitis in prison and are more likely to develop drug addiction problems or mental illnesses 
over their lifetime than the general population [5,6].  
Most people in European prisons are from poor communities and vulnerable social groups and an increasing 
proportion of people have migrant or minority ethnic backgrounds [7]. Drug users form a large part of the 
imprisoned population and international studies show that a large sub-group of people in prisons have used illicit 
drugs at some point in their lives, with many chronic users and problematic drug use patterns, such as the 
injection of drugs, being common [8]. Data on drug use among prison populations in Europe show that 12–43% 
have used heroin; 9–42% cocaine and 2–29% amphetamines [9]. 
Several communicable diseases are more common among people in prison than among the general population, 
mainly as a result of unsafe drug injection practices - e.g. the prevalence of blood-borne virus (BBV) infections is 
high among current and former drug users entering prison settings. The main risk factors linked with increased 
transmission rates inside prison settings seem to be proximity (aggravated by overcrowding), high-risk sexual 
behaviour, practices of injecting drugs with shared, unclean equipment, and unsafe tattooing and piercing [10,11]. 
The problem can be aggravated by lack of awareness of infection status, and possibly substandard healthcare. 
Primary, secondary and tertiary prevention offered in prison settings, especially with adequate linkage to care, 
could be effective in lowering infection rates [5,12].  
A recent briefing on prison conditions in the Member States by the European Parliament’s policy department on citizens’ 
rights and constitutional affairs addresses the issue of healthcare in prison. It states that the ‘general principle is that 
prisoners should enjoy an equivalent standard of care to persons outside prisons, yet their needs tend to be greater than 
those of free persons, as they often lead a marginalised life before entry to prison and as imprisonment may put a strain 
on their mental health and physical well-being’. This underlines the need for an up-to-date guidance on prison health. 
1.1.1 Guidance on communicable diseases in prison settings 
In 2015, the European Centre for Disease Prevention and Control (ECDC) launched a project to develop evidence-
based guidance on the prevention and control of communicable diseases in prisons, jails and other custodial 
settings, with a special focus on EU/EEA countries. ECDC collaborated closely with the European Monitoring Centre 
for Drugs and Drug Addiction (EMCDDA) in order to explore drug use as a risk factor for the transmission of 
communicable diseases in prison settings and to take into account the high prevalence of people who inject drugs 
(PWID) among prisoners in the EU/EEA. This collaborative ECDC/EMCDDA project, the first of its kind by the two 
EU agencies, involved the development of joint evidence-based guidance for the control of communicable diseases 
in prison settings in the EU/EEA.  
During the scoping phase, evidence published from 2000 to 2014 on the burden of communicable diseases, 
preventive measures and associated costs in prison settings in the EU was assessed, and knowledge gaps on 
communicable diseases in prison settings were identified. An evidence mapping tool was developed, and findings 
were supplemented with information from EU/EEA experts in order to define thematic areas to be addressed by the 
guidance document. This guidance document will be developed as a series of guidance modules on specific 
thematic areas (macro areas). The following macro areas will be covered: 
• Macro area 1: Active case finding for selected communicable diseases on admission and during prison stay 
• Macro area 2: Vaccination strategy, including vaccination at entry and vaccination in outbreak situations 
• Macro area 3: Diagnosis, treatment, care and prevention of TB 
• Macro area 4: Prevention, care and treatment of HIV, including throughcare 
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• Macro area 5: Prevention, care and treatment of viral hepatitis, with a focus on treatment for hepatitis C, 
including throughcare 
• Macro area 6: Prevention and control of injecting-related infections among current or former drug users, 
including throughcare. 
This systematic review report focuses on macro areas 4, 5 and 6 (i.e. prevention and control of HIV, viral hepatitis 
and injecting-related infections).  
1.1.2 Blood-borne viruses and burden of disease in prison 
settings 
BBVs are those viruses that can be spread through contamination by blood or other body fluids [NICE, Physical 
health, 2016], namely HIV, HBV and HCV for the purpose of this report. People in prisons are at increased risk of 
hepatitis B, hepatitis C and HIV, due to a combination of factors such as high prevalence of infection during 
incarceration and high prevalence of risk behaviour during detention (e.g. injecting drug use with unclean 
equipment, sex between men, tattooing) compounded by the characteristics of the prison environment [4,5].  
Human immunodeficiency virus 
HIV is a virus with a long incubation period that attacks the immune system and when untreated causes a severe, 
lifelong illness. The end-stage of the infection, acquired immunodeficiency syndrome (AIDS), results from the 
destruction of the immune system. HIV is transmitted when infected blood, semen, vaginal fluids or breast-milk 
enter another person’s body [7,13].  
Prevalence estimates for HIV among the prison population are reported as part of the monitoring of the Dublin 
Declaration. In 2016, 15 EU/EEA countries reported estimates ranging from 0.2% to 15.8%, with Estonia, Italy, 
Spain and Latvia reporting a prevalence above 5% [14]. According to a recent study assessing the global burden of 
HIV infection among the prison population, HIV prevalence in western Europe is estimated to be 4.2% (95% CI 
2.7-6.1) [4]. While there is an overall lack of published research, available data confirm high variability of HIV 
prevalence among people in prisons with a history of injection drug use. Studies among this group conducted in 
prisons in Hungary (2008), Ireland (2010), Latvia (2010, 2011) and Sweden (2007–2010, 2012, 2013) found HIV 
prevalence ranging between 0% (Hungary) and 18% (Latvia) [15]. 
Viral hepatitis 
Hepatitis B is primarily a liver disease that results from being infected with the hepatitis B virus (HBV). The symptoms can 
vary greatly and many of those acutely infected are asymptomatic. The infection may resolve or become chronic, with 
the latter being a more frequent outcome in younger age groups (from >30% among children to <5% among adults) 
[APHA, 2015]. Chronic hepatitis B may result in serious health outcomes such as liver cirrhosis (25%) and liver cancer 
(5%). Chronically infected patients may act as a reservoir for onward disease transmission [16].  
In a recent systematic review of the literature coordinated by ECDC, HBV prevalence estimates that were 
considered representative for people in prisons were available for 12 countries, ranging from 0.3% to 25.2%, 
compared to a prevalence range of 0.1–4.4% in the general population [17]. Countries with the highest HBV 
prevalence in prison settings were Bulgaria (25.2%), Portugal (10.8%), Luxembourg (7.0%) and Italy (6.7%) [17]. 
According to a recent study assessing the global burden of infection among the prison population, HBV prevalence 
in western Europe was estimated to be 2.4% (95% CI 1.6-3.3) [4]. 
Hepatitis C is a liver disease caused by infection with the hepatitis C virus (HCV). HCV can cause both acute and 
chronic hepatitis. Most people with acute HCV infection do not have any symptoms. It is estimated that 75–85% of 
infections become chronic, and these are often asymptomatic until decades after infection when symptoms develop 
secondary to serious liver damage. Reinfection with HCV may occur among people with previously resolved 
infections or among chronically infected patients [7,18,19].  
In many EU/EEA countries, more than half of those who inject drugs have been infected with HCV, and those who 
currently inject drugs or have done so in the past constitute the largest risk group for HCV transmission in the 
region [20,21]. In a recent systematic review of the literature coordinated by ECDC, HCV prevalence estimates 
considered representative for people in prisons were available for 11 countries. These estimates ranged from 4.3% 
to 86.3%, as compared to a prevalence range of 0.1–5.9% in the general population [17]. According to a recent 
study assessing the global burden of infections among the prison population, the estimated HCV prevalence among 
prison populations in western Europe is 15.5% (12.2–19.1), which was much higher when only looking at 
imprisoned PWID [4]. Even though the prison setting – together with drug treatment centres and other settings – 
is included in prevalence studies among PWID in several countries, research exclusively conducted in the prison 
setting is very limited, and those studies available are sometimes based on small samples. Available studies from 
Hungary (2008, 2009, 2011), Ireland (2010), Latvia (2010) and Sweden (2007-2010, 2012, 2013) among PWID 
found anti-HCV prevalence ranging from 12% (Hungary) to 97% (Sweden) [15]. 
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1.1.3 Drug use and drug-related infections among prisoners 
According to a recently published systematic review, substance use disorders are highly prevalent in people in 
prisons and much more common than in the general population [8]. The pooled prevalence estimate for drug use 
disorders (i.e. substance abuse and/or dependence, excluding nicotine-related disorders) in male prisoners was 
30% (95% CI 22–38; I2 = 98%; 13 studies; range 10–61%) and in female prisoners it was 51% (95% CI 43–58; 
I2 = 95%; 10 studies; range 30–69%). Data reported to EMCCDA showed large variations in the proportion of 
people in prisons with experience of drug use, depending on the country and on the substance [9]. In particular, 
people in prisons differ greatly from the general population in their reported experience with heroin and cocaine. In 
recent studies, lifetime prevalence levels among prisoner populations ranged between 12% and 43% for heroin 
and between 9% and 42% for cocaine, versus less than 1% and less than 2% respectively for the general 
population having used these drugs. Harmful drug use patterns are common among people in prisons, with 
between 6% and 48% of detainees reporting injecting drug use prior to imprisonment [9]. 
Studies among problem drug users show that many have spent time in prison - between one-third and three 
quarters of the samples of opioid, cocaine and amphetamine users and PWID had been incarcerated [22]. Problem 
drug use and drug dependence increase the risk of imprisonment, due to the illegality of the drugs market and 
high cost of drugs. Incarceration and problem drug use patterns are intertwined and result in overlapping 
vulnerability, increased risks of infection with communicable diseases and worse health outcomes [14,22]. 
As noted above, prevalence of BBVs among PWID and people in prisons are many times higher than in the general 
population. PWID are also at increased risk of bacterial skin and soft tissue infections (SSTIs). Although SSTIs pose 
significant health risks, little is known about their prevalence and characteristics in this population, and even less in 
prison sub-populations. Furthermore, cases of injection-related botulism have been reported among PWID in the 
community, possibly related to contamination of the injecting substance [23]. 
1.1.4 Prevention of blood-borne viruses 
Studies show that prevalence of BBVs is high when entering prison [24]. As risk behaviour for BBV transmission in 
prison settings is common, there is considerable potential for implementing prevention measures to control onward 
transmission among the prison population.  
PWID and other drug users are overrepresented in prison. Despite being illegal, drugs are reported as being 
available and in use among the incarcerated population [14,22]. Sex is a major taboo in prison settings, however 
consensual and non-consensual sexual intercourses may occur; with the latter increasing the risk of transmission 
due to trauma. Tattooing or piercing is highly prevalent in prison settings and closely linked to the prison sub-
culture. Research has demonstrated that PWID tend to get tattooed in prison settings more frequently than other 
people in prisons. Sharing tattooing or piercing equipment which has not been appropriately sterilised is considered 
to be one of the main transmission routes for BBVs in prison settings, as is the sharing of equipment for snorting 
drugs, such as straws or rolled notes. In addition, the potential for transmission through medical procedures should 
be considered, as well as vertical transmission for incarcerated pregnant women [7].  
The similarities in modes of transmission of BBVs mean that prevention measures are virtually all valid for the three 
diseases in focus (HIV, hepatitis B and C) [7]. A solid evidence base exists for a number of public health 
interventions to reduce and control BBV infections in the community. HIV Pre-Exposure Prophylaxis (PrEP) is the 
latest addition to the existing basket of prevention options. Other prevention measures include health education; 
vaccination (hepatitis B only); active case finding and subsequent treatment; condoms and lubricants; use of sterile 
syringes, needles and other drug injecting equipment; safe tattooing and piercing programmes; post-exposure 
prophylaxis (HIV only); prevention of mother-to-child transmission; universal precautions for safe workplaces and 
health services, and reducing the sharing of everyday items (WHO, Prisons and Health, 2014; UK Dep 2011 a&b; 
ECDC/EMCDDA guidance 2011) [23]. However, data on the coverage of such interventions in EU/EEA prison 
settings are currently scarce. According to the 2016 Dublin Declaration monitoring, only six EU/EEA countries 
attribute high priority to HIV prevention targeting prison populations [14]. In 2016, although 12 EU/EEA countries 
reported having laws or policies in place that authorise the provision of condoms in prison settings, 15 countries 
reported that they had implemented condom distribution and promotion programmes. In contrast, lubricant 
promotion and distribution programmes were reported by five EU/EEA countries only. HIV PrEP was reportedly 
implemented in prison settings in one country, while HIV Post-Exposure Prophylaxis (PEP) was implemented in 13 
countries. Half of the countries reported having health promotion or behaviour change programmes in place [14]. 
Prevention of injection-related infections 
As injecting drug use is one of the most important types of risk behaviour for BBV infection in prison settings, 
measures specifically aiming to prevent injection-related infections are of the utmost importance. A solid evidence 
base exists for a number of cost-effective public health interventions to reduce and control infections among drug 
users in the community [25]. These include testing, vaccination and treatment of infections, as well as harm 
reduction interventions aiming to reduce drug use and injection-related risk behaviour, ranging from health 
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promotion and drug dependence treatment to needle and syringe programmes (NSPs) [25]. The principle that 
people in prison should enjoy an equivalent standard of care to that available to people outside of prison, includes 
the care associated with problem drug use and drug dependence among people in prison. Accordingly, various 
drug treatment options, in particular opioid substitution therapy (OST) have been introduced in the penitentiary 
systems of most European countries. In some countries, NSP have been set up as part of a comprehensive range 
of measures to respond to problem drug use and reduce drug-related harms in prisons. Furthermore, links 
between prison health services and drug treatment and rehabilitation programmes in the community aim to 
increase the effectiveness of services by creating a continuum of care [9,26].  
However, the coverage of harm reduction interventions is low in prison settings [14,21,22,27]. Although in principle 
OST is reported to be widely available in EU/EEA prisons (except in Lithuania and the Slovak Republic1 [9,21,27] ), 
levels of provision do not match those in the community, and often those entering prison are subjected to 
detoxification treatment while on OST. NSPs are far less available in prisons; only three EU/EEA countries (Spain, 
Luxembourg and Germany) report NSP availability in all or some prisons, while Romania reports no use of the 
available prison NSP [14,27]. Specialised harm reduction programmes for people who inject non-opioid drugs were 
also available in seven EU/EEA countries. In some prison systems, disinfectants are made available for any 
equipment that comes into contact with blood2 [27]. 
1.1.5 Treatment of blood-borne viruses 
Human immunodeficiency virus 
Nowadays, treatment with combination antiretroviral therapy (ART) enables people with HIV infection to live a 
long, healthy and productive life. Early treatment of HIV infection has been associated with both clinical benefits to 
individual patients and a dramatic decrease in the risk of transmission to sexual partners [28,29]. The effectiveness 
of HIV treatment as prevention (TasP) depends on starting treatment early and adhering to it. Retention in care is 
an essential component of HIV care, to correctly monitor treatment and to provide for other health issues such as 
co-morbidities, mental health, etc. 
In the past few years, an increasing number of countries in the broader European region have eliminated CD4 cell 
count thresholds altogether or have introduced higher thresholds for starting ART. This is consistent with the 
European AIDS Clinical Society guidance, recommending immediate ART initiation among persons found to be HIV 
positive, regardless of CD4 cell count (i.e. ‘test and treat’) [30]. The number of countries reporting that HIV 
treatment is initiated regardless of CD4 cell count has increased from four in 2014 to 30 in 2016 [31]. Still, the 
proportion of all people estimated to be living with HIV in the EU/EEA and receiving HIV treatment is low. Based on 
reporting by 19 countries that had data in 2016, it is estimated that 69% of all people currently living with HIV are 
on treatment. However, the viral suppression rate among those who are on ART is estimated to be as high as 89%, 
suggesting a good level of care with successful retention strategies in place [27,31]. Based on this assumption, 
correctional facilities may offer a suitable platform to scale-up diagnosis and treatment among higher-risk 
population groups, and contribute to reaching underserved and marginalised communities bearing a 
disproportionate burden of HIV infection (e.g. PWID, sex workers). However, data on ART initiation and treatment 
coverage in prison settings in the EU/EEA are currently not available. 
Barriers still exist limiting ART coverage and uptake in the EU/EEA and broader European region, including 
unfavourable laws and policies. More specifically, criminalisation of drug use is reported to be a potential barrier to 
treatment access or uptake in one particular EU/EEA country [27]. Half of the countries in the EU/EEA do not 
provide HIV treatment for undocumented migrants. While 15 countries provide ART for undocumented migrants on 
the same basis or at the same cost as for others in the country, 15 countries do not. In many of the latter, 
undocumented migrants are only entitled to emergency healthcare and cannot access longer-term HIV treatment, 
in the absence of legal residence status and/or health insurance [27,31].  
Viral hepatitis  
The release of new direct active antivirals (DAAs) for the management of HCV has opened new avenues for the 
treatment and cure of the infection. Evidence is accumulating on the high rates of safety, tolerability and efficacy of 
DAA regimens for the treatment of HCV-infected and HIV-HCV co-infected patients compared with 
interferon/ribavirin (IFN/RBV) [32,33]. IFN-free regimens with new DAAs are considered best treatment options, 
because of their virological efficacy, ease of use and tolerability. Since contraindications to the use of interferon 
include severe psychiatric illness, particularly depression, which is not uncommon among people who use drugs, 
the new medications represent the first real treatment option for many of them. 
 
                                                                    
1 No data available for Lichtenstein 
22 European Monitoring Office for Drugs and Drug Addiction. Reitox national reporting 2016, - Prison workbooks 
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However, affordability remains a substantial barrier to the scale-up of DAA treatment in the EU/EEA. Limited data 
are currently available on the extent of DAA coverage in the EU/EEA region, based on reported consumption of 
HCV antivirals. In 2015, 25 of the 27 EU/EEA countries reported at least some consumption of DAAs, with great 
variations in relation to RBV. PWID with hepatitis C and people in prisons have been identified as a priority group 
for HCV treatment due to the fact that they are likely to constitute important transmission groups [34]. However, 
HCV testing, linkage to care, and treatment of these groups remain low, due to various barriers [35]. A review of 
data on treatment and prevention of HCV infection among PWIDs in Europe found high levels of undiagnosed HCV 
infection, and a low proportion of treatment initiation among those diagnosed [36]. The proportion of PWID with 
diagnosed chronic HCV infection entering antiviral treatment was found in this systematic review of 26 studies to 
range between 1% and 19% (median 9.5, IQR 3.5-15) in six non-clinical observational studies (four EU/EEA 
countries, total n=3,017). Moreover, three observational studies with non-clinical recruitment settings provided 
estimates of the proportion of diagnosed PWID referred to a specialist for treatment evaluation: median 57%, 
range 9.0–59 (3 EU/EEA countries, total n=2 958). Although access to DAAs is restricted in most EU/EEA countries, 
data on DAA coverage in prison settings across the EU/EEA are currently not available. A recent survey among 168 
prison health units in France (response rate 38%, representing 39% of the prisoner population), reported that 
70% systematically offered HCV screening to prisoners and 60% had introduced at least one DAA treatment, with 
130 patients treated during 2015 [37]. 
However, according to guidelines from the European Association for the Study of the Liver [34], HCV treatment 
with new DAAs should be considered without delay in individuals at risk of transmitting HCV, including active 
PWIDs, MSM with high-risk sexual practices, and incarcerated individuals.  
Treatment for chronic HBV infection is also available. However, there is currently no cure and the main endpoint of 
all current treatment strategies is the long-term suppression of HBV DNA levels. Treatment outcomes have 
improved over the past few decades, with the use of conventional and then pegylated interferon, and more 
recently with the advent of nucleos(t)ides analogues [38-40]. Similarly, as for HCV, no European level data are 
available on the coverage of HBV treatment in prison settings.  
1.1.6 Throughcare 
Transition planning to prepare for release from prison has long been identified as the weakest link in the effective 
re-entry of incarcerated individuals with substance use disorders, or with special health needs (e.g. chronic 
diseases, TB treatment, HIV treatment, mental disorders) into the community. This is especially relevant in the 
context of prevention and control measures for BBV infections to ensure continuity of and adherence to treatment 
for HIV, HBV and drug addiction (i.e. OST). While HCV treatment with DAAs may be less important, given its 
limited duration, HBV vaccination may require long-term follow-up and boosters when administered according to 
the rapid and very rapid schedules. The long-term efficacy of healthcare interventions and programmes for risk 
reduction are greatly diminished if intervention and care provision are terminated or disrupted when the individual 
transitions from one institution to another, or from a custodial institution back into the community. Many factors 
may contribute to such situations. For example, limited budget and resources, including staff and infrastructure, 
separate sphere of influence and institutional responsibility over prison and community health, and challenges in 
inter-sectorial cooperation [41].  
For the purposes of this report, throughcare entails both continuity of care from the community to prison settings, 
as well as from prison settings back into the community. The latter covers both interventions starting in prison 
settings aimed at prevention of BBVs post-release, as well as interventions starting in prison settings to increase 
linkage to care for BBVs post-release. 
1.2 Scope and objectives 
The objective of this systematic review was to gain insight into the evidence base for the prevention and control of 
HIV, viral hepatitis and injecting-related infections in prisons, jails and other custodial settings.  
This systematic review aims at collating and synthesising all relevant evidence (peer-reviewed as well as grey 
literature) with regard to prevention and control of HIV, viral hepatitis and injecting-related infections (see specific 
research questions in the methodology section). This report does not include BBV active case finding and HBV 
vaccination as these topics are covered by separate systematic reviews [24]. Assuming there are no plausible 
biological reasons for differences in the effectiveness of HIV and viral hepatitis treatment inside or outside prison 
settings, the focus of this systematic review is on treatment models of care and service delivery rather than on 
treatment regimens, as the latter is already extensively covered in existing and well-established guidance 
documents [30,34,38,42]. 
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2. Review methods 
This systematic review applies a rigorous high-quality methodology, adhering to international methodological 
standards as established by Cochrane [43] and PRISMA [44]. It also uses the same methodology employed by 
ECDC during the scoping phase of the project for the systematic reviews targeting the other macro-areas [11,24]. 
The screening and selection phases of the systematic review were carried out jointly for the three macro areas (i.e. 
HIV prevention and care, viral hepatitis prevention and care, and prevention and control of infections among 
PWID). This section summarises the methodology relevant to these macro areas. For a detailed overview of the 
overall process used for the three macro areas, please see Annex 1.  
2.1 Review questions 
The following objectives, questions, populations and settings were defined for the systematic review:  
Review objectives:  
• To gain insights into the evidence base (peer-reviewed and grey literature) for the prevention, care and 
treatment of HIV in prison settings, including throughcare. 
• To gain insights into the evidence base (peer-reviewed and grey literature) for the prevention, care and 
treatment of viral hepatitis in prison settings, with a focus on treatment of hepatitis C, including 
throughcare. 
• To gain insights into the evidence base (peer-reviewed and grey literature) for the prevention and control of 
injecting-related infections among current drug users in prison settings, including throughcare. 
The objectives do not include active case finding and vaccination as these topics are covered by separate 
systematic reviews [24].  
The PICOS (Population-Intervention-Comparison-Outcome-Settings) method was used to develop specific research 
questions from these review objectives (Table 1). 
  
TECHNICAL REPORT  Systematic review on the prevention and control of blood-borne viruses in prison settings 
9 
Table 1. PICO table 
 Prevention, care and treatment of HIV 
P Adult individuals (≥18 years) in prison settings (i.e. both those detained and those who work in prison 
settings (‘going through the gate’)) 
I Prevention, care and treatment of HIV 
C • Comparison with no intervention 
• Comparison with alternative intervention 
• No comparison 
• Comparison between populations in prison settings (e.g. between different prison types, risk groups, etc.) 
• Comparison with community setting 
O Qualitative outcomes: 
• Accessibility 
• Suitability, feasibility and acceptability of interventions 
• Qualitative description of interventions/modes of service delivery 
Quantitative outcomes: 
• Uptake (number of persons using a certain intervention or number of persons reached by a certain 
intervention) 
• Measures of effectiveness (e.g. change in HIV incidence or prevalence, number of people who adhered to 
treatment, number of people who are linked to care – including community care after release) 
• Cost-effectiveness (based on study-specific metrics)  
S Prisons, jails and other custodial settings (excluding migrant centres and police detention rooms) 
 Prevention, care and treatment of viral hepatitis 
P Adult individuals (≥18 years) in prison settings (i.e. both those detained and those who work in prison 
settings (‘going through the gate’)) 
I Prevention, care and treatment of viral hepatitis 
C • Comparison with no intervention 
• Comparison with alternative intervention 
• No comparison 
• Comparison between populations in prison settings (e.g. between different prison types, risk groups, etc.) 
• Comparison with community setting 
O Qualitative outcomes: 
• Accessibility 
• Suitability, feasibility and acceptability of interventions  
• Qualitative description of interventions/modes of service delivery 
Quantitative outcomes: 
• Uptake (number of persons using a certain intervention or number of persons reached by a certain 
intervention) 
• Measures of effectiveness (e.g. change in hepatitis incidence or prevalence, number of people who have 
completed treatment, number of people who are linked to care – including community care after release) 
• Cost-effectiveness (defined based on study specific metrics) 
S Prisons, jails and other custodial settings (excluding migrant centres and police detention rooms) 
 Prevention and control of injecting-related infections among PWID 
P Adult individuals (≥18 years) in prison settings (i.e. both those detained and those who work in prison 
settings (‘going through the gate’)) 
I Prevention and control of injecting-related infections among former/current PWID 
C • Comparison with no intervention 
• Comparison with alternative intervention 
• No comparison 
• Comparison between populations in prison settings (e.g. between different prison types, risk groups, etc.) 
• Comparison with community setting 
O Qualitative outcomes: 
• Accessibility 
• Suitability, feasibility and acceptability of interventions  
• Qualitative description of interventions/modes of service delivery 
Quantitative outcomes: 
• Uptake (number of persons using a certain intervention or number of persons reached by a certain 
intervention) 
• Measures of effectiveness (e.g. change in BBVs incidence or prevalence) 
• Cost-effectiveness (defined based on study specific metrics) 
S Prisons, jails and other custodial settings (excluding migrant centres and police detention rooms) 
TECHNICAL REPORT  Systematic review on the prevention and control of blood-borne viruses in prison settings 
10 
Review questions: 
• Which prevention interventions for BBVs and injecting-related infections are effective in prison settings? 
• Which care and/or treatment interventions aimed at control of BBVs and injecting-related infections are 
effective in prison settings? 
• Which service models for prevention, care and/or treatment of BBVs and injecting-related infections are 
effective in prison settings? 
• Which service models for prevention, care and/or treatment of BBVs and injecting-related infections are 
cost-effective in prison settings? 
• What is the acceptance/uptake/coverage of prevention, care and/or treatment of BBVs and injecting-related 
infections in prison settings? 
• How can the acceptance/uptake/coverage of prevention, care and/or treatment of BBVs and injecting-
related infections be improved in prison settings? 
• Who should be targeted for prevention, care and/or treatment of BBVs and injecting-related infections in 
prison settings? 
2.2 Search and selection strategy 
The search and selection phases were done jointly for the three macro areas; see Annex 1 for a detailed 
description of the process. A brief description of the strategies and specific issues can be found below.  
2.2.1 Search strategies for peer-reviewed articles 
A peer-reviewed literature search was carried out on 12 January 2017 (PubMed, Embase and Cochrane Library). 
The search included search strings relevant for all three macro areas (Annex 1). Two search limits were applied: a 
time limit and a geographical limit. Literature published from 1990 onwards was searched in PubMed and Embase, 
while literature published in 1980 and later was searched in the Cochrane Library on account of the difference in 
scope and breadth of the three databases. The literature searches in PubMed and Embase were further limited to 
include only literature from EU/EEA/EFTA countries or EU candidate countries and other western countries (i.e. 
USA, Canada, Australia and New Zealand, see Annex I).  
2.2.2 Selection of peer-reviewed articles 
Articles were screened by title and abstract, and if considered possibly relevant, in full text. Further scrutiny of the 
articles during the extraction phase could have led to exclusion. Inclusion and exclusion criteria by study 
design/type, study quality, study population, geographical area, comparison and specific outcomes are described in 
detail in Annex 1. Meta-analyses and systematic reviews were checked for any relevant primary articles, and 
included if necessary (i.e. not already included and of sufficient methodological quality). No data extraction was 
performed for meta-analyses or systematic reviews.  
2.2.3 Critical appraisal for peer-reviewed articles 
During the selection process, the methodological quality of the articles that appeared to present relevant data for 
the review was critically appraised using standardised evidence-based medicine checklists in order to identify 
quality issues. 
For this review, the National Institute for Health and Clinical Excellence (NICE) checklists were used for selection 
purposes as they cover tools for both quantitative and qualitative checklists. NICE checklists3 are available for the 
following study designs: systematic reviews and meta-analyses, randomised controlled trials (RCTs), cohort studies, 
case-control studies, diagnostic accuracy studies, economic evaluations and qualitative studies. Each study is 
awarded an overall study quality grading for internal validity and a separate one for external validity:  
++: all or most of the checklist criteria have been fulfilled, where they have not been fulfilled the conclusions are 
very unlikely to alter;  
+: some of the checklist criteria have been fulfilled, where they have not been fulfilled, or are inadequately 
described, the conclusions are unlikely to alter;  
−: few or no checklist criteria have been fulfilled and the conclusions are likely or very likely to alter.  
If an article received a score of ‘–‘ for both the internal and external validity, the article was excluded (exclusion 
reason ‘insufficient methodology’, see Annex 5). If methods and/or results were unclear, articles were excluded. 
Otherwise, articles were included and limitations, if present, were described in the data extraction tables. 
 
                                                                    
3 National Institute for Health and Clinical Excellence. The guidelines manual: Appendices B-I. London: NICE; 2012. 
Available from: https://www.nice.org.uk/process/pmg6/resources/the-guidelines-manual-pdf-3304416006853 
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Relevant publications in the field of infectious disease also include outbreak investigations, surveillance studies or 
other observational studies. For these types of studies no standardised checklists are available, and therefore 
quality was assessed based on relevant aspects of the existing NICE checklists, supplemented with questions 
concerning the study design (e.g. whether – in a cross-sectional study – the study population is a representative 
sample of the source population). See Annex 3 for a complete list of questions on study design. Predefined aspects 
of a study were qualitatively scored using - - or -, +/-, + or ++. The checklist was not designed to calculate a total 
quality score to assess quality differences between studies. The final decision on whether the quality of a study 
was sufficient for inclusion was taken by the reviewer, based on his/her expertise and knowledge. 
2.2.4 Search strategies for grey literature documents 
A grey literature search with a focus on EU/EEA countries was performed to complement the peer-reviewed 
literature. Articles, abstracts, reports, case studies, service models, guidelines and protocols which focused on 
prisons and people in prisons were recovered. The search was conducted through a pre-defined list of websites 
and a call for papers/experts input. More details can be found in Annexes 1 and 7.  
2.2.5 Selection of grey literature documents 
Documents were included if the reported information was relevant and of sufficient quality. Inclusion and exclusion 
criteria by period of publication, type of document, document quality, population, subject of the study, geographical 
area, and specific outcomes of interest are described in Annex 1. If prison-focused guidelines could not be 
retrieved/were not available, guidelines with a relevant section on prisoners were searched for in order to 
complement the data. If these were lacking, general population guidelines were reviewed (i.e. without a section on 
prisoners). 
2.2.6 Critical appraisal for grey literature 
Only grey literature documents with clearly-stated methods for compiling data and/or with clear data 
sources/references were included. The following document types were identified (in order of quality, highest quality 
first): 
Conference abstracts and unpublished research reports 
Conference abstracts were checked against included peer-reviewed literature in order to avoid duplication; if 
duplication was found, the full-text article from the peer-reviewed literature was preferred. Conference abstracts 
and unpublished research reports focussing on prison settings were included if they contained information relevant 
to the review objectives. They were screened using the same inclusion/exclusion criteria as the peer-reviewed 
literature. 
Guidelines 
The following types of guidelines were identified (highest quality first):  
• Evidence-based: largely based on the scientific literature. Good clinical practices or expert opinions could be 
used to supplement the scientific literature 
• Practice-based: reflecting expert opinion or information derived from good clinical practices; some literature 
references (not systematic) possibly included. 
Relevant guidelines were critically appraised with a selection of criteria derived from the AGREE instrument: 
• The overall objectives of the guidelines are described in detail 
• Systematic/clearly-stated methods were used to compile the data, and/or data sources/references were 
given 
• The recommendations are specific and unambiguous. 
Each of the three criteria were qualitatively scored on a 5-tier scale: - -, -, 0, +, ++. The final decision whether the 
quality of a guideline was sufficient for inclusion in the evidence base was taken by the reviewer, based on his/her 
expertise and knowledge.  
Case studies/ service models 
Case studies/service models were included to provide insights into the way specific interventions are implemented 
in a given setting. Case studies/service models were only included when at least both of the criteria (a AND b) 
were met: 
a) Clearly described accounts of their intervention/service model related to the relevant macro area; 
b) Elements of monitoring or evidence of success (e.g. pre- and post- intervention testing positivity rate for 
case finding interventions). 
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2.3 Data extraction 
2.3.1 Data extraction for peer-reviewed articles 
All relevant information from included articles was summarised in a standardised evidence table. The evidence 
tables contain the following information: 
• Bibliographic reference: author, year, journal, country 
• Study characteristics: study design, study period, follow-up, prison setting, study objective 
• Study population: population description, inclusion and exclusion criteria, sample description: sample size, 
gender, age, risk groups  
• Data sources and definitions: description of data source/s and relevant definitions 
• Macro area-specific methods: methods for prevention, care and treatment of HIV/viral hepatitis, methods 
for prevention and control of injecting-related infections among PWID 
• Macro area-specific outcome results: prevention, care, and treatment of HIV/viral hepatitis, prevention and 
control of injecting-related infections among PWID 
• Reviewer comments, limitations and level of evidence: any additional information which was relevant for 
interpreting the study results, major issues with regard to the critical appraisal, and the final level of 
evidence based on these considerations. 
2.3.2 Data extraction for grey literature documents 
Included documents were collated into evidence tables. The evidence tables contain information on the following 
topics: 
• Bibliographic reference: title, year, place of publication 
• Source: institute/company, etc. that prepared the document 
• Type of document: conference abstract, guideline, etc. 
• Setting and population: country, prison setting, risk groups, etc. to which the results apply 
• Intervention: type of intervention and brief description 
• Results: relevant results on the objectives given in the document, by objective 
• Comments: any additional information which is relevant for interpreting the results. 
2.3.3 Level of evidence peer-reviewed literature 
The included studies showed a large degree of heterogeneity, therefore the strength of evidence was not assessed 
beyond individual studies. For the studies included in the review, the level of evidence per individual article was 
determined based on the study design and the risk of bias, following the GRADE approach criteria (Grading of 
Recommendations Assessment, Development and Evaluation). 
For RCTs, the following aspects were included to assess the risk of bias: 
• Randomisation 
• Allocation concealment 
• Blinding 
• Loss to follow-up 
• Intention to treat 
• Other limitations (e.g. non-validated method to assess the outcome).  
For observational studies, the following aspects were included to assess the risk of bias: 
• Appropriateness of eligibility criteria (e.g. the study population is not a representative sample of the source 
population; selection of exposed and unexposed individuals in cohort studies from different populations) 
• Measurement of exposure and outcome (e.g. not measured in a standardised, valid and reliable way or not 
clearly described; differences in measurement in exposed and non-exposed populations or measurement of 
the outcome while not blinded/with knowledge of the exposure) 
• Control for confounding (e.g. degree of accuracy when measuring relevant confounders or adjustment in 
statistical analyses) 
• Follow-up (e.g. no follow-up, short follow-up or different follow-up for exposed and non-exposed 
populations) 
• Other limitations (e.g. participants and non-participants differ regarding relevant characteristics). 
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For cost-effectiveness studies, the following aspects were included to assess the risk of bias: 
• Nature of health condition reflected by the model 
• Time horizon 
• Perspective 
• Discount rate 
• Relevant health outcomes and costs 
• Sources used for model input 
• Reporting of incremental cost-effectiveness ratio 
• Sensitivity analyses 
• Other limitations. 
In general, this led to the following levels of evidence for individual studies (based on study design and 
methodological quality; see risk of bias criteria above): 
• High (i.e. high quality RCTs) 
• Moderate (i.e. lower quality RCTs; high-quality cohort/case-control studies, and cost-effectiveness studies) 
• Low (i.e. lower quality cohort/case-control studies and cost-effectiveness studies, cross-sectional studies 
with comparison, high-quality surveillance studies) 
• Very low (i.e. low-quality surveillance or other observational studies, outbreak studies, cross-sectional 
studies without comparison). 
2.4 Evidence summary 
Separate summary tables were created for effectiveness outcomes, acceptability/barriers outcomes, and cost-effectiveness 
outcomes. Rather than structuring the evidence summary per macro area, a categorisation by overlapping topics was used, 
namely: BBVs prevention, prevention of injecting-related infections, HIV treatment, viral hepatitis treatment, and BBVs 
throughcare (see Annexes 9-12).  
The effectiveness summary tables contain the following information: 
• Region (EU/EEA or non-EU/EEA) and source (peer-reviewed literature or grey literature) 
• Bibliographic reference, country, study design 
• Setting (e.g. jail, prison), time period, sample description and size 
• Methods: description intervention/model of care, eligibility, comparator 
• Results:  
− BBV prevention: BBV prevalence/incidence, other outcomes of interest, sub-group considerations 
− PWID: seroconversion, adverse events, other outcomes of interest 
− HIV care and treatment: viral load, CD4 count, treatment adherence, linkage to care post-release, 
other outcomes of interest, sub-group considerations 
− HCV care and treatment: SVR, predictors of SVR, treatment completion, linkage to care post-release, 
other outcomes of interest, sub-group considerations 
− Throughcare:  
Prevention: BBV prevalence/incidence, other outcomes of interest, sub-group considerations 
Linkage to care: viral load, CD4 count, treatment adherence, linkage to care post-release, other 
outcomes of interest, sub-group considerations 
• Level of evidence. 
The acceptability/barriers summary tables contain the following information: 
• Region (EU/EEA or non-EU/EEA) and source (peer-reviewed literature or grey literature) 
• Bibliographic reference, country, study design 
• Setting (e.g. jail, prison), sample description and size, time period 
• Methods: description intervention/model of care 
• Results:  
− BBV prevention: eligibility/access, acceptance, intervention adherence, attrition, other outcomes of 
interest, sub-group considerations 
− PWID: eligibility/access, acceptance, attrition, sub-group considerations 
− HIV care and treatment: eligibility/access, acceptance, treatment discontinuation/non-adherence, 
attrition, other outcomes of interest, sub-group considerations 
− HCV care and treatment: eligibility/access, treatment discontinuation/non-adherence, attrition, other 
outcomes of interest, sub-group considerations 
− Throughcare:  
Prevention: eligibility/access, acceptance, intervention adherence, attrition, other outcomes of 
interest, sub-group considerations 
Linkage to care: eligibility/access, acceptance, treatment discontinuation/non-adherence, attrition, 
other outcomes of interest, sub-group considerations. 
• Level of evidence. 
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The cost-effectiveness summary tables contain the following information: 
• Region (EU/EEA or non-EU/EEA) and source (peer-reviewed literature or grey literature) 
• Bibliographic reference, country, study design 
• Setting (e.g. jail, prison), sample description and size 
• Methods: perspective, time horizon, scenarios 
• Results: cost-effectiveness results/conclusions, sub-group considerations 
• Level of evidence. 
Guidelines, protocols and service models were summarised in the narrative sections only.  
2.5 Quality control 
During the review process, the following quality control measures were used to search and select peer-reviewed literature: 
• Peer-review of the search strings by ECDC librarians and expert panel members. 
• Selection based on title and abstract performed by two independent researchers. All hits that could be 
excluded for clearly explicable reasons (inclusion/exclusion criteria) were excluded. When in doubt, the title 
and abstract were assessed by two researchers and discussed. All articles cited by these two researchers 
(including articles when doubts remain) were checked by another researcher with expertise in the field of 
prison health, who then took the final decision on inclusion or exclusion. 
• Duplicate screening and critical appraisal of 50% of the full-text articles was performed by two independent 
reviewers to refine inclusion/exclusion criteria in order to minimise inconsistencies among reviewers. The 
results were compared and discussed early in the review process, and any disagreements were adjudicated 
by a third reviewer. Any doubts arising during the screening of the remainder of the full-text articles were 
discussed in the project team. 
• Evidence tables were compiled by two researchers (not in duplicate), and all evidence tables were reviewed 
by an independent researcher. 
The following quality control measures were applied to search and select grey literature: 
• Evidence tables were compiled by a researcher and reviewed by a second researcher of the project.  
• Early in the process, a senior researcher also checked a sample of 10% of the articles included in the 
evidence tables to allow for refinement of data extraction. 
• Critical appraisal of the guidelines was performed by a researcher and reviewed by a second researcher.  
2.5.1 Role of the ad-hoc scientific panel 
As part of the project, a multi-disciplinary expert panel was consulted. The panel members were selected based on 
their expertise in prison health, prevention and control of communicable diseases and evidence-based public 
health. The experts came from a variety of organisations, such as clinical professional associations, public health 
institutions, ministries, EU-funded initiatives, international agencies, and civil society organisations. Experts were 
based in the Czech Republic, France, Germany, Italy, Portugal, Romania, Spain, Switzerland and the UK. ECDC and 
EMCDDA staff members were also on the expert panel, adding further areas of expertise (e.g. disease-specific 
knowledge, preparedness, social sciences, health determinants). See Annex 4 for a complete list of expert panel 
members. The panel members were involved in the prioritisation of the systematic review topics, methodology and 
evidence gathering. 
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3. Review results 
In the peer-reviewed article search, the PubMed search returned 4 405 hits, the Embase search 4 921 hits, and the 
Cochrane Library search 62 hits. Following the removal of duplicates and the addition of 12 items after a manual 
search, 6 119 unique hits remained. After screening the titles and abstracts, a total of 329 articles were selected. 
The main reasons for the exclusion of articles during the title and abstract screening were: 
• Incorrect setting (not in prison setting) 
• Ineligible health outcomes (cancer, mental disease, etc.) 
• Non-pertinent publication types (e.g. news, letter to the editor, editorial). 
After reviewing the full text of the selected articles, 246 articles were excluded. Articles excluded and reasons for 
exclusion during the full-text selection step can be found in Annex 5. Additionally, a total of 17 articles could not be 
retrieved and could therefore not be assessed (see Annex 6). 
In total, 66 articles were included, of which 36 reported on prevention, care and treatment of HIV (macro area 4), 
21 were on prevention, care and treatment of viral hepatitis (macro area 5), one was on both HIV and viral 
hepatitis, and eight dealt with prevention and control of injecting-related infections among PWID (macro-area 6). 
When stratifying by topics of interest, of the 66 included articles, five reported on BBV prevention, 16 were on HIV 
treatment, 21 were on HCV treatment, five dealt with PWID, and 19 reported on throughcare. Figure 1 shows a 
flowchart of the selection process. It is worth noting that the searches were conducted for the three macro areas 
combined, and therefore no complete macro area-specific flowchart could be developed. The majority of these 
studies was conducted in the USA, while only 16 (24%) came from the EU/EEA region. 
The grey literature search focused solely on the EU/EEA; a pre-defined website search returned 13 documents, and 
a call for papers yielded 109 documents. The grey literature gathering process using a call for papers is detailed in 
Annex 7.  
Documents received from field researchers were screened based on title and content, and a total of 84 documents 
were excluded. Articles excluded during this selection step can be found in Annex 8. Exclusion reasons were: 
• Not relevant for the review objective = 74 
• No country of interest = 7 
• More recent documents available = 1  
• Duplicate with included peer-reviewed literature article = 1 
• Outside date range = 1. 
Overall, a total of 38 documents met the pre-defined inclusion criteria, including 20 conference 
abstracts/unpublished research reports and 18 guidelines. Of the conference abstracts/unpublished research 
reports, five reported on HIV treatment, 13 were on treatment of viral hepatitis, one reported on BBV prevention 
and one dealt with prevention and control of injecting-related infections among PWID. Six of the guidelines 
reported on treatment of HIV, four were on treatment of viral hepatitis, 10 dealt with BBV prevention, six dealt with 
prevention and control of injecting-related infections among PWID, and seven reported on throughcare. Several 
guideline documents reported on more than one topic. Figure 2 presents a flowchart of the selection process. Of 
note, the searches were conducted for all the three macro areas, and therefore no complete macro area-specific 
flowchart could be developed.  
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Figure 1. Flowchart selection process peer-reviewed literature 
 
 
 
 
 
 
 
 
 
 
 
 
# One article contained relevant data for two macro areas 
$ Systematic reviews were checked for relevant individual articles that were possibly missed. 
  
Embase search 
n=4 921 
Selected based on title 
and abstract 
n=39 
Excluded, based on title and 
abstracts 
n=5 790 
Included: n=66# 
- Macro area 4, HIV prevention 
and care: n=37 
- Macro area 5, viral hepatitis 
prevention and care: n=22 
- Macro area 6, PWID infection 
prevention and control: n=8 
Excluded: n=246 
- No/limited data on objectives: n=123 
- Narrative reviews: n=31 
- Insufficient methodology: n=27 
- Non-pertinent publication types: n=18 
- Case report/small case series: n=14 
- Systematic review: n=12$ 
- Incorrect study population: n=9 
- Duplicate articles: n=5 
- Modelling studies: n=2 
- More recent data available: n=2 
- No country of interest: n=2 
 
Not available: n=17 
PubMed search 
n=4 405 
Cochrane Library search 
n=62 
Unique hits 
n=6 107 
Via references 
systematic reviews 
n=12 
- BBVs prevention: n=5 
- HIV treatment: n=16 
- Hepatitis treatment: n=21 
- PWID: n=5 
- Throughcare: n=19 
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Figure 2. Flowchart selection process for the grey literature 
 
# Some documents included data on more than one macro area 
& Some documents included data on more than one topic. 
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3.1 Prevention of transmission of blood-borne viruses 
The combined findings from the systematic review on prevention of BBVs (peer-reviewed and grey literature) are 
summarised below. Results are presented separately for general BBV prevention and prevention of injecting-related 
infections among PWID. See Annex 9 for a more detailed summary of relevant information. 
3.1.1 Prevention of transmission of blood-borne viruses  
Five studies from the peer-reviewed literature, all from outside the EU/EEA, and one conference abstract reported 
on prevention of BBVs in prison settings and were included [45-50]. Overall the quality of the included studies from 
the peer-reviewed literature was low to very low.  
Effectiveness 
Four of the six included studies reported on effectiveness of interventions to prevent BBV infection in prison 
settings (see Table 2) [45-47,50]. None of these studies reported on the primary effectiveness outcome (i.e. 
seroconversion after the introduction of a BBV prevention intervention.)  
One cross-sectional study reported on a free condom distribution programme in prison, where 150 condom vending 
machines were installed, dispensing boxes containing one sachet of lubricant, one sealable disposal bag, and an 
information card [45]. Overall, 28% of inmates used the condom machine. Of those, 40% used it for sex, 25% for 
self-masturbation, and 19% used the sealable disposal bags for storage of substances. During the study period, 
24 571 condoms were dispensed per month. 
A conference abstract reporting on a safe tattooing programme in prison (not further defined), found that 66% of 
inmates requested safe tattoos, 68% of whom underwent safe tattooing [46]. 
In a randomised controlled trial (RCT) comparing a group behaviour intervention, using six weekly one-hour 
interactive group sessions, with usual care where inmates received didactic lectures, a greater improvement in the 
intervention group was found for all five measured outcomes: HIV knowledge confidence, avoiding risky sex, 
avoiding risky drug use, HIV services and testing, and risk reduction skills [47]. 
In another RCT comparing six weekly group sessions using skills training to six weekly group sessions using 
unstructured discussion, those in the skills building intervention showed greater improvements in acknowledging a 
partner’s request and in condom application skills, while those in the discussion intervention group showed greater 
improvements in commitment to change [50]. However, there were no significant differences for many other 
outcomes, such as refusing unprotected sex or the sharing of used drug injecting equipment and intention to use 
condoms. 
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Table 2. Evidence base for the effectiveness of interventions to prevent BBVs in prison settings 
Intervention 
description 
Studies 
included  
Outcome 
1: Sero-
conversion 
Outcome 2: behaviour 
change 
Other outcomes Level of 
evidence 
Condom 
distribution 
N=1 study; 
cross-sectional 
[45], sample 
size [606] 
EU/EEA (0) 
NR Frequency of condom use 
among sexually active 
inmates for anal and oral 
intercourse was every time 
(52%, 28%), often (7%, 
2%), sometimes (16%, 
22%), never (21%, 44%) 
and no sex since condom 
availability (4%, 4%). 
294,853 condoms 
dispensed during study 
period; 24,571 per month 
Use condom machine: 28% 
40% used condoms for sex, 
25% for self-masturbation, 
19% used the sealable 
disposal bags for storage of 
substances. 
Very low 
Safe tattooing 
programme 
N=1 study; 
conference 
abstract [46], 
sample size 
[86] 
EU/EEA (1) 
NR 68% of those who 
requested, performed safe 
tattooing (69.5% had 
previously been tattooed, 
mostly using uncontrolled 
equipment and often during 
imprisonment) 
66% requested safe tattoos NA 
Group 
behaviour 
intervention 
vs. usual care 
N=1 study; 
RCT [47], 
follow-up [one 
week post-
intervention], 
sample size 
[1257] 
EU/EEA (0) 
NR Greater improvement in 
intervention group and 
higher mean score at post-
test in intervention group 
than control group for: HIV 
knowledge confidence, 
avoiding risky sex, avoiding 
risky drug use, HIV services 
and testing, and risk 
reduction skills. 
NR Low 
Group skills-
building 
intervention 
vs. discussion 
intervention. 
N=1 study; 
RCT [50], 
follow-up [6 
months post-
intervention], 
sample size 
[90]: EU/EEA 
(0) 
NR Skills building intervention: 
greater improvements in 
acknowledging a partner’s 
request and condom 
application skills. 
Discussion intervention: 
greater improvements in 
commitment to change. 
NR Very low 
NR: not reported, RCT: randomised controlled trial. 
Acceptability and barriers 
Three of the six included studies reported on acceptability and barriers, with a focus on condom distribution and 
safe tattooing programmes [45,46,49]. 
In a cross-sectional study, inmates and staff were asked about experiences with condom vending machines [45]: 
84% of inmates, 85% of commissioned/senior officers, and 43% of prison officers supported condom provision. Of 
the inmates, 68% did not experience harassment for obtaining condoms, while 15% experienced harassment by 
other inmates and 7% by officers. Of the inmates, 14% believed condom availability would increase the occurrence 
of rape. In a cross-sectional study examining condom provision during weekly health education classes, HIV test 
counselling or upon request, 11% of inmates had been given a condom while in jail [49]. Overall, 55% of inmates 
and 64% of staff reported that distributing condoms is a good idea as condoms are an effective and low-risk 
method to prevent the transmission of HIV or STIs. Those objecting mentioned: concern of institutional and 
personal safety; perception of the intervention as an endorsement of same gender relationships; inconsistent 
message of condom availability given that sexual activity is prohibited by institutional policy. Among inmates, 42% 
believed condoms would increase likelihood of sex in jail, and 13% of staff reported occurrence of problems caused 
by condom distribution (not further defined). Both studies reported no major incidents comprising prison safety.  
In the conference abstract reporting on a safe tattooing programme in prison, 32% of those who requested safe 
tattooing were reported not to have successfully received tattoos under the programme because of lack of money 
(50%) or release from prison (50%) [46]. 
Cost-effectiveness 
One cost-effectiveness study was included, focusing on condom distribution (see Table 3) [48]. In this study, staff visited 
an MSM unit once a week, at which time inmates could receive one single condom. According to the model and 
compared with usual care, this programme resulted in 25% of HIV transmissions averted, reducing the number of new 
infections from 0.8 to 0.6 per month, and in cost savings over the next 32 years of almost USD 75 000. 
  
TECHNICAL REPORT  Systematic review on the prevention and control of blood-borne viruses in prison settings 
20 
Table 3. Evidence base for the cost-effectiveness of interventions to prevent BBVs in prison settings 
Intervention 
description 
Studies included  Scenarios Conclusions Level of 
evidence 
Condom 
distribution 
vs. no 
condom 
distribution. 
N=1 study [48], 
perspective 
[societal], time 
horizon [32 years] 
EU/EEA (0) 
Condom distribution: staff visit 
the unit once a week, at which 
time inmates line up and may 
receive a single condom vs. no 
condom distribution. 
- 25% of HIV transmissions averted, 
reducing the number of new 
infections from 0.8 to 0.6 per month 
- Cost savings over the next 32 
years of USD 74 777. 
Low 
Guidelines 
Ten guidelines reporting on BBV prevention were included, eight of which were specific to prison settings (four 
supranational and four national guidelines) and two were supranational but not specific to prison settings (Table 4). 
See Annex 9 for a more detailed summary of relevant information. In short, the guidelines set out the 
recommendations below which were of interest for this project:  
Table 4. Guidelines providing recommendations on prevention of BBVs in prison settings  
Guideline 
 
Specific to prison setting – supranational guidelines 
WHO, 2014 
[7] 
All information on blood-borne diseases that is available to the community should be tailored to the 
needs, cultural and educational backgrounds and languages of the prison population, both staff and 
prisoners. The preferred strategies to reduce BBV transmission include: 
− Provision of condoms and lubricants 
− Safe tattooing and piercing equipment 
− Prevention of mother-to-child transmission 
− Universal precautions and safe health services 
− Post-exposure prophylaxis. 
UNAIDS, 
2014 [51] 
Condoms need to be easily and discreetly available, ideally in areas such as toilets, shower areas, 
waiting rooms, workshops or day rooms where prisoners can pick up a condom without being seen by 
others. Condoms should be provided free of charge, and can be made available to all prisoners in a 
health kit given to them upon entry to the facility. The proper (correct) and consistent (every time) use 
of condoms for sexual intercourse, vaginal, anal or oral can greatly reduce a person’s risk of acquiring or 
transmitting sexually transmitted infections, including HIV infection. New infections can be prevented by 
providing easy, anonymous access to condoms and lubricants. Preventing the transmission of blood-
borne diseases through tattooing requires efforts at individual, institution and population level. 
UNODC, 
2013 [52] 
It is essential to provide HIV interventions in these (prison) settings, both for prisoners and for those 
employed by prison authorities.  
The comprehensive package includes 15 key interventions: 
1. Information, education and communication 
2. Condom programmes 
3. Prevention of sexual violence 
4. Drug dependence treatment, including opioid substitution therapy 
5. Needle and syringe programmes 
6. Prevention of transmission through medical or dental services 
7. Prevention of transmission through tattooing, piercing and other forms of skin penetration 
8. Post-exposure prophylaxis 
9. HIV testing and counselling 
10. HIV treatment, care and support 
11. Prevention, diagnosis and treatment of tuberculosis 
12. Prevention of mother-to-child transmission of HIV 
13. Prevention and treatment of sexually transmitted infections 
14. Vaccination, diagnosis and treatment of viral hepatitis 
15. Protecting staff from occupational hazards. 
WHO, 2007 
[53] 
 
 
 
The proper (correct) and consistent (every time) use of condoms for sexual intercourse, vaginal, anal or 
oral can greatly reduce a person’s risk of acquiring or transmitting sexually transmitted infections, 
including HIV infection. Preventing new infections can be achieved through providing easy, anonymous 
access to condoms and lubricants. Preventing the transmission of blood-borne diseases through 
tattooing requires efforts at individual, institution and population level. 
Specific to prison setting – national guidelines 
NICE, 2016 
[54] 
Ensure that people in prison have discreet access to condoms, dental dams and water-based lubricants 
without the need to ask for them 
UK 
Department 
of Health, 
2011_a [55] 
HIV prevention advice for prisoners: 
− Always use a condom during sex. 
− Never share tattooing or body piercing equipment. 
− Use disinfecting tablets to clean injecting equipment, razors, etc. 
− Post-exposure prophylaxis. 
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Guideline 
 
UK 
Department 
of Health, 
2011_b [56] 
Prevention 
− Condoms should be used for all sexual contact with a partner whose HIV status is unknown. 
− Individuals who undergo body piercing/ tattooing should ensure that disposable sterile needles 
are used. 
− Sharing of personal items like toothbrushes, injecting equipment and razors should be 
avoided. 
− Post-exposure prophylactic antiviral drugs begun within hours (and certainly no later than 48 
to 72 hours after exposure) of a significant exposure to HIV virus may prevent infection 
occurring. 
SIMIT/Minist
ero della 
Salute 
(Italy), 2016 
[57] 
In order to reduce HIV transmission the panel recommends: 
− Free distribution of sterile tattooing equipment. 
− Free distribution of condoms and condoms vending machines in freely accessible but 
reserved areas within the prison. 
− Provide pre-exposure prophylaxis by the prison infectious disease specialist, if needed. 
− Assure the continuation of Opioid Substitution Treatment since it is highly effective in 
reducing HIV transmission among PWID. 
Other guidelines – supranational guidelines 
WHO, 2016 
[58] 
In addition to the recommended interventions for people in the community, interventions relevant to 
closed settings include: 
− Prevention of HIV transmission through medical and dental services. 
− Prevention of transmission of HIV and other blood-borne diseases through tattooing, piercing 
and other forms of skin penetration 
− The correct and consistent use of condoms with condom-compatible lubricants is 
recommended for all key populations to prevent sexual transmission of HIV 
− Oral pre-exposure prophylaxis (containing tenofovir disoproxil fumarate) should be offered as 
an additional prevention choice for key populations (including prisoners) at substantial risk for 
HIV infection as part of combination prevention approaches 
− PEP given to reduce the likelihood of acquiring HIV infection after possible exposure. 
European 
AIDS Clinical 
Society, 
2017 [30] 
Effective measures to reduce sexual transmission of HIV include: 
− Male condom or female condom use 
− Post-exposure prophylaxis  
− Pre-exposure prophylaxis 
− ART for HIV-positive partner. 
 
3.1.2 Prevention of injecting-related infections among people who 
inject drugs 
Five peer-reviewed literature studies and one conference abstract reported on prevention of injecting-related 
infections among people who inject drugs in prison settings and were included [Stark, 2006; Heinemann, 2001; 
Dolan, 2003; Dolan, 2005; Arroyo, 2015; Warren, 2006]. Three studies were from the EU/EEA. Overall the quality 
of the included studies from the peer-reviewed literature was low to very low. 
Effectiveness 
Five of the six included studies reported on the effectiveness of interventions to prevent injecting-related infections 
among PWID in prison settings (see Table 5) [59-63]. Three studies reported on needle and syringe programmes 
(NSPs), and two on opioid substitution treatment (OST). 
One study examined NSPs in one female and one male prison. Automatic dispensers were used in the female 
prison, while in the male prison used material was exchanged for sterile material through social workers three 
times a week [62]. The investigators found no HIV and HBV seroconversions and a seroconversion incidence rate 
of 18/100 person-years for HCV during the study period. All four HCV seroconverters denied tattooing, piercing, 
sexual risk behaviour, sharing syringes in prison, but three out of four reported front-loading or sharing of spoons 
for drug preparation prior to seroconversion. The other study reporting on an NSP based on the installation of 
syringe vending machines, found no seroconversions during the intervention period and no adverse events were 
reported [61]. Almost all subjects in the latter study reported frequency of sharing used injecting equipment as 
unchanged or only slightly decreased. Arroyo reported on the implementation and impact of a nation-wide NSP in 
the Spanish prison system in a longitudinal study [63], during which the number of participating prisons increased 
from one (in 1997) to 38 (in 2003), before declining again to 22 (in 2014). The prevalence of HCV infection in the 
Spanish prison system decreased from 48.6% in 1998 to 20% in 2014, and the prevalence of HIV infection from 
12.1% in 2003 to 5.8% in 2014. The decrease in prevalence of HCV and HIV among people in prison in Spain 
reflects the introduction of a range of effective harm reduction measures, including OST, NSP and ARV in the 
community and in prisons, which coincided with a decline at national level of injecting drug use and a reduction in 
new injecting-related infections. 
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One RCT comparing introduction of an OST programme to usual care (no OST) found no difference in HIV and HCV 
seroconversion between the OST and the control group after four months [59]. In a follow-up study of the above 
mentioned RCT, all participants were offered OST after four deferral period months and were followed up for 
approximately four years [60]. A seroconversion incidence rate of 21/100 person-years was found for HCV, and of 
0.28 per 100 person-years for HIV. Individuals incarcerated for less than two months and those on OST for less 
than five months had a significantly increased risk of HCV seroconversion [60]. 
Table 5. Evidence base for the effectiveness of interventions to prevent injecting-related infections 
among PWID in prison settings 
Intervention 
description 
Studies 
included  
Outcome 1: 
seroconversion 
Outcome 2: adverse 
events/attrition1 
Other outcomes Level of 
evidence 
NSPs N=3 studies; 2 
longitudinal 
studies 
[61,62], follow-
up [NR; 
median 12 
months], 
sample size 
[231, 174] 
1 conference 
abstract [63], 
follow-up [18 
years], sample 
size [NR] 
EU/EEA (3) 
Median 12 months 
follow-up:  
- HIV: 0 
- HBV: 0  
- HCV: four out of 22 HCV 
seronegative at baseline 
(IR 18/100 person-years) 
- 12 HBV and 11 HCV 
between M0 (1-12 weeks 
before intervention start) 
and M1 (1-10 months 
after intervention start), 
at least five HBV and two 
HCV seroconversions 
probably occurred during 
imprisonment 
- No seroconversions 
were observed during the 
intervention period 
- Prevalence of HCV 
infection in Spanish 
prison system decreased 
from 48.6% in 1998 to 
20% in 2014 
- Prevalence of HIV 
infection in Spanish 
prison system decreased 
from 12% in 1998 to 
5.8% in 2014. 
No adverse events 
possibly related to the 
programne (n=1 
study) 
Attrition: 28.7% 
-3 383 – 10 439 
syringes exchanged; 
in one study the 
number of syringes 
exchanged rose 
from 2 582 to nearly 
23 000 in 2004 and 
decreased since 
then to 4 393 in 
2014 
- All seroconverters 
denied tattooing, 
piercing, sexual risk 
behaviour, sharing 
syringes in prison, 
but three reported 
front-loading2 or 
sharing of spoons 
for drug preparation 
prior to 
seroconversion (1 
study) 
- Almost all subjects 
reported frequency 
of sharing of 
injecting equipment 
as unchanged or 
only slightly 
decreased (1 study)  
All very 
low 
Opioid 
substitution 
treatment 
N=2 studies; 2 
RCTs [59,60], 
follow-up [four 
months; four 
years], sample 
size [both 
studies 191 
OST, 191 
control] 
EU/EEA (0) 
~4 months follow-up: 
- HIV: 0 at baseline and 
follow-up 
- HCV: four out of 32 OST 
and four out of 35 control 
HCV-negative subjects at 
baseline (12.5% and 
11.4%, resp., p=ns) 
Median 4.2 years follow-
up: 
 - HCV: 39 of 95 HCV-
negative subjects (IR 
21.3/100 person-years, 
95% CI 15.6-29.2), p=ns 
between original RCT 
groups 
- HIV: two (seronegative 
at baseline NR; IR 0.276/ 
100 person-years, 95% 
CI 0.033-0.996) 
Adverse events: NR 
Attrition: 
- 22.5% in OST and 
26.6% in control 
group 
- 80.6% dropped out 
of their first OST 
episode over 436 
person-years at risk 
(attrition rate 63.1 per 
100 person-years, 
95% CI 56.1-71.0) 
Significant 
association with 
increased risk of 
HCV seroconversion 
(n=1 study): periods 
of imprisonment of 
<2 months 
(p≤0.001), OST 
periods of <5 
months (p=0.01) 
All very 
low 
 
HBV: hepatitis B virus, HCV: hepatitis C virus, HIV: human immunodeficiency virus, IDU: injecting drug user, IR: incidence rate, 
NR: not reported, ns: not significant, NSP: needle and syringe programme, OST: opioid substitution treatment, RCT: randomised 
controlled trial 
1 Proportion lost to follow-up during study  
2 Dividing up drug doses between ≥2 IDUs involving a used syringe. 
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Acceptability and barriers 
Four of the five included studies reported on acceptability and barriers to NSP and OST programmes in prison 
settings [59-62]. 
In a German longitudinal study reporting on an NSP, the loss to follow-up was primarily due to pre-term release or 
transfer of people in prison [62]. Another German longitudinal study reported that over 90% of the NSP users 
reported unreliability of syringe vending machines [61]. Additional reported challenges by the two studies were: 
not enough syringes provided, insufficient anonymity, poor supply of dummies, and lack of special injecting 
paraphernalia (no percentages reported). The acceptance (not defined in the study) of the overall project among 
incarcerated PWID was significantly higher than among non-injectors (p-value not reported). Furthermore, the two 
studies reported a similar proportion (58-61%) of prison employees who evaluated the programme as ‘bad’ or ‘very 
bad’. At the end of the study period, the majority of the employees were still not convinced of the need for an NSP. 
Two studies from Australia reported on an OST programme in prison [59,60]. Among the intervention group who 
were offered OST immediately and were followed up for four months, 9.3% did not start treatment (reasons not 
reported) [59]. In the four-year follow-up study of this RCT, where the control group received OST after a four-
month delay, 97% of all original intervention and control subjects had received OST at some time during the 
complete study period [60]. According to the studies, the loss to follow-up was due to release from prison. The 
OST dropout risk was ten times higher during short prison sentences (≤1 month) compared to when subjects were 
in the community (p<0.001), although after four months, imprisonment proved significantly effective against OST 
dropout (p≤0.002) [60]. 
Cost-effectiveness 
One cost-effectiveness study was included that assessed the impact of a one-year OST programme compared with 
usual care (see Table 6) [64]. According to the study, the introduction of the OST programme resulted in an 
incremental cost per additional heroin-free day of AUD 38, per death avoided of almost AUD 460 and per HCV case 
avoided of approximately AUD 40 000. The authors concluded that an OST programme in prison was no more 
costly than analogous community programmes. 
Table 6. Evidence base for the cost-effectiveness of interventions to prevent injecting-related 
infections among PWID in prison settings 
Intervention 
description 
Studies included  Scenarios Conclusions Level of 
evidence 
Opioid 
substitution 
treatment 
N=1 study 
[64], perspective 
provider/finder of 
prison services, 
time horizon NR 
EU/EEA (0) 
OST 
programme for 
one year vs. 
no OST 
programme 
- Incremental cost per additional heroin-free day: 
AUD 38 
- Incremental cost per death avoided: AUD 458 074 
- Incremental cost per HCV case avoided: AUD 
40 428. 
- OST programme in prison is no more costly than 
community programmes. 
Low 
 
AUD: Australian dollar, HCV: hepatitis C virus, NR: not reported, OST: opioid substitution treatment. 
Supplementary evidence 
The systematic review of the evidence on prevention interventions for injecting-related infections yielded a very 
limited body of evidence. Most of the studies identified through the search reported on indirect outcome measures 
(e.g. change in drug-injecting behaviour) rather than on infection-related outcomes. The project team decided to 
integrate the available evidence through a pragmatic approach, along the dimensions of analogy (i.e. evidence 
reporting on prevention intervention targeting PWID in the community) and of proxy measures (i.e. indirect 
outcome measures within the group of PWID in prison settings). The relevant evidence was sources taken from the 
EMCDDA best practice portal (http://www.emcdda.europa.eu/best-practice/answer-sheets/prison_en). 
Guidelines 
Six guidelines on prevention of BBV infection in PWID were included, three of which were specific to the prison 
setting (two supranational and one national guideline), and the other three were supranational guidelines not 
specific to the prison setting (Table 7). See Annex 9 for a more detailed summary of relevant information. In short, 
these guidelines set out the following recommendations of interest for this project:  
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Table 7. Guidelines providing recommendations on prevention of injecting-related infections among 
PWID in prison settings 
Guideline  
Specific to prison setting – supranational guidelines 
WHO, 2014 [7] Different modalities have been adopted in several countries to make safe injection equipment available 
in prisons through health staff, by peers or through dispensing machines. There is evidence that these 
programmes are effective and not the source of security problems. Drug dependence treatment, 
including opioid substitution therapy for maintenance, is an essential component of the prevention of 
transmission through injection equipment. 
WHO, 2007 [53] Prevention is based on blocking transmission caused by using contaminated syringes. The individual 
drug user should avoid sharing injecting equipment and, when needle and syringe programmes are 
available, take part.  
Specific to prison setting – national guidelines 
UK Department of 
Health, 2011 [55] 
Never share injecting drug equipment; this includes syringes, filters, spoons, tourniquets, swabs and 
water, as well as needles. 
Use disinfecting tablets to clean injecting equipment, razors, and any other items that may have come 
into contact with blood or body fluids.  
Other guidelines – supranational guidelines 
WHO, 2016 [58] All people from key populations who are dependent on opioids should be offered opioid substitution 
therapy in keeping with WHO guidance (strong recommendation, low quality of evidence), including 
those in prison and other closed settings. 
People in prisons should have access to the same evidence-based treatment options for substance 
dependence as people in the community.  
ECDC/EMCDDA, 
2011 [25] 
Based on the most robust evidence available, expert opinion, and best practice used within the 
EU/EEA, the following key intervention components should be applied and, if possible, be combined to 
achieve the maximum prevention effect through synergy: 
− Provision of, and legal access to, clean drug injection equipment, including sufficient supply 
of sterile needles and syringes, free of charge, as part of a combined multi-component 
approach, implemented through harm-reduction, counselling and treatment programmes. 
− Opioid substitution treatment and other effective forms of drug dependence treatment; 
− Vaccination: Hepatitis A and B, tetanus, influenza vaccines, and, in particular for HIV-positive 
individuals, pneumococcal vaccine.  
− Testing: Voluntary and confidential testing with informed consent for HIV, hepatitis C 
(hepatitis B for unvaccinated) and other infections, including TB, should be routinely offered 
and linked to referral to treatment.  
− Infectious disease treatment: Antiviral treatment based on clinical indications for those who 
are HIV-, hepatitis B- or C-infected. Anti-tuberculosis treatment for active TB cases. TB 
prophylactic therapy should be considered for latent TB cases. Treatment for other infectious 
diseases should be offered as clinically indicated. 
− Health promotion: Health promotion focused on safer injecting behaviour; sexual health 
including condom use; and disease prevention, testing and treatment. 
− Targeted delivery of services: Services should be combined and organised and delivered 
according to user needs and local conditions; this includes the provision of services through 
outreach and fixed sites offering drug treatment, harm reduction, counselling and testing, 
and referrals to general primary health and specialist medical services. 
EMCDDA, 2010 [65] Technical guidelines for a wide range of health service providers to PWID, recommending 
comprehensive health examination, testing and counselling in different health settings including 
primary healthcare, special health services for PWID, low threshold service centres visited by PWID, 
rehabilitation centres, dedicated sexually transmitted infections (STI) clinics and prison healthcare 
facilities.  
3.2 Modes of care for HIV treatment 
A total of 21 studies reporting on HIV treatment provision in prison settings were included. Fifteen were peer-
reviewed articles and five were conference abstracts, of which eleven were from the EU/EEA. Overall the quality of 
the included peer-reviewed literature studies was very low. See Annex 10 for a more detailed summary of relevant 
information. 
Effectiveness 
Overall, 19 of the 21 included studies reported on the effectiveness of different models of care to achieve retention 
and adherence to HIV treatment in prison settings (see Table 8). Thirteen studies were descriptive studies of usual 
models of care. Six reported on self-administered therapy (SAT) [66-71] and seven reported on a combination of 
directly observed therapy (DOT) and SAT [72-78]. In three studies a DOT-based HIV treatment approach was 
compared to a SAT-based approach [79-81]. In addition, one study reported on a telemedicine intervention to 
improve HIV quality of care [82], another investigated a clinical pharmacist-led HIV treatment approach [83], and 
one conference abstract reported on a monthly nurse evaluation intervention [84]. 
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Adherence to HIV treatment was reported in ten studies [68-70,72,73,76,77,79,80,83]. It ranged from 42% to 72% in 
studies reporting on usual care with SAT, from 62% to 94% in studies reporting on usual care with a combination of 
DOT and SAT, and was 73% in the clinical pharmacist-led treatment study. The studies comparing DOT with SAT 
reported a median adherence range of 90%-100% in the SAT group and 82%-100% in the DOT group (depending on 
definition used), with no significant difference between the two approaches. 
Viral suppression as the main treatment endpoint was reported by thirteen studies [66,67,69-71,73-75,78,79,82-84]. 
The proportion of patients achieving viral suppression ranged from 46% to 83% in studies reporting on usual care 
with SAT, and from 23% to 62% in studies reporting on usual care with a combination of DOT and SAT. Five studies 
reporting on usual care examined whether viral suppression from start of treatment improved significantly. Three 
studies found a significant improvement, two measured at release and one measured six months after start of 
treatment. The other two studies did not find a significant improvement in viral suppression after start of treatment, 
one after 24 weeks and one after 12 months. One study comparing DOT with SAT reported viral suppression rates of 
53% and 56% for DOT and 32% and 44% for SAT, at 24 weeks and 48 weeks, respectively, with no significant 
difference between the two approaches. The study reporting on the telemedicine approach found a significant 
increase in the likelihood of achieving viral suppression in the telemedicine group compared to the usual care group 
(OR 7.0, 95% CI 5.1–9.8; p< 0.001). 
Attrition was reported in six studies and ranged from 4% to 52% [68-70,73,79,80]. Possible factors associated with it 
are presented below. 
Table 8. Evidence base for the effectiveness of different care models to achieve retention of and 
adherence to HIV treatment in prison settings 
Intervention 
description 
Studies included  Outcome 1: 
Adherence1  
Outcome 2: Viral 
suppression2 
Attrition3 Level of 
evidence 
Usual care - 
SAT 
N=6 studies; 2 longitudinal [68,70], 
follow-up [6 months; 12 months], 
sample size [75; 281]; 1 cross-sectional 
[69], sample size [50], 3 conference 
abstracts [66,67,71], sample size [102; 
600; 144] EU/EEA (6) 
42%-72% 
No significant 
changes over 
time reported in 
n=2 studies  
46%-82.8% 
No significant changes 
over time reported in 
n=1 studies on people 
on ART; significant 
decrease in viral load in 
n=1 study on people 
started on ART. 
4%-45% All very low 
Usual care - 
Combination of 
DOT and SAT 
N=7 studies; 3 longitudinal 
[73,75,78], follow-up [24 weeks; until 
release; until release], sample size 
[108; 882; 1099];  
3 cross-sectional [72,76,77], sample 
size [205; 102; 177] 
1 conference abstract [74], sample 
size [170] 
EU/EEA (2) 
62%-94% 23%-62% 
Significant decrease in 
viral load in n=2 
studies, decrease 
without reported 
significance in n=1 
study, from baseline to 
follow-up 
6% All very low 
Comparison 
DOT vs. SAT 
N=3 studies; 2 longitudinal [80,81], 
follow-up [3-4 months; 16-19 
months], sample size [31; 84]; 
1 RCT [79], follow-up [48 weeks], 
sample size [43] EU/EEA (1) 
No significant 
difference 
between DOT 
and SAT 
[measured by 
electronic 
monitoring, pill-
count or self-
reported]. 
No significant 
difference between 
DOT and SAT. 62.1% 
of patients in DOT 
group had viral load 
<400 copies/ml vs 
34% in the non-DOT 
group (p=0.01) 
5%-52% All very low 
Telemedicine 
with HIV 
specialist 
N=1 study; 1 comparative [82], 
sample size [1201], follow-up [18 
months] EU/EEA (0) 
NR Significant increase in 
likelihood of achieving 
viral suppression in 
telemedicine group. 
NR Very low 
Clinical 
pharmacist-led 
treatment 
N=1 study; 1 longitudinal [83], 
follow-up [NR], sample size [135] 
EU/EEA (0) 
73% Increased from 32% to 
66% following 
intervention 
(significance NR) 
NR Very low 
Monthly nurse 
evaluation 
N=1 study; 1 conference abstract 
[84], follow-up [NR], sample size [54] 
NR Decreased from 
8 341.57 to 4 040.31 
copies/ml following 
intervention 
(significance NR). 
NR NA 
ART: antiretroviral therapy, DOT: directly observed therapy, NR: not reported, RCT: randomised controlled trial, SAT: self-
administered therapy 
1Adherence defined as self-reported adherence measure according to study specific methodology 
2Viral suppression defined as viral load <50 copies/ml unless otherwise specified 
3Proportion lost to follow-up during study. 
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Acceptability and barriers 
Fifteen of the 21 included studies reported on the acceptability and barriers to HIV treatment in prison settings 
[66,68-77,79,80,85,86]. 
Acceptance 
The proportion of treatment acceptance among those eligible was reported in three cross-sectional studies 
reporting on HIV usual care and ranged from 73.0% to 80.0% [72,76,77]. Two studies reported having trust in the 
physician and in the medication as significant predictors of treatment acceptance [72,76]. Another study compared 
individuals who refused ART to those either eligible or on treatment. Those refusing ART were characterised by a 
higher proportion being on OST, using heroin/cocaine in prison, having HCV co-infection, worse self-perceived 
health, viral load>50,000 copies/ml, and a lower mean CD4 count [85]. 
Two studies reporting on the combination of SAT and DOT modalities of treatment administration registered a 
proportion of patients transitioning from DOT to SAT (1.6% and 13.5%) much lower than that of those 
transitioning from SAT to DOT reported in one study (23.5%) [74,75]. 
Discontinuation/ adherence 
Causes of HIV treatment discontinuation and non-adherence were reported in five [68,71,73,74,85] and two 
studies [77,86], respectively. In addition to clinical reasons such as adverse effects of treatment and virological 
failure, personal reasons varied: forgetfulness, having exhausted medication or not having medication at hand, 
problems with dispensing or confusion, feeling nervous or depressed, feeling tired or being ill. 
Significant predictors of adherence were reported in six studies [68,69,72,76,77,86] and were classified as 
personal, clinical or environmental/structural factors:  
• Personal: good general/medication management, perception of the benefits of ART and acceptance of 
treatment, no depression, no fatigue, higher academic background, no IDU as risk factor for HIV 
transmission 
• Clinical: good CD4 level/viral load, absence of HIV-related symptoms, no treatment-related side effects 
• Environmental: active occupation inside prison, having flexible prison officials who would open the cell to 
make it possible to take medication when needed, having a social network, including having support outside 
prison and receiving visits, reliance on doctor and other healthcare staff. 
Attrition  
Reasons for loss to follow-up/attrition were reported in four studies and was mostly due to environmental reasons, 
i.e. transfer or release [69,70,79,80]. 
Opinions and beliefs: healthcare services in prison settings 
Of those inmates treated in a longitudinal study on usual HIV care, 60% reported having received limited support 
from healthcare staff [68].  
In two cross-sectional studies on usual care using a combination of DOT and SAT (one conducted in three prisons 
in 2002, the other in two of these prisons in 2000), 86.8% and 87.0% respectively had trust in treatment, 68.7% 
and 55.9% had trust in doctors, 57.7% and 57.7% received necessary help from doctors, and 44.4% and 43.5% 
received support in prison from professionals, other inmates, or non-governmental organisations/others [77,86].  
In another cross-sectional study on usual care with DOT and SAT [76], 29% of inmates believed that healthcare 
offered to all inmates is excellent-outstanding, approximately half of them (55%) believed the HIV-related 
healthcare they received was excellent-outstanding, 71% that the HIV doctor always listens to them, and three in 
five patients (59%) thought that the HIV doctors always understands what they are saying.  
Finally, in a cross-sectional study on usual care with DOT and SAT, 82% of females and 65% of males had high 
level of trust in their current HIV doctor, 55% of females and 72% of males had high level of trust in current HIV 
nurse, only 16% believed that taking medications for HIV was most essential for remaining healthy, but 83% had 
high level of trust in HIV medications [72]. 
Cost-effectiveness 
No studies were found on the cost-effectiveness of care models for HIV treatment in prison settings. 
Guidelines 
Six guidelines on HIV treatment were included, four of which were specific to prison settings (two supranational 
and two national guidelines), and the other two were supranational guidelines not specific to prison settings (Table 
9). See Annex 10 for a more detailed summary of relevant information. In short, these guidelines set out the 
following recommendations which are of interest for this project:   
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Table 9. Guidelines providing recommendations on HIV treatment in prison settings 
Guideline 
 
Specific to prison setting – supranational guidelines 
WHO, 2014 [7] There is evidence that ART is feasible in prison settings. One of the problems of ART is resistance. 
In addition, specific attention should be paid to adherence to the treatment. Clinical and laboratory 
follow-up is needed to monitor the response to treatment. Prevention of opportunistic infections is 
part of the treatment for HIV. 
WHO, 2007 [53] 
 
 
Providing access to ART for those in need in the context of prisons, particularly in resource-
constrained settings, is a challenge, but it is necessary and feasible. Studies have shown that when 
prisoners are provided care and access to ART, they respond well. 
Specific to prison setting – national guidelines 
UK Department 
of Health, 2011 
[55]  
All prisoners with HIV will require referral for specialist care. ART is the main type of treatment for 
HIV.  
SIMIT/Ministero 
della Salute 
(Italy), 2016 [57] 
 
ART should be offered to every HIV-infected prisoner, independently of CD4 cell count. Early 
treatment, apart from individual benefit, could result in better linkage to care of the prisoner and 
the HIV RNA reduction lowers the possibility of HIV transmission during prison stay and after 
release. ART should be provided according to the specialist prescription and as Directly Observed 
Therapy (DOT).  
Other guidelines – supranational guidelines 
WHO, 2016 [58] The use of ART for HIV in key populations should follow the same general principles and 
recommendations as for all adults. 
Special consideration should be given to ensuring that pregnant female prisoners have ready access 
to PMTCT services, as women often face greater barriers to HIV testing, counselling, care, and 
treatment in prison than outside prison. 
European AIDS 
Clinical Society, 
2017 [30] 
ART is recommended in all adults with chronic HIV infection, irrespective of CD4 counts 
ART should always be recommended irrespective of the CD4 count, but the lower the CD4 count, 
the greater the urgency to start ART immediately. 
3.3 Models of care for viral hepatitis C treatment 
A total of 34 studies reporting on HCV treatment provision in prison settings were included. Twenty-one were peer-
reviewed articles, of which seven came from the EU/EEA, eleven were conference abstracts and two were 
unpublished research reports. Of these, twenty studies reported on INF-based treatment, and the remainder on 
DAAs. No studies were retrieved reporting on HBV treatment in prison settings. The quality of the included peer-
reviewed literature studies was mostly very low. See Annex 11 for a more detailed summary of relevant 
information. 
Effectiveness 
Twenty-nine of the 34 studies reported on the effectiveness of different models of care to achieve sustained viral 
response (SVR) and completion to HCV treatment [87-115]. Of the twenty studies on INF-based regimens using 
ribavirin (RBV) and interferon (IFN), 15 studies were descriptive studies on usual care models [87,89-
94,96,99,102,103,105,110-112], including DOT, SAT or a combination. Two were comparative studies assessing 
DOT-based treatment versus SAT-based treatment [108,109]. One study reported on a telemedicine intervention to 
support treatment provision in prison settings [98]. Finally, two studies compared community-based treatment to 
prison-based treatment outcomes [88,107]. Nine studies, none from the peer-reviewed literature, reported 
descriptive data on DAA treatment in prison settings (see Table 10) [95,97,100,101,104,106,113-115]. 
Among studies investigating the older treatment regimens, the proportion achieving an SVR ranged from 28% to 
67% in studies on SAT-based usual care, from 29% to 50% in studies on the combination of DOT and SAT, and 
was 44% in the telemedicine study. The studies comparing DOT with SAT reported an SVR rate of 62%-64% with 
no significant difference between DOT or SAT models of care. The studies comparing prison-based treatment to 
community-based treatment reported an SVR rate ranging from 38% to 63% with no significant difference in 
achieving SVR between the two settings. Among studies investigating DAAs, the proportion achieving an SVR was 
higher and ranged from 85% to 95%. 
Among studies investigating the INF-based regimens, the proportion achieving HCV treatment completion ranged 
from 47% to 91% in studies on SAT-based usual care, from 46% to 98% in studies on the combination of DOT and 
SAT, and was 69% in the telemedicine study.  
Among studies investigating DAAs, the proportion of HCV treatment completion was higher and ranged from 88% 
to 96%. 
Attrition in these studies varied broadly and ranged from 6% to 50%.  
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Table 10. Evidence base for the effectiveness of different care models to achieve sustained viral 
response and HCV treatment completion in prison settings 
Intervention 
description 
Studies included  Outcome 1: SVR1  Outcome 2: 
Treatment 
completion2 
Attrition3 Level of 
evidence 
Usual care – 
SAT4  
IFN+RBV  
N=11 studies;  
7 longitudinal [89,91-94,110,112], 
follow-up [all 24 weeks/6 months after 
end treatment], sample size [79; 71; 
431; 114; 90; 32; 268] 
1 cross-sectional [102], sample size 
[162]  
1 nested case-control [90], follow-up 
[NR], sample size [185] 
2 conference abstract [99,105], 
sample size [513; 41], EU/EEA (5) 
27.6%-67.1% 46.5%-91.4% 5.8%-50.0% 
before SVR 
assessment 
All very low 
Usual care - 
Combination of 
DOT and SAT 
IFN+RBV 
N=4 studies 
4 longitudinal [87,96,103,111], follow-
up [12 months; 24 weeks; 6 months; 
24 weeks after end treatment], sample 
size [90; 50; 68; 59], EU/EEA (1) 
28.9%-50.0% 45.6%-98.3% 13.6%-
14.4% 
before SVR 
assessment 
All very low 
Comparison 
DOT vs. SAT 
IFN+RBV 
N=2 studies 
1 RCT [109], follow-up [24 weeks 
after end of treatment], sample size 
[244] 1 conference abstract [108]; 
follow-up [24 weeks after end of 
treatment], sample size [244], EU/EEA 
(2) 
Overall: 63.5%, 
62.2% 
- DOT: 60.6%, 
58.5% 
- SAT: 65.9%, 65.9% 
No significant 
difference in SVR 
between DOT and 
SAT in both studies. 
Overall: 83.0%, 
79.8% 
4.9% before 
completion of 
treatment 
Very low 
Telemedicine 
IFN+RBV 
N=1 study 
1 longitudinal [98], follow-up [24 
weeks after end of treatment], sample 
size [108], EU/EEA (0) 
43.5% 69.4% 26.9% 
before SVR 
assessment. 
Very low 
Comparison 
community-
based vs. 
prison-based 
treatment 
IFN+RBV (+ or 
– a protease 
inhibitor in n=1 
study) 
N=2 studies 
1 matched cohort [88]; follow-up [24 
weeks after end of treatment], sample 
size [1428] 1 comparative [107], follow-
up [≥24 weeks after end of treatment], 
sample size [553], EU/EEA (1). 
- Inmates: 42.9%-
73.6% 
- Community: 
38.0%-62.9% 
No significant 
difference in SVR 
between inmates and 
community members 
in n=2 studies. 
- Inmates: 
75.0%-73.5% 
- Community: 
86.6% 
No significant 
difference in 
completion 
between inmates 
and community 
members in n=1 
study. 
NR Moderate; 
low 
Provision of first 
generation 
DAAs 
N=2 studies  
2 conference abstracts [100,101]; 
follow-up [NR; NR], sample size [24; 
32], EU/EAA (2) 
62.5% eRVR (time 
period NR), 85.7% 
(as treated, time 
period NR). 
87.5% NR NA 
Provision of 
second 
generation 
DAAs 
N=7 studies 
5 conference abstracts 
[95,97,104,106,113], follow-up [12 
weeks after end of treatment in n=4; 
NR in n=1], sample size [83; 50; 40; 
142; 207] 2 unpublished research 
reports [114,115], follow-up [12 
weeks after end of treatment; NR], 
sample size [141; 23], EU/EAA (7) 
8 5.0%-98%  90.0%-95.5% 10% (time 
period NR) 
NA 
DAAs: Direct-acting antiviral agents; DOT: directly observed therapy, eRVR: extended rapid virological response4, IFN: interferon, 
NR: not reported, RBV: ribavirin, SAT: self-administered therapy, SVR: sustained viral response 
1 Proportion achieving undetectable viral load at 24 weeks/6 months after treatment completion or – in case of DAAs – 12 
weeks/3 months after DAAs therapy completion 
2 Proportion completing the treatment course  
3 Proportion lost to follow-up during study 
4 If studies on usual care did not report the use of DOT, it was assumed treatment was SAT only.  
 
                                                                    
4 eRVR indicates an undetectable viral load at week 4 of treatment and maintenance of viral load suppression through week 12 
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Acceptability and barriers 
Twenty-nine of the 34 included studies reported on the acceptability and barriers to HCV treatment in prison 
settings [87-113,116,117]. 
Acceptance 
Nine studies on HCV usual care with the INF-based regimens (some with partly DOT) reported on the proportion 
initiating treatment among HCV-positive evaluated inmates to range from 25.8% to 68.6% 
[87,90,92,94,96,103,110-112]. Compared to treated patients, untreated patients were more likely to be PWID in 
the community or to be co-infected with HBV [90]. 
In an RCT comparing INF-based treatment where RBV was administered via DOT or SAT, 7.4% of participants 
randomly allocated to DOT transitioned to SAT modality of treatment administration [109]. 
In a comparative study of HCV INF-based treatment outcomes for incarcerated versus non-incarcerated HCV-
positive patients, there was no difference in the likelihood of being started on treatment between the two groups 
(60.3% vs. 61.2%) [107]. Substance abuse, medical and psychiatric issues and patient refusal were reported 
significantly less as a reason for not initiating treatment among inmates compared to community patients. 
In a longitudinal study where nurses independently performed triage on patients for treatment and asked for 
specialist support either via discussion only, through a teleconference, or a face-to-face assessment, the shortest lead 
time from assessment to treatment initiation was found among those patients who needed a discussion with the 
specialist only (no p-value reported), indicating that nurse-led treatment may speed up treatment initiation for 
uncomplicated cases [98].  
Reasons for not initiating treatment were reported in eleven studies on IFN-based regimens only 
[87,90,94,96,98,103,107,109,110,112,116], and were categorised as personal, clinical or environmental/structural 
factors: 
• Personal: lack of motivation/awareness, fear of adverse events, influence by relatives/others, lack of 
confidence in health professionals, preference to be treated after release, medical and/or psychiatric 
contraindications including hepatic decompensation, uncontrolled HIV or diabetes disease, patient deemed 
to be non-compliant, drug use. 
• Clinical: normal transaminases, normal/mild liver biopsy. 
• Environmental: release, transfer, delays in laboratory work-up, lack of material resources.  
Discontinuation/ adherence 
Causes of HCV treatment discontinuation were reported in sixteen studies covering the IFN-based regimens 
[87,89,91-94,96,98,99,102,103,105,108-110]. In addition to clinical reasons, such as treatment side effects and 
non-response to therapy, a number of personal reasons were reported: voluntary patient withdrawal/gave up, drug 
use/addiction relapse/drug overdose, non-compliance, tuberculosis relapse, mental health issues, deceased. 
Environmental factors were frequently reported to be release or transfer. In the longitudinal study of De Juan et al., 
2014, most treatment discontinuations occurred in the first trimester of treatment, and release from prison was the 
most frequent cause for treatment discontinuation during all trimesters except the first, where the main cause was 
lack of motivation [92]. Studies on DAAs did not report on any additional factors for adherence/discontinuation. On 
the contrary, fewer reasons were reported (i.e. release, adverse events, non-response and voluntary withdrawal) 
[60,97,100,101,106,113,117].  
Significant predictors of discontinuation of INF-based treatment regimens were personal reasons: injecting drug 
use in and out of prison (p=0.006) and having cirrhosis (p=0.03), and environmental reasons – e.g. transfer 
(p=0.05) or release (p<0.01) [88,102]. 
Attrition 
Reasons for loss to follow-up were only environmental, namely release or transfer [90,98,102,112].  
Predictors of sustained viral response 
Three studies reported on various predictors of an SVR apart from having a low viral load [88,93,109]. These were 
classified as personal and environmental factors. Significant personal predictors of achieving an SVR were no IDU, 
and having no HIV infection. Not being released from prison during treatment was a significant predictor of 
achieving an SVR. 
Cost-effectiveness 
Three cost-effectiveness studies were found on HCV treatment delivery in prisons, two of moderate quality and one 
of low quality (see Table 11). 
In a US study comparing no HCV treatment to a 2-drug INF-based regimen and a 3-drug treatment with DAAs 
(sofosbuvir), the latter was likely to be cost-effective (based on incremental cost per QALY gained) for incarcerated 
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persons. However, given the high market price of sofosbuvir at the time of the analysis, affordability was flagged as 
an important consideration by the authors [118]. 
In two US cost-effectiveness studies, a strategy in which inmates with chronic HCV undergo liver biopsy and only 
those with a histologically significant liver disease undergo treatment with standard IFN and RBV was overall cost-
effective (based on incremental cost per SVR and incremental cost per QALY gained) compared to treating all 
inmates without a biopsy or elevated liver enzyme ALT [119,120]. However, the findings from these studies may 
have limited relevance now, in the light of the technological advances on non-invasive diagnosis methods and the 
advent of DAAs. 
Table 11. Evidence base for the cost-effectiveness of models of care for HCV treatment in prison settings 
Intervention 
description 
Studies 
included  
Scenarios Conclusions Level of 
evidence 
No treatment 
vs. 2 drug 
therapy vs. 3-
drug therapy 
N=1 study; 
[118], 
perspective 
[societal], time 
horizon 
[lifetime] 
EU/EEA (0) 
No treatment vs.2-drug 
therapy (pegylated IFN + 
RBV for 48 weeks) vs. 3-
drug therapy with either 
boceprevir or sofosbuvir (4 
weeks of pegylated IFN + 
RBV followed by 24 weeks of 
triple therapy) 
Short sentences (<1.5 years) 
- Sofosbuvir 3-drug therapy costs $25,700 
per QALY gained compared with no 
treatment  
Long sentences (≥1.5 years) 
- Sofosbuvir 3-drug therapy dominated 
other treatments, costing $28,800 per 
QALY gained compared with no treatment 
Sofosbuvir-based treatment is cost-
effective for incarcerated persons. Given 
the high price of sofosbuvir, affordability is 
an important consideration 
Moderate 
Treatment 
with or 
without 
elevated ALT 
or liver biopsy 
N=1 study; 
[119], 
perspective 
[Virginia 
Department of 
Corrections], 
time horizon 
[until 24 months 
after end of 
treatment] 
EU/EEA (0) 
Treating (IFN + RBV) all 
patients without a liver 
biopsy vs. treating (IFN + 
RBV) only those with 
elevated ALT without 
performing a liver biopsy vs. 
liver biopsy and examination 
of liver histology to define 
sufficient liver injury from 
chronic HCV (Knodell score 
<5 and no fibrosis) to 
warrant treatment (IFN + 
RBV) 
- Cost savings biopsy-directed strategy: 
USD 124 700 for 100 patients; incremental 
cost associated with treating all patients: 
3 334 for each additional SVR. Cost 
savings would increase to USD 408 857 
when only those with fibrosis were treated 
(69% of the cohort) 
- Cost savings ALT-directed strategy: USD 
870 191 for the 100 patients; incremental 
cost associated with treating all patients: 
USD 0 for each additional SVR 
A strategy in which inmates with chronic 
HCV undergo liver biopsy and only those 
with a histologically significant liver 
disease undergo therapy with standard 
IFN and RBV is cost-effective compared to 
treating all inmates without a biopsy or 
elevated ALT. 
Low 
Treatment 
with or 
without liver 
biopsy 
N=1 study; 
[120], 
perspective [US 
prison 
healthcare 
system], time 
horizon 
[lifetime] 
EU/EEA (0) 
No liver biopsy prior to 
starting treatment 
(pegylated IFN + RBV) vs. 
liver biopsy prior to 
beginning therapy 
(pegylated IFN + RBV) in 
order to determine stage of 
fibrosis. 
- Treatment was cost-effective based on 
cost per QALY gained compared to no 
treatment in prisoners of all age ranges 
and genotypes when liver biopsy was not 
a prerequisite to starting ART 
- Treatment after pre-treatment biopsy 
was cost-effective compared to no 
treatment in prisoners of all age ranges 
and genotypes with portal fibrosis, 
bridging fibrosis or compensated cirrhosis  
Pegylated IFN and RBV combination 
therapy is cost-effective in the prison 
population based on incremental cost per 
QALY gained. The strategy with pre-
treatment biopsy was the most cost-
effective, however not for inmates 
between 40 and 49 years old with 
genotype 1 and no fibrosis. 
Moderate 
ALT: alanine transaminase, IFN: interferon, QALY: quality-adjusted life year, RBV: ribavirin, SVR: sustained viral response 
Guidelines 
Four guidelines on HCV treatment were included, three of which were specific to prison settings (one supranational 
and two national guidelines), and the other one was a supranational guideline not specific to prison settings (Table 
12). See Annex 11 for a more detailed summary of relevant information. In short, these guidelines and documents 
set out the following recommendations which are of interest for this project:   
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Table 12. Guidelines providing recommendations on HCV treatment in prison settings 
Guideline 
 
Specific to prison setting – supranational guidelines 
WHO, 2014 [7] Diagnosis and treatment for HCV are expensive and not available in all countries. 
Assessment for HCV is very similar to assessment for HBV. In addition to assessment of the severity 
of liver disease, it includes the determination of the genotype of the virus. Both components are 
critical to treatment decisions.  
National Hepatitis 
C Strategy 2011-
2014 (Ireland) 
[121] 
The principle that treatment should be available in an equitable manner for all those infected with 
HCV. Improving access to treatment and supporting patients through treatment will reduce the 
progression from viral infection to liver damage for many patients. It should also contribute to a 
reduction in the prevalence of HCV infection, thus reducing the associated clinical and social burden 
of the disease. 
Technical Group 
of Italian experts 
on Hepatitis 
management 
(Italy), 2009 
[122] 
It is advisable to take advantage of a prison stay as a unique occasion to provide information on 
health and hepatitis in a population which is ‘hard-to-reach’ when outside the prison walls. It is 
advisable to start antiviral therapy using DOT only in prisoners with an imprisonment duration that 
allows the completion of treatment or when the linkage and continuity of care is guaranteed. It is 
also advisable to start or maintain OST with methadone or buprenorphine in active PWID in order to 
limit hepatitis transmission and reinfection. 
Other guidelines – supranational guidelines 
European 
Association for 
the Study of the 
Liver (EASL), 
2016 [34] 
The goal of therapy is to cure HCV infection to prevent hepatic cirrhosis, decompensation of 
cirrhosis, hepatocellular carcinoma (HCC), severe extrahepatic manifestations and death. 
In 2016 and onwards, IFN-free regimens are the best options in treatment-naïve and treatment-
experienced, DAA-naïve patients with compensated and decompensated liver disease, because of 
their virological efficacy, ease of use and tolerability.  
Treatment should be considered without delay in individuals at risk of transmitting HCV (active 
injection drug users, men who have sex with men with high-risk sexual practices, women of child-
bearing age who wish to get pregnant, haemodialysis patients, incarcerated individuals). 
However, more EU/EEA countries may have or be in the process of developing policies, strategy documents or 
guidelines covering prevention of HCV in prison settings and the above list may therefore not be exhaustive. 
3.4 Throughcare 
3.4.1 Throughcare at prison entrance 
No studies were found on throughcare at prison entrance (i.e. from the community to prison settings). 
3.4.2 Throughcare on release from prison 
Nineteen studies were included which reported on throughcare models of care upon release from prison. Results 
are presented separately for interventions aimed at prevention of BBVs post-release, and interventions aimed at 
linkage to care post-release. Most interventions were focused on HIV. See Annex 12 for a more detailed summary 
of relevant information. 
3.4.3 Prevention of blood-borne viruses post-release 
Eight studies reporting on prevention of BBV infections post-release were included from the peer-reviewed 
literature, all from outside the EU/EEA [123-130]. No conference abstracts were found on this topic. The study 
quality of the peer-reviewed literature was mostly low to very low, even though most studies were RCTs. 
Effectiveness 
All eight included studies reporting on effectiveness of interventions to prevent BBVs post-release (see Table 13). 
The included studies investigated a range of different interventions, with three studies covering more individually-
oriented interventions [123,126,130], and five covering group-oriented interventions [124,125,127-129]. The 
interventions were multifaceted and included counselling, case management, peer- or regular education, skills 
building, social support, and relationship-focused contents. As there was considerable heterogeneity between these 
interventions, and different comparison groups were used, it was not possible to group the studies or perform a 
meta-analysis. 
Overall, none of the studies included reported on seroconversion after the introduction of a BBV prevention 
intervention as a study outcome. Studies investigated a range of different behaviour outcomes, while similar 
behaviour outcomes were often investigated differently between studies. Overall, in all but one comparative study, 
the interventions resulted in greater improvements for several of the measured behavioural outcomes compared to 
usual care. However, this was not the case for all measured outcomes. In general, in almost all comparative 
studies, unprotected sexual intercourse was less frequent in the intervention group than in the control group, while 
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generally no difference was found in drug-injecting behaviour and likelihood of sharing injecting equipment 
between intervention and control groups. One study did not find a significant difference between the intervention 
group and control group in any of the outcomes [129]. In this study, which is quite old, the intervention group 
consisted of four educational group sessions before release while the control group received no education at all.  
Attrition in these studies ranged from 17% to 49% in intervention groups, and from 18% to 56% in control groups. 
Table 13. Evidence base for the effectiveness of interventions to prevent BBVs post-release 
Intervention 
description 
Studies included  Outcome 
1: sero-
conversion 
Outcome 2: behaviour change Attrition1 Level of 
evidence 
Individual counselling 
and case management 
services (7 modules 
before release) 
N=1 study; 
Longitudinal study 
[123], follow-up 
[NR], sample size 
[745], EU/EEA (0) 
NR Significant improvement after 
intervention in: attitude towards 
condoms, self-efficacy to use 
condoms, self-efficacy to reduce 
IDU and other substances risk, 
safe sex intentions and likelihood 
having HIV/AIDS. 
NR Very low 
Individual 30-minute 
peer-education session 
before release vs. no 
intervention 
N=1 study;  
RCT [126], follow-
up [2 weeks after 
release], sample 
size [404] 
EU/EEA (0) 
NR After release, intervention group 
significantly more condom use 
during first time sex after release 
compared to control, but no 
significant difference in drug use, 
IDU and sharing injecting 
equipment since release 
- Inter-
vention: 
42.5%  
- Control: 
42.0% 
Very low 
Individual enhanced 
multisession 
intervention (2 before, 
4 after release) vs. 
individual single-
session intervention 
(before release) 
N=1 study;  
RCT [130], follow-
up [24 weeks after 
release], sample 
size [522] EU/EEA 
(0). 
NR 24 weeks after release, 
significantly less unprotected sex 
with any partner, main partner, 
and at-risk partner, but not with 
non-main partner in enhanced 
intervention compared to single-
session intervention group. 
No significant differences at 1 and 
12 weeks post-release. 
- Single 
session: 
17.8%  
- Other: 
16.7% 
Low 
Group sessions skills 
building and social 
support intervention 
(16 before, 6 after 
release) vs. standard 
care (3 AIDS 
information group 
sessions before 
release) 
N=1 study;  
RCT [124], follow-
up [1 month after 
release], sample 
size [145], EU/EEA 
(0) 
NR Significantly greater improvement 
post-release in the intervention 
group compared to standard care 
in safer sex behaviour, coping 
skills, and perceived emotional 
support, but no significant 
difference between groups in 
perceived vulnerability to HIV, 
sexual self-efficacy and AIDS 
knowledge  
- Inter-
vention: 
26.9%  
- Control: 
33.3% 
Very low 
Group sessions 
behavioural 
intervention (9 before, 
3 short phone calls 
after release) vs. 
standard care (single 
STI education in 1st 3 
months of 
incarceration). 
N=1 study;  
RCT [125], follow-
up [6 months after 
release], sample 
size [521]  
EU/EEA (0). 
NR Significantly more improvement 
post-release in intervention group 
compared to standard care in HIV 
knowledge, health-protective 
communication, motivational 
barriers to condoms, physical 
spousal abuse (all at 3 months 
after release), and unprotected 
vaginal sex outside monogamous 
relationships, condom use during 
sex with main partner, HIV 
knowledge, motivational, partner 
and physical effect barriers to 
condom use, and tangible support 
(all at 6 months after release). 
See summary table for non-
significant differences. 
- Inter-
vention: 
40.4% 
- Control: 
44.5% 
Moderate 
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Intervention 
description 
Studies included  Outcome 
1: sero-
conversion 
Outcome 2: behaviour change Attrition1 Level of 
evidence 
Group sessions 
relationship-focused 
intervention (5 before, 
1 after release) vs. 
standard care (short 
HIV/AIDS information 
video) 
N=1 study;  
RCT [127,128], 
follow-up [90 
days], sample size 
[378/344] EU/EEA 
(0) 
NR Intervention group reported post-
release significantly fewer past-
month unprotected sexual 
behaviours than control group; 
greater improvement in 
intervention group in overall HIV 
knowledge of HIV risk behaviours, 
self-esteem, sexual relationship 
power, relationship control, 
specific HIV risk knowledge items, 
and specific myths. See summary 
table for non-significant 
differences. 
9% Low 
Group educational 
sessions intervention 
(4 before release) vs. 
standard of care (no 
health education) 
N=1 study;  
Comparative 
[129], follow-up 
[median 7months 
after release], 
sample size [101] 
EU/EEA (0) 
NR No significant difference at post-
release between both groups in 
drug injection, needle/syringe 
sharing and sterilisation, heroin 
use, crack use, multiple sexual 
partners, high-risk sexual 
partners, condom use, and 
enrolling or remaining in drug 
dependency treatment. 
Being in drug dependency 
treatment at the time of follow-up 
was associated with reductions in 
heroin use and drug dealing 
- Inter-
vention 
48.5%  
- Control: 
55.6% 
Very low 
NR: not reported, RCT: randomised controlled trial 
1Proportion lost to follow-up during study. 
Acceptability and barriers 
Seven of the eight studies included reported on barriers and acceptance to the prevention interventions [123-
128,130]. 
In a longitudinal study evaluating an individual counselling and case management intervention, completion rates 
per mandatory module varied from 21.2% to 95.8%, and 88% of participants completed ≥2 mandatory modules, 
but only 39% completed three or four modules [123]. Despite the goal of individualised attention, participants 
completed more modules and spent more programme time in group sessions. 
In an RCT comparing an individual 30-minute peer-education session to no session, 19% refused to participate 
(reasons not reported), and only 60.3% of those randomised to the intervention group, received the intervention 
[126]. Reasons for this were: failure to appear for their intervention appointment (not further specified), unable to 
attend due to institutional lock-downs, or unexpectedly paroled (percentages not reported).  
In an RCT comparing an enhanced individually-focused intervention (two sessions before release and four after 
release) to a single-session intervention before release, 5.2% refused to participate (reasons not reported) [130]. 
Attendance of the enhanced intervention sessions was 88.6%-98.5% for the pre-release sessions and 65.8%-
79.8% after release; 18.6% chose to receive additional sessions. Attendance was 94.2% for the one session in the 
single-session intervention.  
El Bassel et al. 1995 compared a skills building and social support group intervention (16 sessions before release, 
six sessions after release) with an information group intervention (three sessions before release) [124]. In the skills 
building and social support group intervention 52.2% attended ≥13 sessions, 28.4% 4-12 sessions, and 19.4% 
attended ≤3 sessions. In the information group intervention 85.9% attended all three sessions. 
Fogel et al. 2005 compared a behavioural group sessions intervention (nine sessions before release, short phone 
calls after release) to standard care (STI education in first three months of incarceration), and found that 12.0% 
refused to participate (reasons not reported), and 12.8% of participants did not attend any of the behavioural 
group sessions [125].  
In an RCT comparing a relationship-focussed group sessions intervention (five sessions before release, one after 
release) with standard care (short HIV/AIDS informational video), 4.3% of screened women refused to participate 
(reasons not reported) [127,128]. 
Although most studies reported attrition during the study, none reported the corresponding reasons.  
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Cost-effectiveness 
No studies were found on the cost-effectiveness of interventions to prevent BBVs post-release.  
Guidelines 
No specific guidelines have been found on BBVs prevention post-release. 
3.4.4 Linkage to care post-release 
Eleven studies reporting on linkage to care post-release were included from the peer-reviewed literature, all from 
outside the EU/EEA. No conference abstracts were found on this topic. The study quality of the peer-reviewed 
literature was mostly low to very low, even though half were RCTs. All but three studies focused on HIV.  
Effectiveness 
Eight included studies reported on effectiveness of interventions to increase linkage to care post-release for HIV 
treatment (see Table 14) [131-138]. As a large heterogeneity exists between these interventions, and different 
comparison groups were used, it was not possible to group the studies nor to perform a meta-analysis. 
One RCT compared an ecosystem intervention with an individually focused intervention. The participants in the 
ecosystem group were significantly less likely to be taking anti-HIV medication and to be adherent at four months 
post-release, but no significant difference was observed in groups and between groups at eight and twelve months 
post-release [134]. No significant difference was observed in sexual behaviour after release in the two groups. 
Two studies compared an individual-level intervention with usual care, one focusing on education and skills building 
[133] and the other on intensive case management [136]. The two studies did not find significant differences 
between intervention and control groups in adherence to HIV treatment, accessing HIV and outpatient substance 
abuse services in the community after release. Moreover, no significant difference between both groups was found 
on sexual behaviour, STIs occurrence and injecting drug use after release. 
One comparative study assessed the impact of a multifaceted intervention involving education, individual 
counselling, discharge planning, and being met at the gate or soon after release by a case manager [132]. Those 
being met at the gate by a case manager were significantly more likely to access drug/alcohol treatment in the 
community and engaged significantly less in sex exchange and street drug use, compared to those not being met 
at the gate. Another comparative study assessed the impact of retention in OST for PWID on ART after release. 
Those on OST (with buprenorphine) were significantly more likely to achieve viral suppression than the other 
groups [138]. 
In a descriptive study of usual care, inmates were actively referred to community health care services and received 
a medication supply prescription at release. However, only 71% of those who were give a prescription collected it 
before release. A follow up among those individuals subsequently re-jailed showed that 46% had accessed HIV 
care services in the community [135]. In another descriptive study of usual care, 58% were linked to care in the 
community [131]. No significant association was found between length of incarceration and linkage to care. 
Another descriptive study [137] reported similar proportion of HIV visit attendance post-release. Retention in care 
post-release was higher among male individuals having an HIV care provider before incarceration and receiving 
individual support services before release (e.g. disease management session and discharge planning) and in the 
community (e.g. needs assessment, HIV education, and transportation assistance). 
Finally, three similar RCT assessed the impact of induction on OST during imprisonment on linkage and retention in 
drug-dependence community programmes [139-141]. The studies concurrently reported a significantly higher 
likelihood of enrolment and retention in OST programmes for those who received OST while in prison.  
Attrition in these studies ranged from 3% to 46%. 
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Table 14. Evidence base for the effectiveness of interventions in increasing linkage to care post-release 
Intervention 
description 
Studies included  Outcome 1:  
Linkage to care 
Outcome 2:  
Behaviour 
change 
Attrition1 Level of 
evidence 
HIV treatment 
Ecosystem vs. 
individually 
focused (both 
medication supply 
at release) 
N=1 study; 1 RCT 
[134], follow-up [12 
months post-
release], sample 
size [151] EU/EEA 
(0). 
Ecosystem significantly less 
likely to be taking anti-HIV 
medications and to be adherent 
at four months post-release 
(both groups significant 
decrease vs. baseline), but no 
significant difference in groups 
and between groups at eight 
and 12 months post-release. 
No significant 
difference 
between both 
groups in sexual 
behaviour after 
release. 
15% Moderate 
Individual-level 
educational and 
skills-building 
intervention vs. 
usual care 
(medication supply 
at release NR). 
N=1 study;  
1 RCT [133], 
follow-up [3 
months post-
release], sample 
size [73], EU/EEA 
(0). 
No significant change in taking 
HIV medication from time of 
release to three months post-
release in both groups and 
between groups.  
Intervention recipients reported 
a statistically significant increase 
in receiving healthcare at HIV 
clinics at 3-month post-release 
(62.5–84.4 %); no significant 
difference between groups. 
No significant 
change in 
unprotected 
vaginal or anal 
sex, IDU, and STI 
diagnosis from 
three months pre-
incarceration to 
three months 
post-release 
between groups. 
14%-25% Low 
Individual-level 
intensive case 
management vs. 
usual care (both 
30-day medication 
supply at release). 
N=1 study;  
1 RCT [136], 
follow-up [48 
weeks post-
release], sample 
size [89], EU/EEA 
(0). 
No significant difference 
between both groups in % 
medical care access ≥once, 
median time to clinic access, 
mean number of clinic visits, 
rate of hospitalisations, ER or 
urgent care centre visits, and 
outpatient substance abuse care 
post-release. 
NR 40%-46% Low 
Being met at the 
gate vs. not being 
met at the gate, 
(both education, 
counselling and 
discharge 
planning, 
medication supply 
on release NR). 
N=1 study; 1 
comparative 
[132], follow-up [6 
months post-
release], sample 
size [226], EU/EEA 
(0) 
Those being met at the gate 
participated significantly more in 
drug/alcohol treatment after 
release than those not met at 
the gate. 
After release those 
met at the gate 
were significantly 
less engaged in 
sex exchange and 
use of street drugs 
than those not 
met at the gate. 
35% Very low 
Provision of OST 
for PWID on ART 
vs. no OST (ART 
administered 
either DOT or 
SAT). 
N=1 study; 
1 comparative 
[138], follow-up [6 
month post-
release], sample 
size [94], EU/EEA 
(0). 
Retention on OST 
(buprenorphine) was 
significantly associated with 
increased likelihood of achieving 
viral suppression (<50 
copies/ml) (p=0.03), receiving 
DOT or methadone were not 
associated with viral 
suppression post-release. 
NR 8% Low 
Usual care (active 
referral after 
release, with or 
without 
medication 
supply). 
N=2 study; 2 
longitudinal 
[135,137], follow-
up [NR, 6-month], 
sample size [77; 
867], EU/EEA (0). 
In total, 69% received 3-day 
supply prescription, of whom 
71% picked it up; 46% of those 
re-jailed received HIV 
medications in community. In 
total, 61% had an appointment 
with a community HIV care 
services; 58% attended HIV 
care in the first 3 months; 475 
in the second 3 months post 
release; 38% attended twice in 
6-month period. 
NR NR Very low 
Usual care 
(referral after 
release only, 
unclear if active or 
passive) 
N=1 study;  
1 longitudinal 
[131], follow-up 
[NR], sample size 
[64], EU/EEA (0). 
In total, 58% linkage to care 
No significant association 
between length of incarceration 
and linkage to care. 
 
 
NR NR Very low 
TECHNICAL REPORT  Systematic review on the prevention and control of blood-borne viruses in prison settings 
36 
Intervention 
description 
Studies included  Outcome 1:  
Linkage to care 
Outcome 2:  
Behaviour 
change 
Attrition1 Level of 
evidence 
Opioid Substitution Treatment 
No OST in prison 
without (Group 
1)/with (Group 2) 
referral to 
community OST vs 
OST in prison and 
referral.  
N=1 study;  
1 longitudinal 
[139], 
follow-up [12-
month], sample 
size [204], EU/EEA 
(0) 
-Group 1:25% enrolled in care; 
0% were on OST at 12-month 
-Group 2: 53.6% enrolled in 
care; 17.3% were on OST at 
12-months. 
-Group 3: 70.4% enrolled in 
care; 36.7% were on OST at 12 
months. 
Pair-wise comparison all 
significant (p<0.01) 
Positive urine test 
for opioid at 12-
month post-
release: 
-Group 1: 65.6% 
-Group 2: 48.7% 
-Group 3: 25% 
Group 3 
significantly less 
as compared to 
Group 1 & 2. 
3.3% Low 
No OST in prison 
with referral to 
community OST vs 
OST in prison and 
referral. 
N=1 study;  
1 RCT [140], 
follow-up [12-
month], sample 
size [211], EU/EEA 
(0). 
Participants in the in-prison BPN 
group were significantly more 
likely (p=0.012) to enrol into 
community OST programmes 
(47.5% vs. 33.7%). 
No statistically 
significant 
difference for days 
of heroin use and 
crime, and opioid 
and cocaine 
positive urine 
screening test 
results (all 
Ps>0.14)  
NR Low 
OST in prison and 
financial support 
(Arm 1) vs. no 
OST in prison with 
(Arm 2)/without 
(Arm 3) financial 
support. 
All participants 
received referral. 
N=1 study;  
1 RCT [141], 
follow-up [6-
month], sample 
size [90], EU/EEA 
(0). 
Participants on OST prior to 
release were significantly more 
likely to enter treatment post 
release (P < 0.001). 
Among participants who 
enrolled in community OST, 
those who received OST in 
prison did so within fewer days 
(P =0.03). 
Participants on 
OST prior to 
release reported 
less heroin use (P 
= .008), other 
opiate use (P 
= .09), and 
injection drug use 
(P = .06) at six 
months. 
30% Very Low 
BNP: Buprenorphine, ER: emergency room, OST: Opioid Substitution Treatment, NR: not reported, RCT: randomised controlled 
trial 
1Proportion lost to follow-up during study. 
Acceptability and barriers 
Among the four studies reporting on attrition, only two reported the relevant reasons, which were release/transfer 
and loss to follow-up (not further specified) [132,136].  
In two intervention studies, the intervention did not proceed according to plan. In the RCT comparing an 
ecosystem intervention to an individually focused intervention, 28% of those in the ecosystem group did not 
succeed in identifying a support person to participate in the intervention [134]. In the comparative study, where 
the protocol indicated that a case manager meets the inmate soon after release, only 46% were successfully met 
at the gate (reasons not reported) [132].  
In a longitudinal study, 72% of those eligible for HIV treatment, were on treatment in jail, while 15% refused 
therapy (reasons not reported), 6% were scheduled for release before receiving therapy, and an additional 7% did 
not receive the treatment for unreported reasons [White, 2001]. A total of 29% of those on treatment at the time 
of release did not receive a prescription as per protocol, either because they were transferred to a residential drug 
treatment programme or were released early. 
Cost-effectiveness 
No studies were found on the cost-effectiveness of interventions to increase linkage to care post-release.  
Guidelines 
Seven guidelines that reported on throughcare were included, five of which were specific to the prison setting (two 
supranational and three national guidelines). One was a supranational document not specific to prison settings, 
and one was a national document not specific to prison settings (Table 15). See Annex 12 for a more detailed 
summary of relevant information. In short, these guidelines set out the following recommendations which are of 
interest for this project.  
  
TECHNICAL REPORT  Systematic review on the prevention and control of blood-borne viruses in prison settings 
37 
Table 15. Guidelines providing recommendations on throughcare at release (linkage to care) 
Guidelines 
 
Specific to prison setting – supranational guidelines 
WHO, 2014 
[7] 
For both HIV and hepatitis C, continuity of treatment is essential to ensure the best outcomes and 
prevent the development of resistance. Health programmes in prisons should therefore work in close 
collaboration with the HIV programme in the community to ensure that treatment is not interrupted 
when people enter and leave prison. 
WHO, 2007 
[53] 
Ensuring continuity of care from the community to the prison and back to the community, as well as 
continuity of care within the prison system is a fundamental component of successful efforts to scale up 
treatment.  
Specific to prison setting – national guidelines 
SIMIT/ 
Ministero 
della Salute 
(Italy), 2016 
[57] 
 
Assure the linkage of HIV infected prisoners to the local Infectious Diseases (ID) division and arrange a 
calendar of weekly visits. In order to assure continuity of care, at least seven days of ART treatment 
should be given to the prisoner upon release. 
In order to guarantee continuity of care (50% of prisoners do not show up at the specialist visit after 
release), the referral ID specialist must be involved in outpatients’ networks present in the community. 
SAMHSA, 
2017 [142] 
Guideline 5: Anticipate that the periods following release (the first hours, days, and weeks) are critical 
and identify appropriate interventions as part of transition planning practices for individuals with mental 
health and co-occurring substance use disorders leaving correctional settings. 
National 
prison 
services 
(Czech 
Republic), 
2012 [143] 
Introduce standardised systems to inform prisoners about drug services provided in the prison by 
specialised providers, including NGOs; and to set up the system to ensure access to service 
- Implement a referral system within the prison system for drug services. 
- Set up a catalogue of services outside the prison system, that is also taking care of prisoners post-
release. 
- Intensify cooperation of the prison HCW providing drug services with regional antidrug coordinators 
and ensure linkage to care after release. 
- Implement interventions in overdose prevention and other risks in the post-release period. 
- Implement on obligatory bases referral to specialised drug dependency care units and drug free zones 
programmes for individuals after release. 
- Include prevention of relapse in therapeutic programmes. 
- The prison needs to provide medical records/treatment report to the individual’s request upon release.  
- In case of treatment ordered by court (coercive treatment), there should be a specialised methodology 
for wards that are implementing this. 
- Notification of drug test results, including negative results, performed on people in detention should be 
recorded. 
- Prisoners can be required to be included in a regime of intensive random testing for drug use.  
- Drug counselling should be available in every prison. 
- OST should be implemented in prison by specialised wards according to national standards. OST can be 
coercive (ordered by court) or voluntary. Patient should be informed about OST regimen and about 
continuation of treatment in the community. Patient can choose from a set of specialised institutions the 
preferred one/the one closed to his/her place of residence. Standard referral process is then initiated by 
the prison 
Other guidelines – supranational guidelines 
WHO, 2016 
[58] 
If and when transferred, people in prisons and other closed settings should be given a supply of ART to 
last until healthcare can be established at the new prison location or, if they are being released, until 
linkage can be made to community-based HIV care. 
Other guidelines – national guidelines 
Department 
of Health 
(UK), 2017 
[41] 
It is the responsibility of the prison healthcare/drug team to ensure that the community 
service/prescriber is notified of a patient’s release from prison. The patient should be reviewed in the 
community drug service on Day One whenever feasible, or otherwise within days of discharge. For 
unplanned weekend release (including short-term release on temporary licence), a community 
pharmacist should be located to provide an interim dispensing service and a prescription should be 
provided to the patient on release requesting supervised daily dispensing as preferable.  
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4. Discussion 
4.1 Main findings 
This systematic review provides an overview of the best available evidence in the peer-reviewed and grey literature 
on prevention and control of BBVs in prison settings. Below, the main findings from the peer-reviewed literature 
and grey literature are summarised.  
4.1.1 Prevention of transmission of blood-borne viruses 
Five peer-reviewed articles and one conference abstract were included reporting on a few prevention interventions 
such as condom provisions, health promotions initiatives and safe tattooing. Additional prevention measures such 
as active case finding and HBV vaccination were covered elsewhere [24] [ECDC unpublished].  
According to the literature, condom distribution was implemented either via vending machines located in various 
places within prison premises or handed out regularly by staff. Overall, regardless of condom provision modalities, 
11–28% of inmates reportedly used condoms through these programmes, but not necessarily for sex [45]. 
Condom use was estimated to reduce HIV transmission by 25% and be cost-saving in one cost-effectiveness study 
[48]. Overall, condom distribution was supported by 55–84% of inmates. Although no major incidents were 
reported during the programmes, concerns were raised over possible increase in sexual activity and the 
inconsistent message of condom availability with the prohibition of sex in prison.  
Safe tattooing in prison was shown to be acceptable for people in detention in one study, however no infection-
related outcomes were reported to assess the effectiveness on the measure in reducing infection transmission [46]. 
Two RCTs investigated a combination of health promotion and skills-building interventions and their impact on HIV 
knowledge and behaviour outcomes. While one study comparing six weekly group behaviour sessions to usual care 
(didactic lectures) revealed greater improvements in all measured HIV knowledge and behaviour outcomes [47], 
another older study comparing six weekly skills building group sessions to unstructured discussion group sessions 
showed conflicting results [50].  
Comparing the results of individual studies is challenging, since the included studies investigated different 
prevention strategies (i.e. condoms, safe tattooing, a group behaviour intervention and a group skills-building 
intervention), using different outcomes, follow-up durations and comparison groups (if any), and among different 
study population sizes and study settings. Due to this heterogeneity, it is hard to draw conclusions based on the 
studies included on which prevention intervention should best be implemented in prison settings.  
On the other hand, a number of supranational and national guidelines were identified providing recommendations 
on prevention for BBVs in prison settings. Based on the existing evidence in prison settings and, by analogy, in 
community settings, these documents promoted a comprehensive basket of prevention measures, including, over 
and above the interventions listed above, prevention of mother-to-child transmission for pregnant women, pre- and 
post-exposure prophylaxis as well as infection control measures to prevent iatrogenic transmission (safe health 
care services). 
Prevention of injecting-related infections among people who inject drugs 
Six studies were included, reporting on the prevention of injecting-related infections in prison settings and covering 
NSP and provision of OST in prison settings. No studies were retrieved reporting on prevention of injecting-related 
infections other than BBVs.  
Two comparative studies on OST found no difference in HIV and HCV seroconversions between the OST and the 
control groups [59,60], possibly due to the study sample size not being powered to detect meaningful changes in 
HIV or HCV incidence. However, periods of imprisonment of less than two months and being on OST for less than 
five months were both significantly associated with increased risk of HCV seroconversion [60]. Moreover, compared 
to community settings, OST dropout risk was higher in prison during short sentences (≤1 month), and lower during 
longer (>4 months) sentences. Finally, according to a cost-effectiveness study OST programmes in prison are no 
more costly than community-based programmes [64].  
The studies reporting on NSP were heterogeneous with two assessing NSP programmes implemented in single 
prison institutions [61,62], and one reporting on a country-wide prison NSP programme [63]. Clean injecting 
equipment was either distributed through vending machines located within prison premises, or by healthcare staff, 
and based on one-to-one exchange. HCV seroconversions were reported in one of the two single-institution studies 
and attributed to sharing of injection paraphernalia; no HIV or HBV seroconversions were reported. In the country-
wide study, a reduction in HCV and HIV prevalence in the prison population over a period of more than 15 years 
was reported, however such reduction is likely to be the result of a comprehensive basket of prevention measures 
targeting PWID, including OST, in community and prison settings. It is noteworthy that prison staff and, to a less 
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extent, people in detention, reported concerns about prison security following the distribution of needles and 
syringes and were not persuaded of the need for such a measure.  
Overall, the evidence on the effectiveness of NSP and OST measures to control BBVs transmission in prison 
settings is limited, mostly due to study designs largely aiming to assess the impact of prevention interventions on 
drug use and injecting behaviour rather than on communicable disease transmission. However, a substantial body 
of evidence regarding these interventions exists from community settings5 showing the effectiveness of combined 
and up-to-scale NSP and OST programmes on disease incidence, which may be considered valid, by analogy, in 
prison settings, given the necessary implementation considerations.  
Along these lines, existing UN-system guidelines recommend the implementation of OST programmes in prison 
settings and the provision of clean and sterile injecting equipment via NSP [7,25,52,58].  
4.1.2 HIV treatment 
Sixteen studies from the peer-reviewed literature, six of which were from the EU/EEA, and five conference 
abstracts were included reporting on HIV treatment in prison settings. No cost-effectiveness studies were found.  
The studies reported largely on two models of care, SAT and DOT, for the provision of ART in prison settings, 
implemented either separately or in combination, based on patients’ needs. Two non-EU/EEA comparative studies 
found no significant difference in the two main treatment endpoints, adherence and viral suppression, between the 
two treatment provision modalities [79,80], while another study from Italy reported a significantly higher 
proportion of individuals achieving viral suppression among those receiving ART via DOT [81]. It is worth noting 
that two studies reported on patients voluntarily transitioning from SAT to DOT modality of ART provision and vice 
versa, which may be suggestive of changing preference over time [74,75].  
Another comparative study assessed the introduction of a telemedicine approach to improve HIV quality of care in 
prison settings [82]. A significant increase in the likelihood of achieving viral suppression was found in the 
telemedicine group compared to the usual care group, which may indicate this to be a potentially effective 
approach in the absence of direct access to HIV specialised care in prison settings. 
Overall, all studies reported sufficiently high ranges of treatment adherence and levels of viral suppression when 
ART was provided in prison settings, indicating a good feasibility of HIV treatment implementation in correctional 
facilities. The proportion of HIV treatment acceptance among those eligible was reasonably high (73–80%) 
[72,76,77]. Significant personal predictors of treatment adherence were good general or medication management, 
perception of the benefits of ART and acceptance of treatment, no depression or fatigue, higher academic 
background, and no IDU as risk factor for HIV transmission. Significant environmental predictors were active 
occupation inside prison, having supportive prison officers (i.e. willing to open cell to let prisoners take pills), 
having a social network inside and outside prison and trust in healthcare staff. 
In conclusion, while there is sufficient evidence to support HIV treatment implementation in prison settings, no 
definitive conclusions can be drawn based on the available evidence on treatment models of care to be best 
implemented in prison settings.  
A number of supranational and national guidelines have been retrieved recommending the provision of ART to 
detained HIV-positive individuals by the same standards as in the community. This includes the initiation of ART 
irrespective of CD4 count at diagnosis [30].  
4.1.3 Viral hepatitis treatment 
Twenty-one studies (seven from the EU/EEA), eleven conference abstracts and two unpublished research reports 
were included reporting on HCV treatment implementation in prison settings, while no study was retrieved on HBV 
treatment.  
The majority of the included studies described provision of IFN-based regimens for the treatment of HCV, using 
SAT, DOT, or combination of the two as main models of care delivery. One study reported on the introduction of a 
telemedicine approach to provide specialised care in one prison [98]. Two comparative studies found no significant 
difference in the two main treatment endpoints, treatment completion and SVR, between SAT and DOT models of 
care provision [108,109]. Alternative clinical protocols were assessed in two similar economic evaluation studies. 
The studies concurred that performing a liver biopsy before starting IFN-based treatment is likely to be a cost-
effective approach compared to treating all patients [119,120], however this approach may be superseded with the 
advent of new non-invasive diagnostic technologies to assess liver disease stage (i.e. transient elastography). 
When assessing the impact of the setting (community vs prison) on treatment initiation, completion and outcome, 
two comparative studies found no significant difference between the two groups, unless patients were released or 
 
                                                                    
5 Refer to EMCDDA Best Practice portal for an overview of the most recent available evidence: 
http://www.emcdda.europa.eu/best-practice/harm-reduction/opioid-injectors 
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transferred from prison while on treatment [88,107]. Similarly, release or transfer was reported as a major 
predictor of treatment discontinuation in a number of studies, alongside IDU in and out of prison and having 
cirrhosis. Furthermore, the acceptance of IFN-based regimens varied widely (26–69%), as reported in nine studies 
[87,90,92,94,96,103,110-112]. 
The recent advent of DAAs has opened up new opportunities for the treatment and cure of HCV, in the community 
as well as in prison. Due to the recent developments in the field, only grey literature sources were retrieved 
reporting on DAA provision in prison. According to those, and as observed in the community, the proportion of 
detained patients achieving SVR was much higher (85–98%) compared with IFN-based regimens (42.8-73.6%). 
These studies indicate a good feasibility for DAA provision in prison settings, while a US cost-effectiveness study 
suggests that HCV treatment with DAAs is cost-effective for incarcerated persons compared to no treatment or 
treatment with older regimens [118]. 
The studies included investigated diverse sets of factors associated with treatment adherence, completion and SVR 
(e.g. different treatment regiments, adherence interventions). It is challenging to determine the relative effect of 
each single factor, as they were often investigated in combination, used among different populations, and applied 
in different settings. However, the available evidence shows that HCV treatment in prison settings is feasible and 
the introduction of DAAs will result in better treatment outcomes for the prison populations, given the caveat of 
affordability. 
A number of national and supranational guidelines recommend treatment for HCV in the prison settings, with at 
least one document listing detained individuals as one of the priority groups for treatment initiation on the basis of 
the risk of further transmission [34].  
4.1.4 Throughcare 
Nineteen studies, all from outside the EU/EEA, were included reporting on throughcare, and no economic 
evaluation was retrieved. While throughcare encompasses the two transition periods of admission to and release 
from prison, all retrieved studies only reported on the latter.  
A number of comparative studies described and reported on the impact of behavioural and skills-building 
interventions aimed at improving BBV prevention post-release [124-130]. In most cases the interventions resulted 
in significant improvements in several behavioural outcomes, such as occurrence of unprotected sexual intercourse, 
compared to usual care. However, this was not the case for all measured outcomes, including some specifically 
relevant ones such as IDU and sharing needles. In general, interventions were well accepted with low rates of 
refusal. Attendance at intervention sessions varied widely and different measures were used, however it was 
reported to be higher for pre-release sessions [130].  
Linkage to HIV care post-release was investigated in five comparative studies assessing the impact of a range of 
interventions, from individual education and skills-building programmes to active referral, intensified case 
management and retention on OST [132-134,136,138]. A study describing an intensified post-release case 
management approach (being met at the gate by a case manager) showed a significantly higher likelihood of 
participation in drug/alcohol treatment and significantly less engagement in sex exchange and street drug use in 
the intervention group compared with the control group [132]. A study reported that retention on OST post release 
was associated with better treatment outcome, such as viral suppression [138]. No significant difference was 
reported in access to HIV care or substance abuse services, and adherence to HIV treatment post-release between 
intervention and control groups in the other studies. Other studies described usual care approaches such as active 
referral to community healthcare services, including provision of drug prescription to the patient upon release 
[131,135]. 
Linkage to and retention on drug dependency treatment post-release was investigated in three RCTs assessing the 
impact of induction on OST pre-release [139-141]. All studies showed increased likelihood of enrolment and 
retention in OST programmes among those receiving OST pre-release. 
Based on the available evidence, it is hard to draw conclusions on the intervention to be best implemented in 
prison settings, since all studies investigated different intervention and prevention strategies and comparison 
groups (or none at all), among different populations and applied in different settings, using diverse outcomes over 
variable follow-up periods.  
Linkage to care post-release is identified as a key step in providing continuity of care in several national and 
supranational guidelines. In particular, these documents stress the responsibility of the prison healthcare system for 
designing and implementing effective referral pathways to guarantee linkage and promote access to adequate care 
after release to avoid treatment discontinuation, including HIV, OST and viral hepatitis.  
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4.2 Knowledge gaps 
4.2.1 General gaps 
Overall, this review highlighted a large heterogeneity among studies in both the peer-reviewed and grey literature, 
making comparisons and conclusions difficult. Moreover, a substantial part of the research was carried out in the 
USA, which raises concerns on the applicability of the findings to the EU/EEA situation. More well-designed 
comparative studies are needed on the effectiveness and impact of the different prevention and control strategies 
for BBVs in the EU/EEA. Moreover, implementation research is needed to report on the operational aspects of 
intervention set-up, implementation and impact in EU/EEA prison settings.  
Topic-specific knowledge gaps are outlined below. 
4.2.2 Topic-specific gaps 
Prevention of blood-borne viruses 
Hardly any data were available on the effectiveness, acceptability and cost-effectiveness of prevention of BBVs in 
prison settings, especially in the EU/EEA. No studies were found reporting on the outcome seroconversion after the 
introduction of a BBV prevention intervention. The evidence was largely focused on HIV, and the included studies 
covered very few of the available prevention interventions (e.g. pre- or post-exposure prophylaxis, safe piercing, 
sharing everyday items, etc. were not covered).  
Prevention of injecting-related infections among people who inject drugs 
Very few studies were found that reported on direct infection outcomes of prevention interventions among PWID in 
prison settings. Only one cost-effectiveness study was found. The studies included covered no alternative 
prevention interventions other than NSPs or OST. Finally, no evidence was found on prevention of other injecting-
related infections, such as bacterial infections at the site of injections. 
HIV treatment 
Literature on HIV treatment in prison settings was sizeable, although largely using a descriptive design and from 
non-EU/EEA countries. No cost-effectiveness studies were found.  
Viral hepatitis treatment 
No evidence was identified on treatment for HBV in prison settings. In the peer-reviewed literature, no evidence 
was found on provision of DAAs in prison settings, with the exception of one cost-effectiveness study. Hardly any 
comparative studies were retrieved that could support decision-making on models of care to deliver HCV treatment 
in prison settings to achieve treatment completion and a sustained viral response.  
Throughcare 
No studies were found on throughcare when transitioning from community to prison. No studies were found 
reporting on the outcome seroconversion after the introduction of a BBV prevention intervention in preparation for 
release from prison. The evidence on linkage to care post-release was mainly focused on HIV treatment, while no 
studies were found on treatment for hepatitis or OST after release. No cost-effectiveness studies were found. None 
of the included studies was conducted in the EU/EEA region.  
4.3 Strengths and limitations 
4.3.1 General strengths and limitations 
The strengths of this systematic review include the use of three peer-reviewed literature databases. A broad search 
over a long period of time was conducted, not limited by outcomes of interest or language. Additional searches for 
grey literature, such as guidelines, protocols, conference abstracts and unpublished research reports were 
conducted to counterbalance the fact that research on the topic of prisons and health is generally 
underrepresented in peer-reviewed literature databases. Multiple grey literature sources were searched. 
Supplemental documents were retrieved by experts (including documents in languages other than English). Four 
field researchers performed extensive literature searches in their countries. 
A rigorous methodology was applied to identify, critically appraise, analyse and summarise the relevant evidence in 
order to minimise selection and confirmation bias due to preconceived notions. Researchers adhered to 
international methodological standards such as Cochrane [43] and PRISMA [44]. The same methodology was also 
employed by ECDC during the scoping phase of the project. A multi-sectorial expert panel in the field of prison 
health, prevention and control of communicable diseases and guidance development was closely involved during all 
stages of the review process. 
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This systematic review is mainly limited by the scarcity of the literature found. A large number of studies had a 
descriptive and observational design, which cannot be used to assess effectiveness or causality because of the lack 
of control groups. Moreover, descriptive studies are subject to certain biases - e.g. a risk of confounding, poor 
sampling procedures, and loss to follow-up. Drawing conclusions based on indirect comparisons between studies 
has serious limitations, as differences in population characteristics, settings, countries, treatment regimens, follow-
up periods etc. can influence study outcomes. In addition, study characteristics, interventions and outcomes were 
often poorly described, hampering comparisons. Most studies did not compare the characteristics of participants 
with those who did not participate in the study. Moreover, most studies did not take confounding or modifying 
factors into account, and making corrections for such factors can substantially influence the results of a study. 
Many studies were also conducted in only one institution and had relatively small sample sizes (several below 100 
persons), which limits their generalisability. These limitations resulted in the inclusion of studies of mostly low or 
very low quality. Although for topics other from treatment, some direct comparative studies were found, these 
were often of lower quality due to methodological flaws (e.g. no or limited description of the randomisation method 
and allocation concealment, small follow-up periods, and the possibility of contamination between intervention 
groups due to the confined setting). Limitations of each study were added to the evidence tables (see annexes).  
The focus of this report was on EU/EEA countries. Unfortunately, few studies were retrieved from these countries, 
while the majority of studies came from the USA. While studies from non-EU/EEA countries may be a valuable 
source of data on the topics of interest, their findings cannot simply be extrapolated to the EU/EEA context due to 
differences in population structure, healthcare delivery, and correctional systems. 
Although this review was focused on adults, the researchers did not reject studies that included people below 18 
years of age. Studies focusing solely on young populations were not included. 
It was difficult to determine the factors responsible for the observed outcomes in many studies because 
interventions were often part of a bundle of measures which were not examined separately (i.e. different drugs, 
regimens, use of DOT, use of and place of adherence interventions for treatment studies; or different intervention 
contents, duration/intensity, formats, comparison groups, outcomes for prevention studies). 
Study settings varied widely among the studies included. In detention centres where people are generally 
incarcerated for shorter periods, treatment completion is often hampered by the fact that inmates are released or 
transferred soon after entry. This is less of a problem in prisons, where inmates are incarcerated for longer periods 
of time. Moreover, detention centres or prisons tend to be different in different countries (e.g. prison setting, 
composition of the population). Similar settings are therefore not directly comparable between countries. This also 
applies to healthcare settings, which can differ considerably among countries, even within the EU/EEA.  
Outcome definitions varied between studies, and were lacking in some studies. This mostly related to the 
denominators used for various rates, such as the treatment adherence rate or treatment completion rate. Where 
possible, outcome values were recalculated to prevent incorrect comparisons. Additionally, many outcomes in the 
studies included were based on self-reported data, mostly collected during interviews and therefore creating 
additional bias.  
  
TECHNICAL REPORT  Systematic review on the prevention and control of blood-borne viruses in prison settings 
43 
5. Conclusions 
The overall objective of this project was to develop a series of evidence-based guidance documents on prevention 
and control of communicable diseases in prisons. This specific systematic review focused on HIV, viral hepatitis and 
PWID-targeted interventions and is designed to inform guidance on prevention and control of BBVs in prison 
settings. In this systematic review we have retrieved evidence on prevention, treatment and care for BBVs, namely 
HIV, HBV and HCV, including interventions specifically targeting PWID. While the number of studies was sizable for 
some of these topics (e.g. HIV treatment), we have found an overall weak evidence base, with few comparative 
studies and a wide variation among studies. In addition, a sizeable fraction of the identified evidence comes from 
non-EU/EEA countries, posing concerns regarding the generalisability of the findings to the region. Thus, collating 
and comparing the studies is extremely challenging and it is impossible to provide clear conclusions on which 
interventions are most effective in prison settings in the EU/EEA. However, through this systematic review we 
identified a wide variety of interventions that use a range of prevention measures, treatment service models and 
linkage to care interventions directed at different sub-populations within the prison setting. We also identified 
predictors of intervention uptake, as well as barriers to their implementation. Most notably, release or transfer from 
prison was identified as the main factor hampering adherence to and/or completion of treatment for HIV, HCV and 
OST. These findings are relevant for informing and devising public health interventions to increase coverage and 
uptake of BBV prevention measures and to scale up treatment in the EU/EEA.  
This systematic review highlighted important knowledge gaps. More operational research is needed to assess the 
effectiveness and cost-effectiveness of BBV prevention and control intervention in prison settings. At the same time 
this review revealed the value of grey literature as a source of evidence on prevention and control of HIV and viral 
hepatitis in prison settings in the EU/EEA. Sharing of knowledge and experiences among EU/EEA countries may be 
a useful approach to stimulate research on this specific topic and to promote spreading of good practices in the 
region.  
Against this perspective, the findings from the systematic review will inform the development of a public health 
guidance on prevention and control of BBVs in prison setting. 
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6. Next steps 
The findings of this systematic review will serve as the evidence base for the development of an ECDC public 
health guidance document on prevention and control of BBVs in prison settings. This guidance will be part of a 
broader set of guidance documents on the prevention and control of communicable diseases in prison settings, 
which will also encompass other specific interventions, such as active case finding, vaccination, and diagnosis, 
treatment, care and prevention of TB. 
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Annex 1. Search and selection strategy for 
MA1, MA2 and MA3 
This Annex covers the general methodology used for all three macro areas (MA). This annex is attached to give a 
more extensive overview of the methodology used, while in the methods section of this systematic review report 
only a summary of the process is presented.  
1. Review objectives and questions 
The following three review objectives were defined: 
Macro area 4: HIV prevention and care 
To gain insight in the evidence base (peer-reviewed as well as grey literature) for prevention, care and treatment 
of HIV in prison settings, including throughcare. 
Macro area 5: Viral hepatitis prevention and care 
To gain insight in the evidence base (peer-reviewed as well as grey literature) for prevention, care and treatment 
of viral hepatitis in prison settings, with a focus on treatment of hepatitis C, including throughcare. 
Macro area 6: injecting-related infections prevention and control 
To gain insight in the evidence base (peer-reviewed as well as grey literature) for prevention and control of 
injecting-related infections among current and former drug users, including throughcare. 
  
TECHNICAL REPORT  Systematic review on the prevention and control of blood-borne viruses in prison settings 
52 
The PICO method was used to develop specific research questions from these review objectives 
4 Prevention, care and treatment of HIV 
P Adult individuals (≥18 years) in prison settings (i.e. both those detained and those who work in prison 
settings (‘going through the gate’)) 
I Prevention, care and treatment of HIV 
C • Comparison with no intervention 
• Comparison with alternative intervention 
• No comparison 
• Comparison between populations in prison settings (e.g. between different prison types, risk groups, etc.) 
• Comparison with community setting 
O Qualitative outcomes: 
• Accessibility 
• Suitability, feasibility and acceptability of interventions  
• Qualitative description of interventions/modes of service delivery 
Quantitative outcomes: 
• Uptake (number of persons using a certain intervention or number of persons reached by a certain 
intervention) 
• Measures of effectiveness (e.g. change in HIV incidence or prevalence, number of people who adhered to 
treatment, number of people who are linked to care – including community care after release) 
• Cost-effectiveness 
S Prisons, jails and other custodial settings (excluding migrant centres and police detention rooms) 
5 Prevention, care and treatment of viral hepatitis 
P Adult individuals (≥18 years) in prison settings (i.e. both those detained and those who work in prison 
settings (‘going through the gate’)) 
I Prevention, care and treatment of viral hepatitis 
C • Comparison with no intervention 
• Comparison with alternative intervention 
• No comparison 
• Comparison between populations in prison settings (e.g. between different prison types, risk groups, etc.) 
• Comparison with community setting 
O Qualitative outcomes: 
• Accessibility 
• Suitability, feasibility and acceptability of interventions  
• Qualitative description of interventions/modes of service delivery 
Quantitative outcomes: 
• Uptake (number of persons using a certain intervention or number of persons reached by a certain 
intervention) 
• Measures of effectiveness (e.g. change in hepatitis incidence or prevalence, number of people who have 
completed treatment, number of people who are linked to care – including community care after release) 
• Cost-effectiveness 
S Prisons, jails and other custodial settings (excluding migrant centres and police detention rooms) 
6 Prevention and control of injecting-related infections among PWID 
P Adult individuals (≥18 years) in prison settings (i.e. both those detained and those who work in prison 
settings (‘going through the gate’)) 
I Prevention and control of injecting-related infections among former/current PWID 
C • Comparison with no intervention 
• Comparison with alternative intervention 
• No comparison 
• Comparison between populations in prison settings (e.g. between different prison types, risk groups, etc.) 
• Comparison with community setting 
O Qualitative outcomes: 
• Accessibility 
• Suitability, feasibility and acceptability of interventions  
• Qualitative description of interventions/modes of service delivery 
Quantitative outcomes: 
• Uptake (number of persons using a certain intervention or number of persons reached by a certain 
intervention) 
• Measures of effectiveness (e.g. change in BBVs incidence or prevalence) 
• Cost-effectiveness 
S Prisons, jails and other custodial settings (excluding migrant centres and police detention rooms) 
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For each of these macro areas specific review questions were defined and formulated: 
Macro area 4: HIV prevention and care 
1. Which prevention interventions for HIV are effective in prison settings? 
2. Which care and/or treatment interventions aimed at control of HIV are effective in prison settings? 
3. Which service models for prevention, care and/or treatment of HIV are effective in prison settings? 
4. Which prevention interventions for HIV are cost-effective in prison settings? 
5. Which care and/or treatment interventions aimed at control of HIV are cost-effective in prison settings? 
6. Which service models for prevention, care and/or treatment of HIV are cost-effective in prison settings? 
7. What is the acceptance/uptake/coverage of prevention, care and/or treatment of HIV in prison settings? 
8. How to improve the acceptance/uptake/coverage of prevention, care and/or treatment of HIV in prison 
settings? 
9. Who should be targeted for prevention, care and/or treatment of HIV in prison settings? 
Macro area 5: Viral hepatitis prevention and care 
10. Which prevention interventions for viral hepatitis are effective in prison settings? 
11. Which care and/or treatment interventions aimed at control of viral hepatitis are effective in prison settings? 
12. Which service models for prevention, care and/or treatment of viral hepatitis are effective in prison settings? 
13. Which prevention interventions for viral hepatitis are cost-effective in prison settings? 
14. Which care and/or treatment interventions aimed at control of viral hepatitis are cost-effective in prison 
settings? 
15. Which service models for prevention, care and/or treatment of viral hepatitis are cost-effective in prison 
settings? 
16. What is the acceptance/uptake/coverage of prevention, care and/or treatment of viral hepatitis in prison 
settings? 
17. How to improve the acceptance/uptake/coverage of prevention, care and/or treatment of viral hepatitis in 
prison settings? 
18. Who should be targeted for prevention, care and/or treatment of viral hepatitis in prison settings? 
Macro area 6: injecting-related infections prevention and control 
19. Which prevention interventions for injecting-related infections among current drug users are effective in prison 
settings? 
20. Which interventions aimed at control of injecting-related infections among current or former drug users are 
effective in prison settings? 
21. Which service models for prevention and control of injecting-related infections among current or former drug 
users are effective in prison settings? 
22. Which prevention interventions for injecting-related infections among current or drug users are cost-effective 
in prison settings? 
23. Which interventions aimed at control of injecting-related infections among current or former drug users are 
cost-effective in prison settings? 
24. Which service models for prevention and control of injecting-related infections among current or former drug 
users are cost-effective in prison settings? 
25. What is the acceptance/uptake/coverage of prevention and control of injecting-related infections among 
current or former drug users in prison settings? 
26. How to improve the acceptance/uptake/coverage of prevention and control of injecting-related infections 
among current or former drug users in prison settings? 
2. Peer reviewed literature search 
The search strategy was developed building on the scoping phase by ECDC with respect to using PubMed and 
Embase as peer-reviewed data sources. Additionally, the Cochrane Library database was searched for systematic 
reviews and economic evaluations. 
Search strings 
In order to find relevant articles for the macro areas in PubMed and Embase.com, search strings were developed 
for each of the following concepts:  
1. Prisons, jails and other custodial settings 
2. HIV 
3. Viral hepatitis 
4. Injecting-related infections 
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It was decided not to add a search string on outcomes, to prevent missing relevant articles. In PubMed and 
Embase search string #1 was combined using ‘AND’ with each of the macro area specific search strings (i.e. #1 
AND (#2 OR #3 OR #4)).  
For Cochrane Library one generic search using the terms for prisons was used to search for all relevant systematic 
reviews and economic evaluations.  
PUBMED 
#1 Prisons and other custodial settings 
"Prisons"[Mesh] OR "Prisoners"[Mesh] OR prison*[tw] OR penal[tw] OR jail*[tw] OR reformator*[tw] OR 
custodial[tw] OR custody[tw] OR gaol*[tw] OR remand*[tw] OR penitentiar*[tw] OR detention*[tw] OR 
correctional[tw] OR detainee*[tw] OR inmate*[tw] OR imprison*[tw] OR confinement[tw] OR incarcerat*[tw] OR 
cellmate*[tw] 
#2 HIV 
“HIV”[Mesh] OR HIV[tw] OR “human immunodeficiency virus”[tw] OR “human immuno-deficiency virus”[tw] OR 
“human immune-deficiency virus”[tw] OR “human immune deficiency virus”[tw] OR “human immunodeficiency 
viruses”[tw] OR “human immuno-deficiency viruses”[tw] OR “human immune-deficiency viruses”[tw] OR “human 
immune deficiency viruses”[tw] OR "Acquired Immunodeficiency Syndrome"[Mesh] OR “acquired immunodeficiency 
syndrome”[tw] OR “acquired immuno-deficiency syndrome”[tw] OR “acquired immune deficiency syndrome”[tw] 
OR “acquired immunodeficiency syndromes”[tw] OR “acquired immuno-deficiency syndromes”[tw] OR “acquired 
immune deficiency syndromes”[tw] OR AIDS[tw] 
#3 Viral hepatitis 
"Hepatitis"[Mesh] OR "Hepatitis, Viral, Human"[Mesh] OR "Hepatitis Viruses"[Mesh] OR hepatitis[tw] OR HAV[tw] 
OR HBV[tw] OR HCV[tw] OR HDV[tw] OR HEV[tw] OR “hep a”[tw] OR “hep b”[tw] OR “hep c”[tw] OR “hep d”[tw] 
OR “hep e”[tw] OR hepacivirus*[tw] OR hepatovirus*[tw] 
#4 Injecting-related infections 
("Communicable Diseases”[Mesh] OR "Infection"[Mesh] OR infection*[tw] OR virus*[tw] OR pathogen*[tw] OR 
((communicable[tw] OR infectious[tw]) AND disease*[tw])) AND ("Drug Users"[Mesh] OR "Needle Sharing"[Mesh] 
OR "Syringes"[Mesh] OR inject*[tw] OR needle*[tw] OR syringe*[tw] OR paraphernalia*[tw] OR IDU[tw] OR 
PWID[tw] OR intravenous*[tw] OR intramuscular*[tw] OR subcutaneous*[tw] OR "Cocaine"[Mesh] OR cocaine[tw] 
OR coke[tw] OR crack[tw] OR "Heroin"[Mesh] OR heroin[tw] OR dope[tw] OR "Methamphetamine"[Mesh] OR 
methamphetamine*[tw] OR meth[tw] OR "Amphetamine"[Mesh] OR amphetamine*[tw] OR speed[tw] OR 
crystal[tw] OR speedball[tw] OR "cathinone" [Supplementary Concept] OR cathinone*[tw] OR 
"Cannabinoids"[Mesh] OR cannabinoid*[tw] OR cannabis[tw] OR "Methadone"[Mesh] OR methadone*[tw] OR 
"Buprenorphine"[Mesh] OR buprenorphine*[tw] OR "Steroids"[Mesh] OR steroid*[tw] OR "Central Nervous System 
Stimulants"[Mesh] OR stimulant*[tw] OR "Analgesics, Opioid"[Mesh] OR opioid*[tw] OR "Tattooing"[Mesh] OR 
"Body Piercing"[Mesh] OR tattoo*[tw] OR pierc*[tw]) 
Embase 
#1 Prisons and other custodial settings 
'prison'/exp OR 'prisoner'/exp OR prison*:ti,ab OR penal:ti,ab OR jail*:ti,ab OR reformator*:ti,ab OR custodial:ti,ab 
OR custody:ti,ab OR gaol*:ti,ab OR remand*:ti,ab OR penitentiar*:ti,ab OR detention*:ti,ab OR correctional:ti,ab 
OR detainee*:ti,ab OR inmate*:ti,ab OR imprison*:ti,ab OR confinement:ti,ab OR incarcerat*:ti,ab OR 
cellmate*:ti,ab  
#2 HIV 
'Human immunodeficiency virus'/exp OR HIV:ti,ab OR “human immunodeficiency virus”:ti,ab OR “human immuno-
deficiency virus”:ti,ab OR “human immune-deficiency virus”:ti,ab OR “human immune deficiency virus”:ti,ab OR 
“human immunodeficiency viruses”:ti,ab OR “human immuno-deficiency viruses”:ti,ab OR “human immune-
deficiency viruses”:ti,ab OR “human immune deficiency viruses”:ti,ab OR 'acquired immune deficiency 
syndrome'/exp OR “acquired immunodeficiency syndrome”:ti,ab OR “acquired immuno-deficiency syndrome”:ti,ab 
OR “acquired immune deficiency syndrome”:ti,ab OR “acquired immunodeficiency syndromes”:ti,ab OR “acquired 
immuno-deficiency syndromes”:ti,ab OR “acquired immune deficiency syndromes”:ti,ab OR AIDS:ti,ab 
#3 Viral hepatitis 
'hepatitis'/exp OR hepatitis:ti,ab OR HAV:ti,ab OR HBV:ti,ab OR HCV:ti,ab OR HDV:ti,ab OR HEV:ti,ab OR “hep 
a”:ti,ab OR “hep b”:ti,ab OR “hep c”:ti,ab OR “hep d”:ti,ab OR “hep e”:ti,ab OR hepacivirus*:ti,ab OR 
hepatovirus*:ti,ab 
#4 Injecting-related infections 
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('communicable disease'/exp OR 'infection'/exp OR infection*:ti,ab OR virus*:ti,ab OR pathogen*:ti,ab OR 
((communicable:ti,ab OR infectious:ti,ab) AND disease*:ti,ab)) AND ('intravenous drug abuse'/exp OR 'drug 
abuse'/exp OR 'drug use'/exp OR 'syringe'/exp OR inject*:ti,ab OR needle*:ti,ab OR syringe*:ti,ab OR 
paraphernalia*:ti,ab OR IDU:ti,ab OR PWID:ti,ab OR intravenous*:ti,ab OR intramuscular*:ti,ab OR 
subcutaneous*:ti,ab OR 'cocaine'/exp OR cocaine:ti,ab OR coke:ti,ab OR crack:ti,ab OR 'diamorphine'/exp OR 
heroin:ti,ab OR dope:ti,ab OR 'methamphetamine'/exp OR methamphetamine*:ti,ab OR meth:ti,ab OR 
'amphetamine'/exp OR amphetamine*:ti,ab OR speed:ti,ab OR crystal:ti,ab OR speedball:ti,ab OR 'cathinone'/exp 
OR cathinone*:ti,ab OR 'cannabinoid'/exp OR cannabinoid*:ti,ab OR cannabis:ti,ab OR 'methadone'/exp OR 
methadone*:ti,ab OR 'buprenorphine'/exp OR buprenorphine*:ti,ab OR 'steroid'/exp OR steroid*:ti,ab OR 'central 
stimulant agent'/exp OR stimulant*:ti,ab OR 'narcotic analgesic agent'/exp OR opioid*:ti,ab OR 'tattooing'/exp OR 
'body piercing'/exp OR tattoo*:ti,ab OR pierc*:ti,ab) 
Cochrane Library 
#1 Prisons and other custodial settings 
MeSH descriptor: [prisons] explode all trees OR MeSH descriptor: [prisoners] explode all trees OR prison*:ti,ab,kw 
OR penal:ti,ab,kw OR jail*:ti,ab,kw OR reformator*:ti,ab,kw OR custodial:ti,ab,kw OR custody:ti,ab,kw OR 
gaol*:ti,ab,kw OR remand*:ti,ab,kw OR penitentiar*:ti,ab,kw OR detention*:ti,ab,kw OR correctional:ti,ab,kw OR 
detainee*:ti,ab,kw OR inmate*:ti,ab,kw OR imprison*:ti,ab,kw OR confinement:ti,ab,kw OR incarcerat*:ti,ab,kw 
OR cellmate*:ti,ab,kw  
Search limits 
The only search limits that were applied for this systematic review are a time limit and a geographical limit. 
Literature was searched in PubMed and Embase from 1990 onwards and in Cochrane Library, systematic reviews 
and economic evaluations were searched from 1980 onwards. The literature search was further limited to include 
only literature from EU/EEA/EFTA countries or their candidate countries and other Western countries (i.e. USA, 
Canada, Australia and New Zealand). Articles from these non-EU/EEA/EFTA high-income countries were included to 
broaden the evidence base. A geographical search string was used to limit the searches in PubMed and Embase 
(see Annex 2). 
Language limits were not applied. Additionally, an age limit was not applied in the search phase. Rather, during title 
and abstract screening phase, articles focusing only on those <18 years were not included.  
Running the literature search 
The final searches in PubMed, Embase and Cochrane Library were run on the 12th of January 2017. Due to overlap 
between the three macro areas, the search strings were combined in a single search. The relevant full text 
publications were subdivided into the three separate macro areas during the screening of full article phase.  
PubMed, Embase, and Cochrane Library output, including all indexed fields per hit (e.g. title, authors, abstract), 
were exported to Endnote version X7.4 and saved in separate folders per database. Duplicate articles were 
removed through automatic and manual duplicate removal.  
Hand search 
Reference lists of good quality systematic review articles were checked for further potentially relevant articles. 
3. Peer reviewed literature selection 
From the articles retrieved from PubMed, Embase, and Cochrane Library the relevant references were selected by a 
three-phase selection procedure, based on: 
• Screening of title and abstract (first selection phase): in this phase, titles of publications were screened 
based on the inclusion and exclusion criteria (see below). If the title was inconclusive, the abstract was 
read. Articles with titles and abstracts that suggest that they did not contain information relevant to the 
review objectives were not selected for full-text assessment (no reason for exclusion documented per 
article). In case of doubt, the article was checked full-text in the second selection step. Articles that were 
excluded during screening of title and abstract were stored in an indexed folder in Endnote.  
• Screening of full article (second selection phase): the articles selected during the first phase were assessed 
in full text. PDF-files of the original articles were downloaded and stored. Articles were included if the 
reported information was relevant (based on the inclusion and exclusion criteria, see below) and of 
sufficient quality (see section 2.3). The reasons for exclusion of full-text papers were documented per 
article and summarised in an exclusion table.  
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• Screening during data-extraction phase: further scrutiny of the article during the data-extraction phase 
could have led to exclusion. For example, when articles make use of the same dataset and present identical 
outcome measures, the most recent or the most extensive article was included.  
The process of selection and inclusion and exclusion of articles was registered in an Excel file and an Endnote 
library.  
Inclusion and exclusion criteria 
The inclusion and exclusion criteria are listed in Table 1 below.  
Table 1. Inclusion and exclusion criteria peer-reviewed literature 
 Inclusion Exclusion 
Study design/ 
type 
• Randomised controlled trials (RCTs) 
• Non-randomised, prospective comparative 
studies 
• Prospective observational studies (e.g. 
cohort studies) 
• Retrospective observational studies (e.g. 
case-control studies) 
• Cross-sectional studies 
• Meta-analysis or systematic review1 
• Narrative review 
• Case reports/small case series 
• Non-pertinent publication types (e.g. 
expert opinions, letters to the editor, 
editorials, comments, conference 
abstract/poster, news, consensus 
document, chapter) 
• Animal studies 
• Genetic studies, biochemistry or 
molecular studies 
• Modelling studies (i.e. this did not apply 
to economic evaluation studies) 
Study quality • Study duration (no minimum) 
• Number of subjects (no minimum) 
• Insufficient methodological quality (both 
inherent methodology as well as 
insufficient description of inherent 
methodology provided; based on quality 
checklists) 
Study 
population 
Adults in prisons, jails and other custodial 
settings that function as a prison 
• Detained persons, including persons in 
remand 
• Persons ‘going through the gate’ (e.g. 
prison guards, healthcare workers, etc.) 
• Children (<18 years)  
• Persons in police custody 
• Persons in migrant detention centres 
 
Study 
comparison 
• Comparison appropriate for a specific 
outcome 
 
Specific 
outcomes of 
interest 
• Quantitative outcomes  
• Qualitative outcomes 
• No exclusion based on outcomes 
1 Relevant meta-analyses and systematic reviews will be selected during the screening of title and abstract phase. During the full 
text phase, reference lists of these meta-analyses and systematic reviews will be checked for possibly missed relevant individual 
articles. No data extraction will be performed for meta-analyses or systematic reviews, only for relevant individual articles. 
4. Grey literature search 
A grey literature search with a focus on EU/EEA countries was performed to complement the evidence from the 
peer-reviewed literature. Reports and documents focusing on prisons and people in prisons were searched for.  
The following types of documents were searched for: 
• Articles, abstracts, research reports 
• Guidelines and protocols 
• Case studies, service models 
This grey literature search comprised the following sources: 
• A pre-defined list of websites 
• Call for papers/experts input 
  
TECHNICAL REPORT  Systematic review on the prevention and control of blood-borne viruses in prison settings 
57 
Search on websites of conference abstracts 
In order to capture studies not published yet in peer-reviewed literature, conference abstracts published from 2010 
onwards were searched for on all the following websites of relevant congresses: 
• International Corrections and Prisons Association (ICPA, http://icpa.ca/)  
• American Correctional Association (http://www.aca.org/aca_prod_imis/aca_member)  
• Experiencing Prison 7th Global Conference (http://www.inter-disciplinary.net/probing-the-
boundaries/persons/experiencing-prison/)  
• National Conference on Correctional Health Care (http://www.ncchc.org/national-conference)  
Search on other websites 
The following sources were searched for other grey literature documents published from 2005 onwards: 
Guidelines: 
• Guidelines International Network (http://www.g-i-n.net/) 
• NICE guidelines (https://www.evidence.nhs.uk/)  
Organisations and institutes: 
• WHO – Health in prisons programme (HIPP) (http://www.euro.who.int/prisons) 
• WHO – EU (http://www.euro.who.int/en/home) 
• WHO – IRIS (http://apps.who.int/iris/)  
• Council of Europe/POMPIDOU Group (http://www.coe.int/T/DG3/Pompidou/AboutUs/default_en.asp), and 
other Council of Europe documents 
• UNODC (http://www.unodc.org/)  
• ECDC (http://ecdc.europa.eu/en/Pages/home.aspx)  
• Public Health England (PHE) – (http://www.gov.uk)  
• European Monitoring Centre for Drugs and Drug Addition (EMCDDA) (http://www.emcdda.europa.eu/) 
• International Corrections and Prisons Association (ICPA, http://icpa.ca/) 
Bibliographies: 
• Campbell Collaboration (http://www.campbellcollaboration.org/)  
• Bibliography on HIV/AIDS and Hepatitis C in prisons (http://www.aidslaw.ca/)  
• IDEAS (https://ideas.repec.org/)  
• Evidence in Health and Social Care (NHS Evidence, https://www.evidence.nhs.uk/)  
• Open grey (http://www.opengrey.eu) 
Conduct of the main search on pre-defined websites and 
corresponding search terms 
The main search for grey literature on the pre-defined websites was performed by two senior researchers. The 
main search was performed in English. On each website, a more general search was conducted at first using only 
terms for prisons (i.e. prison, jail, correctional, incarcerated). If this resulted in many hits, a more specific search 
was performed by combining the prison terms with e.g. ‘HIV’, ‘hepatitis’, ‘vaccination’ and ‘injecting drug users’. In 
case a website was only focused on prison populations, only this latter search was performed. 
Expert input 
In addition to the search on pre-defined websites, expert input was used in the form of:  
• A search for documents conducted by field researchers of the HWBs Federation Network 
• A ‘call for paper’ issued to experts contacted via the HWBs Federation Network and members of the ECDC 
expert panel  
See Annex 7 for more details. 
Activities of field researchers 
Five national field researchers and infectious diseases specialists were identified within the HwBs network, one for 
each of the EU/EEA countries represented in the Federation, namely France, Germany, Italy, the Netherlands and 
Spain. The field researchers conducted a search for national guidelines, protocols (clinical/intervention), and 
unpublished research reports relevant to the objectives (based on the inclusion and exclusion criteria, see below); 
documents written in English or in other EU/EEA languages were searched. This was done by searching the 
national websites of HWBs member organisations: 
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• SIMSPe-Onlus: Italian Society for Prison Health and Medicine (http://www.sanitapenitenziaria.org/) 
• APSEP: Association des Professionnels de Santé Exerçant en Prison (http://www.sante-prison.com/fr/) 
• NAPDUK: National Association of Prison Dentistry UK (http://www.napduk.org/) 
• SESP: Sociedad Espanola de Sanidad Penitenciaria (http://www.sesp.es/) 
• DJI: Netherlands National Agency for Correctional Institutions (https://www.dji.nl/).  
Call for paper 
A ‘call for paper’ was issued to stakeholders in the field by the selected national field researchers, via e-mail. The grey 
literature search officially started on 18 April 2016, with an official letter and call to the researchers sent by HWBs’ 
Secretariat. After two weeks, an e-mail reminder was sent. If clarifications or additional details were needed, the 
respective national contact point was contacted. The call was also shared with the ECDC expert panel members. 
The initial deadline was set on 2 May 2016. However, due to the low number of contributions received in particular 
on MA 6, the replacement of some field researchers and the possibility to collect further documents by the panel 
members, the definitive deadline for the collection of documents was extended to 31 July 2016. 
A further call for papers was issued on 7th July 2017 2017 and to the expert panel members during the Lisbon 
meeting on 21-23 June 2017 on specific topics of interest that were raised during the extensive discussion. The 
additional grey literature documents from the expert panel were received on June 28th and those from the field 
researchers were sent by HWB on July 14th, 2017. 
The call targeted stakeholders, service providers or technical experts working in the field to submit additional documents 
including abstracts, national guidelines, protocols, unpublished research reports and/or intervention case studies/service 
models regarding the three macro areas. For the latter, a short pre-defined format was provided to collect clearly 
described accounts of their intervention/service model related to the relevant macro areas. 
5. Grey literature selection 
All retrieved documents were reviewed by two researchers. Documents were included if the reported information 
was relevant and of sufficient quality (see inclusion and exclusion criteria below). A record was kept of the reasons 
for exclusion of documents screened in full text.  
Inclusion and exclusion criteria 
Table 2. Inclusion and exclusion criteria grey literature 
 Inclusion Exclusion 
Period of 
publication 
Conference abstracts: from 2010 onwards 
Other documents: from 2005 onwards 
 
Type of 
document 
• Conference abstracts 
• Guidelines  
• Intervention or clinical protocols 
• Unpublished research results 
• Case studies/service models, including 
measures of effectiveness 
• Published article 
Document 
quality 
Only grey literature documents with a 
methods section or an overview of sources 
Document without a clear source/reference for 
the relevant information 
Document 
population 
Adults in prisons, jails and other custodial 
settings that function as a prison 
• Detained persons, including persons in 
remand 
• Persons ‘going through the gate’ (e.g. 
prison guards, healthcare workers, etc.) 
• Children (<18 years)  
• Persons in police custody 
• Persons in migrant centres 
Subject of the 
document 
• Prevention, care and treatment of HIV 
• Prevention, care and treatment of viral 
hepatitis 
• Prevention and control of injecting-
related infections among current or 
former drug users 
 
Geographical 
area 
• EU/EEA   
Specific 
outcomes of 
interest 
• Quantitative outcomes  
• Qualitative outcomes 
• No exclusion based on outcomes 
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Guidelines selection 
Guidelines were selected in a three-step approach. First, only prison-focused guidelines were searched for relevant 
information. However, when there was not sufficient information on certain review objectives coming from these 
prison-focused guidelines, guidelines that have a relevant section on prisoners were searched for relevant 
information. To include such guidelines, multiple transparent sources should have been stated for the prisoner 
group and a recommendation for this specific group should have been made. In case there was still a lack of 
information on a certain topic, general population guidelines were reviewed for relevant information. 
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Annex 2. Geographical search string used for 
PubMed and Embase 
PubMed 
(((((((Europe*[ad] OR Europa*[ad] OR EU[ad] OR EEA[ad] OR EFTA[ad] OR "EU/EEA"[ad] OR "EU/EFTA"[ad] OR ECSC[ad] OR 
Euratom[ad] OR Eurozone[ad] OR EEC[ad] OR ec[ad] OR (Schengen[ad] AND (area[ad] OR countr*[ad] OR region*[ad] OR 
state[ad] OR states[ad])) OR Euroregion[ad] OR Euroregions[ad] OR Balkan[ad] OR Balkans[ad] OR Baltic[ad] OR 
(Mediterranean[ad] AND (area[ad] OR countr*[ad] OR region*[ad] OR state[ad] OR states[ad])) OR (Alpine[ad] AND (area[ad] 
OR countr*[ad] OR region*[ad] OR state[ad] OR states[ad])) OR Scandinavia[ad] OR Scandinavian[ad] OR "Nordic country"[ad] 
OR "Nordic countries"[ad] OR "Nordic state"[ad] OR "Nordic states"[ad] OR Danubian[ad] OR "Iberian peninsula"[ad] OR 
"Peninsula iberica"[ad] OR "Peninsule Iberique"[ad] OR "Iberiar Penintsula"[ad] OR Iberia[ad] OR Anatolia[ad] OR Anadolu[ad] 
OR Anatole[ad] OR Anatolian[ad] OR Yugoslavia[ad] OR Czechoslovakia[ad] OR "Czecho Slovakia"[ad] OR Ceskoslovensko[ad] 
OR "Cesko slovensko"[ad] OR Benelux[ad] OR Fennoscandia[ad] OR "Fenno Scandinavia"[ad] OR Fennoskandi*[ad] OR 
(Visegrad[ad] AND (Group[ad] OR Four[ad] OR Triangle[ad])) OR "Visegradska ctyrka"[ad] OR "Visegradska skupina"[ad] OR 
"Visegradi Egyuttmukodes"[ad] OR "Visegradi negyek"[ad] OR "Grupa Wyszehradzka"[ad] OR "Vysehradska skupina"[ad] OR 
"Vysehradska stvorka"[ad])) OR (("Serbia"[Mesh] OR Serbia*[tw] OR Srbija[tw] OR Serb[tw] OR Serbs[tw] OR Srbi[tw] OR 
Vojvodina[tw] OR Belgrade[tw] OR Beograd[tw] OR Sumadija[tw] OR Kolubara[tw] OR Kolubarski[tw] OR Macva[tw] OR 
Macvanski[tw] OR Moravica[tw] OR Moravicki[tw] OR Pomoravlje[tw] OR Pomoravski[tw] OR Rasinski[tw] OR Rasina[tw] OR 
Raska[tw] OR Raski[tw] OR Sumadijski[tw] OR Zlatibor[tw] OR Zlatiborski[tw] OR Bor[tw] OR Borski[tw] OR Branicevo[tw] OR 
Branicevski[tw] OR Jablanica[tw] OR Jablanicki[tw] OR Nisava[tw] OR Nisavski[tw] OR Pcinja[tw] OR Pcinjski[tw] OR Pirot[tw] 
OR Pirotski[tw] OR Podunavlje[tw] OR Podunavski[tw] OR Toplica[tw] OR Toplicki[tw] OR Zajecar[tw] OR Zajecarski[tw] OR 
Banat[tw] OR Srendjebanatski[tw] OR Backa[tw] OR Severnobacki[tw] OR Severnobanatski[tw] OR Juznobacki[tw] OR 
Juznobanatski[tw] OR Srem[tw] OR Sremski[tw] OR Zapadnobacki[tw] OR "Novi Sad"[tw] OR "Novy Sad"[tw] OR Ujvidek[tw] OR 
Nis[tw] OR Nish[tw] OR Nissa[tw] OR Kragujevac[tw] OR Subotica[tw] OR Szabadka[tw] OR Zrenjanin[tw] OR Pancevo[tw] OR 
Cacak[tw] OR Kraljevo[tw] OR "Novi Pazar"[tw] OR "Novy Pazar"[tw]) OR (("Albania"[Mesh] OR Albania*[tw] OR Shqiperi*[tw] 
OR Schqipt*[tw] OR Berat[tw] OR Beratit[tw] OR Diber[tw] OR Dibres[tw] OR Durres[tw] OR Durresit[tw] OR Elbasan[tw] OR 
Elbasanit[tw] OR Fier[tw] OR Fierit[tw] OR Gjirokaster[tw] OR Gjirokastres[tw] OR Korce[tw] OR Korces[tw] OR Kukes[tw] OR 
Kukesit[tw] OR Lezhes[tw] OR Lezhe[tw] OR Shkodres[tw] OR Shkoder[tw] OR Tirana[tw] OR Tirane*[tw] OR Vlore[tw] OR 
Vlores[tw] OR Kamez[tw] OR Beraz[tw] OR Lushnje[tw]) OR ("Macedonia (Republic)"[Mesh] OR Makedon*[tw] OR Macedon*[tw] 
OR Fyrom[tw] OR Istocen[tw] OR Severoistocen[tw] OR Jugoistocen[tw] OR Jugozapaden[tw] OR Pelagonski[tw] OR 
Pelagonia[tw] OR Poloski[tw] OR Polog[tw] OR Skopski[tw] OR Skopje[tw] OR Ckonje[tw] OR Vardar*[tw] OR Bitola[tw] OR 
Kumanovo[tw] OR Prilep[tw] OR Tetovo[tw] OR Tetova[tw] OR Tetove[tw] OR Veles[tw] OR Stip[tw] OR Shtip[tw] OR Ohrid[tw] 
OR Gostivar[tw] OR Gostivari[tw] OR Strumica[tw]) OR ("Iceland"[Mesh] OR Iceland[tw] OR Icelandic*[tw] OR islenska*[tw] OR 
Icelander*[tw] OR islendinga*[tw] OR Islendigar[tw] OR Inslenska[tw] OR Reykjavik[tw] OR Reykjavikurborg[tw] OR 
Hofudborgarsvaedi[tw] OR Sudurnes[tw] OR Vesturland[tw] OR Vestfirdir[tw] OR Westfjords[tw] OR Nordurland[tw] OR 
Austurland[tw] OR Sudurland[tw] OR Kopavogur[tw] OR Hafnarfjordur[tw] OR Akureyri[tw] OR Gardabaer[tw] OR 
Mosfellsbaer[tw] OR Keflavik[tw] OR Akranes[tw] OR Selfoss[tw] OR Seltjarnarnes[tw]) OR ("Montenegro"[Mesh] OR 
Montenegr*[tw] OR "Crna Gora"[tw] OR Crnogorci[tw] OR Andrijevica[tw] OR (Bar[tw] AND (Opstina[tw] OR municipality[tw] OR 
city[tw] OR town[tw])) OR Berane[tw] OR "Bijelo polje"[tw] OR Budva[tw] OR Cetinje[tw] OR Danilovgrad[tw] OR Gusinje[tw] 
OR "herceg Novi"[tw] OR Kolasin[tw] OR Kotor[tw] OR Mojkovac[tw] OR Niksic[tw] OR Petnija[tw] OR Plav[tw] OR Pluzine[tw] 
OR Pljevlja[tw] OR Podgorica[tw] OR Rozaje[tw] OR Savnik[tw] OR Tivat[tw] OR Ulcinj[tw] OR Zabljak[tw]) OR ("Turkey"[Mesh] 
OR Turkey[tw] OR Turkiye[tw] OR Turkish[tw] OR Turk[tw] OR Turkc*[tw] OR Adana[tw] OR Adiyaman[tw] OR Ayfon*[tw] OR 
Agri[tw] OR Aksaray[tw] OR Aksaray[tw] OR Amasya[tw] OR Ankara[tw] OR Antalya[tw] OR Ardahan[tw] OR Artvin[tw] OR 
Aydin[tw] OR Balikesir[tw] OR Bartin[tw] OR Batman[tw] OR Bayburt[tw] OR Bilecik[tw] OR Bingol[tw] OR Bitlis[tw] OR Bolu[tw] 
OR Burdur[tw] OR Bursa[tw] OR Canakkale[tw] OR Cannkiri[tw] OR Corum[tw] OR Denizli[tw] OR Diyarbarkir[tw] OR Duzce[tw] 
OR Edirne[tw] OR Elazig[tw] OR Erzincan[tw] OR Erzurum[tw] OR Eskishir[tw] OR Gaziantep[tw] OR Giresun[tw] OR 
Gumushane[tw] OR Hakkari[tw] OR Hatay[tw] OR Igdir[tw] OR Isparta[tw] OR Istanbul[tw] OR Izmir[tw] OR 
Kahramanmaras[tw] OR Karabuk[tw] OR Karaman[tw] OR Kars[tw] OR Kastamonu[tw] OR Kayseri[tw] OR Kirikkale[tw] OR 
Kirklarely[tw] OR Kirklareli[tw] OR Kirsheir[tw] OR Kocaeli[tw] OR Konya[tw] OR Kutahya[tw] OR Malatya[tw] OR Manisa[tw] OR 
Mardin[tw] OR Mersin[tw] OR Mugla[tw] OR Mus[tw] OR Nevsehir[tw] OR Nigde[tw] OR Ordu[tw] OR Osmaniye[tw] OR Rize[tw] 
OR Sakarya[tw] OR Samsun[tw] OR Sanliurfa[tw] OR Siirt[tw] OR Sinop[tw] OR Sivas[tw] OR Sirnak[tw] OR Tekirdag[tw] OR 
Tokat[tw] OR Trabzon[tw] OR Tunceli[tw] OR Usak[tw] OR (Van[tw] AND (province[tw] OR ili[tw])) OR Yalova[tw] OR 
Yozgat[tw] OR Kilis[tw]) OR ("Bosnia-Herzegovina"[Mesh] OR Bosnia*[tw] OR Herzegov*[tw] OR Herzegonine[tw] OR Bosna[tw] 
OR Bosne[tw] OR Bosanski[tw] OR Bosanac[tw] OR Bosanci[tw] OR Srpska[tw] OR Brcko[tw] OR Posavski[tw] OR Posavina[tw] 
OR posavska[tw] OR Tuzlanski[tw] OR Tuzla[tw] OR Tuzlanska[tw] OR "Zenickho dobojski"[tw] OR "Zenicko dobojska"[tw] OR 
Zenica[tw] OR "Bosansko Podrinjski"[tw] OR "Bosansko Podrinjska"[tw] OR Srednjobosanski[tw] OR hercegovacko[tw] OR 
Zapadnohercegovacki[tw] OR Zapadnohercegovacka[tw] OR Sarajevo[tw] OR Sarajevska[tw] OR "Kanton 10"[tw] OR "10 
kanton"[tw] OR Hercegbosanska[tw] OR "Unsko sanski"[tw] OR "Una Sana"[tw] OR "Banja Luka"[tw] OR bijeljina[tw] OR 
Mostar[tw] OR Prijedor[tw] OR Cazin[tw] OR Doboj[tw] OR Zupanija[tw]) OR ("Kosovo"[Mesh] OR Kosov*[tw] OR Ferizaj*[tw] 
OR Urosevac*[tw] OR Gjakov*[tw] OR Dakovic*[tw] OR Gjilan*[tw] OR Gnjilan*[tw] OR Mitrovic*[tw] OR Pejes[tw] OR Peja[tw] 
OR Peje[tw] OR Pecki[tw] OR Pec[tw] OR Pristin*[tw] OR Prishtin*[tw] OR Pristinski[tw] OR Prizrenit[tw] OR Prizrenski[tw] OR 
Prizen[tw] OR Prizren[tw] OR Prizreni[tw] OR Produjev*[tw] OR Vucitrn[tw] OR Vushtrri*[tw] OR "Suva reka"[tw] OR 
Suhareka[tw] OR Besiana[tw] OR Metohija[tw] OR Dukagjini[tw] OR Dukagjinit[tw])))) OR ((Iceland[ad] OR Icelandic*[ad] OR 
islenska*[ad] OR Icelander*[ad] OR islendinga*[ad] OR Islendigar[ad] OR Inslenska[ad] OR Reykjavik[ad] OR 
Reykjavikurborg[ad] OR Hofudborgarsvaedi[ad] OR Sudurnes[ad] OR Vesturland[ad] OR Vestfirdir[ad] OR Westfjords[ad] OR 
Nordurland[ad] OR Austurland[ad] OR Sudurland[ad] OR Kopavogur[ad] OR Hafnarfjordur[ad] OR Akureyri[ad] OR 
Gardabaer[ad] OR Mosfellsbaer[ad] OR Keflavik[ad] OR Akranes[ad] OR Selfoss[ad] OR Seltjarnarnes[ad]) OR (Switzerland[ad] 
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OR Schweiz[ad] OR Schweizerische[ad] OR Swiss[ad] OR Suisse*[ad] OR Svizzera[ad] OR Svizzeri[ad] OR Svizzers[ad] OR 
Svizra[ad] OR Helvetica[ad] OR Aargau[ad] OR Argovia[ad] OR Ausserrhoden[ad] OR "Outer Rhodes"[ad] OR Innerrhoden[ad] 
OR "Inner Rhodes"[ad] OR Basel[ad] OR Bale[ad] OR Basilea[ad] OR Bern[ad] OR Berne[ad] OR Berna[ad] OR Fribourg[ad] OR 
Freiburg[ad] OR Friburg[ad] OR Geneva[ad] OR Geneve[ad] OR Genf[ad] OR Ginevra[ad] OR Genevra[ad] OR Glarus[ad] OR 
Graubunden[ad] OR Graubuenden[ad] OR Grisons[ad] OR Grigioni[ad] OR Grischun[ad] OR jura[ad] OR Lucerne[ad] OR 
Luzern[ad] OR Losanna[ad] OR Neuchatel[ad] OR Nidwalden[ad] OR Nidwald[ad] OR Obwalden[ad] OR Obwald[ad] OR 
Schaffhausen[ad] OR Schaffhouse[ad] OR Schwyz[ad] OR Solothurn[ad] OR Soleure[ad] OR Thurgau[ad] OR Thurgovia[ad] OR 
Ticino[ad] OR Tessin[ad] OR Uri[ad] OR Valais[ad] OR Wallis[ad] OR Vaud[ad] OR Zug[ad] OR Zurich[ad] OR Zuerich[ad] OR 
Zurigo[ad] OR Lausanne[ad] OR Losanna[ad] OR Winterthur[ad] OR Winterthour[ad] OR "St Gallen"[ad] OR "Saint Gallen"[ad] 
OR "Sankt Gallen"[ad] OR "Saint Gall"[ad] OR "San Gallo"[ad] OR "Son Gagl"[ad] OR Turitg[ad]) OR (Norway[ad] OR 
Norwegian*[ad] OR Norge[ad] OR Noreg[ad] OR Norgga[ad] OR Akershus[ad] OR "Aust Agder"[ad] OR Buskerud[ad] OR 
Finnmark[ad] OR Hedmark[ad] OR Hordaland[ad] OR "More og Romsdal"[ad] OR "More and Romsdal"[ad] OR "More 
Romsdal"[ad] OR Nordland[ad] OR Trondelag[ad] OR Oppland[ad] OR Oslo[ad] OR Ostfold[ad] OR Rogaland[ad] OR "Sogn og 
fjordane"[ad] OR "Sogn and fjordane"[ad] OR "sogn fjordane"[ad] OR Telemark[ad] OR Troms[ad] OR Romsa[ad] OR 
Romssa[ad] OR "Vest Agder"[ad] OR Vestfold[ad] OR Bergen[ad] OR Stavanger[ad] OR Sandnes[ad] OR Trondheim[ad] OR 
Trondhjem[ad] OR Kaupangen[ad] OR Nidaros[ad] OR Drammen[ad] OR Fredrikstad[ad] OR Skien[ad] OR Tromso[ad] OR 
Sarpsborg[ad]) OR (Liechtenstein[ad] OR Lienchtensteiner*[ad] OR Balzers[ad] OR Eschen[ad] OR Gamprin[ad] OR Mauren[ad] 
OR Planken[ad] OR Ruggell[ad] OR Schaan[ad] OR Schellenberg[ad] OR Triesen[ad] OR Triesenberg[ad] OR Vaduz[ad]))) OR 
((Albania*[ad] OR Shqiperi*[ad] OR Schqipt*[ad] OR Berat[ad] OR Beratit[ad] OR Diber[ad] OR Dibres[ad] OR Durres[ad] OR 
Durresit[ad] OR Elbasan[ad] OR Elbasanit[ad] OR Fier[ad] OR Fierit[ad] OR Gjirokaster[ad] OR Gjirokastres[ad] OR Korce[ad] OR 
Korces[ad] OR Kukes[ad] OR Kukesit[ad] OR Lezhes[ad] OR Lezhe[ad] OR Shkodres[ad] OR Shkoder[ad] OR Tirana[ad] OR 
Tirane*[ad] OR Vlore[ad] OR Vlores[ad] OR Kamez[ad] OR Beraz[ad] OR Lushnje[ad]) OR (Makedon*[ad] OR Macedon*[ad] OR 
Fyrom[ad] OR Istocen[ad] OR Severoistocen[ad] OR Jugoistocen[ad] OR Jugozapaden[ad] OR Pelagonski[ad] OR Pelagonia[ad] 
OR Poloski[ad] OR Polog[ad] OR Skopski[ad] OR Skopje[ad] OR Ckonje[ad] OR Vardar*[ad] OR Bitola[ad] OR Kumanovo[ad] OR 
Prilep[ad] OR Tetovo[ad] OR Tetova[ad] OR Tetove[ad] OR Veles[ad] OR Stip[ad] OR Shtip[ad] OR Ohrid[ad] OR Gostivar[ad] 
OR Gostivari[ad] OR Strumica[ad]) OR (Iceland[ad] OR Icelandic*[ad] OR islenska*[ad] OR Icelander*[ad] OR islendinga*[ad] 
OR Islendigar[ad] OR Inslenska[ad] OR Reykjavik[ad] OR Reykjavikurborg[ad] OR Hofudborgarsvaedi[ad] OR Sudurnes[ad] OR 
Vesturland[ad] OR Vestfirdir[ad] OR Westfjords[ad] OR Nordurland[ad] OR Austurland[ad] OR Sudurland[ad] OR Kopavogur[ad] 
OR Hafnarfjordur[ad] OR Akureyri[ad] OR Gardabaer[ad] OR Mosfellsbaer[ad] OR Keflavik[ad] OR Akranes[ad] OR Selfoss[ad] 
OR Seltjarnarnes[ad]) OR (Montenegr*[ad] OR "Crna Gora"[ad] OR Crnogorci[ad] OR Andrijevica[ad] OR (Bar[ad] AND 
(Opstina[ad] OR municipality[ad] OR city[ad] OR town[ad])) OR Berane[ad] OR "Bijelo polje"[ad] OR Budva[ad] OR Cetinje[ad] 
OR Danilovgrad[ad] OR Gusinje[ad] OR "herceg Novi"[ad] OR Kolasin[ad] OR Kotor[ad] OR Mojkovac[ad] OR Niksic[ad] OR 
Petnija[ad] OR Plav[ad] OR Pluzine[ad] OR Pljevlja[ad] OR Podgorica[ad] OR Rozaje[ad] OR Savnik[ad] OR Tivat[ad] OR 
Ulcinj[ad] OR Zabljak[ad]) OR (Serbia*[ad] OR Srbija[ad] OR Serb[ad] OR Serbs[ad] OR Srbi[ad] OR Vojvodina[ad] OR 
Belgrade[ad] OR Beograd[ad] OR Sumadija[ad] OR Kolubara[ad] OR Kolubarski[ad] OR Macva[ad] OR Macvanski[ad] OR 
Moravica[ad] OR Moravicki[ad] OR Pomoravlje[ad] OR Pomoravski[ad] OR Rasinski[ad] OR Rasina[ad] OR Raska[ad] OR 
Raski[ad] OR Sumadijski[ad] OR Zlatibor[ad] OR Zlatiborski[ad] OR Bor[ad] OR Borski[ad] OR Branicevo[ad] OR Branicevski[ad] 
OR Jablanica[ad] OR Jablanicki[ad] OR Nisava[ad] OR Nisavski[ad] OR Pcinja[ad] OR Pcinjski[ad] OR Pirot[ad] OR Pirotski[ad] 
OR Podunavlje[ad] OR Podunavski[ad] OR Toplica[ad] OR Toplicki[ad] OR Zajecar[ad] OR Zajecarski[ad] OR Banat[ad] OR 
Srendjebanatski[ad] OR Backa[ad] OR Severnobacki[ad] OR Severnobanatski[ad] OR Juznobacki[ad] OR Juznobanatski[ad] OR 
Srem[ad] OR Sremski[ad] OR Zapadnobacki[ad] OR "Novi Sad"[ad] OR "Novy Sad"[ad] OR Ujvidek[ad] OR Nis[ad] OR Nish[ad] 
OR Nissa[ad] OR Kragujevac[ad] OR Subotica[ad] OR Szabadka[ad] OR Zrenjanin[ad] OR Pancevo[ad] OR Cacak[ad] OR 
Kraljevo[ad] OR "Novi Pazar"[ad] OR "Novy Pazar"[ad]) OR (Turkey[ad] OR Turkiye[ad] OR Turkish[ad] OR Turk[ad] OR 
Turkc*[ad] OR Adana[ad] OR Adiyaman[ad] OR Ayfon*[ad] OR Agri[ad] OR Aksaray[ad] OR Aksaray[ad] OR Amasya[ad] OR 
Ankara[ad] OR Antalya[ad] OR Ardahan[ad] OR Artvin[ad] OR Aydin[ad] OR Balikesir[ad] OR Bartin[ad] OR Batman[ad] OR 
Bayburt[ad] OR Bilecik[ad] OR Bingol[ad] OR Bitlis[ad] OR Bolu[ad] OR Burdur[ad] OR Bursa[ad] OR Canakkale[ad] OR 
Cannkiri[ad] OR Corum[ad] OR Denizli[ad] OR Diyarbarkir[ad] OR Duzce[ad] OR Edirne[ad] OR Elazig[ad] OR Erzincan[ad] OR 
Erzurum[ad] OR Eskishir[ad] OR Gaziantep[ad] OR Giresun[ad] OR Gumushane[ad] OR Hakkari[ad] OR Hatay[ad] OR Igdir[ad] 
OR Isparta[ad] OR Istanbul[ad] OR Izmir[ad] OR Kahramanmaras[ad] OR Karabuk[ad] OR Karaman[ad] OR Kars[ad] OR 
Kastamonu[ad] OR Kayseri[ad] OR Kirikkale[ad] OR Kirklarely[ad] OR Kirklareli[ad] OR Kirsheir[ad] OR Kocaeli[ad] OR Konya[ad] 
OR Kutahya[ad] OR Malatya[ad] OR Manisa[ad] OR Mardin[ad] OR Mersin[ad] OR Mugla[ad] OR Mus[ad] OR Nevsehir[ad] OR 
Nigde[ad] OR Ordu[ad] OR Osmaniye[ad] OR Rize[ad] OR Sakarya[ad] OR Samsun[ad] OR Sanliurfa[ad] OR Siirt[ad] OR 
Sinop[ad] OR Sivas[ad] OR Sirnak[ad] OR Tekirdag[ad] OR Tokat[ad] OR Trabzon[ad] OR Tunceli[ad] OR Usak[ad] OR (Van[ad] 
AND (province[ad] OR ili[ad])) OR Yalova[ad] OR Yozgat[ad] OR Kilis[ad]) OR (Bosnia*[ad] OR Herzegov*[ad] OR 
Herzegonine[ad] OR Bosna[ad] OR Bosne[ad] OR Bosanski[ad] OR Bosanac[ad] OR Bosanci[ad] OR Srpska[ad] OR Brcko[ad] OR 
Posavski[ad] OR Posavina[ad] OR posavska[ad] OR Tuzlanski[ad] OR Tuzla[ad] OR Tuzlanska[ad] OR "Zenickho dobojski"[ad] OR 
"Zenicko dobojska"[ad] OR Zenica[ad] OR "Bosansko Podrinjski"[ad] OR "Bosansko Podrinjska"[ad] OR Srednjobosanski[ad] OR 
hercegovacko[ad] OR Zapadnohercegovacki[ad] OR Zapadnohercegovacka[ad] OR Sarajevo[ad] OR Sarajevska[ad] OR "Kanton 
10"[ad] OR "10 kanton"[ad] OR Hercegbosanska[ad] OR "Unsko sanski"[ad] OR "Una Sana"[ad] OR "Banja Luka"[ad] OR 
bijeljina[ad] OR Mostar[ad] OR Prijedor[ad] OR Cazin[ad] OR Doboj[ad] OR Zupanija[ad]) OR (Kosov*[ad] OR Ferizaj*[ad] OR 
Urosevac*[ad] OR Gjakov*[ad] OR Dakovic*[ad] OR Gjilan*[ad] OR Gnjilan*[ad] OR Mitrovic*[ad] OR Pejes[ad] OR Peja[ad] OR 
Peje[ad] OR Pecki[ad] OR Pec[ad] OR Pristin*[ad] OR Prishtin*[ad] OR Pristinski[ad] OR Prizrenit[ad] OR Prizrenski[ad] OR 
Prizen[ad] OR Prizren[ad] OR Prizreni[ad] OR Produjev*[ad] OR Vucitrn[ad] OR Vushtrri*[ad] OR "Suva reka"[ad] OR 
Suhareka[ad] OR Besiana[ad] OR Metohija[ad] OR Dukagjini[ad] OR Dukagjinit[ad]))) OR ((((("Liechtenstein"[Mesh] OR 
Liechtenstein[tw] OR Lienchtensteiner*[tw] OR Balzers[tw] OR Eschen[tw] OR Gamprin[tw] OR Mauren[tw] OR Planken[tw] OR 
Ruggell[tw] OR Schaan[tw] OR Schellenberg[tw] OR Triesen[tw] OR Triesenberg[tw] OR Vaduz[tw])) OR ("Norway"[Mesh] OR 
Norway[tw] OR Norwegian*[tw] OR Norge[tw] OR Noreg[tw] OR Norgga[tw] OR Akershus[tw] OR "Aust Agder"[tw] OR 
Buskerud[tw] OR Finnmark[tw] OR Hedmark[tw] OR Hordaland[tw] OR "More og Romsdal"[tw] OR "More and Romsdal"[tw] OR 
"More Romsdal"[tw] OR Nordland[tw] OR Trondelag[tw] OR Oppland[tw] OR Oslo[tw] OR Ostfold[tw] OR Rogaland[tw] OR 
"Sogn og fjordane"[tw] OR "Sogn and fjordane"[tw] OR "sogn fjordane"[tw] OR Telemark[tw] OR Troms[tw] OR Romsa[tw] OR 
Romssa[tw] OR "Vest Agder"[tw] OR Vestfold[tw] OR Bergen[tw] OR Stavanger[tw] OR Sandnes[tw] OR Trondheim[tw] OR 
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Trondhjem[tw] OR Kaupangen[tw] OR Nidaros[tw] OR Drammen[tw] OR Fredrikstad[tw] OR Skien[tw] OR Tromso[tw] OR 
Sarpsborg[tw])) OR ("Switzerland"[Mesh] OR Switzerland[tw] OR Schweiz[tw] OR Schweizerische[tw] OR Swiss[tw] OR 
Suisse*[tw] OR Svizzera[tw] OR Svizzeri[tw] OR Svizzers[tw] OR Svizra[tw] OR Helvetica[tw] OR Aargau[tw] OR Argovia[tw] OR 
Ausserrhoden[tw] OR "Outer Rhodes"[tw] OR Innerrhoden[tw] OR "Inner Rhodes"[tw] OR Basel[tw] OR Bale[tw] OR Basilea[tw] 
OR Bern[tw] OR Berne[tw] OR Berna[tw] OR Fribourg[tw] OR Freiburg[tw] OR Friburg[tw] OR Geneva[tw] OR Geneve[tw] OR 
Genf[tw] OR Ginevra[tw] OR Genevra[tw] OR Glarus[tw] OR Graubunden[tw] OR Graubuenden[tw] OR Grisons[tw] OR 
Grigioni[tw] OR Grischun[tw] OR jura[tw] OR Lucerne[tw] OR Luzern[tw] OR Losanna[tw] OR Neuchatel[tw] OR Nidwalden[tw] 
OR Nidwald[tw] OR Obwalden[tw] OR Obwald[tw] OR Schaffhausen[tw] OR Schaffhouse[tw] OR Schwyz[tw] OR Solothurn[tw] 
OR Soleure[tw] OR Thurgau[tw] OR Thurgovia[tw] OR Ticino[tw] OR Tessin[tw] OR Uri[tw] OR Valais[tw] OR Wallis[tw] OR 
Vaud[tw] OR Zug[tw] OR Zurich[tw] OR Zuerich[tw] OR Zurigo[tw] OR Lausanne[tw] OR Losanna[tw] OR Winterthur[tw] OR 
Winterthour[tw] OR "St Gallen"[tw] OR "Saint Gallen"[tw] OR "Sankt Gallen"[tw] OR "Saint Gall"[tw] OR "San Gallo"[tw] OR "Son 
Gagl"[tw] OR Turitg[tw])) OR ("Iceland"[Mesh] OR Iceland[tw] OR Icelandic*[tw] OR islenska*[tw] OR Icelander*[tw] OR 
islendinga*[tw] OR Islendigar[tw] OR Inslenska[tw] OR Reykjavik[tw] OR Reykjavikurborg[tw] OR Hofudborgarsvaedi[tw] OR 
Sudurnes[tw] OR Vesturland[tw] OR Vestfirdir[tw] OR Westfjords[tw] OR Nordurland[tw] OR Austurland[tw] OR Sudurland[tw] 
OR Kopavogur[tw] OR Hafnarfjordur[tw] OR Akureyri[tw] OR Gardabaer[tw] OR Mosfellsbaer[tw] OR Keflavik[tw] OR 
Akranes[tw] OR Selfoss[tw] OR Seltjarnarnes[tw]))) OR (("European Union"[Mesh] OR "Europe"[Mesh:noexp] OR Europe*[tw] 
OR Europa*[tw] OR EU[tw] OR EEA[tw] OR EFTA[tw] OR "EU/EEA"[tw] OR "EU/EFTA"[tw] OR ECSC[tw] OR Euratom[tw] OR 
Eurozone[tw] OR EEC[tw] OR ec[tw] OR (Schengen[tw] AND (area[tw] OR countr*[tw] OR region*[tw] OR state[tw] OR 
states[tw])) OR Euroregion[tw] OR Euroregions[tw] OR "Europe, Eastern"[Mesh:noexp] OR "Balkan Peninsula"[Mesh] OR 
Balkan[tw] OR Balkans[tw] OR "Baltic States"[Mesh] OR Baltic[tw] OR "Mediterranean Region"[Mesh] OR (Mediterranean[tw] 
AND (area[tw] OR countr*[tw] OR region*[tw] OR state[tw] OR states[tw])) OR (Alpine[tw] AND (area[tw] OR countr*[tw] OR 
region*[tw] OR state[tw] OR states[tw])) OR "Scandinavian and Nordic Countries"[Mesh] OR Scandinavia[tw] OR 
Scandinavian[tw] OR "Nordic country"[tw] OR "Nordic countries"[tw] OR "Nordic state"[tw] OR "Nordic states"[tw] OR 
Danubian[tw] OR "Iberian peninsula"[tw] OR "Peninsula iberica"[tw] OR "Peninsule Iberique"[tw] OR "Iberiar Penintsula"[tw] OR 
Iberia[tw] OR Anatolia[tw] OR Anadolu[tw] OR Anatole[tw] OR Anatolian[tw] OR "Yugoslavia"[Mesh] OR Yugoslavia[tw] OR 
"Czechoslovakia"[Mesh] OR Czechoslovakia[tw] OR "Czecho Slovakia"[tw] OR Ceskoslovensko[tw] OR "Cesko slovensko"[tw] OR 
Benelux[tw] OR Fennoscandia[tw] OR "Fenno Scandinavia"[tw] OR Fennoskandi*[tw] OR (Visegrad[tw] AND (Group[tw] OR 
Four[tw] OR Triangle[tw])) OR "Visegradska ctyrka"[tw] OR "Visegradska skupina"[tw] OR "Visegradi Egyuttmukodes"[tw] OR 
"Visegradi negyek"[tw] OR "Grupa Wyszehradzka"[tw] OR "Vysehradska skupina"[tw] OR "Vysehradska stvorka"[tw]) OR 
("Austria"[Mesh] OR Austria*[tw] OR Osterreich*[tw] OR Oesterreich*[tw] OR Ostosterreich[tw] OR Ostoesterreich[tw] OR 
Sudosterreich[tw] OR Sudoesterreich[tw] OR Westosterreich[tw] OR Westoesterreich[tw] OR Burgenland[tw] OR Carinthia[tw] 
OR Karnten[tw] OR Kaernten[tw] OR Niederosterreich[tw] OR Niederoesterreich[tw] OR Oberosterreich[tw] OR 
Oberoesterreich[tw] OR Salzburg[tw] OR Saizburg[tw] OR Styria[tw] OR Steiermark[tw] OR Tyrol[tw] OR Tirol[tw] OR 
Vorarlberg[tw] OR Vienna[tw] OR Wien[tw] OR Graz[tw] OR Linz[tw] OR Innsbruck[tw] OR Klagenfurt[tw] OR Villach[tw] OR 
Wels[tw] OR "St Polten"[tw] OR "St Poelten"[tw] OR "Sankt Polten"[tw] OR "Sankt Poelten"[tw] OR Dornbirn[tw]) OR 
("Belgium"[Mesh] OR Belgi*[tw] OR Belge*[tw] OR Belg[tw] OR Brussel*[tw] OR Bruxelles[tw] OR Bruxelloise[tw] OR 
Walloon*[tw] OR Wallon*[tw] OR Vlaams[tw] OR Flander*[tw] OR Flandern[tw] OR Flandre[tw] OR Flemish[tw] OR Flamand[tw] 
OR Flemisch[tw] OR Flamisch*[tw] OR Vlaanderen[tw] OR Flamande[tw] OR Waals[tw] OR Antwerp*[tw] OR Anvers[tw] OR 
Henegouwen[tw] OR Hennegau[tw] OR Hainault[tw] OR Hainaut[tw] OR Liege[tw] OR Luik[tw] OR Luttich[tw] OR Limbourg[tw] 
OR Limburg[tw] OR Namur[tw] OR Namen[tw] OR Ostflandern[tw] OR Westflandern[tw] OR Ghent[tw] OR Gent[tw] OR 
Gand[tw] OR Charleroi[tw] OR Bruges[tw] OR Brugge*[tw] OR Schaerbeek[tw] OR Schaarbeek[tw] OR Anderlecht[tw] OR 
Leuven[tw] OR Louvain[tw]) OR ("Bulgaria"[Mesh] OR Bulgaria*[tw] OR Balgariya[tw] OR Balgarija[tw] OR Blagoevgrad*[tw] OR 
"Pirin Macedonia"[tw] OR Burgas[tw] OR Dobrich[tw] OR Gabrovo[tw] OR Haskovo[tw] OR Kardzhali[tw] OR Kurdzhali[tw] OR 
Kyustendil[tw] OR Lovech[tw] OR Lovec[tw] OR Montana[tw] OR Pazardzhik[tw] OR Pernik[tw] OR Pleven*[tw] OR Plovdiv[tw] 
OR Razgrad[tw] OR Rousse[tw] OR Ruse[tw] OR Rusenka[tw] OR Shumen[tw] OR Silistra[tw] OR Sliven[tw] OR Smolyan[tw] OR 
Sofia[tw] OR Sofyiska[tw] OR Sofiiska[tw] OR "Stara Zagora"[tw] OR Targovishte[tw] OR Varna[tw] OR "Veliko Tarnovo"[tw] OR 
Vidin[tw] OR Vratsa[tw] OR Vratza[tw] OR Yambol[tw]) OR ("Croatia"[Mesh] OR Croat*[tw] OR Hrvatsk*[tw] OR hrvati[tw] OR 
Bjelovar[tw] OR "Bjelovarsko bilogorska"[tw] OR "Brod Posavina"[tw] OR "Brodsko posavska"[tw] OR "Dubrovnik Neretva"[tw] 
OR "dubrovacko neretvanska"[tw] OR Zagreb[tw] OR Zagrebacka[tw] OR Istria[tw] OR Istarska[tw] OR Karlovacka[tw] OR 
Karlovac[tw] OR "Koprivnicko krizevacka"[tw] OR Koprivnica[tw] OR Krizevci[tw] OR "Krapina Zagorje"[tw] OR "Krapinsko 
zagorska"[tw] OR "Lika Senj"[tw] OR "Licko senjska"[tw] OR Medimurska[tw] OR Medimurje[tw] OR Osijek[tw] OR Baranja[tw] 
OR "Osjecko baranjska"[tw] OR "Pozega Slavonia"[tw] OR "Pozesko slavonska"[tw] OR "Primorje Gorski Kotar"[tw] OR 
"Primorsko goranska"[tw] OR "Sibensko kninska"[tw] OR "Sibensko kninske"[tw] OR Sibenik[tw] OR Knin[tw] OR Sisak[tw] OR 
"Sisacko moslavacka"[tw] OR Moslavina[tw] OR "Splitsko dalmatinska"[tw] OR Split[tw] OR Dalmatia[tw] OR Varazdin[tw] OR 
Varazdinska[tw] OR Viroviticko[tw] OR podravska[tw] OR Virovitica[tw] OR Podravina[tw] OR "Vukovarsko srijemska"[tw] OR 
Vukovar[tw] OR Srijem[tw] OR Zadar[tw] OR Zadarska[tw] OR Rijeka[tw] OR "Velika gorica"[tw] OR "Slavonski brod"[tw] OR 
Pula[tw]) OR ("Cyprus"[Mesh] OR Cyprus[tw] OR Cypriot*[tw] OR Kypros[tw] OR Kibris*[tw] OR kypriaki[tw] OR Kyprioi[tw] OR 
Nicosia[tw] OR Lefkosa[tw] OR Lefkosia[tw] OR Famagusta[tw] OR Magusa[tw] OR Ammochostos[tw] OR Gazimagusa[tw] OR 
Kyrenia[tw] OR Girne[tw] OR Keryneia[tw] OR Larnaca[tw] OR Larnaka[tw] OR Iskele[tw] OR Limassol[tw] OR Lemesos[tw] OR 
Limasol[tw] OR Leymosun[tw] OR Paphos[tw] OR Pafos[tw] OR Baf[tw] OR Strovolos[tw] OR Lakatamia[tw] OR Lakadamya[tw] 
OR "Kato Polemidia"[tw] OR "Kato Polemidhia"[tw] OR Aglandjia[tw] OR Eglence[tw] OR Aglantzia[tw] OR Aradhippou[tw] OR 
Aradippou[tw] OR Engomi[tw]) OR ("Czech Republic"[Mesh] OR Czech*[tw] OR Cesky[tw] OR Ceska[tw] OR Cech[tw] OR 
Cestina[tw] OR Prague[tw] OR Praha[tw] OR Prag[tw] OR Stredoces*[tw] OR Jihoces*[tw] OR Bohemia[tw] OR Bohemian[tw] 
OR Plzen*[tw] OR Pilsen[tw] OR Karlovars*[tw] OR "Karlovy Vary"[tw] OR Usteck*[tw] OR Usti[tw] OR Liberec*[tw] OR "Hradec 
Kralove"[tw] OR Kralovehradec*[tw] OR Pardubic*[tw] OR Olomouc*[tw] OR Olomoc[tw] OR Holomoc[tw] OR 
Moravskoslezs*[tw] OR Jihomorav*[tw] OR Moravia[tw] OR Moravian[tw] OR Morava[tw] OR Vysocina[tw] OR Zlin[tw] OR 
Zlinsk*[tw] OR "Ceske Budejovice"[tw] OR Budweis[tw] OR Brno[tw] OR Ostrava[tw]) OR ("Denmark"[Mesh] OR Denmark[tw] 
OR Danish*[tw] OR dane[tw] OR danes[tw] OR Danmark[tw] OR dansk*[tw] OR Hovedstaden[tw] OR Midtjylland[tw] OR 
Nordjylland[tw] OR Sjaelland[tw] OR Sealand[tw] OR "Zealand region"[tw] OR "region Zealand"[tw] OR Syddanmark[tw] OR 
Jutland[tw] OR Jylland[tw] OR Sonderjyllands[tw] OR Copenhagen[tw] OR Kobenhavn[tw] OR Arhus[tw] OR Aarhus[tw] OR 
Bornholm[tw] OR Frederiksberg[tw] OR Frederiksborg[tw] OR Ringkjobing[tw] OR Viborg[tw] OR Vejle[tw] OR Roskilde[tw] OR 
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Storstrom[tw] OR Vestsjaellands[tw] OR "West Zealand"[tw] OR Funen[tw] OR Ribe[tw] OR "Kalaallit Nunaat"[tw] OR 
Gronland[tw] OR Foroyar[tw] OR Faeroerne[tw] OR "Faroe islands"[tw] OR Aalborg[tw] OR Alborg[tw] OR Odense[tw] OR 
Esbjerg[tw] OR Gentofte[tw] OR Gladsaxe[tw] OR Randers[tw] OR Kolding[tw]) OR ("Estonia"[Mesh] OR Estonia*[tw] OR 
Eesti[tw] OR Eestlased[tw] OR Eestlane[tw] OR Harju[tw] OR Harjumaa[tw] OR Hiiu[tw] OR Hiiumaa[tw] OR "Ida Viru"[tw] OR 
"Ida Virumaa"[tw] OR Jarvamaa[tw] OR Jarva[tw] OR Jogevamaa[tw] OR Jogeva[tw] OR Laanemaa[tw] OR Laane[tw] OR 
"Laane Virumaa"[tw] OR Parnu[tw] OR Parnumaa[tw] OR Polva[tw] OR Polvamaa[tw] OR Rapla[tw] OR Raplamaa[tw] OR 
Saare[tw] OR Saaremaa[tw] OR Tartu[tw] OR Tartumaa[tw] OR Valga[tw] OR Valgamaa[tw] OR Viljandimaa[tw] OR Viljandi[tw] 
OR Voru[tw] OR Vorumaa[tw] OR Tallinn[tw] OR Narva[tw] OR "Kohtla Jarve"[tw] OR Rakvere[tw] OR Maardu[tw] OR 
Sillamae[tw] OR Kuressaare[tw]) OR ("Finland"[Mesh] OR Finland[tw] OR Finnish*[tw] OR Finn[tw] OR Finns[tw] OR Suomi[tw] 
AND Suomen[tw] OR Suomalaiset[tw] OR Aland[tw] OR Ahvenanmaa[tw] OR Uusimaa[tw] OR Nyland[tw] OR Karelia[tw] OR 
Karjala[tw] OR Karelen[tw] OR Ostrobothnia[tw] OR Pohjanmaa[tw] OR Osterbotten[tw] OR Savonia[tw] OR Savo[tw] OR 
Savolax[tw] OR Kainuu[tw] OR Kajanaland*[tw] OR "Kanta Hame"[tw] OR Tavastia[tw] OR Tavastland[tw] OR Kymenlaakso[tw] 
OR Kymmenedalen[tw] OR Lapland[tw] OR Lappi[tw] OR Lappland[tw] OR "Paijat Hame"[tw] OR Pirkanmaa[tw] OR 
Birkaland[tw] OR Satakunta[tw] OR Satakunda[tw] OR Helsinki[tw] OR Helsingfors[tw] OR Espoo[tw] OR Esbo[tw] OR 
Tampere[tw] OR Tammerfors[tw] OR Vantaa[tw] OR Vanda[tw] OR Oulu[tw] OR Uleaborg[tw] OR Turku[tw] OR Abo[tw] OR 
Jyvaskyla[tw] OR Kuopio[tw] OR Lahti[tw] OR Lahtis[tw] OR Kouvola[tw]) OR ("France"[Mesh] OR France[tw] OR French*[tw] 
OR Francais*[tw] OR Alsace[tw] OR Elsass[tw] OR Aquitaine[tw] OR Aquitania[tw] OR Akitania[tw] OR Aguiene[tw] OR 
Auvergne[tw] OR Auvernhe[tw] OR Auvernha[tw] OR Normandie[tw] OR Normandy[tw] OR Normaundie[tw] OR Bourgogne[tw] 
OR Burgundy[tw] OR Bregogne[tw] OR Borgoegne[tw] OR Borgogne[tw] OR Brittany[tw] OR Breizh[tw] OR Bertaeyn[tw] OR 
Bretagne[tw] OR "Champagne Ardenne"[tw] OR Corse[tw] OR Corsica[tw] OR "Franche Comte"[tw] OR "Frantche Comte"[tw] OR 
"Franche Comtat"[tw] OR Guadeloupe[tw] OR Guyane[tw] OR Guiana[tw] OR "Languedoc Roussillon"[tw] OR "Lengadoc 
Rosselhon"[tw] OR "Llenguadoc-Rossello"[tw] OR Limousin[tw] OR Lemosin[tw] OR Lorraine[tw] OR Lothringen[tw] OR 
Lottringe[tw] OR Martinique[tw] OR "Midi Pyrenees"[tw] OR "Miegjorn Pireneus"[tw] OR "Mieidia Pireneus"[tw] OR "Mediodia 
Pirineos"[tw] OR "Pays de la Loire"[tw] OR "Broiou al Liger"[tw] OR Picardie[tw] OR Picardy[tw] OR "Poitou Charentes"[tw] OR 
"Peitau Charantas"[tw] OR "Poetou-Cherentes"[tw] OR Provence[tw] OR Provenca[tw] OR Prouvenco[tw] OR "Cote d Azur"[tw] 
OR "Cote d'Azur"[tw] OR "Costo d'Azur"[tw] OR "Costo d Azur"[tw] OR "Costa d'Azur"[tw] OR "Costa d Azur"[tw] OR Reunion[tw] 
OR "Rhone Alpes"[tw] OR "Rono Arpes"[tw] OR "Rose Aups"[tw] OR Ain[tw] OR Aisne[tw] OR Allier[tw] OR "Alpes de Haute 
Provence"[tw] OR "Haute Alpes"[tw] OR "Alpes Maritimes"[tw] OR Ardeche[tw] OR Ardennes[tw] OR Ariege[tw] OR Aube[tw] OR 
Aude[tw] OR Aveyron[tw] OR "Bas Rhin"[tw] OR "Bouches du Rhone"[tw] OR Calvados[tw] OR Cantal[tw] OR Charente[tw] OR 
Cher[tw] OR Correze[tw] OR "Corse du Sud"[tw] OR "Cote d Or"[tw] OR "Cote d'Or"[tw] OR "Cotes d Armor"[tw] OR "Cotes 
d'Armor"[tw] OR Creuse[tw] OR "Deux Sevres"[tw] OR Dordogne[tw] OR Doubs[tw] OR Drome[tw] OR Essonne[tw] OR Eure[tw] 
OR Finistere[tw] OR Gard[tw] OR Gers[tw] OR Gironde[tw] OR "Haute Corse"[tw] OR "Haute Garonne"[tw] OR "Haute 
Marne"[tw] OR "Hautes Alpes"[tw] OR "Haute Saone"[tw] OR "Haute Savoie"[tw] OR "Hautes Pyrenees"[tw] OR "Haute 
Vienne"[tw] OR "Haut Rhin"[tw] OR "Hauts de Seine"[tw] OR Herault[tw] OR "Ile de France"[tw] OR "Ille et Vilaine"[tw] OR 
Indre[tw] OR Isere[tw] OR Jura[tw] OR Landes[tw] OR Loire[tw] OR Loiret[tw] OR (Lot[tw] AND (departement[tw] OR 
department[tw])) OR "Lot et Garonne"[tw] OR "Loir et Cher"[tw] OR Lozere[tw] OR Manche[tw] OR Marne[tw] OR Mayenne[tw] 
OR Mayotte[tw] OR "Meurthe et Moselle"[tw] OR Meuse[tw] OR Morbihan[tw] OR Moselle[tw] OR (Nord[tw] AND 
(department[tw] OR departement[tw])) OR Nievre[tw] OR Oise[tw] OR Orne[tw] OR "Pas de calais"[tw] OR "Noord-Nauw van 
Kales"[tw] OR Paris[tw] OR "Puy de dome"[tw] OR "Pyrenees Atlantiques"[tw] OR "Pyrenees Orientales"[tw] OR Rhone[tw] OR 
Sarthe[tw] OR Savoie[tw] OR "Seine et Marne"[tw] OR "Seine Maritime"[tw] OR Somme[tw] OR Tarn[tw] OR "Territoire de 
Belfort"[tw] OR "Val de Marne"[tw] OR "Val d Oise"[tw] OR Var[tw] OR Vaucluse[tw] OR Vendee[tw] OR Vienne[tw] OR 
Vosges[tw] OR Yonne[tw] OR Yvelines[tw] OR Marseille[tw] OR Lyon[tw] OR Nice[tw] OR Nantes[tw] OR Strasbourg[tw] OR 
Montpellier[tw] OR Bordeaux[tw] OR Lille[tw] OR Toulouse[tw] OR "Outre Mer"[tw] OR "Seine Saint Denis"[tw]) OR 
("Germany"[Mesh] OR German*[tw] OR Deutsch*[tw] OR Bundesrepublik[tw] OR Westdeutschland[tw] OR Ostdeutschland[tw] 
OR Baden[tw] OR Wuerttemberg[tw] OR Wurttemberg[tw] OR Bayern[tw] OR Bavaria[tw] OR Berlin[tw] OR Brandenburg[tw] OR 
Bremen[tw] OR Oldenburg[tw] OR Mitteldeutschland[tw] OR Rhein[tw] OR Rhine[tw] OR Hannover[tw] OR Braunschweig[tw] OR 
Gottingen[tw] OR Goettingen[tw] OR Nurnberg[tw] OR Nuernberg[tw] OR Ruhr[tw] OR Koln[tw] OR koeln[tw] OR Bonn[tw] OR 
Hamburg[tw] OR Hessen[tw] OR Hesse[tw] OR Hessia[tw] OR Mecklenburg[tw] OR Vorpommern[tw] OR Pomerania[tw] OR 
Niedersachsen[tw] OR Neddersassen[tw] OR Saxony[tw] OR Niederbayern[tw] OR "Northern Rhine"[tw] OR "North Rhine"[tw] 
OR Westphalia[tw] OR Westfalen[tw] OR "Rhineland Palatinate"[tw] OR "Rheinland Pfalz"[tw] OR Saarland[tw] OR Sachsen[tw] 
OR "Schleswig Holstein"[tw] OR Thuringia[tw] OR Thuringen[tw] OR Thueringen[tw] OR Munchen[tw] OR Muenchen[tw] OR 
Munich[tw] OR Frankfurt[tw] OR Stuttgart[tw] OR Dusseldorf[tw] OR Duesseldorf[tw] OR Dortmund[tw] OR Essen[tw]) OR 
("Greece"[Mesh] OR Greece[tw] OR "Hellenic republic"[tw] OR Greek*[tw] OR Ellada[tw] OR Elladas[tw] OR "Elliniki 
Dimokratia"[tw] OR Hellas[tw] OR Hellenes[tw] OR Attica[tw] OR Attiki[tw] OR Makedonia*[tw] OR Macedonia[tw] OR Thraki[tw] 
OR Thrace[tw] OR Crete[tw] OR Kriti[tw] OR "Ionia Nisia"[tw] OR "Ionion neson"[tw] OR "Ionion nIson"[tw] OR "Ionian 
islands"[tw] OR "Ionian island"[tw] OR Epirus[tw] OR Ipeiros[tw] OR "Perifereia Ipeirou"[tw] OR "North aegean"[tw] OR 
"Northern Aegean"[tw] OR "Aegean islands"[tw] OR "Aegean island"[tw] OR "Nisoi Agaiou"[tw] OR "Notio Aigaio"[tw] OR 
Peloponnese[tw] OR Peloponniso*[tw] OR Thessaly[tw] OR Thessalia[tw] OR Thessalian[tw] OR Petthalia[tw] OR "Voreio 
Aigaio"[tw] OR "Voreio Aigaiou"[tw] OR "South aegean"[tw] OR "Southern Aegean"[tw] OR "Mount athos"[tw] OR "Oros 
Athos"[tw] OR Cyclades[tw] OR Cycklades[tw] OR Kiklades[tw] OR Dodecanese[tw] OR Dodekanisa[tw] OR Athens[tw] OR 
Athina[tw] OR Thessaloniki[tw] OR Thessalonica[tw] OR Patras[tw] OR Patra[tw] OR Pireas[tw] OR Piraeus[tw] OR Larissa[tw] 
OR Larisa[tw] OR Heraklion[tw] OR Heraclion[tw] OR Iraklion[tw] OR Irakleion[tw] OR Iraklio[tw] OR Volos[tw] OR Rhodes[tw] 
OR Rodos[tw] OR Ioannina[tw] OR Janina[tw] OR Yannena[tw] OR Chania[tw] OR Chalcis[tw] OR Chalkida[tw]) OR 
("Hungary"[Mesh] OR Hungar*[tw] OR Magyarorszag[tw] OR Magyar*[tw] OR Dunantuli[tw] OR Transdanubia[tw] OR 
Dunantul[tw] OR "Great Plain"[tw] OR "Eszak Alfold"[tw] OR "Del Alfold"[tw] OR "Alfold es eszak"[tw] OR "Northern Alfold"[tw] 
OR "North Alfold"[tw] OR "South Alfold"[tw] OR "Southern Alfold"[tw] OR Bacs[tw] OR Kiskun[tw] OR Baranya[tw] OR Bekes[tw] 
OR Borsod[tw] OR Abauj[tw] OR Zemplen[tw] OR Budapest[tw] OR Csongrad[tw] OR Fejer[tw] OR gyor[tw] OR moson[tw] OR 
sopron[tw] OR hajdu[tw] OR bihar[tw] OR Heves[tw] OR "jasz nagykun szolnok"[tw] OR komarom[tw] OR esztergom[tw] OR 
Nograd[tw] OR (Pest[tw] AND (megye[tw] OR county[tw])) OR Somogy[tw] OR szabolcs[tw] OR szatmar[tw] OR bereg[tw] OR 
Tolna[tw] OR Vas[tw] OR Veszprem[tw] OR Zala[tw] OR Debrecen[tw] OR Miskolc[tw] OR Szeged[tw] OR Pecs[tw] OR Gyor[tw] 
OR Nyiregyhaza[tw] OR Kecskemet[tw] OR Szekesfehervar[tw] OR Szombathely[tw]) OR ("Ireland"[Mesh] OR Ireland[tw] OR 
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Eire[tw] OR Irish*[tw] OR Fingal[tw] OR "Fine Gall"[tw] OR Dublin[tw] OR "Ath Cliath"[tw] OR "Dun Laoghaire"[tw] OR 
Wicklow[tw] OR "Cill Mhantain"[tw] OR "Chill Mhantain"[tw] OR Wexford[tw] OR "Loch Garman"[tw] OR Carlow[tw] OR 
Ceatharlach[tw] OR Kildare[tw] OR "Cill Dara"[tw] OR "Chill Dara"[tw] OR Meath[tw] OR "An Mhi"[tw] OR "Contae na Mi"[tw] OR 
Louth[tw] OR "Contae Lu"[tw] OR Monaghan[tw] OR Muineachan[tw] OR Mhuineachain[tw] OR Cavan[tw] OR "An Cabhan"[tw] 
OR "An Cabhain"[tw] OR Longford[tw] OR "An Longfort"[tw] OR "an Longfoirt"[tw] OR Langfurd[tw] OR Westmeath[tw] OR "An 
Iarmhi"[tw] OR "na Iarmhi"[tw] OR Offaly[tw] OR "Uibh Fhaili"[tw] OR Laois[tw] OR Laoise[tw] OR Kilkenny[tw] OR "Chill 
Chainnigh"[tw] OR "Cill Chainnigh"[tw] OR Waterford[tw] OR "Port Lairge"[tw] OR Watterford[tw] OR Cork[tw] OR Corcaigh[tw] 
OR Chorcai[tw] OR Kerry[tw] OR Ciarrai[tw] OR Chiarrai[tw] OR Limerick[tw] OR Luimneach[tw] OR Luimnigh[tw] OR 
Tipperary[tw] OR "Tiobraid Arann"[tw] OR "Thiobraid Arann"[tw] OR Clare[tw] OR "An Clar"[tw] OR "an Chlair"[tw] OR 
Galway[tw] OR Gaillimh[tw] OR "na Gaillimhe"[tw] OR Mayo[tw] OR "Maigh Eo"[tw] OR "Mhaigh Eo"[tw] OR Roscommon[tw] OR 
"Ros comain"[tw] OR Sligo[tw] OR Sligeach[tw] OR Shligigh[tw] OR Leitrim[tw] OR Liatroim[tw] OR Liatroma[tw] OR 
Donegal[tw] OR "Dhun na nGall"[tw] OR Dinnygal[tw] OR Dunnyga[tw] OR Leinster[tw] OR Laighin[tw] OR "Cuige Laighean"[tw] 
OR Munster[tw] OR Mumhain[tw] OR "Cuige Mumhan"[tw] OR Connacht[tw] OR Connachta[tw] OR Drogheda[tw] OR "Droichead 
Atha"[tw] OR Dundalk[tw] OR "Dun Dealgan"[tw] OR Swords[tw] OR Sord[tw] OR Bray[tw] OR Bre[tw] OR Navan[tw] OR "An 
Uaimh"[tw]) OR ("Italy"[Mesh] OR Italy[tw] OR Italia*[tw] OR Abruzzo[tw] OR Abruzzi[tw] OR Basilicata[tw] OR Lucania[tw] OR 
Calabria[tw] OR Campania[tw] OR "Emilia Romagna"[tw] OR "friuli venezia giulia"[tw] OR Lazio[tw] OR Latium[tw] OR 
Liguria*[tw] OR Lombardy[tw] OR Lombardia[tw] OR Marche[tw] OR Marches[tw] OR Molisano[tw] OR Molise[tw] OR 
Piedmont*[tw] OR Piemonte[tw] OR Bolzano[tw] OR Bozen[tw] OR Trentino[tw] OR Trento[tw] OR Puglia[tw] OR Apulia[tw] OR 
Sardinia[tw] OR Sardegna[tw] OR Sicily[tw] OR Sicilia[tw] OR Toscana[tw] OR Tuscany[tw] OR Umbria[tw] OR "Valle d 
Aosta"[tw] OR "Vallee d Aoste"[tw] OR "Valle d'Aosta"[tw] OR "Vallee d'Aoste"[tw] OR "Aosta Valley"[tw] OR Veneto[tw] OR 
Venetia[tw] OR Triveneto[tw] OR Rome[tw] OR Roma[tw] OR Milan[tw] OR Milano[tw] OR Naples[tw] OR Napoli[tw] OR 
Turin[tw] OR Torino[tw] OR Palermo[tw] OR Genoa[tw] OR Genova[tw] OR Bologna[tw] OR Florence[tw] OR Firenze[tw] OR 
Bari[tw] OR Catania[tw]) OR ("Latvia"[Mesh] OR Latvi*[tw] OR Riga[tw] OR Courland[tw] OR Kurzeme[tw] OR Kurland[tw] OR 
Latgale[tw] OR Lettgallia[tw] OR Latgola[tw] OR Latgalia[tw] OR Vidzeme[tw] OR Vidumo[tw] OR Semigallia[tw] OR 
Semigalia[tw] OR Zemgale[tw] OR Pieriga[tw] OR Daugavpils[tw] OR Dinaburg[tw] OR Jekabpils[tw] OR Jakobstadt[tw] OR 
Jelgava[tw] OR Jurmala[tw] OR Liepaja[tw] OR Libau[tw] OR Rezekne[tw] OR Rezne[tw] OR Rositten[tw] OR Valmiera[tw] OR 
Wolmar[tw] OR Ventspils[tw] OR Windau[tw] OR Ogre[tw]) OR ("Lithuania"[Mesh] OR Lithuania*[tw] OR "Lietuvos 
Respublika"[tw] OR Lietuva[tw] OR lietuviu[tw] OR Alytus[tw] OR Alytaus[tw] OR Kaunas[tw] OR Kauno[tw] OR Klaipeda[tw] OR 
Klaipedos[tw] OR Marijampoles[tw] OR Marijampole[tw] OR Panevezys[tw] OR Panevezio[tw] OR Siauliai[tw] OR Siauliu[tw] OR 
Taurages[tw] OR Taurage[tw] OR Telsiu[tw] OR Telsiai[tw] OR Utenos[tw] OR Utena[tw] OR Vilnius[tw] OR Vilniaus[tw] OR 
Mazeikiai[tw] OR Jonava[tw] OR Mazeikiu[tw] OR Jonavos[tw]) OR ("Luxembourg"[Mesh] OR Luxembourg*[tw] OR 
Luxemburg[tw] OR Letzebuerg[tw] OR Diekirch[tw] OR Grevenmacher[tw] OR "Esch sur Alzette"[tw] OR "Esch Uelzecht"[tw] OR 
"Esch an der Alzette"[tw] OR "Esch an der Alzig"[tw] OR Dudelange[tw] OR Diddeleng[tw] OR Dudelingen[tw] OR 
Duedelingen[tw] OR Schifflange[tw] OR Scheffleng[tw] OR Schifflingen[tw] OR Bettembourg[tw] OR Beetebuerg[tw] OR 
Bettemburg[tw] OR Petange[tw] OR Peiteng[tw] OR Petingen[tw] OR Ettelbruck[tw] OR Ettelbreck[tw] OR Ettelbrueck[tw] OR 
Diekirch[tw] OR Dikrech[tw] OR Strassen[tw] OR Stroossen[tw] OR Bertrange[tw] OR Bartreng[tw] OR Bartringen[tw]) OR 
("Malta"[Mesh] OR Malta[tw] OR Maltese*[tw] OR Maltin[tw] OR Gozo[tw] OR Ghawdex[tw] OR Valletta[tw] OR "Ill Belt"[tw] OR 
Birkirkara[tw] OR "B Kara"[tw] OR "B'Kara"[tw] OR Birchircara[tw] OR Mosta[tw] OR Qormi[tw] OR "St Paul s Bay"[tw] OR "St 
Paul's Bay"[tw] OR "Pawl il Bahar"[tw] OR Zabbar[tw] OR Sliema[tw] OR Naxxar[tw] OR Gwann[tw] OR "St John"[tw] OR 
Zebbug[tw] OR "Citta rohan"[tw] OR Fgura[tw]) OR ("Netherlands"[Mesh] OR Netherlands[tw] OR Nederland*[tw] OR 
Dutch*[tw] OR Drenthe[tw] OR Flevoland[tw] OR Friesland[tw] OR Fryslan[tw] OR Frisia[tw] OR Gelderland[tw] OR Guelders[tw] 
OR Groningen[tw] OR Limburg[tw] OR Brabant[tw] OR Holland[tw] OR Overijssel[tw] OR Overissel[tw] OR Utrecht[tw] OR 
Zeeland[tw] OR Amsterdam[tw] OR Rotterdam[tw] OR Hague[tw] OR "s-Gravenhage"[tw] OR "Den Haag"[tw] OR Eindhoven[tw] 
OR Tilburg[tw] OR Almere[tw] OR Breda[tw] OR Nijmegen[tw] OR Nimeguen[tw]) OR ("Poland"[Mesh] OR Poland[tw] OR 
Polska[tw] OR Polish[tw] OR Pole[tw] OR Poles[tw] OR Polski[tw] OR Polak[tw] OR Polka[tw] OR Polacy[tw] OR Dolnoslaskie[tw] 
OR Silesia*[tw] OR Slask[tw] OR Pomorskie[tw] OR Pomerania*[tw] OR Kujawsko[tw] OR Kuyavian[tw] OR Lodzkie[tw] OR 
Lodz[tw] OR Lubelskie[tw] OR Lublin[tw] OR Lubuskie[tw] OR Lubusz[tw] OR Lubus[tw] OR Malopolskie[tw] OR Mazowieckie[tw] 
OR Mazowske[tw] OR Masovia[tw] OR Masovian[tw] OR Opolskie[tw] OR Opole[tw] OR Podkarpackie[tw] OR Subcarpathian*[tw] 
OR Podlaskie[tw] OR Podlachia[tw] OR Podlasie[tw] OR Slaskie[tw] OR Swietokrzyskie[tw] OR "Varmia Mazuria"[tw] OR "Varmian 
Mazurian"[tw] OR "Varmia Masuria"[tw] OR "Varmian Masurian"[tw] OR "Warmia Mazury"[tw] OR "Warminsko Mazurskie"[tw] OR 
"Warmian Masurian"[tw] OR Wielkopolskie[tw] OR Zachodniopomorskie[tw] OR Warsaw[tw] OR Warszawa[tw] OR Krakow[tw] 
OR Cracow[tw] OR Wroclaw[tw] OR Poznan[tw] OR Gdansk[tw] OR Szczecin[tw] OR Bydgoszcz[tw] OR Katowice[tw]) OR 
("Portugal"[Mesh] OR Portugal[tw] OR Portugues*[tw] OR Azores[tw] OR Acores[tw] OR Madeira[tw] OR Alentejo[tw] OR 
Algarve[tw] OR Lisboa[tw] OR Lisbon[tw] OR "Alto Tras-os-Montes"[tw] OR (Ave[tw] AND (community[tw] OR intermunicipal[tw] 
OR comunidade[tw])) OR Mondego[tw] OR Vouga[tw] OR Beira[tw] OR Cavado[tw] OR Lafoes[tw] OR Douro[tw] OR Porto[tw] 
OR Oporto[tw] OR Tejo[tw] OR Minho[tw] OR Setubal[tw] OR Pinhal[tw] OR "Serra da Estrela"[tw] OR Tamega[tw] OR Leira[tw] 
OR Santarem[tw] OR Beja[tw] OR Faro[tw] OR Evora[tw] OR Portalegre[tw] OR "Castelo Branco"[tw] OR Guarda[tw] OR 
Cimbra[tw] OR Aveiro[tw] OR Viseu[tw] OR Braganca[tw] OR Braganza[tw] OR Braga[tw] OR "Vila real"[tw] OR "Viana do 
Castelo"[tw] OR Gaia[tw] OR Amadora[tw] OR Funchal[tw] OR Coimbra[tw] OR Almada[tw] OR (Agualva[tw] AND Cacem[tw])) 
OR ("Romania"[Mesh] OR Romania*[tw] OR Rumania*[tw] OR Roumania*[tw] OR Romani[tw] OR Rumani[tw] OR Alba[tw] OR 
Arad[tw] OR Arges[tw] OR Bacau[tw] OR Bihor[tw] OR "Bistrita Nasaud"[tw] OR Botosani[tw] OR Braila[tw] OR Brasov[tw] OR 
Kronstadt[tw] OR Brasso[tw] OR Brassovia[tw] OR Coron[tw] OR Bucharest[tw] OR Bucuresti[tw] OR Buzau[tw] OR Calarasi[tw] 
OR "Caras-Severin"[tw] OR Cluj[tw] OR Klausenburg[tw] OR Kolozsvar[tw] OR Constanta[tw] OR Tomis[tw] OR Konstantia[tw] 
OR Kostence[tw] OR Covasna[tw] OR Dambovita[tw] OR Dolj[tw] OR Galati[tw] OR Galatz[tw] OR Galac[tw] OR Kalas[tw] OR 
Giurgiu[tw] OR Gorj[tw] OR Harghita[tw] OR Hunedoara[tw] OR Ialomita[tw] OR Iasi[tw] OR Jassy[tw] OR Lassy[tw] OR 
Ilfov[tw] OR Maramures[tw] OR Mehedinti[tw] OR Mures[tw] OR Neamt[tw] OR (Olt[tw] AND (river[tw] OR county[tw] OR 
region[tw] OR judetul[tw] OR Raul[tw])) OR Prahova[tw] OR Salaj[tw] OR "Satu Mare"[tw] OR Sibiu[tw] OR Suceava[tw] OR 
Teleorman[tw] OR Timis[tw] OR Tulcea[tw] OR Valcea[tw] OR Vilcea[tw] OR Vaslui[tw] OR Vrancea[tw] OR Timisoara[tw] OR 
Temeswar[tw] OR Temeschburg[tw] OR Temeschwar[tw] OR Temesvar[tw] OR Temisvar[tw] OR Timisvar[tw] OR Temesva[tw] 
OR Craiova[tw] OR Ploiesti[tw] OR Ploesti[tw] OR Oradea[tw] OR Varad[tw] OR Varat[tw]) OR ("Slovakia"[Mesh] OR Slovakia[tw] 
OR Slovensk*[tw] OR Slovak*[tw] OR Slovaci[tw] OR Slovenki[tw] OR Bratislav*[tw] OR Presporok[tw] OR Pressburg[tw] OR 
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Pressburg[tw] OR Posonium[tw] OR Banskobystri*[tw] OR "Banska Bystrica"[tw] OR Neusohl[tw] OR Besztercebanya[tw] OR 
Kosic*[tw] OR Kaschau[tw] OR Kassa[tw] OR Nitrian*[tw] OR Nitra[tw] OR Neutra[tw] OR Nyitra[tw] OR Nyitria[tw] OR 
Trnav*[tw] OR Tyrnau[tw] OR Nagyszombat[tw] OR Tyrnavia[tw] OR Presov*[tw] OR Trencian*[tw] OR Trencin[tw] OR 
Trentschin[tw] OR Trencsen[tw] OR Zilina[tw] OR Sillein[tw] OR Zsolna[tw] OR Zylina[tw] OR (Martin[tw] AND (city[tw] OR 
Svaty[tw])) OR Turocszentmarton[tw] OR Poprad[tw] OR Deutschendorf[tw] OR Zvolen[tw]) OR ("Slovenia"[Mesh] OR 
Slovenia*[tw] OR Slovenija[tw] OR slovensk*[tw] OR Slovenci[tw] OR Slovene*[tw] OR Gorenjska[tw] OR Carniola[tw] OR 
Goriska[tw] OR Gorizia[tw] OR Jugovzhodna[tw] OR Koroska[tw] OR Carinthia[tw] OR "Notranjsko kraska"[tw] OR "Obalno 
kraska"[tw] OR "Coastal karst"[tw] OR Osrednjeslovenska[tw] OR Podravska[tw] OR Drava[tw] OR Pomurska[tw] OR Mura[tw] 
OR Savinjska[tw] OR Savinja[tw] OR Spodnjeposavska[tw] OR Zasavska[tw] OR "Central Sava"[tw] OR Posavska[tw] OR "Lower 
Sava"[tw] OR Ljubljana[tw] OR Laibach[tw] OR Lubiana[tw] OR Maribor[tw] OR "Marburg an der Drau"[tw] OR Kranj[tw] OR 
Carnium[tw] OR Creina[tw] OR Chreina[tw] OR Krainbur[tw] OR Koper[tw] OR Capodistria[tw] OR Kopar[tw] OR Celje[tw] OR 
"Novo mesto"[tw] OR Neustadtl[tw] OR Domzale[tw] OR Velenje[tw] OR Wollan[tw] OR Woellan[tw] OR "Nova Gorica"[tw] OR 
Kamnik[tw]) OR ("Spain"[Mesh] OR Spain[tw] OR Espana[tw] OR Spanish[tw] OR Espanol*[tw] OR Spaniard*[tw] OR 
Andalucia[tw] OR Andalusia[tw] OR Aragon[tw] OR Arago[tw] OR Cantabria[tw] OR Canarias[tw] OR "Canary Islands"[tw] OR 
(Canaries[tw] AND island*[tw]) OR "Castile and leon"[tw] OR "Castilla y Leon"[tw] OR "Castile La Mancha"[tw] OR "Castilla La 
Mancha"[tw] OR Cataluna[tw] OR Catalonia[tw] OR Ceuta[tw] OR Madrid[tw] OR Melilla[tw] OR Navarra[tw] OR Navarre[tw] OR 
Valencia*[tw] OR Extremadura[tw] OR Galicia[tw] OR Balears[tw] OR "Balearic Islands"[tw] OR "Balear Islands"[tw] OR 
Baleares[tw] OR "La Rioja"[tw] OR "Pais Vasco"[tw] OR "Basque Country"[tw] OR "Baske region"[tw] OR Euskadi[tw] OR 
Asturias[tw] OR Murcia[tw] OR Coruna[tw] OR Alava[tw] OR Araba[tw] OR Albacete[tw] OR Alicante[tw] OR Alacant[tw] OR 
Almeria[tw] OR Avila[tw] OR Badajoz[tw] OR Badajos[tw] OR Barcelona[tw] OR Burgos[tw] OR Caceres[tw] OR Cadiz[tw] OR 
Castellon[tw] OR Castello[tw] OR "Ciudad Real"[tw] OR Cordoba[tw] OR Cuenca[tw] OR Eivissa[tw] OR Ibiza[tw] OR 
Formentera[tw] OR "El Hierro"[tw] OR Fuerteventura[tw] OR Galiza[tw] OR Girona[tw] OR Gerona[tw] OR "Gran Canaria"[tw] OR 
Granada[tw] OR Guadalajara[tw] OR Guipuzcoa[tw] OR Gipuzkoa[tw] OR Huelva[tw] OR Huesca[tw] OR Jaen[tw] OR "La 
Gomera"[tw] OR "La Palma"[tw] OR Lanzarote[tw] OR Leon[tw] OR Lleida[tw] OR Lerida[tw] OR Lugo[tw] OR Malaga[tw] OR 
Mallorca[tw] OR Majorca[tw] OR Menorca[tw] OR Minorca[tw] OR Murcia[tw] OR Ourense[tw] OR Orense[tw] OR Palencia[tw] 
OR Pontevedra[tw] OR Salamanca[tw] OR Segovia[tw] OR Sevilla[tw] OR Seville[tw] OR Soria[tw] OR Tarragona[tw] OR 
Tenerife[tw] OR Teruel[tw] OR Toledo[tw] OR Valladolid[tw] OR Vizcaya[tw] OR Biscay[tw] OR Zamora[tw] OR Zaragoza[tw] OR 
Saragossa[tw] OR "Las Palmas"[tw] OR Bilbao[tw] OR Bilbo[tw]) OR ("Sweden"[Mesh] OR Sweden[tw] OR Sverige[tw] OR 
Swedish[tw] OR Svenska[tw] OR svenskar[tw] OR Swede[tw] OR Swedes[tw] OR Norrland[tw] OR Mellansverige[tw] OR 
Smaland[tw] OR Stockholm*[tw] OR Sydsverige[tw] OR Vastsverige[tw] OR Blekinge[tw] OR Dalarna[tw] OR Gavleborg*[tw] OR 
Gotland*[tw] OR Halland*[tw] OR Jamtland*[tw] OR Jonkoping*[tw] OR Kalmar[tw] OR Kronoberg*[tw] OR Norrbotten*[tw] OR 
Orebro[tw] OR Ostergotland*[tw] OR Skane[tw] OR Sodermanlands[tw] OR Uppsala[tw] OR Varmland*[tw] OR 
Vasterbotten*[tw] OR Vasternorrland*[tw] OR Vastmanland*[tw] OR vastergotland*[tw] OR Gotaland*[tw] OR Gothenburg[tw] 
OR Goteborg[tw] OR Malmo[tw] OR Vasteras[tw] OR Linkoping[tw] OR Helsingborg[tw] OR Halsingborg[tw] OR Norrkoping[tw]) 
OR ("Great Britain"[Mesh] OR GB[tw] OR "United kingdom"[tw] OR UK[tw] OR Britain[tw] OR British[tw] OR England[tw] OR 
English[tw] OR Scotland[tw] OR Scottish[tw] OR Scots[tw] OR Wales[tw] OR Cymru[tw] OR Welsh[tw] OR "North Ireland"[tw] 
OR "Northern Ireland"[tw] OR Irish[tw] OR Avon[tw] OR Bedfordshire[tw] OR Berkshire[tw] OR Bristol[tw] OR 
Buckinghamshire[tw] OR Cambridgeshire[tw] OR "Isle of Ely"[tw] OR Cheshire[tw] OR Cleveland[tw] OR Cornwall[tw] OR 
Cumberland[tw] OR Cumbria[tw] OR Derbyshire[tw] OR Devon[tw] OR Dorset[tw] OR Durham[tw] OR Essex[tw] OR 
Gloucestershire[tw] OR Hampshire[tw] OR Southampton[tw] OR (Hereford[tw] AND Worcester[tw]) OR Hertfordshire[tw] OR 
Herefordshire[tw] OR Humberside[tw] OR Huntingdon[tw] OR Huntingdonshire[tw] OR "Isle of Wight"[tw] OR Kent[tw] OR 
Lancashire[tw] OR Leicestershire[tw] OR Lincolnshire[tw] OR London[tw] OR Manchester[tw] OR Merseyside[tw] OR 
Middlesex[tw] OR Norfolk[tw] OR Northamptonshire[tw] OR Northumberland[tw] OR Nottinghamshire[tw] OR Oxfordshire[tw] OR 
Peterborough[tw] OR Rutland[tw] OR Shropshire[tw] OR Salop[tw] OR Somerset[tw] OR Yorkshire[tw] OR Staffordshire[tw] OR 
Suffolk[tw] OR Surrey[tw] OR Sussex[tw] OR (Tyne[tw] AND Wear[tw]) OR Warwickshire[tw] OR Midlands[tw] OR 
Westmorland[tw] OR Wiltshire[tw] OR Worcestershire[tw] OR "Isle of Man"[tw] OR Jersey[tw] OR Guernsey[tw] OR "Channel 
Islands"[tw] OR Aberdeen[tw] OR Aberdeenshire[tw] OR Angus[tw] OR Forfarshire[tw] OR Argyll[tw] OR Ayrshire[tw] OR 
Banffshire[tw] OR Berwickshire[tw] OR Bute[tw] OR Caithness[tw] OR Clackmannanshire[tw] OR Cromartyshire[tw] OR 
Dumfriesshire[tw] OR Dunbartonshire[tw] OR Dumbarton[tw] OR Dundee[tw] OR Lothian[tw] OR Haddingtonshire[tw] OR 
Edinburgh[tw] OR Fife[tw] OR Glasgow[tw] OR Inverness-shire[tw] OR Kincardineshire[tw] OR Kinross-shire[tw] OR 
Kirkcudbrightshire[tw] OR Lanarkshire[tw] OR Midlothian[tw] OR Moray[tw] OR Elginshire[tw] OR Nairnshire[tw] OR Orkney[tw] 
OR Peeblesshire[tw] OR Perthshire[tw] OR Renfrewshire[tw] OR (Ross[tw] AND Cromarty[tw]) OR Ross-shire[tw] OR 
Roxburghshire[tw] OR Selkirkshire[tw] OR Shetland[tw] OR Zetland[tw] OR Stirlingshire[tw] OR Sutherland[tw] OR 
Linlithgowshire[tw] OR Wigtownshire[tw] OR Anglesey[tw] OR Brecknockshire[tw] OR Caernarfonshire[tw] OR 
Carmarthenshire[tw] OR Cardiganshire[tw] OR Ceredigion[tw] OR Clwyd[tw] OR Denbighshire[tw] OR Dyfed[tw] OR 
Flintshire[tw] OR Glamorgan[tw] OR Gwent[tw] OR Gwynedd[tw] OR Merionethshire[tw] OR Montgomeryshire[tw] OR 
Monmouthshire[tw] OR Pembrokeshire[tw] OR Powys[tw] OR Radnorshire[tw] OR Antrim[tw] OR Aontroim[tw] OR "Contae 
Aontroma"[tw] OR Anthrim[tw] OR Antrim[tw] OR Entrim[tw] OR Armagh[tw] OR "Ard Mhacha"[tw] OR Airmagh[tw] OR 
Belfast[tw] OR (Down[tw] AND (district[tw] OR council[tw] OR County[tw])) OR "An Dun"[tw] OR "an Duin"[tw] OR Doon[tw] OR 
Doun[tw] OR Fermanagh[tw] OR "Fear Manach"[tw] OR "Fhear Manach"[tw] OR Fermanay[tw] OR Londonderry[tw] OR 
Doire[tw] OR Dhoire[tw] OR Lunnonderrie[tw] OR Derry[tw] OR Birmingham[tw] OR Leeds[tw] OR Sheffield[tw] OR Bradford[tw] 
OR Liverpool[tw]))) OR ((GB[ad] OR "United kingdom"[ad] OR UK[ad] OR Britain[ad] OR British[ad] OR England[ad] OR 
English[ad] OR Scotland[ad] OR Scottish[ad] OR Scots[ad] OR Wales[ad] OR Cymru[ad] OR Welsh[ad] OR "North Ireland"[ad] 
OR "Northern Ireland"[ad] OR Irish[ad] OR Avon[ad] OR Bedfordshire[ad] OR Berkshire[ad] OR Bristol[ad] OR 
Buckinghamshire[ad] OR Cambridgeshire[ad] OR "Isle of Ely"[ad] OR Cheshire[ad] OR Cleveland[ad] OR Cornwall[ad] OR 
Cumberland[ad] OR Cumbria[ad] OR Derbyshire[ad] OR Devon[ad] OR Dorset[ad] OR Durham[ad] OR Essex[ad] OR 
Gloucestershire[ad] OR Hampshire[ad] OR Southampton[ad] OR (Hereford[ad] AND Worcester[ad]) OR Hertfordshire[ad] OR 
Herefordshire[ad] OR Humberside[ad] OR Huntingdon[ad] OR Huntingdonshire[ad] OR "Isle of Wight"[ad] OR Kent[ad] OR 
Lancashire[ad] OR Leicestershire[ad] OR Lincolnshire[ad] OR London[ad] OR Manchester[ad] OR Merseyside[ad] OR 
Middlesex[ad] OR Norfolk[ad] OR Northamptonshire[ad] OR Northumberland[ad] OR Nottinghamshire[ad] OR Oxfordshire[ad] OR 
Peterborough[ad] OR Rutland[ad] OR Shropshire[ad] OR Salop[ad] OR Somerset[ad] OR Yorkshire[ad] OR Staffordshire[ad] OR 
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Suffolk[ad] OR Surrey[ad] OR Sussex[ad] OR (Tyne[ad] AND Wear[ad]) OR Warwickshire[ad] OR midlands[ad] OR 
Westmorland[ad] OR Wiltshire[ad] OR Worcestershire[ad] OR "Isle of Man"[ad] OR Jersey[ad] OR Guernsey[ad] OR "Channel 
Islands"[ad] OR Aberdeen[ad] OR Aberdeenshire[ad] OR Angus[ad] OR Forfarshire[ad] OR Argyll[ad] OR Ayrshire[ad] OR 
Banffshire[ad] OR Berwickshire[ad] OR bute[ad] OR Caithness[ad] OR Clackmannanshire[ad] OR Cromartyshire[ad] OR 
Dumfriesshire[ad] OR Dunbartonshire[ad] OR Dumbarton[ad] OR Dundee[ad] OR Lothian[ad] OR Haddingtonshire[ad] OR 
Edinburgh[ad] OR Fife[ad] OR Glasgow[ad] OR Inverness-shire[ad] OR Kincardineshire[ad] OR Kinross-shire[ad] OR 
Kirkcudbrightshire[ad] OR Lanarkshire[ad] OR Midlothian[ad] OR Moray[ad] OR Elginshire[ad] OR Nairnshire[ad] OR Orkney[ad] 
OR Peeblesshire[ad] OR Perthshire[ad] OR Renfrewshire[ad] OR (Ross[ad] AND Cromarty[ad]) OR Ross-shire[ad] OR 
Roxburghshire[ad] OR Selkirkshire[ad] OR Shetland[ad] OR Zetland[ad] OR Stirlingshire[ad] OR Sutherland[ad] OR 
Linlithgowshire[ad] OR Wigtownshire[ad] OR Anglesey[ad] OR Brecknockshire[ad] OR Caernarfonshire[ad] OR 
Carmarthenshire[ad] OR Cardiganshire[ad] OR Ceredigion[ad] OR Clwyd[ad] OR Denbighshire[ad] OR Dyfed[ad] OR 
Flintshire[ad] OR Glamorgan[ad] OR Gwent[ad] OR Gwynedd[ad] OR Merionethshire[ad] OR Montgomeryshire[ad] OR 
Monmouthshire[ad] OR Pembrokeshire[ad] OR Powys[ad] OR Radnorshire[ad] OR Antrim[ad] OR Aontroim[ad] OR "Contae 
Aontroma"[ad] OR Anthrim[ad] OR Antrim[ad] OR Entrim[ad] OR Armagh[ad] OR "Ard Mhacha"[ad] OR Airmagh[ad] OR 
Belfast[ad] OR (Down[ad] AND (district[ad] OR council[ad] OR County[ad])) OR "An Dun"[ad] OR "an Duin"[ad] OR Doon[ad] OR 
Doun[ad] OR Fermanagh[ad] OR "Fear Manach"[ad] OR "Fhear Manach"[ad] OR Fermanay[ad] OR Londonderry[ad] OR 
Doire[ad] OR Dhoire[ad] OR Lunnonderrie[ad] OR Derry[ad] OR Birmingham[ad] OR Leeds[ad] OR Sheffield[ad] OR Bradford[ad] 
OR Liverpool[ad]) OR (Sweden[ad] OR Sverige[ad] OR Swedish[ad] OR Svenska[ad] OR svenskar[ad] OR Swede[ad] OR 
Swedes[ad] OR Norrland[ad] OR Mellansverige[ad] OR Smaland[ad] OR Stockholm*[ad] OR Sydsverige[ad] OR Vastsverige[ad] 
OR Blekinge[ad] OR Dalarna[ad] OR Gavleborg*[ad] OR Gotland*[ad] OR Halland*[ad] OR Jamtland*[ad] OR Jonkoping*[ad] OR 
Kalmar[ad] OR Kronoberg*[ad] OR Norrbotten*[ad] OR Orebro[ad] OR Ostergotland*[ad] OR Skane[ad] OR Sodermanlands[ad] 
OR Uppsala[ad] OR Varmland*[ad] OR Vasterbotten*[ad] OR Vasternorrland*[ad] OR Vastmanland*[ad] OR vastergotland*[ad] 
OR Gotaland*[ad] OR Gothenburg[ad] OR Goteborg[ad] OR Malmo[ad] OR Vasteras[ad] OR Linkoping[ad] OR Helsingborg[ad] 
OR Halsingborg[ad] OR Norrkoping[ad]) OR (Spain[ad] OR Espana[ad] OR Spanish[ad] OR Espanol*[ad] OR Spaniard*[ad] OR 
Andalucia[ad] OR Andalusia[ad] OR Aragon[ad] OR Arago[ad] OR Cantabria[ad] OR Canarias[ad] OR "Canary Islands"[ad] OR 
(Canaries[ad] AND island*[ad]) OR "Castile and leon"[ad] OR "Castilla y Leon"[ad] OR "Castile La Mancha"[ad] OR "Castilla La 
Mancha"[ad] OR Cataluna[ad] OR Catalonia[ad] OR Ceuta[ad] OR Madrid[ad] OR Melilla[ad] OR Navarra[ad] OR Navarre[ad] OR 
Valencia*[ad] OR Extremadura[ad] OR Galicia[ad] OR Balears[ad] OR "Balearic Islands"[ad] OR "Balear Islands"[ad] OR 
Baleares[ad] OR "La Rioja"[ad] OR "Pais Vasco"[ad] OR "Basque Country"[ad] OR "Baske region"[ad] OR Euskadi[ad] OR 
Asturias[ad] OR Murcia[ad] OR Coruna[ad] OR Alava[ad] OR Araba[ad] OR Albacete[ad] OR Alicante[ad] OR Alacant[ad] OR 
Almeria[ad] OR Avila[ad] OR Badajoz[ad] OR Badajos[ad] OR Barcelona[ad] OR Burgos[ad] OR Caceres[ad] OR Cadiz[ad] OR 
Castellon[ad] OR Castello[ad] OR "Ciudad Real"[ad] OR Cordoba[ad] OR Cuenca[ad] OR Eivissa[ad] OR Ibiza[ad] OR 
Formentera[ad] OR "El Hierro"[ad] OR Fuerteventura[ad] OR Galiza[ad] OR Girona[ad] OR Gerona[ad] OR "Gran Canaria"[ad] OR 
Granada[ad] OR Guadalajara[ad] OR Guipuzcoa[ad] OR Gipuzkoa[ad] OR Huelva[ad] OR Huesca[ad] OR Jaen[ad] OR "La 
Gomera"[ad] OR "La Palma"[ad] OR Lanzarote[ad] OR Leon[ad] OR Lleida[ad] OR Lerida[ad] OR Lugo[ad] OR Malaga[ad] OR 
Mallorca[ad] OR Majorca[ad] OR Menorca[ad] OR Minorca[ad] OR Murcia[ad] OR Ourense[ad] OR Orense[ad] OR Palencia[ad] 
OR Pontevedra[ad] OR Salamanca[ad] OR Segovia[ad] OR Sevilla[ad] OR Seville[ad] OR Soria[ad] OR Tarragona[ad] OR 
Tenerife[ad] OR Teruel[ad] OR Toledo[ad] OR Valladolid[ad] OR Vizcaya[ad] OR Biscay[ad] OR Zamora[ad] OR Zaragoza[ad] OR 
Saragossa[ad] OR "Las Palmas"[ad] OR Bilbao[ad] OR Bilbo[ad]) OR (Slovenia*[ad] OR Slovenija[ad] OR slovensk*[ad] OR 
Slovenci[ad] OR Slovene*[ad] OR Gorenjska[ad] OR Carniola[ad] OR Goriska[ad] OR Gorizia[ad] OR Jugovzhodna[ad] OR 
Koroska[ad] OR Carinthia[ad] OR "Notranjsko kraska"[ad] OR "Obalno kraska"[ad] OR "Coastal karst"[ad] OR 
Osrednjeslovenska[ad] OR Podravska[ad] OR Drava[ad] OR Pomurska[ad] OR Mura[ad] OR Savinjska[ad] OR Savinja[ad] OR 
Spodnjeposavska[ad] OR Zasavska[ad] OR "Central Sava"[ad] OR Posavska[ad] OR "Lower Sava"[ad] OR Ljubljana[ad] OR 
Laibach[ad] OR Lubiana[ad] OR Maribor[ad] OR "Marburg an der Drau"[ad] OR Kranj[ad] OR Carnium[ad] OR Creina[ad] OR 
Chreina[ad] OR Krainbur[ad] OR Koper[ad] OR Capodistria[ad] OR Kopar[ad] OR Celje[ad] OR "Novo mesto"[ad] OR 
Neustadtl[ad] OR Domzale[ad] OR Velenje[ad] OR Wollan[ad] OR Woellan[ad] OR "Nova Gorica"[ad] OR Kamnik[ad]) OR 
(Slovakia[ad] OR Slovensk*[ad] OR Slovak*[ad] OR Slovaci[ad] OR Slovenki[ad] OR Bratislav*[ad] OR Presporok[ad] OR 
Pressburg[ad] OR Pressburg[ad] OR Posonium[ad] OR Banskobystri*[ad] OR "Banska Bystrica"[ad] OR Neusohl[ad] OR 
Besztercebanya[ad] OR Kosic*[ad] OR Kaschau[ad] OR Kassa[ad] OR Nitrian*[ad] OR Nitra[ad] OR Neutra[ad] OR Nyitra[ad] OR 
Nyitria[ad] OR Trnav*[ad] OR Tyrnau[ad] OR Nagyszombat[ad] OR Tyrnavia[ad] OR Presov*[ad] OR Trencian*[ad] OR 
Trencin[ad] OR Trentschin[ad] OR Trencsen[ad] OR Zilina[ad] OR Sillein[ad] OR Zsolna[ad] OR Zylina[ad] OR (Martin[ad] AND 
(city[ad] OR Svaty[ad])) OR Turocszentmarton[ad] OR Poprad[ad] OR Deutschendorf[ad] OR Zvolen[ad]) OR (Romania*[ad] OR 
Rumania*[ad] OR Roumania*[ad] OR Romani[ad] OR Rumani[ad] OR Alba[ad] OR Arad[ad] OR Arges[ad] OR Bacau[ad] OR 
Bihor[ad] OR "Bistrita Nasaud"[ad] OR Botosani[ad] OR Braila[ad] OR Brasov[ad] OR Kronstadt[ad] OR Brasso[ad] OR 
Brassovia[ad] OR Coron[ad] OR Bucharest[ad] OR Bucuresti[ad] OR Buzau[ad] OR Calarasi[ad] OR "Caras-Severin"[ad] OR 
Cluj[ad] OR Klausenburg[ad] OR Kolozsvar[ad] OR Constanta[ad] OR Tomis[ad] OR Konstantia[ad] OR Kostence[ad] OR 
Covasna[ad] OR Dambovita[ad] OR Dolj[ad] OR Galati[ad] OR Galatz[ad] OR Galac[ad] OR Kalas[ad] OR Giurgiu[ad] OR Gorj[ad] 
OR Harghita[ad] OR Hunedoara[ad] OR Ialomita[ad] OR Iasi[ad] OR Jassy[ad] OR Lassy[ad] OR Ilfov[ad] OR Maramures[ad] OR 
Mehedinti[ad] OR Mures[ad] OR Neamt[ad] OR (Olt[ad] AND (river[ad] OR county[ad] OR region[ad] OR judetul[ad] OR 
Raul[ad])) OR Prahova[ad] OR Salaj[ad] OR "Satu Mare"[ad] OR Sibiu[ad] OR Suceava[ad] OR Teleorman[ad] OR Timis[ad] OR 
Tulcea[ad] OR Valcea[ad] OR Vilcea[ad] OR Vaslui[ad] OR Vrancea[ad] OR Timisoara[ad] OR Temeswar[ad] OR 
Temeschburg[ad] OR Temeschwar[ad] OR Temesvar[ad] OR Temisvar[ad] OR Timisvar[ad] OR Temesva[ad] OR Craiova[ad] OR 
Ploiesti[ad] OR Ploesti[ad] OR Oradea[ad] OR Varad[ad] OR Varat[ad]) OR (Portugal[ad] OR Portugues*[ad] OR Azores[ad] OR 
Acores[ad] OR Madeira[ad] OR Alentejo[ad] OR Algarve[ad] OR Lisboa[ad] OR Lisbon[ad] OR "Alto Tras-os-Montes"[ad] OR 
(Ave[ad] AND (community[ad] OR intermunicipal[ad] OR comunidade[ad])) OR Mondego[ad] OR Vouga[ad] OR Beira[ad] OR 
Cavado[ad] OR Lafoes[ad] OR Douro[ad] OR Porto[ad] OR Oporto[ad] OR Tejo[ad] OR Minho[ad] OR Setubal[ad] OR Pinhal[ad] 
OR "Serra da Estrela"[ad] OR Tamega[ad] OR Leira[ad] OR Santarem[ad] OR Beja[ad] OR Faro[ad] OR Evora[ad] OR 
Portalegre[ad] OR "Castelo Branco"[ad] OR Guarda[ad] OR Cimbra[ad] OR Aveiro[ad] OR Viseu[ad] OR Braganca[ad] OR 
Braganza[ad] OR Braga[ad] OR "Vila real"[ad] OR "Viana do Castelo"[ad] OR Gaia[ad] OR Amadora[ad] OR Funchal[ad] OR 
Coimbra[ad] OR Almada[ad] OR (Agualva[ad] AND Cacem[ad])) OR (Poland[ad] OR Polska[ad] OR Polish[ad] OR Pole[ad] OR 
Poles[ad] OR Polski[ad] OR Polak[ad] OR Polka[ad] OR Polacy[ad] OR Dolnoslaskie[ad] OR Silesia*[ad] OR Slask[ad] OR 
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Pomorskie[ad] OR Pomerania*[ad] OR Kujawsko[ad] OR Kuyavian[ad] OR Lodzkie[ad] OR Lodz[ad] OR Lubelskie[ad] OR 
Lublin[ad] OR Lubuskie[ad] OR Lubusz[ad] OR Lubus[ad] OR Malopolskie[ad] OR Mazowieckie[ad] OR Mazowske[ad] OR 
Masovia[ad] OR Masovian[ad] OR Opolskie[ad] OR Opole[ad] OR Podkarpackie[ad] OR Subcarpathian*[ad] OR Podlaskie[ad] OR 
Podlachia[ad] OR Podlasie[ad] OR Slaskie[ad] OR Swietokrzyskie[ad] OR "Varmia Mazuria"[ad] OR "Varmian Mazurian"[ad] OR 
"Varmia Masuria"[ad] OR "Varmian Masurian"[ad] OR "Warmia Mazury"[ad] OR "Warminsko Mazurskie"[ad] OR "Warmian 
Masurian"[ad] OR Wielkopolskie[ad] OR Zachodniopomorskie[ad] OR Warsaw[ad] OR Warszawa[ad] OR Krakow[ad] OR 
Cracow[ad] OR Wroclaw[ad] OR Poznan[ad] OR Gdansk[ad] OR Szczecin[ad] OR Bydgoszcz[ad] OR Katowice[ad]) OR 
(Netherlands[ad] OR Nederland*[ad] OR Dutch*[ad] OR Drenthe[ad] OR Flevoland[ad] OR Friesland[ad] OR Fryslan[ad] OR 
Frisia[ad] OR Gelderland[ad] OR Guelders[ad] OR Groningen[ad] OR Limburg[ad] OR Brabant[ad] OR Holland[ad] OR 
Overijssel[ad] OR Overissel[ad] OR Utrecht[ad] OR Zeeland[ad] OR Amsterdam[ad] OR Rotterdam[ad] OR Hague[ad] OR "s-
Gravenhage"[ad] OR "Den Haag"[ad] OR Eindhoven[ad] OR Tilburg[ad] OR Almere[ad] OR Breda[ad] OR Nijmegen[ad] OR 
Nimeguen[ad]) OR (Malta[ad] OR Maltese*[ad] OR Maltin[ad] OR Gozo[ad] OR Ghawdex[ad] OR Valletta[ad] OR "Ill Belt"[ad] OR 
Birkirkara[ad] OR "B Kara"[ad] OR "B'Kara"[ad] OR Birchircara[ad] OR Mosta[ad] OR Qormi[ad] OR "St Paul s Bay"[ad] OR "St 
Paul's Bay"[ad] OR "Pawl il Bahar"[ad] OR Zabbar[ad] OR Sliema[ad] OR Naxxar[ad] OR Gwann[ad] OR "St John"[ad] OR 
Zebbug[ad] OR "Citta rohan"[ad] OR Fgura[ad]) OR (Luxembourg*[ad] OR Luxemburg[ad] OR Letzebuerg[ad] OR Diekirch[ad] 
OR Grevenmacher[ad] OR "Esch sur Alzette"[ad] OR "Esch Uelzecht"[ad] OR "Esch an der Alzette"[ad] OR "Esch an der Alzig"[ad] 
OR Dudelange[ad] OR Diddeleng[ad] OR Dudelingen[ad] OR Duedelingen[ad] OR Schifflange[ad] OR Scheffleng[ad] OR 
Schifflingen[ad] OR Bettembourg[ad] OR Beetebuerg[ad] OR Bettemburg[ad] OR Petange[ad] OR Peiteng[ad] OR Petingen[ad] 
OR Ettelbruck[ad] OR Ettelbreck[ad] OR Ettelbrueck[ad] OR Diekirch[ad] OR Dikrech[ad] OR Strassen[ad] OR Stroossen[ad] OR 
Bertrange[ad] OR Bartreng[ad] OR Bartringen[ad]) OR (Lithuania*[ad] OR "Lietuvos Respublika"[ad] OR Lietuva[ad] OR 
lietuviu[ad] OR Alytus[ad] OR Alytaus[ad] OR Kaunas[ad] OR Kauno[ad] OR Klaipeda[ad] OR Klaipedos[ad] OR Marijampoles[ad] 
OR Marijampole[ad] OR Panevezys[ad] OR Panevezio[ad] OR Siauliai[ad] OR Siauliu[ad] OR Taurages[ad] OR Taurage[ad] OR 
Telsiu[ad] OR Telsiai[ad] OR Utenos[ad] OR Utena[ad] OR Vilnius[ad] OR Vilniaus[ad] OR Mazeikiai[ad] OR Jonava[ad] OR 
Mazeikiu[ad] OR Jonavos[ad]) OR (Latvi*[ad] OR Riga[ad] OR Courland[ad] OR Kurzeme[ad] OR Kurland[ad] OR Latgale[ad] OR 
Lettgallia[ad] OR Latgola[ad] OR Latgalia[ad] OR Vidzeme[ad] OR Vidumo[ad] OR Semigallia[ad] OR Semigalia[ad] OR 
Zemgale[ad] OR Pieriga[ad] OR Daugavpils[ad] OR Dinaburg[ad] OR Jekabpils[ad] OR Jakobstadt[ad] OR Jelgava[ad] OR 
Jurmala[ad] OR Liepaja[ad] OR Libau[ad] OR Rezekne[ad] OR Rezne[ad] OR Rositten[ad] OR Valmiera[ad] OR Wolmar[ad] OR 
Ventspils[ad] OR Windau[ad] OR Ogre[ad]) OR (Italy[ad] OR Italia*[ad] OR Abruzzo[ad] OR Abruzzi[ad] OR Basilicata[ad] OR 
Lucania[ad] OR Calabria[ad] OR Campania[ad] OR "Emilia Romagna"[ad] OR "friuli venezia giulia"[ad] OR Lazio[ad] OR 
Latium[ad] OR Liguria*[ad] OR Lombardy[ad] OR Lombardia[ad] OR Marche[ad] OR Marches[ad] OR Molisano[ad] OR Molise[ad] 
OR Piedmont*[ad] OR Piemonte[ad] OR Bolzano[ad] OR Bozen[ad] OR Trentino[ad] OR Trento[ad] OR Puglia[ad] OR Apulia[ad] 
OR Sardinia[ad] OR Sardegna[ad] OR Sicily[ad] OR Sicilia[ad] OR Toscana[ad] OR Tuscany[ad] OR Umbria[ad] OR "Valle d 
Aosta"[ad] OR "Vallee d Aoste"[ad] OR "Valle d'Aosta"[ad] OR "Vallee d'Aoste"[ad] OR "Aosta Valley"[ad] OR Veneto[ad] OR 
Venetia[ad] OR Triveneto[ad] OR Rome[ad] OR Roma[ad] OR Milan[ad] OR Milano[ad] OR Naples[ad] OR Napoli[ad] OR 
Turin[ad] OR Torino[ad] OR Palermo[ad] OR Genoa[ad] OR Genova[ad] OR Bologna[ad] OR Florence[ad] OR Firenze[ad] OR 
Bari[ad] OR Catania[ad]) OR (Ireland[ad] OR Eire[ad] OR Irish*[ad] OR Fingal[ad] OR "Fine Gall"[ad] OR Dublin[ad] OR "Ath 
Cliath"[ad] OR "Dun Laoghaire"[ad] OR Wicklow[ad] OR "Cill Mhantain"[ad] OR "Chill Mhantain"[ad] OR Wexford[ad] OR "Loch 
Garman"[ad] OR Carlow[ad] OR Ceatharlach[ad] OR Kildare[ad] OR "Cill Dara"[ad] OR "Chill Dara"[ad] OR Meath[ad] OR "An 
Mhi"[ad] OR "Contae na Mi"[ad] OR Louth[ad] OR "Contae Lu"[ad] OR Monaghan[ad] OR Muineachan[ad] OR Mhuineachain[ad] 
OR Cavan[ad] OR "An Cabhan"[ad] OR "An Cabhain"[ad] OR Longford[ad] OR "An Longfort"[ad] OR "an Longfoirt"[ad] OR 
Langfurd[ad] OR Westmeath[ad] OR "An Iarmhi"[ad] OR "na Iarmhi"[ad] OR Offaly[ad] OR "Uibh Fhaili"[ad] OR Laois[ad] OR 
Laoise[ad] OR Kilkenny[ad] OR "Chill Chainnigh"[ad] OR "Cill Chainnigh"[ad] OR Waterford[ad] OR "Port Lairge"[ad] OR 
Watterford[ad] OR Cork[ad] OR Corcaigh[ad] OR Chorcai[ad] OR Kerry[ad] OR Ciarrai[ad] OR Chiarrai[ad] OR Limerick[ad] OR 
Luimneach[ad] OR Luimnigh[ad] OR Tipperary[ad] OR "Tiobraid Arann"[ad] OR "Thiobraid Arann"[ad] OR Clare[ad] OR "An 
Clar"[ad] OR "an Chlair"[ad] OR Galway[ad] OR Gaillimh[ad] OR "na Gaillimhe"[ad] OR Mayo[ad] OR "Maigh Eo"[ad] OR "Mhaigh 
Eo"[ad] OR Roscommon[ad] OR "Ros comain"[ad] OR Sligo[ad] OR Sligeach[ad] OR Shligigh[ad] OR Leitrim[ad] OR Liatroim[ad] 
OR Liatroma[ad] OR Donegal[ad] OR "Dhun na nGall"[ad] OR Dinnygal[ad] OR Dunnyga[ad] OR Leinster[ad] OR Laighin[ad] OR 
"Cuige Laighean"[ad] OR Munster[ad] OR Mumhain[ad] OR "Cuige Mumhan"[ad] OR Connacht[ad] OR Connachta[ad] OR 
Drogheda[ad] OR "Droichead Atha"[ad] OR Dundalk[ad] OR "Dun Dealgan"[ad] OR Swords[ad] OR Sord[ad] OR Bray[ad] OR 
Bre[ad] OR Navan[ad] OR "An Uaimh"[ad]) OR (Hungar*[ad] OR Magyarorszag[ad] OR Magyar*[ad] OR Dunantuli[ad] OR 
Transdanubia[ad] OR Dunantul[ad] OR "Great Plain"[ad] OR "Eszak Alfold"[ad] OR "Del Alfold"[ad] OR "Alfold es eszak"[ad] OR 
"Northern Alfold"[ad] OR "North Alfold"[ad] OR "South Alfold"[ad] OR "Southern Alfold"[ad] OR Bacs[ad] OR Kiskun[ad] OR 
Baranya[ad] OR Bekes[ad] OR Borsod[ad] OR Abauj[ad] OR Zemplen[ad] OR Budapest[ad] OR Csongrad[ad] OR Fejer[ad] OR 
gyor[ad] OR moson[ad] OR sopron[ad] OR hajdu[ad] OR bihar[ad] OR Heves[ad] OR "jasz nagykun szolnok"[ad] OR 
komarom[ad] OR esztergom[ad] OR Nograd[ad] OR (Pest[ad] AND (megye[ad] OR county[ad])) OR Somogy[ad] OR 
szabolcs[ad] OR szatmar[ad] OR bereg[ad] OR Tolna[ad] OR Vas[ad] OR Veszprem[ad] OR Zala[ad] OR Debrecen[ad] OR 
Miskolc[ad] OR Szeged[ad] OR Pecs[ad] OR Gyor[ad] OR Nyiregyhaza[ad] OR Kecskemet[ad] OR Szekesfehervar[ad] OR 
Szombathely[ad]) OR (Greece[ad] OR "Hellenic republic"[ad] OR Greek*[ad] OR Ellada[ad] OR Elladas[ad] OR "Elliniki 
Dimokratia"[ad] OR Hellas[ad] OR Hellenes[ad] OR Attica[ad] OR Attiki[ad] OR Makedonia*[ad] OR Macedonia[ad] OR Thraki[ad] 
OR Thrace[ad] OR Crete[ad] OR Kriti[ad] OR "Ionia Nisia"[ad] OR "Ionion neson"[ad] OR "Ionion nIson"[ad] OR "Ionian 
islands"[ad] OR "Ionian island"[ad] OR Epirus[ad] OR Ipeiros[ad] OR "Perifereia Ipeirou"[ad] OR "North aegean"[ad] OR 
"Northern Aegean"[ad] OR "Aegean islands"[ad] OR "Aegean island"[ad] OR "Nisoi Agaiou"[ad] OR "Notio Aigaio"[ad] OR 
Peloponnese[ad] OR Peloponniso*[ad] OR Thessaly[ad] OR Thessalia[ad] OR Thessalian[ad] OR Petthalia[ad] OR "Voreio 
Aigaio"[ad] OR "Voreio Aigaiou"[ad] OR "South aegean"[ad] OR "Southern Aegean"[ad] OR "Mount athos"[ad] OR "Oros 
Athos"[ad] OR Cyclades[ad] OR Cycklades[ad] OR Kiklades[ad] OR Dodecanese[ad] OR Dodekanisa[ad] OR Athens[ad] OR 
Athina[ad] OR Thessaloniki[ad] OR Thessalonica[ad] OR Patras[ad] OR Patra[ad] OR Pireas[ad] OR Piraeus[ad] OR Larissa[ad] 
OR Larisa[ad] OR Heraklion[ad] OR Heraclion[ad] OR Iraklion[ad] OR Irakleion[ad] OR Iraklio[ad] OR Volos[ad] OR Rhodes[ad] 
OR Rodos[ad] OR Ioannina[ad] OR Janina[ad] OR Yannena[ad] OR Chania[ad] OR Chalcis[ad] OR Chalkida[ad]) OR 
(German*[ad] OR Deutsch*[ad] OR Bundesrepublik[ad] OR Westdeutschland[ad] OR Ostdeutschland[ad] OR Baden[ad] OR 
Wuerttemberg[ad] OR Wurttemberg[ad] OR Bayern[ad] OR Bavaria[ad] OR Berlin[ad] OR Brandenburg[ad] OR Bremen[ad] OR 
Oldenburg[ad] OR Mitteldeutschland[ad] OR Rhein[ad] OR Rhine[ad] OR Hannover[ad] OR Braunschweig[ad] OR Gottingen[ad] 
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OR Goettingen[ad] OR Nurnberg[ad] OR Nuernberg[ad] OR Ruhr[ad] OR Koln[ad] OR koeln[ad] OR Bonn[ad] OR Hamburg[ad] 
OR Hessen[ad] OR Hesse[ad] OR Hessia[ad] OR Mecklenburg[ad] OR Vorpommern[ad] OR Pomerania[ad] OR Niedersachsen[ad] 
OR Neddersassen[ad] OR Saxony[ad] OR Niederbayern[ad] OR "Northern Rhine"[ad] OR "North Rhine"[ad] OR Westphalia[ad] 
OR Westfalen[ad] OR "Rhineland Palatinate"[ad] OR "Rheinland Pfalz"[ad] OR Saarland[ad] OR Sachsen[ad] OR "Schleswig 
Holstein"[ad] OR Thuringia[ad] OR Thuringen[ad] OR Thueringen[ad] OR Munchen[ad] OR Muenchen[ad] OR Munich[ad] OR 
Frankfurt[ad] OR Stuttgart[ad] OR Dusseldorf[ad] OR Duesseldorf[ad] OR Dortmund[ad] OR Essen[ad]) OR (France[ad] OR 
French*[ad] OR Francais*[ad] OR Alsace[ad] OR Elsass[ad] OR Aquitaine[ad] OR Aquitania[ad] OR Akitania[ad] OR Aguiene[ad] 
OR Auvergne[ad] OR Auvernhe[ad] OR Auvernha[ad] OR Normandie[ad] OR Normandy[ad] OR Normaundie[ad] OR 
Bourgogne[ad] OR Burgundy[ad] OR Bregogne[ad] OR Borgoegne[ad] OR Borgogne[ad] OR Brittany[ad] OR Breizh[ad] OR 
Bertaeyn[ad] OR Bretagne[ad] OR "Champagne Ardenne"[ad] OR Corse[ad] OR Corsica[ad] OR "Franche Comte"[ad] OR 
"Frantche Comte"[ad] OR "Franche Comtat"[ad] OR Guadeloupe[ad] OR Guyane[ad] OR Guiana[ad] OR "Languedoc 
Roussillon"[ad] OR "Lengadoc Rosselhon"[ad] OR "Llenguadoc-Rossello"[ad] OR Limousin[ad] OR Lemosin[ad] OR Lorraine[ad] 
OR Lothringen[ad] OR Lottringe[ad] OR Martinique[ad] OR "Midi Pyrenees"[ad] OR "Miegjorn Pireneus"[ad] OR "Mieidia 
Pireneus"[ad] OR "Mediodia Pirineos"[ad] OR "Pays de la Loire"[ad] OR "Broiou al Liger"[ad] OR Picardie[ad] OR Picardy[ad] OR 
"Poitou Charentes"[ad] OR "Peitau Charantas"[ad] OR "Poetou-Cherentes"[ad] OR Provence[ad] OR Provenca[ad] OR 
Prouvenco[ad] OR "Cote d Azur"[ad] OR "Cote d'Azur"[ad] OR "Costo d'Azur"[ad] OR "Costo d Azur"[ad] OR "Costa d'Azur"[ad] 
OR "Costa d Azur"[ad] OR Reunion[ad] OR "Rhone Alpes"[ad] OR "Rono Arpes"[ad] OR "Rose Aups"[ad] OR Ain[ad] OR 
Aisne[ad] OR Allier[ad] OR "Alpes de Haute Provence"[ad] OR "Haute Alpes"[ad] OR "Alpes Maritimes"[ad] OR Ardeche[ad] OR 
Ardennes[ad] OR Ariege[ad] OR Aube[ad] OR Aude[ad] OR Aveyron[ad] OR "Bas Rhin"[ad] OR "Bouches du Rhone"[ad] OR 
Calvados[ad] OR Cantal[ad] OR Charente[ad] OR Cher[ad] OR Correze[ad] OR "Corse du Sud"[ad] OR "Cote d Or"[ad] OR "Cote 
d'Or"[ad] OR "Cotes d Armor"[ad] OR "Cotes d'Armor"[ad] OR Creuse[ad] OR "Deux Sevres"[ad] OR Dordogne[ad] OR 
Doubs[ad] OR Drome[ad] OR Essonne[ad] OR Eure[ad] OR Finistere[ad] OR Gard[ad] OR Gers[ad] OR Gironde[ad] OR "Haute 
Corse"[ad] OR "Haute Garonne"[ad] OR "Haute Marne"[ad] OR "Hautes Alpes"[ad] OR "Haute Saone"[ad] OR "Haute Savoie"[ad] 
OR "Hautes Pyrenees"[ad] OR "Haute Vienne"[ad] OR "Haut Rhin"[ad] OR "Hauts de Seine"[ad] OR Herault[ad] OR "Ile de 
France"[ad] OR "Ille et Vilaine"[ad] OR Indre[ad] OR Isere[ad] OR Jura[ad] OR Landes[ad] OR Loire[ad] OR Loiret[ad] OR 
(Lot[ad] AND (departement[ad] OR department[ad])) OR "Lot et Garonne"[ad] OR "Loir et Cher"[ad] OR Lozere[ad] OR 
Manche[ad] OR Marne[ad] OR Mayenne[ad] OR Mayotte[ad] OR "Meurthe et Moselle"[ad] OR Meuse[ad] OR Morbihan[ad] OR 
Moselle[ad] OR (Nord[ad] AND (department[ad] OR departement[ad])) OR Nievre[ad] OR Oise[ad] OR Orne[ad] OR "Pas de 
calais"[ad] OR "Noord-Nauw van Kales"[ad] OR Paris[ad] OR "Puy de dome"[ad] OR "Pyrenees Atlantiques"[ad] OR "Pyrenees 
Orientales"[ad] OR Rhone[ad] OR Sarthe[ad] OR Savoie[ad] OR "Seine et Marne"[ad] OR "Seine Maritime"[ad] OR Somme[ad] 
OR Tarn[ad] OR "Territoire de Belfort"[ad] OR "Val de Marne"[ad] OR "Val d Oise"[ad] OR Var[ad] OR Vaucluse[ad] OR 
Vendee[ad] OR Vienne[ad] OR Vosges[ad] OR Yonne[ad] OR Yvelines[ad] OR Marseille[ad] OR Lyon[ad] OR Nice[ad] OR 
Nantes[ad] OR Strasbourg[ad] OR Montpellier[ad] OR Bordeaux[ad] OR Lille[ad] OR Toulouse[ad] OR "Outre Mer"[ad] OR "Seine 
Saint Denis"[ad]) OR (Finland[ad] OR Finnish*[ad] OR Finn[ad] OR Finns[ad] OR Suomi[ad] AND Suomen[ad] OR 
Suomalaiset[ad] OR Aland[ad] OR Ahvenanmaa[ad] OR Uusimaa[ad] OR Nyland[ad] OR Karelia[ad] OR Karjala[ad] OR 
Karelen[ad] OR Ostrobothnia[ad] OR Pohjanmaa[ad] OR Osterbotten[ad] OR Savonia[ad] OR Savo[ad] OR Savolax[ad] OR 
Kainuu[ad] OR Kajanaland*[ad] OR "Kanta Hame"[ad] OR Tavastia[ad] OR Tavastland[ad] OR Kymenlaakso[ad] OR 
Kymmenedalen[ad] OR Lapland[ad] OR Lappi[ad] OR Lappland[ad] OR "Paijat Hame"[ad] OR Pirkanmaa[ad] OR Birkaland[ad] 
OR Satakunta[ad] OR Satakunda[ad] OR Helsinki[ad] OR Helsingfors[ad] OR Espoo[ad] OR Esbo[ad] OR Tampere[ad] OR 
Tammerfors[ad] OR Vantaa[ad] OR Vanda[ad] OR Oulu[ad] OR Uleaborg[ad] OR Turku[ad] OR Abo[ad] OR Jyvaskyla[ad] OR 
Kuopio[ad] OR Lahti[ad] OR Lahtis[ad] OR Kouvola[ad]) OR (Estonia*[ad] OR Eesti[ad] OR Eestlased[ad] OR Eestlane[ad] OR 
Harju[ad] OR Harjumaa[ad] OR Hiiu[ad] OR Hiiumaa[ad] OR "Ida Viru"[ad] OR "Ida Virumaa"[ad] OR Jarvamaa[ad] OR 
Jarva[ad] OR Jogevamaa[ad] OR Jogeva[ad] OR Laanemaa[ad] OR Laane[ad] OR "Laane Virumaa"[ad] OR Parnu[ad] OR 
Parnumaa[ad] OR Polva[ad] OR Polvamaa[ad] OR Rapla[ad] OR Raplamaa[ad] OR Saare[ad] OR Saaremaa[ad] OR Tartu[ad] OR 
Tartumaa[ad] OR Valga[ad] OR Valgamaa[ad] OR Viljandimaa[ad] OR Viljandi[ad] OR Voru[ad] OR Vorumaa[ad] OR Tallinn[ad] 
OR Narva[ad] OR "Kohtla Jarve"[ad] OR Rakvere[ad] OR Maardu[ad] OR Sillamae[ad] OR Kuressaare[ad]) OR (Denmark[ad] OR 
Danish*[ad] OR dane[ad] OR danes[ad] OR Danmark[ad] OR dansk*[ad] OR Hovedstaden[ad] OR Midtjylland[ad] OR 
Nordjylland[ad] OR Sjaelland[ad] OR Sealand[ad] OR "Zealand region"[ad] OR "region Zealand"[ad] OR Syddanmark[ad] OR 
Jutland[ad] OR Jylland[ad] OR Sonderjyllands[ad] OR Copenhagen[ad] OR Kobenhavn[ad] OR Arhus[ad] OR Aarhus[ad] OR 
Bornholm[ad] OR Frederiksberg[ad] OR Frederiksborg[ad] OR Ringkjobing[ad] OR Viborg[ad] OR Vejle[ad] OR Roskilde[ad] OR 
Storstrom[ad] OR Vestsjaellands[ad] OR "West Zealand"[ad] OR Funen[ad] OR Ribe[ad] OR "Kalaallit Nunaat"[ad] OR 
Gronland[ad] OR Foroyar[ad] OR Faeroerne[ad] OR "Faroe islands"[ad] OR Aalborg[ad] OR Alborg[ad] OR Odense[ad] OR 
Esbjerg[ad] OR Gentofte[ad] OR Gladsaxe[ad] OR Randers[ad] OR Kolding[ad]) OR (Czech*[ad] OR Cesky[ad] OR Ceska[ad] OR 
Cech[ad] OR Cestina[ad] OR Prague[ad] OR Praha[ad] OR Prag[ad] OR Stredoces*[ad] OR Jihoces*[ad] OR Bohemia[ad] OR 
Bohemian[ad] OR Plzen*[ad] OR Pilsen[ad] OR Karlovars*[ad] OR "Karlovy Vary"[ad] OR Usteck*[ad] OR Usti[ad] OR 
Liberec*[ad] OR "Hradec Kralove"[ad] OR Kralovehradec*[ad] OR Pardubic*[ad] OR Olomouc*[ad] OR Olomoc[ad] OR 
Holomoc[ad] OR Moravskoslezs*[ad] OR Jihomorav*[ad] OR Moravia[ad] OR Moravian[ad] OR Morava[ad] OR Vysocina[ad] OR 
Zlin[ad] OR Zlinsk*[ad] OR "Ceske Budejovice"[ad] OR Budweis[ad] OR Brno[ad] OR Ostrava[ad]) OR (Cyprus[ad] OR 
Cypriot*[ad] OR Kypros[ad] OR Kibris*[ad] OR kypriaki[ad] OR Kyprioi[ad] OR Nicosia[ad] OR Lefkosa[ad] OR Lefkosia[ad] OR 
Famagusta[ad] OR Magusa[ad] OR Ammochostos[ad] OR Gazimagusa[ad] OR Kyrenia[ad] OR Girne[ad] OR Keryneia[ad] OR 
Larnaca[ad] OR Larnaka[ad] OR Iskele[ad] OR Limassol[ad] OR Lemesos[ad] OR Limasol[ad] OR Leymosun[ad] OR Paphos[ad] 
OR Pafos[ad] OR Baf[ad] OR Strovolos[ad] OR Lakatamia[ad] OR Lakadamya[ad] OR "Kato Polemidia"[ad] OR "Kato 
Polemidhia"[ad] OR Aglandjia[ad] OR Eglence[ad] OR Aglantzia[ad] OR Aradhippou[ad] OR Aradippou[ad] OR Engomi[ad]) OR 
(Croat*[ad] OR Hrvatsk*[ad] OR hrvati[ad] OR Bjelovar[ad] OR "Bjelovarsko bilogorska"[ad] OR "Brod Posavina"[ad] OR 
"Brodsko posavska"[ad] OR "Dubrovnik Neretva"[ad] OR "dubrovacko neretvanska"[ad] OR Zagreb[ad] OR Zagrebacka[ad] OR 
Istria[ad] OR Istarska[ad] OR Karlovacka[ad] OR Karlovac[ad] OR "Koprivnicko krizevacka"[ad] OR Koprivnica[ad] OR 
Krizevci[ad] OR "Krapina Zagorje"[ad] OR "Krapinsko zagorska"[ad] OR "Lika Senj"[ad] OR "Licko senjska"[ad] OR 
Medimurska[ad] OR Medimurje[ad] OR Osijek[ad] OR Baranja[ad] OR "Osjecko baranjska"[ad] OR "Pozega Slavonia"[ad] OR 
"Pozesko slavonska"[ad] OR "Primorje Gorski Kotar"[ad] OR "Primorsko goranska"[ad] OR "Sibensko kninska"[ad] OR "Sibensko 
kninske"[ad] OR Sibenik[ad] OR Knin[ad] OR Sisak[ad] OR "Sisacko moslavacka"[ad] OR Moslavina[ad] OR "Splitsko 
dalmatinska"[ad] OR Split[ad] OR Dalmatia[ad] OR Varazdin[ad] OR Varazdinska[ad] OR Viroviticko[ad] OR podravska[ad] OR 
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Virovitica[ad] OR Podravina[ad] OR "Vukovarsko srijemska"[ad] OR Vukovar[ad] OR Srijem[ad] OR Zadar[ad] OR Zadarska[ad] 
OR Rijeka[ad] OR "Velika gorica"[ad] OR "Slavonski brod"[ad] OR Pula[ad]) OR (Bulgaria*[ad] OR Balgariya[ad] OR Balgarija[ad] 
OR Blagoevgrad*[ad] OR "Pirin Macedonia"[ad] OR Burgas[ad] OR Dobrich[ad] OR Gabrovo[ad] OR Haskovo[ad] OR 
Kardzhali[ad] OR Kurdzhali[ad] OR Kyustendil[ad] OR Lovech[ad] OR Lovec[ad] OR Montana[ad] OR Pazardzhik[ad] OR 
Pernik[ad] OR Pleven*[ad] OR Plovdiv[ad] OR Razgrad[ad] OR Rousse[ad] OR Ruse[ad] OR Rusenka[ad] OR Shumen[ad] OR 
Silistra[ad] OR Sliven[ad] OR Smolyan[ad] OR Sofia[ad] OR Sofyiska[ad] OR Sofiiska[ad] OR "Stara Zagora"[ad] OR 
Targovishte[ad] OR Varna[ad] OR "Veliko Tarnovo"[ad] OR Vidin[ad] OR Vratsa[ad] OR Vratza[ad] OR Yambol[ad]) OR 
(Belgi*[ad] OR Belge*[ad] OR Belg[ad] OR Brussel*[ad] OR Bruxelles[ad] OR Bruxelloise[ad] OR Walloon*[ad] OR Wallon*[ad] 
OR Vlaams[ad] OR Flander*[ad] OR Flandern[ad] OR Flandre[ad] OR Flemish[ad] OR Flamand[ad] OR Flemisch[ad] OR 
Flamisch*[ad] OR Vlaanderen[ad] OR Flamande[ad] OR Waals[ad] OR Antwerp*[ad] OR Anvers[ad] OR Henegouwen[ad] OR 
Hennegau[ad] OR Hainault[ad] OR Hainaut[ad] OR Liege[ad] OR Luik[ad] OR Luttich[ad] OR Limbourg[ad] OR Limburg[ad] OR 
Namur[ad] OR Namen[ad] OR Ostflandern[ad] OR Westflandern[ad] OR Ghent[ad] OR Gent[ad] OR Gand[ad] OR Charleroi[ad] 
OR Bruges[ad] OR Brugge*[ad] OR Schaerbeek[ad] OR Schaarbeek[ad] OR Anderlecht[ad] OR Leuven[ad] OR Louvain[ad]) OR 
(Austria*[ad] OR Osterreich*[ad] OR Oesterreich*[ad] OR Ostosterreich[ad] OR Ostoesterreich[ad] OR Sudosterreich[ad] OR 
Sudoesterreich[ad] OR Westosterreich[ad] OR Westoesterreich[ad] OR Burgenland[ad] OR Carinthia[ad] OR Karnten[ad] OR 
Kaernten[ad] OR Niederosterreich[ad] OR Niederoesterreich[ad] OR Oberosterreich[ad] OR Oberoesterreich[ad] OR Salzburg[ad] 
OR Saizburg[ad] OR Styria[ad] OR Steiermark[ad] OR Tyrol[ad] OR Tirol[ad] OR Vorarlberg[ad] OR Vienna[ad] OR Wien[ad] OR 
Graz[ad] OR Linz[ad] OR Innsbruck[ad] OR Klagenfurt[ad] OR Villach[ad] OR Wels[ad] OR "St Polten"[ad] OR "St Poelten"[ad] 
OR "Sankt Polten"[ad] OR "Sankt Poelten"[ad] OR Dornbirn[ad])) OR Gibraltar[tw] OR Gibraltar[ad] OR Hebrid*[tw] OR 
Hebrid*[ad] OR Svalbard*[tw] OR Svalbard*[ad] OR "United States"[Mesh] OR "United States"[ad] OR USA[ad] OR US[ad] OR 
U.S.A.[ad] OR America*[ad] OR “United States”[tw] OR USA[tw] OR US[tw] OR U.S.A.[tw] OR America*[tw] OR Alabama[ad] OR 
Alaska[ad] OR Arizona[ad] OR Arkansas[ad] OR California[ad] OR Colorado[ad] OR Connecticut[ad] OR Delaware[ad] OR 
Florida[ad] OR Georgia[ad] OR Hawaii[ad] OR Idaho[ad] OR Illinois[ad] OR Indiana[ad] OR Iowa[ad] OR Kansas[ad] OR 
Kentucky[ad] OR Louisiana[ad] OR Maine[ad] OR Maryland[ad] OR Massachusetts[ad] OR Michigan[ad] OR Minnesota[ad] OR 
Mississippi[ad] OR Missouri[ad] OR Montana[ad] OR Nebraska[ad] OR Nevada[ad] OR New Hampshire[ad] OR New Jersey[ad] 
OR New Mexico[ad] OR New York[ad] OR North Carolina[ad] OR North Dakota[ad] OR Ohio[ad] OR Oklahoma[ad] OR 
Oregon[ad] OR Pennsylvania[ad] OR Rhode Island[ad] OR South Carolina[ad] OR South Dakota[ad] OR Tennessee[ad] OR 
Texas[ad] OR Utah[ad] OR Vermont[ad] OR Virginia[ad] OR Washington[ad] OR West Virginia[ad] OR Wisconsin[ad] OR 
Wyoming[ad] OR Alabama[tw] OR Alaska[tw] OR Arizona[tw] OR Arkansas[tw] OR California[tw] OR Colorado[tw] OR 
Connecticut[tw] OR Delaware[tw] OR Florida[tw] OR Georgia[tw] OR Hawaii[tw] OR Idaho[tw] OR Illinois[tw] OR Indiana[tw] OR 
Iowa[tw] OR Kansas[tw] OR Kentucky[tw] OR Louisiana[tw] OR Maine[tw] OR Maryland[tw] OR Massachusetts[tw] OR 
Michigan[tw] OR Minnesota[tw] OR Mississippi[tw] OR Missouri[tw] OR Montana[tw] OR Nebraska[tw] OR Nevada[tw] OR New 
Hampshire[tw] OR New Jersey[tw] OR New Mexico[tw] OR New York[tw] OR North Carolina[tw] OR North Dakota[tw] OR 
Ohio[tw] OR Oklahoma[tw] OR Oregon[tw] OR Pennsylvania[tw] OR Rhode Island[tw] OR South Carolina[tw] OR South 
Dakota[tw] OR Tennessee[tw] OR Texas[tw] OR Utah[tw] OR Vermont[tw] OR Virginia[tw] OR Washington[tw] OR West 
Virginia[tw] OR Wisconsin[tw] OR Wyoming[tw] OR "Canada"[Mesh] OR Canada[ad] OR Canada[tw] OR Canadian[tw] OR 
Canadian[ad] OR "Australia"[Mesh] OR Australia*[tw] OR Australia*[ad] OR "New Zealand"[Mesh] OR “New Zealand”[tw] OR 
“New Zealand”[ad] OR global[tw] OR world[tw] OR worldwide[tw] 
Embase 
'european union'/exp OR 'europe'/de OR europe*:ab,ti OR europa*:ab,ti OR eu:ab,ti OR eea:ab,ti OR efta:ab,ti OR 
'eu/eea':ab,ti OR 'eu/efta':ab,ti OR ecsc:ab,ti OR euratom:ab,ti OR eurozone:ab,ti OR eec:ab,ti OR ec:ab,ti OR (schengen:ab,ti 
AND (area:ab,ti OR countr*:ab,ti OR region*:ab,ti OR state:ab,ti OR states:ab,ti)) OR euroregion:ab,ti OR euroregions:ab,ti 
OR 'eastern europe'/de OR 'western europe'/de OR 'balkan peninsula'/exp OR balkan:ab,ti OR balkans:ab,ti OR 'baltic 
states'/de OR baltic:ab,ti OR 'southern europe'/de OR (mediterranean:ab,ti AND (area:ab,ti OR countr*:ab,ti OR region*:ab,ti 
OR state:ab,ti OR states:ab,ti)) OR (alpine:ab,ti AND (area:ab,ti OR countr*:ab,ti OR region*:ab,ti OR state:ab,ti OR 
states:ab,ti)) OR 'scandinavia'/de OR scandinavia:ab,ti OR scandinavian:ab,ti OR (nordic NEXT/1 (countr* OR state*)):ab,ti 
OR danubian:ab,ti OR 'iberian peninsula':ab,ti OR 'peninsula iberica':ab,ti OR 'péninsule ibérique':ab,ti OR 'iberiar 
penintsula':ab,ti OR iberia:ab,ti OR anatolia:ab,ti OR anadolu:ab,ti OR anatole:ab,ti OR anatolian:ab,ti OR 'yugoslavia (pre-
1992)'/de OR 'yugoslavia'/exp OR yugoslavia:ab,ti OR 'czechoslovakia'/de OR czechoslovakia:ab,ti OR 'czecho slovakia':ab,ti 
OR ceskoslovensko:ab,ti OR 'cesko slovensko':ab,ti OR 'benelux'/exp OR benelux:ab,ti OR fennoscandia:ab,ti OR 'fenno 
scandinavia':ab,ti OR fennoskandi*:ab,ti OR (visegrád:ab,ti AND (group:ab,ti OR four:ab,ti OR triangle:ab,ti)) OR 'visegrádská 
čtyřka':ab,ti OR 'visegrádská skupina':ab,ti OR 'visegrádi együttműködés':ab,ti OR 'visegrádi négyek':ab,ti OR 'grupa 
wyszehradzka':ab,ti OR 'vyšehradská skupina':ab,ti OR 'vyšehradská štvorka':ab,ti OR 'European'/de OR 'EU citizen'/de OR  
'Central European'/de OR 'Eastern European'/de OR 'Northern European'/de OR  'Southern European'/de OR 'Western 
European'/de OR 'austrian'/exp OR 'austria'/exp OR austria*:ab,ti OR osterreich*:ab,ti OR oesterreich*:ab,ti OR 
ostosterreich:ab,ti OR ostoesterreich:ab,ti OR sudosterreich:ab,ti OR sudoesterreich:ab,ti OR westosterreich:ab,ti OR 
westoesterreich:ab,ti OR burgenland:ab,ti OR carinthia:ab,ti OR karnten:ab,ti OR kaernten:ab,ti OR niederosterreich:ab,ti OR 
niederoesterreich:ab,ti OR oberosterreich:ab,ti OR oberoesterreich:ab,ti OR salzburg:ab,ti OR saizburg:ab,ti OR styria:ab,ti OR 
steiermark:ab,ti OR tyrol:ab,ti OR tirol:ab,ti OR vorarlberg:ab,ti OR vienna:ab,ti OR wien:ab,ti OR graz:ab,ti OR linz:ab,ti OR 
innsbruck:ab,ti OR klagenfurt:ab,ti OR villach:ab,ti OR wels:ab,ti OR 'st polten':ab,ti OR 'st poelten':ab,ti OR 'sankt polten':ab,ti 
OR 'sankt poelten':ab,ti OR dornbirn:ab,ti OR 'Belgium'/exp OR 'Belgian'/exp OR Belgi*:ti,ab OR Belge*:ti,ab OR Belg:ti,ab OR 
Brussel*:ti,ab OR Bruxelles:ti,ab OR Bruxelloise:ti,ab OR Walloon*:ti,ab OR Wallon*:ti,ab OR Vlaams:ti,ab OR Flander*:ti,ab OR 
Flandern:ti,ab OR Flandre:ti,ab OR Flemish:ti,ab OR Flamand:ti,ab OR Flemisch:ti,ab OR Flämisch*:ti,ab OR Vlaanderen:ti,ab OR 
Flamande:ti,ab OR Waals:ti,ab OR Antwerp*:ti,ab OR Anvers:ti,ab OR Henegouwen:ti,ab OR Hennegau:ti,ab OR Hainault:ti,ab 
OR Hainaut:ti,ab OR Liege:ti,ab OR Luik:ti,ab OR Luttich:ti,ab OR Limbourg:ti,ab OR Limburg:ti,ab OR Namur:ti,ab OR 
Namen:ti,ab OR Ostflandern:ti,ab OR Westflandern:ti,ab OR Ghent:ti,ab OR Gent:ti,ab OR Gand:ti,ab OR Charleroi:ti,ab OR 
Bruges:ti,ab OR Brugge*:ti,ab OR Schaerbeek:ti,ab OR Schaarbeek:ti,ab OR Anderlecht:ti,ab OR Leuven:ti,ab OR Louvain:ti,ab 
OR 'bulgaria'/exp OR 'bulgarian (citizen)'/exp OR 'Bulgarian (people)'/exp OR bulgaria*:ti,ab OR  balgariya:ab,ti OR balgarija:ab,ti 
OR blagoevgrad*:ab,ti OR 'pirin macedonia':ab,ti OR burgas:ab,ti OR dobrich:ab,ti OR gabrovo:ab,ti OR haskovo:ab,ti OR 
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kardzhali:ab,ti OR kurdzhali:ab,ti OR kyustendil:ab,ti OR lovech:ab,ti OR lovec:ab,ti OR montana:ab,ti OR pazardzhik:ab,ti OR 
pernik:ab,ti OR pleven*:ab,ti OR plovdiv:ab,ti OR razgrad:ab,ti OR rousse:ab,ti OR ruse:ab,ti OR rusenka:ab,ti OR shumen:ab,ti 
OR silistra:ab,ti OR sliven:ab,ti OR smolyan:ab,ti OR sofia:ab,ti OR sofyiska:ab,ti OR sofiiska:ab,ti OR 'stara zagora':ab,ti OR 
targovishte:ab,ti OR varna:ab,ti OR 'veliko tarnovo':ab,ti OR vidin:ab,ti OR vratsa:ab,ti OR vratza:ab,ti OR yambol:ab,ti OR 
'croatia'/exp OR 'croatian (citizen)'/exp OR 'Croat (people)'/exp OR croat*:ab,ti OR hrvatsk*:ab,ti OR hrvati:ab,ti OR bjelovar:ab,ti 
OR 'bjelovarsko bilogorska':ab,ti OR 'brod posavina':ab,ti OR 'brodsko posavska':ab,ti OR 'dubrovnik neretva':ab,ti OR 
'dubrovacko neretvanska':ab,ti OR zagreb:ab,ti OR zagrebacka:ab,ti OR istria:ab,ti OR istarska:ab,ti OR karlovacka:ab,ti OR 
karlovac:ab,ti OR 'koprivnicko krizevacka':ab,ti OR koprivnica:ab,ti OR krizevci:ab,ti OR 'krapina zagorje':ab,ti OR 'krapinsko 
zagorska':ab,ti OR 'lika senj':ab,ti OR 'licko senjska':ab,ti OR medimurska:ab,ti OR medimurje:ab,ti OR osijek:ab,ti OR 
baranja:ab,ti OR 'osjecko baranjska':ab,ti OR 'pozega slavonia':ab,ti OR 'pozesko slavonska':ab,ti OR 'primorje gorski kotar':ab,ti 
OR 'primorsko goranska':ab,ti OR 'sibensko kninska':ab,ti OR 'sibensko kninske':ab,ti OR sibenik:ab,ti OR knin:ab,ti OR sisak:ab,ti 
OR 'sisacko moslavacka':ab,ti OR moslavina:ab,ti OR 'splitsko dalmatinska':ab,ti OR split:ab,ti OR dalmatia:ab,ti OR varazdin:ab,ti 
OR varazdinska:ab,ti OR viroviticko:ab,ti OR podravska:ab,ti OR virovitica:ab,ti OR podravina:ab,ti OR 'vukovarsko srijemska':ab,ti 
OR vukovar:ab,ti OR srijem:ab,ti OR zadar:ab,ti OR zadarska:ab,ti OR rijeka:ab,ti OR 'velika gorica':ab,ti OR 'slavonski brod':ab,ti 
OR pula:ab,ti OR 'cyprus'/exp OR 'cypriot'/exp OR cyprus:ab,ti OR cypriot*:ab,ti OR kypros:ab,ti OR kibris*:ab,ti OR kypriaki:ab,ti 
OR kyprioi:ab,ti OR nicosia:ab,ti OR lefkosa:ab,ti OR lefkosia:ab,ti OR famagusta:ab,ti OR magusa:ab,ti OR ammochostos:ab,ti 
OR gazimagusa:ab,ti OR kyrenia:ab,ti OR girne:ab,ti OR keryneia:ab,ti OR larnaca:ab,ti OR larnaka:ab,ti OR iskele:ab,ti OR 
limassol:ab,ti OR lemesos:ab,ti OR limasol:ab,ti OR leymosun:ab,ti OR paphos:ab,ti OR pafos:ab,ti OR baf:ab,ti OR strovolos:ab,ti 
OR lakatamia:ab,ti OR lakadamya:ab,ti OR 'kato polemidia':ab,ti OR 'kato polemidhia':ab,ti OR aglandjia:ab,ti OR eglence:ab,ti 
OR aglantzia:ab,ti OR aradhippou:ab,ti OR aradippou:ab,ti OR engomi:ab,ti OR 'czech (citizen)'/exp OR 'czech republic'/exp OR 
'Czech (people)'/exp OR czech*:ab,ti OR cesky:ab,ti OR ceska:ab,ti OR cech:ab,ti OR cestina:ab,ti OR prague:ab,ti OR praha:ab,ti 
OR prag:ab,ti OR stredoces*:ab,ti OR jihoces*:ab,ti OR bohemia:ab,ti OR bohemian:ab,ti OR plzen*:ab,ti OR pilsen:ab,ti OR 
karlovars*:ab,ti OR 'karlovy vary':ab,ti OR usteck*:ab,ti OR usti:ab,ti OR liberec*:ab,ti OR 'hradec kralove':ab,ti OR 
kralovehradec*:ab,ti OR pardubic*:ab,ti OR olomouc*:ab,ti OR olomoc:ab,ti OR holomoc:ab,ti OR moravskoslezs*:ab,ti OR 
jihomorav*:ab,ti OR moravia:ab,ti OR moravian:ab,ti OR morava:ab,ti OR vysocina:ab,ti OR zlin:ab,ti OR zlinsk*:ab,ti OR 'ceske 
budejovice':ab,ti OR budweis:ab,ti OR brno:ab,ti OR ostrava:ab,ti OR 'Denmark'/exp OR 'Danish citizen'/exp OR 'Dane 
(people)'/exp OR Denmark:ti,ab OR Danish*:ti,ab OR dane:ti,ab OR danes:ti,ab OR Danmark:ti,ab OR dansk*:ti,ab OR 
Hovedstaden:ti,ab OR Midtjylland:ti,ab OR Nordjylland:ti,ab OR Sjaelland:ti,ab OR Sealand:ti,ab OR 'Zealand region':ti,ab OR 
'region Zealand':ti,ab OR Syddanmark:ti,ab OR Jutland:ti,ab OR Jylland:ti,ab OR Sonderjyllands:ti,ab OR Copenhagen:ti,ab OR 
Kobenhavn:ti,ab OR Arhus:ti,ab OR Aarhus:ti,ab OR Bornholm:ti,ab OR Frederiksberg:ti,ab OR Frederiksborg:ti,ab OR 
Ringkjobing:ti,ab OR Viborg:ti,ab OR Vejle:ti,ab OR Roskilde:ti,ab OR Storstrøm:ti,ab OR Vestsjaellands:ti,ab OR 'West 
Zealand':ti,ab OR Funen:ti,ab OR Ribe:ti,ab OR 'Kalaallit Nunaat':ti,ab OR Gronland:ti,ab OR Foroyar:ti,ab OR Faeroerne:ti,ab OR 
'Faroe islands':ti,ab OR Aalborg:ti,ab OR Alborg:ti,ab OR Odense:ti,ab OR Esbjerg:ti,ab OR Gentofte:ti,ab OR Gladsaxe:ti,ab OR 
Randers:ti,ab OR Kolding:ti,ab OR 'Estonia'/exp OR 'Estonian (citizen)'/exp OR 'Estonian (people)'/exp OR Estonia*:ti,ab OR 
Eesti:ti,ab OR Eestlased:ti,ab OR Eestlane:ti,ab OR Harju:ti,ab OR Harjumaa:ti,ab OR Hiiu:ti,ab OR Hiiumaa:ti,ab OR 'Ida 
Viru':ti,ab OR 'Ida Virumaa':ti,ab OR Jarvamaa:ti,ab OR Jarva:ti,ab OR Jogevamaa:ti,ab OR Jogeva:ti,ab OR Laanemaa:ti,ab OR 
Laane:ti,ab OR 'Laane Virumaa':ti,ab OR Parnu:ti,ab OR Parnumaa:ti,ab OR Polva:ti,ab OR Polvamaa:ti,ab OR Rapla:ti,ab OR 
Raplamaa:ti,ab OR Saare:ti,ab OR Saaremaa:ti,ab OR Tartu:ti,ab OR Tartumaa:ti,ab OR Valga:ti,ab OR Valgamaa:ti,ab OR 
Viljandimaa:ti,ab OR Viljandi:ti,ab OR Voru:ti,ab OR Vorumaa:ti,ab OR Tallinn:ti,ab OR Narva:ti,ab OR 'Kohtla Jarve':ti,ab OR 
Rakvere:ti,ab OR Maardu:ti,ab OR Sillamae:ti,ab OR Kuressaare:ti,ab OR 'Finland'/exp OR 'Finn (citizen)'/exp OR 'Finn 
(people)'/exp OR Finland:ti,ab OR Finnish*:ti,ab OR Finn:ti,ab OR Finns:ti,ab OR Suomi:ti,ab Suomen:ti,ab OR Suomalaiset:ti,ab 
OR Aland:ti,ab OR Ahvenanmaa:ti,ab OR Uusimaa:ti,ab OR Nyland:ti,ab OR Karelia:ti,ab OR Karjala:ti,ab OR Karelen:ti,ab OR 
Ostrobothnia:ti,ab OR Pohjanmaa:ti,ab OR Osterbotten:ti,ab OR Savonia:ti,ab OR Savo:ti,ab OR Savolax:ti,ab OR Kainuu:ti,ab OR 
Kajanaland*:ti,ab OR 'Kanta Hame':ti,ab OR Tavastia:ti,ab OR Tavastland:ti,ab OR Kymenlaakso:ti,ab OR Kymmenedalen:ti,ab 
OR Lapland:ti,ab OR Lappi:ti,ab OR Lappland:ti,ab OR 'Paijat Hame':ti,ab OR Pirkanmaa:ti,ab OR Birkaland:ti,ab OR 
Satakunta:ti,ab OR Satakunda:ti,ab OR Helsinki:ti,ab OR Helsingfors:ti,ab OR Espoo:ti,ab OR Esbo:ti,ab OR Tampere:ti,ab OR 
Tammerfors:ti,ab OR Vantaa:ti,ab OR Vanda:ti,ab OR Oulu:ti,ab OR Uleaborg:ti,ab OR Turku:ti,ab OR Abo:ti,ab OR 
Jyvaskyla:ti,ab OR Kuopio:ti,ab OR Lahti:ti,ab OR Lahtis:ti,ab OR Kouvola:ti,ab OR 'France'/exp OR 'Frenchman'/exp OR 
France:ti,ab OR French*:ti,ab OR Francais*:ti,ab OR Alsace:ti,ab OR Elsass:ti,ab OR Aquitaine:ti,ab OR Aquitania:ti,ab OR 
Akitania:ti,ab OR Aguiéne:ti,ab OR Auvergne:ti,ab OR Auvèrnhe:ti,ab OR Auvèrnha:ti,ab OR Normandie:ti,ab OR Normandy:ti,ab 
OR Normaundie:ti,ab OR Bourgogne:ti,ab OR Burgundy:ti,ab OR Bregogne:ti,ab OR Borgoégne:ti,ab OR Borgogne:ti,ab OR 
Brittany:ti,ab OR Breizh:ti,ab OR Bertaèyn:ti,ab OR Bretagne:ti,ab OR 'Champagne Ardenne':ti,ab OR Corse:ti,ab OR Corsica:ti,ab 
OR 'Franche Comte':ti,ab OR 'Frantche Comte':ti,ab OR 'Franche Comtat':ti,ab OR Guadeloupe:ti,ab OR Guyane:ti,ab OR 
Guiana:ti,ab OR 'Languedoc Roussillon':ti,ab OR 'Lengadoc Rosselhon':ti,ab OR 'Llenguadoc-Rossello':ti,ab OR Limousin:ti,ab OR 
Lemosin:ti,ab OR Lorraine:ti,ab OR Lothringen:ti,ab OR Lottringe:ti,ab OR Martinique:ti,ab OR 'Midi Pyrenees':ti,ab OR 'Miègjorn 
Pirenèus':ti,ab OR 'Mieidia Pirenèus':ti,ab OR 'Mediodia Pirineos':ti,ab OR 'Pays de la Loire':ti,ab OR 'Broioù al Liger':ti,ab OR 
Picardie:ti,ab OR Picardy:ti,ab OR 'Poitou Charentes':ti,ab OR 'Peitau Charantas':ti,ab OR 'Poetou-Cherentes':ti,ab OR 
Provence:ti,ab OR Provenca:ti,ab OR Prouvenco:ti,ab OR 'Cote d Azur':ti,ab OR 'Costo d Azur':ti,ab OR 'Costa d Azur':ti,ab OR 
Reunion:ti,ab OR 'Rhone Alpes':ti,ab OR 'Rono Arpes':ti,ab OR 'Rose Aups':ti,ab OR Ain:ti,ab OR Aisne:ti,ab OR Allier:ti,ab OR 
'Alpes de Haute Provence':ti,ab OR 'Haute Alpes':ti,ab OR 'Alpes Maritimes':ti,ab OR Ardeche:ti,ab OR Ardennes:ti,ab OR 
Ariege:ti,ab OR Aube:ti,ab OR Aude:ti,ab OR Aveyron:ti,ab OR 'Bas Rhin':ti,ab OR 'Bouches du Rhone':ti,ab OR Calvados:ti,ab OR 
Cantal:ti,ab OR Charente:ti,ab OR Cher:ti,ab OR Correze:ti,ab OR 'Corse du Sud':ti,ab OR 'Cote d Or':ti,ab OR 'Cotes d 
Armor':ti,ab OR Creuse:ti,ab OR 'Deux Sevres':ti,ab OR Dordogne:ti,ab OR Doubs:ti,ab OR Drome:ti,ab OR Essonne:ti,ab OR 
Eure:ti,ab OR Finistere:ti,ab OR Gard:ti,ab OR Gers:ti,ab OR Gironde:ti,ab OR 'Haute Corse':ti,ab OR 'Haute Garonne':ti,ab OR 
'Haute Marne':ti,ab OR 'Hautes Alpes':ti,ab OR 'Haute Saone':ti,ab OR 'Haute Savoie':ti,ab OR 'Hautes Pyrenees':ti,ab OR 'Haute 
Vienne':ti,ab OR 'Haut Rhin':ti,ab OR 'Hauts de Seine':ti,ab OR Herault:ti,ab OR 'Ile de France':ti,ab OR 'Ille et Vilaine':ti,ab OR 
Indre:ti,ab OR Isere:ti,ab OR Jura:ti,ab OR Landes:ti,ab OR Loire:ti,ab OR Loiret:ti,ab OR (Lot NEAR/3 (departement OR 
department)):ab,ti OR 'Lot et Garonne':ti,ab OR 'Loir et Cher':ti,ab OR Lozere:ti,ab OR Manche:ti,ab OR Marne:ti,ab OR 
Mayenne:ti,ab OR Mayotte:ti,ab OR 'Meurthe et Moselle':ti,ab OR Meuse:ti,ab OR Morbihan:ti,ab OR Moselle:ti,ab OR (Nord 
NEAR/3 (department OR departement)):ti,ab OR Nievre:ti,ab OR Oise:ti,ab OR Orne:ti,ab OR 'Pas de calais':ti,ab OR 'Noord-
Nauw van Kales':ti,ab OR Paris:ti,ab OR 'Puy de dome':ti,ab OR 'Pyrenees Atlantiques':ti,ab OR 'Pyrenees Orientales':ti,ab OR 
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Rhone:ti,ab OR Sarthe:ti,ab OR Savoie:ti,ab OR 'Seine et Marne':ti,ab OR 'Seine Maritime':ti,ab OR Somme:ti,ab OR Tarn:ti,ab OR 
'Territoire de Belfort':ti,ab OR 'Val de Marne':ti,ab OR 'Val d Oise':ti,ab OR Var:ti,ab OR Vaucluse:ti,ab OR Vendee:ti,ab OR 
Vienne:ti,ab OR Vosges:ti,ab OR Yonne:ti,ab OR Yvelines:ti,ab OR Marseille:ti,ab OR Lyon:ti,ab OR Nice:ti,ab OR Nantes:ti,ab OR 
Strasbourg:ti,ab OR Montpellier:ti,ab OR Bordeaux:ti,ab OR Lille:ti,ab OR Toulouse:ti,ab OR 'Outre Mer':ti,ab OR 'Seine Saint 
Denis':ti,ab OR 'Germany'/de OR 'German (citizen)'/exp OR German*:ti,ab OR Deutsch*:ti,ab OR Bundesrepublik:ti,ab OR 
Westdeutschland:ti,ab OR Ostdeutschland:ti,ab OR Baden:ti,ab OR Wuerttemberg:ti,ab OR Wurttemberg:ti,ab OR Bayern:ti,ab 
OR Bavaria:ti,ab OR Berlin:ti,ab OR Brandenburg:ti,ab OR Bremen:ti,ab OR Oldenburg:ti,ab OR Mitteldeutschland:ti,ab OR 
Rhein:ti,ab OR Rhine:ti,ab OR Hannover:ti,ab OR Braunschweig:ti,ab OR Göttingen:ti,ab OR Goettingen:ti,ab OR Nurnberg:ti,ab 
OR Nuernberg:ti,ab OR Ruhr:ti,ab OR Koln:ti,ab OR koeln:ti,ab OR Bonn:ti,ab OR Hamburg:ti,ab OR Hessen:ti,ab OR Hesse:ti,ab 
OR Hessia:ti,ab OR Mecklenburg:ti,ab OR Vorpommern:ti,ab OR Pomerania:ti,ab OR Niedersachsen:ti,ab OR Neddersassen:ti,ab 
OR Saxony:ti,ab OR Niederbayern:ti,ab OR 'Northern Rhine':ti,ab OR 'North Rhine':ti,ab OR Westphalia:ti,ab OR Westfalen:ti,ab 
OR 'Rhineland Palatinate':ti,ab OR 'Rheinland Pfalz':ti,ab OR Saarland:ti,ab OR Sachsen:ti,ab OR 'Schleswig Holstein':ti,ab OR 
Thuringia:ti,ab OR Thuringen:ti,ab OR Thueringen:ti,ab OR Munchen:ti,ab OR Muenchen:ti,ab OR Munich:ti,ab OR Frankfurt:ti,ab 
OR Stuttgart:ti,ab OR Dusseldorf:ti,ab OR Duesseldorf:ti,ab OR Dortmund:ti,ab OR Essen:ti,ab OR 'Greece'/exp OR 'Greek 
(citizen)'/exp OR 'Greek (people)'/exp OR Greece:ti,ab OR 'Hellenic republic':ti,ab OR Greek*:ti,ab OR Ellada:ti,ab OR Elladas:ti,ab 
OR 'Elliniki Dimokratia':ti,ab OR Hellas:ti,ab OR Hellenes:ti,ab OR Attica:ti,ab OR Attiki:ti,ab OR Makedonia*:ti,ab OR 
Macedonia:ti,ab OR Thraki:ti,ab OR Thrace:ti,ab OR Crete:ti,ab OR Kriti:ti,ab OR 'Ionia Nisia':ti,ab OR 'Ionion neson':ti,ab OR 
'Ionion nIson':ti,ab OR 'Ionian islands':ti,ab OR 'Ionian island':ti,ab OR Epirus:ti,ab OR Ipeiros:ti,ab OR 'Periféreia Ipeírou':ti,ab 
OR 'North aegean':ti,ab OR 'Northern Aegean':ti,ab OR 'Aegean islands':ti,ab OR 'Aegean island':ti,ab OR 'Nisoi Agaiou':ti,ab OR 
'Notio Aigaio':ti,ab OR Peloponnese:ti,ab OR Peloponniso*:ti,ab OR Thessaly:ti,ab OR Thessalia:ti,ab OR Thessalian:ti,ab OR 
Petthalia:ti,ab OR 'Voreio Aigaio':ti,ab OR 'Voreio Aigaiou':ti,ab OR 'South aegean':ti,ab OR 'Southern Aegean':ti,ab OR 'Mount 
athos':ti,ab OR 'Oros Athos':ti,ab OR Cyclades:ti,ab OR Cycklades:ti,ab OR Kiklades:ti,ab OR Dodecanese:ti,ab OR 
Dodekanisa:ti,ab OR Athens:ti,ab OR Athina:ti,ab OR Thessaloniki:ti,ab OR Thessalonica:ti,ab OR Patras:ti,ab OR Patra:ti,ab OR 
Pireas:ti,ab OR Piraeus:ti,ab OR Larissa:ti,ab OR Larisa:ti,ab OR Heraklion:ti,ab OR Heraclion:ti,ab OR Iraklion:ti,ab OR 
Irakleion:ti,ab OR Iraklio:ti,ab OR Volos:ti,ab OR Rhodes:ti,ab OR Rodos:ti,ab OR Ioannina:ti,ab OR Janina:ti,ab OR 
Yannena:ti,ab OR Chania:ti,ab OR Chalcis:ti,ab OR Chalkida:ti,ab OR 'Hungary'/exp OR 'Hungarian (citizen)'/exp OR 'Magyar 
(people)'/exp OR Hungar*:ti,ab OR Magyarorszag:ti,ab OR Magyar*:ti,ab OR Dunantuli:ti,ab OR Transdanubia:ti,ab OR 
Dunantul:ti,ab OR 'Great Plain':ti,ab OR 'Eszak Alfold':ti,ab OR 'Del Alfold':ti,ab OR 'Alfold es eszak':ti,ab OR 'Northern Alfold':ti,ab 
OR 'North Alfold':ti,ab OR 'South Alfold':ti,ab OR 'Southern Alfold':ti,ab OR Bacs:ti,ab OR Kiskun:ti,ab OR Baranya:ti,ab OR 
Bekes:ti,ab OR Borsod:ti,ab OR Abauj:ti,ab OR Zemplen:ti,ab OR Budapest:ti,ab OR Csongrad:ti,ab OR Fejer:ti,ab OR gyor:ti,ab 
OR moson:ti,ab OR sopron:ti,ab OR hajdu:ti,ab OR bihar:ti,ab OR Heves:ti,ab OR 'jasz nagykun szolnok':ti,ab OR komarom:ti,ab 
OR esztergom:ti,ab OR Nograd:ti,ab OR (Pest NEXT/3 (megye OR county)):ti,ab OR Somogy:ti,ab OR szabolcs:ti,ab OR 
szatmar:ti,ab OR bereg:ti,ab OR Tolna:ti,ab OR Vas:ti,ab OR Veszprem:ti,ab OR Zala:ti,ab OR Debrecen:ti,ab OR Miskolc:ti,ab OR 
Szeged:ti,ab OR Pecs:ti,ab OR Gyor:ti,ab OR Nyiregyhaza:ti,ab OR Kecskemet:ti,ab OR Szekesfehervar:ti,ab OR 
Szombathely:ti,ab OR 'Ireland'/exp OR 'Irish (citizen)'/exp OR Ireland:ti,ab OR Eire:ti,ab OR Irish*:ti,ab OR Fingal:ti,ab OR 'Fine 
Gall':ti,ab OR Dublin:ti,ab OR 'Ath Cliath':ti,ab OR 'Dun Laoghaire':ti,ab OR Wicklow:ti,ab OR 'Cill Mhantain':ti,ab OR 'Chill 
Mhantain':ti,ab OR Wexford:ti,ab OR 'Loch Garman':ti,ab OR Carlow:ti,ab OR Ceatharlach:ti,ab OR Kildare:ti,ab OR 'Cill Dara':ti,ab 
OR 'Chill Dara':ti,ab OR Meath:ti,ab OR 'An Mhi':ti,ab OR 'Contae na Mi':ti,ab OR Louth:ti,ab OR 'Contae Lu':ti,ab OR 
Monaghan:ti,ab OR Muineachán:ti,ab OR Mhuineacháin:ti,ab OR Cavan:ti,ab OR 'An Cabhan':ti,ab OR 'An Cabhain':ti,ab OR 
Longford:ti,ab OR 'An Longfort':ti,ab OR 'an Longfoirt':ti,ab OR Langfurd:ti,ab OR Westmeath:ti,ab OR 'An Iarmhi':ti,ab OR 'na 
Iarmhi':ti,ab OR Offaly:ti,ab OR 'Uibh Fhaili':ti,ab OR Laois:ti,ab OR Laoise:ti,ab OR Kilkenny:ti,ab OR 'Chill Chainnigh':ti,ab OR 
'Cill Chainnigh':ti,ab OR Waterford:ti,ab OR 'Port Lairge':ti,ab OR Watterford:ti,ab OR Cork:ti,ab OR Corcaigh:ti,ab OR 
Chorcai:ti,ab OR Kerry:ti,ab OR Ciarrai:ti,ab OR Chiarrai:ti,ab OR Limerick:ti,ab OR Luimneach:ti,ab OR Luimnigh:ti,ab OR 
Tipperary:ti,ab OR 'Tiobraid Arann':ti,ab OR 'Thiobraid Arann':ti,ab OR Clare:ti,ab OR 'An Clar':ti,ab OR 'an Chlair':ti,ab OR 
Galway:ti,ab OR Gaillimh:ti,ab OR 'na Gaillimhe':ti,ab OR Mayo:ti,ab OR 'Maigh Eo':ti,ab OR 'Mhaigh Eo':ti,ab OR 
Roscommon:ti,ab OR 'Ros comain':ti,ab OR Sligo:ti,ab OR Sligeach:ti,ab OR Shligigh:ti,ab OR Leitrim:ti,ab OR Liatroim:ti,ab OR 
Liatroma:ti,ab OR Donegal:ti,ab OR 'Dhún na nGall':ti,ab OR Dinnygal:ti,ab OR Dunnyga:ti,ab OR Leinster:ti,ab OR Laighin:ti,ab 
OR 'Cúige Laighean':ti,ab OR Munster:ti,ab OR Mumhain:ti,ab OR 'Cúige Mumhan':ti,ab OR Connacht:ti,ab OR Connachta:ti,ab OR 
Drogheda:ti,ab OR 'Droichead Atha':ti,ab OR Dundalk:ti,ab OR 'Dún Dealgan':ti,ab OR Swords:ti,ab OR Sord:ti,ab OR Bray:ti,ab 
OR Bre:ti,ab OR Navan:ti,ab OR 'An Uaimh':ti,ab OR 'Italy'/exp OR 'Italian (citizen)'/exp OR 'Italic people'/exp OR Italy:ti,ab OR 
Italia*:ti,ab OR Abruzzo:ti,ab OR Abruzzi:ti,ab OR Basilicata:ti,ab OR Lucania:ti,ab OR Calabria:ti,ab OR Campania:ti,ab OR 'Emilia 
Romagna':ti,ab OR 'friuli venezia giulia':ti,ab OR Lazio:ti,ab OR Latium:ti,ab OR Liguria*:ti,ab OR Lombardy:ti,ab OR 
Lombardia:ti,ab OR Marche:ti,ab OR Marches:ti,ab OR Molisano:ti,ab OR Molise:ti,ab OR Piedmont*:ti,ab OR Piemonte:ti,ab OR 
Bolzano:ti,ab OR Bozen:ti,ab OR Trentino:ti,ab OR Trento:ti,ab OR Puglia:ti,ab OR Apulia:ti,ab OR Sardinia:ti,ab OR 
Sardegna:ti,ab OR Sicily:ti,ab OR Sicilia:ti,ab OR Toscana:ti,ab OR Tuscany:ti,ab OR Umbria:ti,ab OR 'Valle d Aosta':ti,ab OR 
'Vallee d Aoste':ti,ab OR 'Aosta Valley':ti,ab OR Veneto:ti,ab OR Venetia:ti,ab OR Triveneto:ti,ab OR Rome:ti,ab OR Roma:ti,ab 
OR Milan:ti,ab OR Milano:ti,ab OR Naples:ti,ab OR Napoli:ti,ab OR Turin:ti,ab OR Torino:ti,ab OR Palermo:ti,ab OR Genoa:ti,ab 
OR Genova:ti,ab OR Bologna:ti,ab OR Florence:ti,ab OR Firenze:ti,ab OR Bari:ti,ab OR Catania:ti,ab OR 'Latvia'/exp OR 'Latvian 
(citizen)'/exp OR 'Lett (people)'/exp OR Latvi*:ti,ab OR Riga:ti,ab OR Courland:ti,ab OR Kurzeme:ti,ab OR Kurland:ti,ab OR 
Latgale:ti,ab OR Lettgallia:ti,ab OR Latgola:ti,ab OR Latgalia:ti,ab OR Vidzeme:ti,ab OR Vidumo:ti,ab OR Semigallia:ti,ab OR 
Semigalia:ti,ab OR Zemgale:ti,ab OR Pieriga:ti,ab OR Daugavpils:ti,ab OR Dinaburg:ti,ab OR Jekabpils:ti,ab OR Jakobstadt:ti,ab 
OR Jelgava:ti,ab OR Jurmala:ti,ab OR Liepaja:ti,ab OR Libau:ti,ab OR Rezekne:ti,ab OR Rezne:ti,ab OR Rositten:ti,ab OR 
Valmiera:ti,ab OR Wolmar:ti,ab OR Ventspils:ti,ab OR Windau:ti,ab OR Ogre:ti,ab OR 'Lithuania'/exp OR 'Lithuanian (citizen)'/exp 
OR Lithuania*:ti,ab OR 'Lietuvos Respublika':ti,ab OR Lietuva:ti,ab OR lietuviu:ti,ab OR Alytus:ti,ab OR Alytaus:ti,ab OR 
Kaunas:ti,ab OR Kauno:ti,ab OR Klaipeda:ti,ab OR Klaipedos:ti,ab OR Marijampoles:ti,ab OR Marijampole:ti,ab OR 
Panevezys:ti,ab OR Panevezio:ti,ab OR Siauliai:ti,ab OR Siauliu:ti,ab OR Taurages:ti,ab OR Taurage:ti,ab OR Telsiu:ti,ab OR 
Telsiai:ti,ab OR Utenos:ti,ab OR Utena:ti,ab OR Vilnius:ti,ab OR Vilniaus:ti,ab OR Mazeikiai:ti,ab OR Jonava:ti,ab OR 
Mazeikiu:ti,ab OR Jonavos:ti,ab OR 'Luxembourg'/exp OR Luxembourg*:ti,ab OR Luxemburg:ti,ab OR Letzebuerg:ti,ab OR 
Diekirch:ti,ab OR Grevenmacher:ti,ab OR 'Esch sur Alzette':ti,ab OR 'Esch Uelzecht':ti,ab OR 'Esch an der Alzette':ti,ab OR 'Esch 
an der Alzig':ti,ab OR Dudelange:ti,ab OR Diddeleng:ti,ab OR Düdelingen:ti,ab OR Duedelingen:ti,ab OR Schifflange:ti,ab OR 
Scheffleng:ti,ab OR Schifflingen:ti,ab OR Bettembourg:ti,ab OR Beetebuerg:ti,ab OR Bettemburg:ti,ab OR Petange:ti,ab OR 
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Peiteng:ti,ab OR Petingen:ti,ab OR Ettelbruck:ti,ab OR Ettelbreck:ti,ab OR Ettelbrueck:ti,ab OR Diekirch:ti,ab OR Dikrech:ti,ab OR 
Strassen:ti,ab OR Stroossen:ti,ab OR Bertrange:ti,ab OR Bartreng:ti,ab OR Bartringen:ti,ab OR 'Malta'/exp OR 'Maltese 
(citizen)'/exp OR Malta:ti,ab OR Maltese*:ti,ab OR Maltin:ti,ab OR Gozo:ti,ab OR Ghawdex:ti,ab OR Valletta:ti,ab OR 'Ill Belt':ti,ab 
OR Birkirkara:ti,ab OR 'B Kara':ti,ab OR Birchircara:ti,ab OR Mosta:ti,ab OR Qormi:ti,ab OR 'St Paul s Bay':ti,ab  OR 'Pawl il 
Bahar':ti,ab OR Zabbar:ti,ab OR Sliema:ti,ab OR Naxxar:ti,ab OR Gwann:ti,ab OR 'St John':ti,ab OR Zebbug:ti,ab OR 'Citta 
rohan':ti,ab OR Fgura:ti,ab OR 'Netherlands'/exp OR 'Dutchman'/exp OR Netherlands:ti,ab OR Nederland*:ti,ab OR 
Dutch*:ti,ab OR Drenthe:ti,ab OR Flevoland:ti,ab OR Friesland:ti,ab OR Fryslan:ti,ab OR Frisia:ti,ab OR Gelderland:ti,ab 
OR Guelders:ti,ab OR Groningen:ti,ab OR Limburg:ti,ab OR Brabant:ti,ab OR Holland:ti,ab OR Overijssel:ti,ab OR Overissel:ti,ab 
OR Utrecht:ti,ab OR Zeeland:ti,ab OR Amsterdam:ti,ab OR Rotterdam:ti,ab OR Hague:ti,ab OR 's-Gravenhage':ti,ab OR 
'Den Haag':ti,ab OR Eindhoven:ti,ab OR Tilburg:ti,ab OR Almere:ti,ab OR Breda:ti,ab OR Nijmegen:ti,ab OR Nimeguen:ti,ab OR 
'Poland'/exp OR  'Polish citizen'/exp OR 'Pole (people)'/exp OR Poland:ti,ab OR Polska:ti,ab OR Polish:ti,ab OR Pole:ti,ab 
OR Poles:ti,ab OR Polski:ti,ab OR Polak:ti,ab OR Polka:ti,ab OR Polacy:ti,ab OR Dolnoslaskie:ti,ab OR Silesia*:ti,ab OR Slask:ti,ab 
OR Pomorskie:ti,ab OR Pomerania*:ti,ab OR Kujawsko:ti,ab OR Kuyavian:ti,ab OR Lodzkie:ti,ab OR Lodz:ti,ab OR Lubelskie:ti,ab 
OR Lublin:ti,ab OR Lubuskie:ti,ab OR Lubusz:ti,ab OR Lubus:ti,ab OR Malopolskie:ti,ab OR Mazowieckie:ti,ab OR Mazowske:ti,ab 
OR Masovia:ti,ab OR Masovian:ti,ab OR Opolskie:ti,ab OR Opole:ti,ab OR Podkarpackie:ti,ab OR Subcarpathian*:ti,ab 
OR Podlaskie:ti,ab OR Podlachia:ti,ab OR Podlasie:ti,ab OR Slaskie:ti,ab OR Swietokrzyskie:ti,ab OR 'Varmia Mazuria':ti,ab 
OR 'Varmian Mazurian':ti,ab OR 'Varmia Masuria':ti,ab OR 'Varmian Masurian':ti,ab OR 'Warmia Mazury':ti,ab 
OR 'Warminsko Mazurskie':ti,ab OR 'Warmian Masurian':ti,ab OR Wielkopolskie:ti,ab OR Zachodniopomorskie:ti,ab 
OR Warsaw:ti,ab OR Warszawa:ti,ab OR Krakow:ti,ab OR Cracow:ti,ab OR Wroclaw:ti,ab OR Poznan:ti,ab OR Gdansk:ti,ab 
OR Szczecin:ti,ab OR Bydgoszcz:ti,ab OR Katowice:ti,ab OR 'Portugal'/exp OR 'Portuguese (citizen)'/exp OR Portugal:ti,ab 
OR Portugues*:ti,ab OR Azores:ti,ab OR Acores:ti,ab OR Madeira:ti,ab OR Alentejo:ti,ab OR Algarve:ti,ab OR Lisboa:ti,ab OR 
Lisbon:ti,ab OR 'Alto Tras-os-Montes':ti,ab OR (Ave NEAR/3 (community OR intermunicipal OR comunidade)):ti,ab OR 
Mondego:ti,ab OR Vouga:ti,ab OR Beira:ti,ab OR Cavado:ti,ab OR Lafoes:ti,ab OR Douro:ti,ab OR Porto:ti,ab OR Oporto:ti,ab 
OR Tejo:ti,ab OR Minho:ti,ab OR Setubal:ti,ab OR Pinhal:ti,ab OR 'Serra da Estrela':ti,ab OR Tamega:ti,ab OR Leira:ti,ab OR 
Santarem:ti,ab OR Beja:ti,ab OR Faro:ti,ab OR Evora:ti,ab OR Portalegre:ti,ab OR 'Castelo Branco':ti,ab OR Guarda:ti,ab OR 
Cimbra:ti,ab OR Aveiro:ti,ab OR Viseu:ti,ab OR Braganca:ti,ab OR Braganza:ti,ab OR Braga:ti,ab OR 'Vila real':ti,ab OR 'Viana do 
Castelo':ti,ab OR Gaia:ti,ab OR Amadora:ti,ab OR Funchal:ti,ab OR Coimbra:ti,ab OR Almada:ti,ab OR (Agualva:ti,ab 
AND Cacem:ti,ab) OR 'Romania'/exp OR 'Romanian (citizen)'/exp OR Romania*:ti,ab OR Rumania*:ti,ab OR Roumania*:ti,ab 
OR Romani:ti,ab OR Rumani:ti,ab OR Alba:ti,ab OR Arad:ti,ab OR Arges:ti,ab OR Bacau:ti,ab OR Bihor:ti,ab OR 
'Bistrita Nasaud':ti,ab OR Botosani:ti,ab OR Braila:ti,ab OR Brasov:ti,ab OR Kronstadt:ti,ab OR Brasso:ti,ab OR Brassovia:ti,ab OR 
Coron:ti,ab OR Bucharest:ti,ab OR Bucuresti:ti,ab OR Buzau:ti,ab OR Calarasi:ti,ab OR 'Caras-Severin':ti,ab OR Cluj:ti,ab OR 
Klausenburg:ti,ab OR Kolozsvar:ti,ab OR Constanta:ti,ab OR Tomis:ti,ab OR Konstantia:ti,ab OR Kostence:ti,ab OR Covasna:ti,ab 
OR Dambovita:ti,ab OR Dolj:ti,ab OR Galati:ti,ab OR Galatz:ti,ab OR Galac:ti,ab OR Kalas:ti,ab OR Giurgiu:ti,ab OR Gorj:ti,ab 
OR Harghita:ti,ab OR Hunedoara:ti,ab OR Ialomita:ti,ab OR Iasi:ti,ab OR Jassy:ti,ab OR Lassy:ti,ab OR Ilfov:ti,ab 
OR Maramures:ti,ab OR Mehedinti:ti,ab OR Mures:ti,ab OR Neamt:ti,ab OR (Olt:ti,ab AND (river:ti,ab OR county:ti,ab OR 
region:ti,ab OR judetul:ti,ab OR Raul:ti,ab)) OR Prahova:ti,ab OR Salaj:ti,ab OR 'Satu Mare':ti,ab OR Sibiu:ti,ab OR Suceava:ti,ab 
OR Teleorman:ti,ab OR Timis:ti,ab OR Tulcea:ti,ab OR Valcea:ti,ab OR Vilcea:ti,ab OR Vaslui:ti,ab OR Vrancea:ti,ab 
OR Timisoara:ti,ab OR Temeswar:ti,ab OR Temeschburg:ti,ab OR Temeschwar:ti,ab OR Temesvar:ti,ab OR Temisvar:ti,ab OR 
Timisvar:ti,ab OR Temesva:ti,ab OR Craiova:ti,ab OR Ploiesti:ti,ab OR Ploesti:ti,ab OR Oradea:ti,ab OR Varad:ti,ab OR Varat:ti,ab 
OR 'Slovakia'/exp OR 'Slovak (citizen)'/exp OR 'Slovak (people)'/exp OR Slovakia:ti,ab OR Slovensk*:ti,ab OR Slovak*:ti,ab OR 
Slovaci:ti,ab OR Slovenki:ti,ab OR Bratislav*:ti,ab OR Presporok:ti,ab OR Pressburg:ti,ab OR Preßburg:ti,ab OR Posonium:ti,ab 
OR Banskobystri*:ti,ab OR 'Banska Bystrica':ti,ab OR Neusohl:ti,ab OR Besztercebánya:ti,ab OR Kosic*:ti,ab OR Kaschau:ti,ab OR 
Kassa:ti,ab OR Nitrian*:ti,ab OR Nitra:ti,ab OR Neutra:ti,ab OR Nyitra:ti,ab OR Nyitria:ti,ab OR Trnav*:ti,ab OR Tyrnau:ti,ab OR 
Nagyszombat:ti,ab OR Tyrnavia:ti,ab OR Presov*:ti,ab OR Trencian*:ti,ab OR Trencin:ti,ab OR Trentschin:ti,ab OR Trencsén:ti,ab 
OR Zilina:ti,ab OR Sillein:ti,ab OR Zsolna:ti,ab OR Zylina:ti,ab OR (Martin:ti,ab AND (city:ti,ab OR Svaty:ti,ab)) OR 
Turócszentmárton:ti,ab OR Poprad:ti,ab OR Deutschendorf:ti,ab OR Zvolen:ti,ab OR 'Slovenia'/exp OR 'Slovenian (citizen)'/exp 
OR 'Slovene (people)'/exp OR Slovenia*:ti,ab OR Slovenija:ti,ab OR slovensk*:ti,ab OR Slovenci:ti,ab OR 
Slovene*:ti,ab OR Gorenjska:ti,ab OR Carniola:ti,ab OR Goriska:ti,ab OR Gorizia:ti,ab OR Jugovzhodna:ti,ab OR Koroska:ti,ab 
OR Carinthia:ti,ab OR 'Notranjsko kraska':ti,ab OR 'Obalno kraska':ti,ab OR 'Coastal karst':ti,ab OR Osrednjeslovenska:ti,ab 
OR Podravska:ti,ab OR Drava:ti,ab OR Pomurska:ti,ab OR Mura:ti,ab OR Savinjska:ti,ab OR Savinja:ti,ab 
OR Spodnjeposavska:ti,ab OR Zasavska:ti,ab OR 'Central Sava':ti,ab OR Posavska:ti,ab OR 'Lower Sava':ti,ab OR Ljubljana:ti,ab 
OR Laibach:ti,ab OR Lubiana:ti,ab OR Maribor:ti,ab OR 'Marburg an der Drau':ti,ab OR Kranj:ti,ab OR Carnium:ti,ab OR 
Creina:ti,ab OR Chreina:ti,ab OR Krainbur:ti,ab OR Koper:ti,ab OR Capodistria:ti,ab OR Kopar:ti,ab OR Celje:ti,ab OR 'Novo 
mesto':ti,ab OR Neustadtl:ti,ab OR Domzale:ti,ab OR Velenje:ti,ab OR Wollan:ti,ab OR Woellan:ti,ab OR 'Nova Gorica':ti,ab OR 
Kamnik:ti,ab OR 'Spain'/exp OR 'Spaniard'/exp OR 'Basque (people)'/exp OR Spain:ti,ab OR Espana:ti,ab OR Spanish:ti,ab 
OR Espanol*:ti,ab OR Spaniard*:ti,ab OR Andalucia:ti,ab OR Andalusia:ti,ab OR Aragon:ti,ab OR Arago:ti,ab OR Cantabria:ti,ab 
OR Canarias:ti,ab OR 'Canary Islands':ti,ab OR (Canaries:ti,ab AND island*:ti,ab) OR 'Castile and leon':ti,ab OR 'Castilla y 
Leon':ti,ab OR 'Castile La Mancha':ti,ab OR 'Castilla La Mancha':ti,ab OR Cataluna:ti,ab OR Catalonia:ti,ab OR Ceuta:ti,ab 
OR Madrid:ti,ab OR Melilla:ti,ab OR Navarra:ti,ab OR Navarre:ti,ab OR Valencia*:ti,ab OR Extremadura:ti,ab OR Galicia:ti,ab 
OR Balears:ti,ab OR 'Balearic Islands':ti,ab OR 'Balear Islands':ti,ab OR Baleares:ti,ab OR 'La Rioja':ti,ab OR 'Pais Vasco':ti,ab 
OR 'Basque Country':ti,ab OR 'Baske region':ti,ab OR Euskadi:ti,ab OR Asturias:ti,ab OR Murcia:ti,ab OR Coruna:ti,ab 
OR Alava:ti,ab OR Araba:ti,ab OR Albacete:ti,ab OR Alicante:ti,ab OR Alacant:ti,ab OR Almeria:ti,ab OR Avila:ti,ab 
OR Badajoz:ti,ab OR Badajos:ti,ab OR Barcelona:ti,ab OR Burgos:ti,ab OR Caceres:ti,ab OR Cadiz:ti,ab OR Castellon:ti,ab 
OR Castello:ti,ab OR 'Ciudad Real':ti,ab OR Cordoba:ti,ab OR Cuenca:ti,ab OR Eivissa:ti,ab OR Ibiza:ti,ab OR Formentera:ti,ab 
OR 'El Hierro':ti,ab OR Fuerteventura:ti,ab OR Galiza:ti,ab OR Girona:ti,ab OR Gerona:ti,ab OR 'Gran Canaria':ti,ab 
OR Granada:ti,ab OR Guadalajara:ti,ab OR Guipuzcoa:ti,ab OR Gipuzkoa:ti,ab OR Huelva:ti,ab OR Huesca:ti,ab OR Jaen:ti,ab 
OR 'La Gomera':ti,ab OR 'La Palma':ti,ab OR Lanzarote:ti,ab OR Leon:ti,ab OR Lleida:ti,ab OR Lerida:ti,ab OR Lugo:ti,ab 
OR Malaga:ti,ab OR Mallorca:ti,ab OR Majorca:ti,ab OR Menorca:ti,ab OR Minorca:ti,ab OR Murcia:ti,ab OR Ourense:ti,ab OR 
Orense:ti,ab OR Palencia:ti,ab OR Pontevedra:ti,ab OR Salamanca:ti,ab OR Segovia:ti,ab OR Sevilla:ti,ab OR Seville:ti,ab 
OR Soria:ti,ab OR Tarragona:ti,ab OR Tenerife:ti,ab OR Teruel:ti,ab OR Toledo:ti,ab OR Valladolid:ti,ab OR Vizcaya:ti,ab 
OR Biscay:ti,ab OR Zamora:ti,ab OR Zaragoza:ti,ab OR Saragossa:ti,ab OR 'Las Palmas':ti,ab OR Bilbao:ti,ab OR Bilbo:ti,ab OR 
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'Sweden'/exp OR 'Swedish citizen'/exp OR 'Swede (people)'/exp  OR Sweden:ti,ab OR Sverige:ti,ab OR 
Swedish:ti,ab OR Svenska:ti,ab OR svenskar:ti,ab OR Swede:ti,ab OR Swedes:ti,ab OR Norrland:ti,ab OR Mellansverige:ti,ab 
OR Smaland:ti,ab OR Stockholm*:ti,ab OR Sydsverige:ti,ab OR Vastsverige:ti,ab OR Blekinge:ti,ab OR 
Dalarna:ti,ab OR Gavleborg*:ti,ab OR Gotland*:ti,ab OR Halland*:ti,ab OR Jamtland*:ti,ab OR Jonkoping*:ti,ab OR Kalmar:ti,ab 
OR Kronoberg*:ti,ab OR Norrbotten*:ti,ab OR Orebro:ti,ab OR Ostergotland*:ti,ab OR Skane:ti,ab OR Sodermanlands:ti,ab OR 
Uppsala:ti,ab OR Varmland*:ti,ab OR Vasterbotten*:ti,ab OR Vasternorrland*:ti,ab OR Vastmanland*:ti,ab OR 
vastergotland*:ti,ab OR Gotaland*:ti,ab OR Gothenburg:ti,ab OR Goteborg:ti,ab OR Malmo:ti,ab OR Vasteras:ti,ab OR 
Linkoping:ti,ab OR Helsingborg:ti,ab OR Halsingborg:ti,ab OR Norrkoping:ti,ab OR 'United Kingdom'/exp OR 'British citizen'/exp 
OR 'GB':ti,ab OR 'United kingdom':ti,ab OR 'UK':ti,ab OR Britain:ti,ab OR British:ti,ab OR England:ti,ab OR English:ti,ab OR 
Scotland:ti,ab OR Scottish:ti,ab OR Scots:ti,ab OR Wales:ti,ab OR Cymru:ti,ab OR Welsh:ti,ab OR 'North Ireland':ti,ab OR 
'Northern Ireland':ti,ab OR Irish:ti,ab OR Avon:ti,ab OR Bedfordshire:ti,ab OR Berkshire:ti,ab OR Bristol:ti,ab OR 
Buckinghamshire:ti,ab OR Cambridgeshire:ti,ab OR 'Isle  of  Ely':ti,ab OR Cheshire:ti,ab OR Cleveland:ti,ab OR Cornwall:ti,ab OR 
Cumberland:ti,ab OR Cumbria:ti,ab OR Derbyshire:ti,ab OR Devon:ti,ab OR Dorset:ti,ab OR Durham:ti,ab OR Essex:ti,ab OR 
Gloucestershire:ti,ab OR Hampshire:ti,ab OR Southampton:ti,ab OR (Hereford:ti,ab AND Worcester:ti,ab) OR Hertfordshire:ti,ab 
OR Herefordshire:ti,ab OR Humberside:ti,ab OR Huntingdon:ti,ab OR Huntingdonshire:ti,ab OR 'Isle of Wight':ti,ab OR Kent:ti,ab 
OR Lancashire:ti,ab OR Leicestershire:ti,ab OR Lincolnshire:ti,ab OR London:ti,ab OR Manchester:ti,ab OR Merseyside:ti,ab OR 
Middlesex:ti,ab OR Norfolk:ti,ab OR Northamptonshire:ti,ab OR Northumberland:ti,ab OR Nottinghamshire:ti,ab OR 
Oxfordshire:ti,ab OR Peterborough:ti,ab OR Rutland:ti,ab OR Shropshire:ti,ab OR Salop:ti,ab OR Somerset:ti,ab OR 
Yorkshire:ti,ab OR Staffordshire:ti,ab OR Suffolk:ti,ab OR Surrey:ti,ab OR Sussex:ti,ab OR (Tyne:ti,ab  AND  Wear:ti,ab) OR 
Warwickshire:ti,ab OR Midlands:ti,ab OR Westmorland:ti,ab OR Wiltshire:ti,ab OR Worcestershire:ti,ab OR 'Isle  of  Man':ti,ab OR 
Jersey:ti,ab OR Guernsey:ti,ab OR 'Channel Islands':ti,ab OR Aberdeen:ti,ab OR Aberdeenshire:ti,ab OR Angus:ti,ab OR 
Forfarshire:ti,ab OR Argyll:ti,ab OR Ayrshire:ti,ab OR Banffshire:ti,ab OR Berwickshire:ti,ab OR Bute:ti,ab OR Caithness:ti,ab OR 
Clackmannanshire:ti,ab OR Cromartyshire:ti,ab OR Dumfriesshire:ti,ab OR Dunbartonshire:ti,ab OR Dumbarton:ti,ab OR 
Dundee:ti,ab OR Lothian:ti,ab OR Haddingtonshire:ti,ab OR Edinburgh:ti,ab OR Fife:ti,ab OR Glasgow:ti,ab OR Inverness-
shire:ti,ab OR Kincardineshire:ti,ab OR Kinross-shire:ti,ab OR Kirkcudbrightshire:ti,ab OR Lanarkshire:ti,ab OR Midlothian:ti,ab OR 
Moray:ti,ab OR Elginshire:ti,ab OR Nairnshire:ti,ab OR Orkney:ti,ab OR Peeblesshire:ti,ab OR Perthshire:ti,ab OR 
Renfrewshire:ti,ab OR (Ross:ti,ab  AND  Cromarty:ti,ab) OR Ross-shire:ti,ab OR Roxburghshire:ti,ab OR Selkirkshire:ti,ab OR 
Shetland:ti,ab OR Zetland:ti,ab OR Stirlingshire:ti,ab OR Sutherland:ti,ab OR Linlithgowshire:ti,ab OR Wigtownshire:ti,ab OR 
Anglesey:ti,ab OR Brecknockshire:ti,ab OR Caernarfonshire:ti,ab OR Carmarthenshire:ti,ab OR Cardiganshire:ti,ab OR 
Ceredigion:ti,ab OR Clwyd:ti,ab OR Denbighshire:ti,ab OR Dyfed:ti,ab OR Flintshire:ti,ab OR Glamorgan:ti,ab OR Gwent:ti,ab OR 
Gwynedd:ti,ab OR Merionethshire:ti,ab OR Montgomeryshire:ti,ab OR Monmouthshire:ti,ab OR Pembrokeshire:ti,ab OR 
Powys:ti,ab OR Radnorshire:ti,ab OR Antrim:ti,ab OR Aontroim:ti,ab OR 'Contae Aontroma':ti,ab OR Anthrim:ti,ab OR Antrìm:ti,ab 
OR Entrim:ti,ab OR Armagh:ti,ab OR 'Ard Mhacha':ti,ab OR Airmagh:ti,ab OR Belfast:ti,ab OR (Down:ti,ab AND (district:ti,ab OR 
council:ti,ab OR County:ti,ab)) OR 'An Dún':ti,ab OR 'an Dúin':ti,ab OR Doon:ti,ab OR Doun:ti,ab OR Fermanagh:ti,ab OR 'Fear  
Manach':ti,ab OR 'Fhear Manach':ti,ab OR Fermanay:ti,ab OR Londonderry:ti,ab OR Doire:ti,ab OR Dhoire:ti,ab OR 
Lunnonderrie:ti,ab OR Derry:ti,ab OR Birmingham:ti,ab OR Leeds:ti,ab OR Sheffield:ti,ab OR Bradford:ti,ab OR Liverpool:ti,ab OR 
'Albania'/exp OR 'Albanian (citizen)'/exp OR 'Albanian (people)'/exp OR Albania*:ti,ab OR Shqiperi*:ti,ab OR Schqipt*:ti,ab OR 
Berat:ti,ab OR Beratit:ti,ab OR Diber:ti,ab OR Dibres:ti,ab OR Durres:ti,ab OR Durresit:ti,ab OR Elbasan:ti,ab OR Elbasanit:ti,ab 
OR Fier:ti,ab OR Fierit:ti,ab OR Gjirokaster:ti,ab OR Gjirokastres:ti,ab OR Korce:ti,ab OR Korces:ti,ab OR Kukes:ti,ab OR 
Kukesit:ti,ab OR Lezhes:ti,ab OR Lezhe:ti,ab OR Shkodres:ti,ab OR Shkoder:ti,ab OR Tirana:ti,ab OR Tirane*:ti,ab OR Vlore:ti,ab 
OR Vlores:ti,ab OR Kamez:ti,ab OR Beraz:ti,ab OR Lushnje:ti,ab OR 'Macedonia (republic)'/exp OR 'Macedonian (citizen)'/exp OR 
'Macedonian (people)'/exp OR Makedon*:ti,ab OR Macedon*:ti,ab OR Fyrom:ti,ab OR Istocen:ti,ab OR Severoistocen:ti,ab OR 
Jugoistocen:ti,ab OR Jugozapaden:ti,ab OR Pelagonski:ti,ab OR Pelagonia:ti,ab OR Poloski:ti,ab OR Polog:ti,ab OR Skopski:ti,ab 
OR Skopje:ti,ab OR Ckonje:ti,ab OR Vardar*:ti,ab OR Bitola:ti,ab OR Kumanovo:ti,ab OR Prilep:ti,ab OR Tetovo:ti,ab OR 
Tetova:ti,ab OR Tetove:ti,ab OR Veles:ti,ab OR Stip:ti,ab OR Shtip:ti,ab OR Ohrid:ti,ab OR Gostivar:ti,ab OR Gostivari:ti,ab OR 
Strumica:ti,ab OR 'Iceland'/exp  OR 'Icelander'/exp OR Iceland:ti,ab OR Icelandic*:ti,ab OR islenska*:ti,ab OR Icelander*:ti,ab 
OR islendinga*:ti,ab OR Islendigar:ti,ab OR Inslenska:ti,ab OR Reykjavík:ti,ab OR Reykjavíkurborg:ti,ab 
OR Hofudborgarsvaedi:ti,ab OR Sudurnes:ti,ab OR Vesturland:ti,ab OR Vestfirdir:ti,ab OR Westfjords:ti,ab OR Nordurland:ti,ab 
OR Austurland:ti,ab OR Sudurland:ti,ab OR Kopavogur:ti,ab OR Hafnarfjordur:ti,ab OR Akureyri:ti,ab OR Gardabaer:ti,ab 
OR Mosfellsbaer:ti,ab OR Keflavik:ti,ab OR Akranes:ti,ab OR Selfoss:ti,ab OR Seltjarnarnes:ti,ab OR 'Montenegro (republic)'/exp 
OR Montenegr*:ti,ab OR 'Crna Gora':ti,ab OR Crnogorci:ti,ab OR Andrijevica:ti,ab OR (Bar:ti,ab AND (Opstina:ti,ab OR 
municipality:ti,ab OR city:ti,ab OR town:ti,ab)) OR Berane:ti,ab OR 'Bijelo polje':ti,ab OR Budva:ti,ab OR Cetinje:ti,ab OR 
Danilovgrad:ti,ab OR Gusinje:ti,ab OR 'herceg Novi':ti,ab OR Kolasin:ti,ab OR Kotor:ti,ab OR Mojkovac:ti,ab OR Niksic:ti,ab OR 
Petnija:ti,ab OR Plav:ti,ab OR Pluzine:ti,ab OR Pljevlja:ti,ab OR Podgorica:ti,ab OR Rozaje:ti,ab OR Savnik:ti,ab OR Tivat:ti,ab OR 
Ulcinj:ti,ab OR Zabljak:ti,ab OR 'Serbia'/exp OR 'Serbian (citizen)'/exp OR 'Serb (people)'/exp OR Serbia*:ti,ab OR Srbija:ti,ab OR 
Serb:ti,ab OR Serbs:ti,ab OR Srbi:ti,ab OR Vojvodina:ti,ab OR Belgrade:ti,ab OR Beograd:ti,ab OR Sumadija:ti,ab OR 
Kolubara:ti,ab OR Kolubarski:ti,ab OR Macva:ti,ab OR Macvanski:ti,ab OR Moravica:ti,ab OR Moravicki:ti,ab OR Pomoravlje:ti,ab 
OR Pomoravski:ti,ab OR Rasinski:ti,ab OR Rasina:ti,ab OR Raska:ti,ab OR Raski:ti,ab OR Sumadijski:ti,ab OR Zlatibor:ti,ab OR 
Zlatiborski:ti,ab OR Bor:ti,ab OR Borski:ti,ab OR Branicevo:ti,ab OR Branicevski:ti,ab OR Jablanica:ti,ab OR Jablanicki:ti,ab OR 
Nisava:ti,ab OR Nisavski:ti,ab OR Pcinja:ti,ab OR Pcinjski:ti,ab OR Pirot:ti,ab OR Pirotski:ti,ab OR Podunavlje:ti,ab OR 
Podunavski:ti,ab OR Toplica:ti,ab OR Toplicki:ti,ab OR Zajecar:ti,ab OR Zajecarski:ti,ab OR Banat:ti,ab OR Srendjebanatski:ti,ab 
OR Backa:ti,ab OR Severnobacki:ti,ab OR Severnobanatski:ti,ab OR Juznobacki:ti,ab OR Juznobanatski:ti,ab OR Srem:ti,ab OR 
Sremski:ti,ab OR Zapadnobacki:ti,ab OR 'Novi Sad':ti,ab OR 'Novy Sad':ti,ab OR Újvidék:ti,ab OR Nis:ti,ab OR Nish:ti,ab OR 
Nissa:ti,ab OR Kragujevac:ti,ab OR Subotica:ti,ab OR Szabadka:ti,ab OR Zrenjanin:ti,ab OR Pancevo:ti,ab OR Cacak:ti,ab OR 
Kraljevo:ti,ab OR 'Novi Pazar':ti,ab OR 'Novy Pazar':ti,ab OR 'Turkey (republic)'/exp OR 'Turkish citizen'/exp OR Turkey:ti,ab OR 
Turkiye:ti,ab OR Turkish:ti,ab OR Turk:ti,ab OR Turkc*:ti,ab OR Adana:ti,ab OR Adiyaman:ti,ab OR Ayfon*:ti,ab OR Agri:ti,ab OR 
Aksaray:ti,ab OR Aksaray:ti,ab OR Amasya:ti,ab OR Ankara:ti,ab OR Antalya:ti,ab OR Ardahan:ti,ab OR Artvin:ti,ab OR 
Aydin:ti,ab OR Balikesir:ti,ab OR Bartin:ti,ab OR Batman:ti,ab OR Bayburt:ti,ab OR Bilecik:ti,ab OR Bingol:ti,ab OR Bitlis:ti,ab OR 
Bolu:ti,ab OR Burdur:ti,ab OR Bursa:ti,ab OR Canakkale:ti,ab OR Cannkiri:ti,ab OR Corum:ti,ab OR Denizli:ti,ab OR 
Diyarbarkir:ti,ab OR Duzce:ti,ab OR Edirne:ti,ab OR Elazig:ti,ab OR Erzincan:ti,ab OR Erzurum:ti,ab OR Eskishir:ti,ab OR 
Gaziantep:ti,ab OR Giresun:ti,ab OR Gumushane:ti,ab OR Hakkari:ti,ab OR Hatay:ti,ab OR Igdir:ti,ab OR Isparta:ti,ab OR 
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Istanbul:ti,ab OR Izmir:ti,ab OR Kahramanmaras:ti,ab OR Karabuk:ti,ab OR Karaman:ti,ab OR Kars:ti,ab OR Kastamonu:ti,ab OR 
Kayseri:ti,ab OR Kirikkale:ti,ab OR Kirklarely:ti,ab OR Kirklareli:ti,ab OR Kirsheir:ti,ab OR Kocaeli:ti,ab OR Konya:ti,ab OR 
Kutahya:ti,ab OR Malatya:ti,ab OR Manisa:ti,ab OR Mardin:ti,ab OR Mersin:ti,ab OR Mugla:ti,ab OR Mus:ti,ab OR Nevsehir:ti,ab 
OR Nigde:ti,ab OR Ordu:ti,ab OR Osmaniye:ti,ab OR Rize:ti,ab OR Sakarya:ti,ab OR Samsun:ti,ab OR Sanliurfa:ti,ab OR Siirt:ti,ab 
OR Sinop:ti,ab OR Sivas:ti,ab OR Sirnak:ti,ab OR Tekirdag:ti,ab OR Tokat:ti,ab OR Trabzon:ti,ab OR Tunceli:ti,ab OR Usak:ti,ab 
OR (Van:ti,ab AND (province:ti,ab OR ili:ti,ab)) OR Yalova:ti,ab OR Yozgat:ti,ab OR Kilis:ti,ab OR 'Bosnia and Herzegovina'/exp 
OR 'Bosnian (citizen)'/exp OR 'Bosniak (people)'/exp OR Bosnia*:ti,ab OR Herzegov*:ti,ab OR Herzegonine:ti,ab OR Bosna:ti,ab 
OR Bosne:ti,ab OR Bosanski:ti,ab OR Bosanac:ti,ab OR Bosanci:ti,ab OR Srpska:ti,ab OR Brcko:ti,ab OR Posavski:ti,ab OR 
Posavina:ti,ab OR posavska:ti,ab OR Tuzlanski:ti,ab OR Tuzla:ti,ab OR Tuzlanska:ti,ab OR 'Zenickho dobojski':ti,ab OR 'Zenicko 
dobojska':ti,ab OR Zenica:ti,ab OR 'Bosansko Podrinjski':ti,ab OR 'Bosansko Podrinjska':ti,ab OR Srednjobosanski:ti,ab OR 
hercegovacko:ti,ab OR Zapadnohercegovacki:ti,ab OR Zapadnohercegovacka:ti,ab OR Sarajevo:ti,ab OR Sarajevska:ti,ab OR 
'Kanton 10':ti,ab OR '10 kanton':ti,ab OR Hercegbosanska:ti,ab OR 'Unsko sanski':ti,ab OR 'Una Sana':ti,ab OR 'Banja Luka':ti,ab 
OR bijeljina:ti,ab OR Mostar:ti,ab OR Prijedor:ti,ab OR Cazin:ti,ab OR Doboj:ti,ab OR Zupanija:ti,ab OR 'Kosovo'/exp OR 
'Kosovar'/exp OR Kosov*:ti,ab OR Ferizaj*:ti,ab OR Urosevac*:ti,ab OR Gjakov*:ti,ab OR Dakovic*:ti,ab OR Gjilan*:ti,ab OR 
Gnjilan*:ti,ab OR Mitrovic*:ti,ab OR Pejes:ti,ab OR Peja:ti,ab OR Peje:ti,ab OR Pecki:ti,ab OR Pec:ti,ab OR Pristin*:ti,ab OR 
Prishtin*:ti,ab OR Pristinski:ti,ab OR Prizrenit:ti,ab OR Prizrenski:ti,ab OR Prizen:ti,ab OR Prizren:ti,ab OR Prizeni:ti,ab OR 
Produjev*:ti,ab OR Vucitrn:ti,ab OR Vushtrri*:ti,ab OR 'Suva reka':ti,ab OR Suhareka:ti,ab OR Besiana:ti,ab OR Metohija:ti,ab OR 
Dukagjini:ti,ab OR Dukagjinit:ti,ab OR 'Liechtenstein'/exp OR Liechtenstein:ti,ab OR Lienchtensteiner*:ti,ab OR Balzers:ti,ab OR 
Eschen:ti,ab OR Gamprin:ti,ab OR Mauren:ti,ab OR Planken:ti,ab OR Ruggell:ti,ab OR Schaan:ti,ab OR Schellenberg:ti,ab OR 
Triesen:ti,ab OR Triesenberg:ti,ab OR Vaduz:ti,ab OR 'Norway'/exp OR 'Norwegian (citizen)'/exp OR 'Norwegian (people)'/exp OR 
Norway:ti,ab OR Norwegian*:ti,ab OR Norge:ti,ab OR Noreg:ti,ab OR Norgga:ti,ab OR Akershus:ti,ab OR 'Aust Agder':ti,ab OR 
Buskerud:ti,ab OR Finnmark:ti,ab OR Hedmark:ti,ab OR Hordaland:ti,ab OR 'More og Romsdal':ti,ab OR 'More and Romsdal':ti,ab 
OR 'More Romsdal':ti,ab OR Nordland:ti,ab OR Trondelag:ti,ab OR Oppland:ti,ab OR 
Oslo:ti,ab OR Ostfold:ti,ab OR Rogaland:ti,ab OR 'Sogn og fjordane':ti,ab OR 'Sogn and fjordane':ti,ab OR 
'sogn fjordane':ti,ab OR Telemark:ti,ab OR Troms:ti,ab OR Romsa:ti,ab OR Romssa:ti,ab OR 'Vest Agder':ti,ab OR Vestfold:ti,ab 
OR Bergen:ti,ab OR Stavanger:ti,ab OR Sandnes:ti,ab OR Trondheim:ti,ab OR Trondhjem:ti,ab OR Kaupangen:ti,ab 
OR Nidaros:ti,ab OR Drammen:ti,ab OR Fredrikstad:ti,ab OR Skien:ti,ab OR Tromso:ti,ab OR Sarpsborg:ti,ab OR 'Switzerland'/exp 
OR 'Swiss'/exp OR Switzerland:ti,ab OR Schweiz:ti,ab OR Schweizerische:ti,ab OR Swiss:ti,ab OR Suisse*:ti,ab OR Svizzera:ti,ab 
OR Svizzeri:ti,ab OR Svizzers:ti,ab OR Svizra:ti,ab OR Helvetica:ti,ab OR Aargau:ti,ab OR Argovia:ti,ab OR Ausserrhoden:ti,ab OR 
'Outer Rhodes':ti,ab OR Innerrhoden:ti,ab OR 'Inner Rhodes':ti,ab OR Basel:ti,ab OR Bale:ti,ab OR Basilea:ti,ab OR Bern:ti,ab OR 
Berne:ti,ab OR Berna:ti,ab OR Fribourg:ti,ab OR Freiburg:ti,ab OR Friburg:ti,ab OR Geneva:ti,ab OR Geneve:ti,ab OR Genf:ti,ab 
OR Ginevra:ti,ab OR Genevra:ti,ab OR Glarus:ti,ab OR Graubunden:ti,ab OR Graubuenden:ti,ab OR Grisons:ti,ab 
OR Grigioni:ti,ab OR Grischun:ti,ab OR jura:ti,ab OR Lucerne:ti,ab OR Luzern:ti,ab OR Losanna:ti,ab OR Neuchatel:ti,ab OR 
Nidwalden:ti,ab OR Nidwald:ti,ab OR Obwalden:ti,ab OR Obwald:ti,ab OR Schaffhausen:ti,ab OR Schaffhouse:ti,ab OR 
Schwyz:ti,ab OR Solothurn:ti,ab OR Soleure:ti,ab OR Thurgau:ti,ab OR Thurgovia:ti,ab OR Ticino:ti,ab OR Tessin:ti,ab OR 
Uri:ti,ab OR Valais:ti,ab OR Wallis:ti,ab OR Vaud:ti,ab OR Zug:ti,ab OR Zurich:ti,ab OR Zuerich:ti,ab OR Zurigo:ti,ab OR 
Lausanne:ti,ab OR Losanna:ti,ab OR Winterthur:ti,ab OR Winterthour:ti,ab OR 'St Gallen':ti,ab OR 'Saint Gallen':ti,ab OR 
'Sankt Gallen':ti,ab OR 'Saint Gall':ti,ab OR 'San Gallo':ti,ab OR 'Son Gagl':ti,ab OR Turitg:ti,ab OR europe*:ad OR europa*:ad OR 
eu:ad OR eea:ad OR efta:ad OR 'eu/eea':ad OR 'eu/efta':ad OR ecsc:ad OR euratom:ad OR eurozone:ad OR eec:ad OR ec:ad 
OR (schengen:ad AND (area:ad OR countr*:ad OR region*:ad OR state:ad OR states:ad)) OR euroregion:ad OR 
euroregions:ad OR balkan:ad OR balkans:ad OR baltic:ad OR (mediterranean:ad AND (area:ad OR countr*:ad OR region*:ad 
OR state:ad OR states:ad)) OR (alpine:ad AND (area:ad OR countr*:ad OR region*:ad OR state:ad OR states:ad)) OR 
scandinavia:ad OR scandinavian:ad OR (nordic NEXT/1 (countr* OR state*)):ad OR danubian:ad OR 'iberian peninsula':ad OR 
'peninsula iberica':ad OR 'péninsule ibérique':ad OR 'iberiar penintsula':ad OR iberia:ad OR anatolia:ad OR anadolu:ad OR 
anatole:ad OR anatolian:ad OR yugoslavia:ad OR czechoslovakia:ad OR 'czecho slovakia':ad OR ceskoslovensko:ad OR 'cesko 
slovensko':ad OR benelux:ad OR fennoscandia:ad OR 'fenno scandinavia':ad OR fennoskandi*:ad OR (visegrád:ad AND 
(group:ad OR four:ad OR triangle:ad)) OR 'visegrádská čtyřka':ad OR 'visegrádská skupina':ad OR 'visegrádi 
együttműködés':ad OR 'visegrádi négyek':ad OR 'grupa wyszehradzka':ad OR 'vyšehradská skupina':ad OR 'vyšehradská 
štvorka':ad OR austria*:ad OR osterreich*:ad OR oesterreich*:ad OR ostosterreich:ad OR ostoesterreich:ad OR sudosterreich:ad 
OR sudoesterreich:ad OR westosterreich:ad OR westoesterreich:ad OR burgenland:ad OR carinthia:ad OR karnten:ad OR 
kaernten:ad OR niederosterreich:ad OR niederoesterreich:ad OR oberosterreich:ad OR oberoesterreich:ad OR salzburg:ad OR 
saizburg:ad OR styria:ad OR steiermark:ad OR tyrol:ad OR tirol:ad OR vorarlberg:ad OR vienna:ad OR wien:ad OR graz:ad OR 
linz:ad OR innsbruck:ad OR klagenfurt:ad OR villach:ad OR wels:ad OR 'st polten':ad OR 'st poelten':ad OR 'sankt polten':ad OR 
'sankt poelten':ad OR dornbirn:ad OR Belgi*:ad OR Belge*:ad OR Belg:ad OR Brussel*:ad OR Bruxelles:ad OR Bruxelloise:ad OR 
Walloon*:ad OR Wallon*:ad OR Vlaams:ad OR Flander*:ad OR Flandern:ad OR Flandre:ad OR Flemish:ad OR Flamand:ad OR 
Flemisch:ad OR Flämisch*:ad OR Vlaanderen:ad OR Flamande:ad OR Waals:ad OR Antwerp*:ad OR Anvers:ad OR 
Henegouwen:ad OR Hennegau:ad OR Hainault:ad OR Hainaut:ad OR Liege:ad OR Luik:ad OR Luttich:ad OR Limbourg:ad OR 
Limburg:ad OR Namur:ad OR Namen:ad OR Ostflandern:ad OR Westflandern:ad OR Ghent:ad OR Gent:ad OR Gand:ad OR 
Charleroi:ad OR Bruges:ad OR Brugge*:ad OR Schaerbeek:ad OR Schaarbeek:ad OR Anderlecht:ad OR Leuven:ad OR Louvain:ad 
OR Bulgaria:ad OR balgariya:ad OR balgarija:ad OR blagoevgrad*:ad OR 'pirin macedonia':ad OR burgas:ad OR dobrich:ad OR 
gabrovo:ad OR haskovo:ad OR kardzhali:ad OR kurdzhali:ad OR kyustendil:ad OR lovech:ad OR lovec:ad OR montana:ad OR 
pazardzhik:ad OR pernik:ad OR pleven*:ad OR plovdiv:ad OR razgrad:ad OR rousse:ad OR ruse:ad OR rusenka:ad OR 
shumen:ad OR silistra:ad OR sliven:ad OR smolyan:ad OR sofia:ad OR sofyiska:ad OR sofiiska:ad OR 'stara zagora':ad OR 
targovishte:ad OR varna:ad OR 'veliko tarnovo':ad OR vidin:ad OR vratsa:ad OR vratza:ad OR yambol:ad OR croat*:ad OR 
hrvatsk*:ad OR hrvati:ad OR bjelovar:ad OR 'bjelovarsko bilogorska':ad OR 'brod posavina':ad OR 'brodsko posavska':ad OR 
'dubrovnik neretva':ad OR 'dubrovacko neretvanska':ad OR zagreb:ad OR zagrebacka:ad OR istria:ad OR istarska:ad OR 
karlovacka:ad OR karlovac:ad OR 'koprivnicko krizevacka':ad OR koprivnica:ad OR krizevci:ad OR 'krapina zagorje':ad OR 
'krapinsko zagorska':ad OR 'lika senj':ad OR 'licko senjska':ad OR medimurska:ad OR medimurje:ad OR osijek:ad OR baranja:ad 
OR 'osjecko baranjska':ad OR 'pozega slavonia':ad OR 'pozesko slavonska':ad OR 'primorje gorski kotar':ad OR 'primorsko 
goranska':ad OR 'sibensko kninska':ad OR 'sibensko kninske':ad OR sibenik:ad OR knin:ad OR sisak:ad OR 'sisacko 
moslavacka':ad OR moslavina:ad OR 'splitsko dalmatinska':ad OR split:ad OR dalmatia:ad OR varazdin:ad OR varazdinska:ad OR 
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viroviticko:ad OR podravska:ad OR virovitica:ad OR podravina:ad OR 'vukovarsko srijemska':ad OR vukovar:ad OR srijem:ad OR 
zadar:ad OR zadarska:ad OR rijeka:ad OR 'velika gorica':ad OR 'slavonski brod':ad OR pula:ad OR cyprus:ad OR cypriot*:ad OR 
kypros:ad OR kibris*:ad OR kypriaki:ad OR kyprioi:ad OR nicosia:ad OR lefkosa:ad OR lefkosia:ad OR famagusta:ad OR 
magusa:ad OR ammochostos:ad OR gazimagusa:ad OR kyrenia:ad OR girne:ad OR keryneia:ad OR larnaca:ad OR larnaka:ad OR 
iskele:ad OR limassol:ad OR lemesos:ad OR limasol:ad OR leymosun:ad OR paphos:ad OR pafos:ad OR baf:ad OR strovolos:ad 
OR lakatamia:ad OR lakadamya:ad OR 'kato polemidia':ad OR 'kato polemidhia':ad OR aglandjia:ad OR eglence:ad OR 
aglantzia:ad OR aradhippou:ad OR aradippou:ad OR engomi:ad OR czech*:ad OR cesky:ad OR ceska:ad OR cech:ad OR 
cestina:ad OR prague:ad OR praha:ad OR prag:ad OR stredoces*:ad OR jihoces*:ad OR bohemia:ad OR bohemian:ad OR 
plzen*:ad OR pilsen:ad OR karlovars*:ad OR 'karlovy vary':ad OR usteck*:ad OR usti:ad OR liberec*:ad OR 'hradec kralove':ad 
OR kralovehradec*:ad OR pardubic*:ad OR olomouc*:ad OR olomoc:ad OR holomoc:ad OR moravskoslezs*:ad OR jihomorav*:ad 
OR moravia:ad OR moravian:ad OR morava:ad OR vysocina:ad OR zlin:ad OR zlinsk*:ad OR 'ceske budejovice':ad OR budweis:ad 
OR brno:ad OR ostrava:ad OR Denmark:ad OR Danish*:ad OR dane:ad OR danes:ad OR Danmark:ad OR dansk*:ad OR 
Hovedstaden:ad OR Midtjylland:ad OR Nordjylland:ad OR Sjaelland:ad OR Sealand:ad OR 'Zealand region':ad OR 'region 
Zealand':ad OR Syddanmark:ad OR Jutland:ad OR Jylland:ad OR Sonderjyllands:ad OR Copenhagen:ad OR Kobenhavn:ad OR 
Arhus:ad OR Aarhus:ad OR Bornholm:ad OR Frederiksberg:ad OR Frederiksborg:ad OR Ringkjobing:ad OR Viborg:ad OR Vejle:ad 
OR Roskilde:ad OR Storstrøm:ad OR Vestsjaellands:ad OR 'West Zealand':ad OR Funen:ad OR Ribe:ad OR 'Kalaallit Nunaat':ad 
OR Gronland:ad OR Foroyar:ad OR Faeroerne:ad OR 'Faroe islands':ad OR Aalborg:ad OR Alborg:ad OR Odense:ad OR 
Esbjerg:ad OR Gentofte:ad OR Gladsaxe:ad OR Randers:ad OR Kolding:ad OR Estonia*:ad OR Eesti:ad OR Eestlased:ad OR 
Eestlane:ad OR Harju:ad OR Harjumaa:ad OR Hiiu:ad OR Hiiumaa:ad OR 'Ida Viru':ad OR 'Ida Virumaa':ad OR Jarvamaa:ad OR 
Jarva:ad OR Jogevamaa:ad OR Jogeva:ad OR Laanemaa:ad OR Laane:ad OR 'Laane Virumaa':ad OR Parnu:ad OR Parnumaa:ad 
OR Polva:ad OR Polvamaa:ad OR Rapla:ad OR Raplamaa:ad OR Saare:ad OR Saaremaa:ad OR Tartu:ad OR Tartumaa:ad OR 
Valga:ad OR Valgamaa:ad OR Viljandimaa:ad OR Viljandi:ad OR Voru:ad OR Vorumaa:ad OR Tallinn:ad OR Narva:ad OR 'Kohtla 
Jarve':ad OR Rakvere:ad OR Maardu:ad OR Sillamae:ad OR Kuressaare:ad OR Finland:ad OR Finnish*:ad OR Finn:ad OR Finns:ad 
OR Suomi:ad Suomen:ad OR Suomalaiset:ad OR Aland:ad OR Ahvenanmaa:ad OR Uusimaa:ad OR Nyland:ad OR Karelia:ad OR 
Karjala:ad OR Karelen:ad OR Ostrobothnia:ad OR Pohjanmaa:ad OR Osterbotten:ad OR Savonia:ad OR Savo:ad OR Savolax:ad 
OR Kainuu:ad OR Kajanaland*:ad OR 'Kanta Hame':ad OR Tavastia:ad OR Tavastland:ad OR Kymenlaakso:ad OR 
Kymmenedalen:ad OR Lapland:ad OR Lappi:ad OR Lappland:ad OR 'Paijat Hame':ad OR Pirkanmaa:ad OR Birkaland:ad OR 
Satakunta:ad OR Satakunda:ad OR Helsinki:ad OR Helsingfors:ad OR Espoo:ad OR Esbo:ad OR Tampere:ad OR Tammerfors:ad 
OR Vantaa:ad OR Vanda:ad OR Oulu:ad OR Uleaborg:ad OR Turku:ad OR Abo:ad OR Jyvaskyla:ad OR Kuopio:ad OR Lahti:ad OR 
Lahtis:ad OR Kouvola:ad OR France:ad OR French*:ad OR Francais*:ad OR Alsace:ad OR Elsass:ad OR Aquitaine:ad OR 
Aquitania:ad OR Akitania:ad OR Aguiéne:ad OR Auvergne:ad OR Auvèrnhe:ad OR Auvèrnha:ad OR Normandie:ad OR 
Normandy:ad OR Normaundie:ad OR Bourgogne:ad OR Burgundy:ad OR Bregogne:ad OR Borgoégne:ad OR Borgogne:ad OR 
Brittany:ad OR Breizh:ad OR Bertaèyn:ad OR Bretagne:ad OR 'Champagne Ardenne':ad OR Corse:ad OR Corsica:ad OR 'Franche 
Comte':ad OR 'Frantche Comte':ad OR 'Franche Comtat':ad OR Guadeloupe:ad OR Guyane:ad OR Guiana:ad OR 'Languedoc 
Roussillon':ad OR 'Lengadoc Rosselhon':ad OR 'Llenguadoc-Rossello':ad OR Limousin:ad OR Lemosin:ad OR Lorraine:ad OR 
Lothringen:ad OR Lottringe:ad OR Martinique:ad OR 'Midi Pyrenees':ad OR 'Miègjorn Pirenèus':ad OR 'Mieidia Pirenèus':ad OR 
'Mediodia Pirineos':ad OR 'Pays de la Loire':ad OR 'Broioù al Liger':ad OR Picardie:ad OR Picardy:ad OR 'Poitou Charentes':ad OR 
'Peitau Charantas':ad OR 'Poetou-Cherentes':ad OR Provence:ad OR Provenca:ad OR Prouvenco:ad OR 'Cote d Azur':ad OR 'Costo 
d Azur':ad OR 'Costa d Azur':ad OR Reunion:ad OR 'Rhone Alpes':ad OR 'Rono Arpes':ad OR 'Rose Aups':ad OR Ain:ad OR 
Aisne:ad OR Allier:ad OR 'Alpes de Haute Provence':ad OR 'Haute Alpes':ad OR 'Alpes Maritimes':ad OR Ardeche:ad OR 
Ardennes:ad OR Ariege:ad OR Aube:ad OR Aude:ad OR Aveyron:ad OR 'Bas Rhin':ad OR 'Bouches du Rhone':ad OR Calvados:ad 
OR Cantal:ad OR Charente:ad OR Cher:ad OR Correze:ad OR 'Corse du Sud':ad OR 'Cote d Or':ad OR 'Cotes d Armor':ad OR 
Creuse:ad OR 'Deux Sevres':ad OR Dordogne:ad OR Doubs:ad OR Drome:ad OR Essonne:ad OR Eure:ad OR Finistere:ad OR 
Gard:ad OR Gers:ad OR Gironde:ad OR 'Haute Corse':ad OR 'Haute Garonne':ad OR 'Haute Marne':ad OR 'Hautes Alpes':ad OR 
'Haute Saone':ad OR 'Haute Savoie':ad OR 'Hautes Pyrenees':ad OR 'Haute Vienne':ad OR 'Haut Rhin':ad OR 'Hauts de Seine':ad 
OR Herault:ad OR 'Ile de France':ad OR 'Ille et Vilaine':ad OR Indre:ad OR Isere:ad OR Jura:ad OR Landes:ad OR Loire:ad OR 
Loiret:ad OR (Lot NEAR/3 (departement OR department)):ad OR 'Lot et Garonne':ad OR 'Loir et Cher':ad OR Lozere:ad OR 
Manche:ad OR Marne:ad OR Mayenne:ad OR Mayotte:ad OR 'Meurthe et Moselle':ad OR Meuse:ad OR Morbihan:ad OR 
Moselle:ad OR (Nord NEAR/3 (department OR departement)):ad OR Nievre:ad OR Oise:ad OR Orne:ad OR 'Pas de calais':ad OR 
'Noord-Nauw van Kales':ad OR Paris:ad OR 'Puy de dome':ad OR 'Pyrenees Atlantiques':ad OR 'Pyrenees Orientales':ad OR 
Rhone:ad OR Sarthe:ad OR Savoie:ad OR 'Seine et Marne':ad OR 'Seine Maritime':ad OR Somme:ad OR Tarn:ad OR 'Territoire de 
Belfort':ad OR 'Val de Marne':ad OR 'Val d Oise':ad OR Var:ad OR Vaucluse:ad OR Vendee:ad OR Vienne:ad OR Vosges:ad OR 
Yonne:ad OR Yvelines:ad OR Marseille:ad OR Lyon:ad OR Nice:ad OR Nantes:ad OR Strasbourg:ad OR Montpellier:ad OR 
Bordeaux:ad OR Lille:ad OR Toulouse:ad OR 'Outre Mer':ad OR 'Seine Saint Denis':ad OR German*:ad OR Deutsch*:ad OR 
Bundesrepublik:ad OR Westdeutschland:ad OR Ostdeutschland:ad OR Baden:ad OR Wuerttemberg:ad OR Wurttemberg:ad OR 
Bayern:ad OR Bavaria:ad OR Berlin:ad OR Brandenburg:ad OR Bremen:ad OR Oldenburg:ad OR Mitteldeutschland:ad OR 
Rhein:ad OR Rhine:ad OR Hannover:ad OR Braunschweig:ad OR Göttingen:ad OR Goettingen:ad OR Nurnberg:ad OR 
Nuernberg:ad OR Ruhr:ad OR Koln:ad OR koeln:ad OR Bonn:ad OR Hamburg:ad OR Hessen:ad OR Hesse:ad OR Hessia:ad OR 
Mecklenburg:ad OR Vorpommern:ad OR Pomerania:ad OR Niedersachsen:ad OR Neddersassen:ad OR Saxony:ad OR 
Niederbayern:ad OR 'Northern Rhine':ad OR 'North Rhine':ad OR Westphalia:ad OR Westfalen:ad OR 'Rhineland Palatinate':ad OR 
'Rheinland Pfalz':ad OR Saarland:ad OR Sachsen:ad OR 'Schleswig Holstein':ad OR Thuringia:ad OR Thuringen:ad OR 
Thueringen:ad OR Munchen:ad OR Muenchen:ad OR Munich:ad OR Frankfurt:ad OR Stuttgart:ad OR Dusseldorf:ad OR 
Duesseldorf:ad OR Dortmund:ad OR Essen:ad OR Greece:ad OR 'Hellenic republic':ad OR Greek*:ad OR Ellada:ad OR Elladas:ad 
OR 'Elliniki Dimokratia':ad OR Hellas:ad OR Hellenes:ad OR Attica:ad OR Attiki:ad OR Makedonia*:ad OR Macedonia:ad OR 
Thraki:ad OR Thrace:ad OR Crete:ad OR Kriti:ad OR 'Ionia Nisia':ad OR 'Ionion neson':ad OR 'Ionion nIson':ad OR 'Ionian 
islands':ad OR 'Ionian island':ad OR Epirus:ad OR Ipeiros:ad OR 'Periféreia Ipeírou':ad OR 'North aegean':ad OR 'Northern 
Aegean':ad OR 'Aegean islands':ad OR 'Aegean island':ad OR 'Nisoi Agaiou':ad OR 'Notio Aigaio':ad OR Peloponnese:ad OR 
Peloponniso*:ad OR Thessaly:ad OR Thessalia:ad OR Thessalian:ad OR Petthalia:ad OR 'Voreio Aigaio':ad OR 'Voreio Aigaiou':ad 
OR 'South aegean':ad OR 'Southern Aegean':ad OR 'Mount athos':ad OR 'Oros Athos':ad OR Cyclades:ad OR Cycklades:ad OR 
Kiklades:ad OR Dodecanese:ad OR Dodekanisa:ad OR Athens:ad OR Athina:ad OR Thessaloniki:ad OR Thessalonica:ad OR 
Patras:ad OR Patra:ad OR Pireas:ad OR Piraeus:ad OR Larissa:ad OR Larisa:ad OR Heraklion:ad OR Heraclion:ad OR Iraklion:ad 
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OR Irakleion:ad OR Iraklio:ad OR Volos:ad OR Rhodes:ad OR Rodos:ad OR Ioannina:ad OR Janina:ad OR Yannena:ad OR 
Chania:ad OR Chalcis:ad OR Chalkida:ad OR Hungar*:ad OR Magyarorszag:ad OR Magyar*:ad OR Dunantuli:ad OR 
Transdanubia:ad OR Dunantul:ad OR 'Great Plain':ad OR 'Eszak Alfold':ad OR 'Del Alfold':ad OR 'Alfold es eszak':ad OR 'Northern 
Alfold':ad OR 'North Alfold':ad OR 'South Alfold':ad OR 'Southern Alfold':ad OR Bacs:ad OR Kiskun:ad OR Baranya:ad OR 
Bekes:ad OR Borsod:ad OR Abauj:ad OR Zemplen:ad OR Budapest:ad OR Csongrad:ad OR Fejer:ad OR gyor:ad OR moson:ad OR 
sopron:ad OR hajdu:ad OR bihar:ad OR Heves:ad OR 'jasz nagykun szolnok':ad OR komarom:ad OR esztergom:ad OR Nograd:ad 
OR (Pest NEXT/3 (megye OR county)):ad OR Somogy:ad OR szabolcs:ad OR szatmar:ad OR bereg:ad OR Tolna:ad OR Vas:ad OR 
Veszprem:ad OR Zala:ad OR Debrecen:ad OR Miskolc:ad OR Szeged:ad OR Pecs:ad OR Gyor:ad OR Nyiregyhaza:ad OR 
Kecskemet:ad OR Szekesfehervar:ad OR Szombathely:ad OR Ireland:ad OR Eire:ad OR Irish*:ad OR Fingal:ad OR 'Fine Gall':ad 
OR Dublin:ad OR 'Ath Cliath':ad OR 'Dun Laoghaire':ad OR Wicklow:ad OR 'Cill Mhantain':ad OR 'Chill Mhantain':ad OR 
Wexford:ad OR 'Loch Garman':ad OR Carlow:ad OR Ceatharlach:ad OR Kildare:ad OR 'Cill Dara':ad OR 'Chill Dara':ad OR 
Meath:ad OR 'An Mhi':ad OR 'Contae na Mi':ad OR Louth:ad OR 'Contae Lu':ad OR Monaghan:ad OR Muineachán:ad OR 
Mhuineacháin:ad OR Cavan:ad OR 'An Cabhan':ad OR 'An Cabhain':ad OR Longford:ad OR 'An Longfort':ad OR 'an Longfoirt':ad 
OR Langfurd:ad OR Westmeath:ad OR 'An Iarmhi':ad OR 'na Iarmhi':ad OR Offaly:ad OR 'Uibh Fhaili':ad OR Laois:ad OR 
Laoise:ad OR Kilkenny:ad OR 'Chill Chainnigh':ad OR 'Cill Chainnigh':ad OR Waterford:ad OR 'Port Lairge':ad OR Watterford:ad 
OR Cork:ad OR Corcaigh:ad OR Chorcai:ad OR Kerry:ad OR Ciarrai:ad OR Chiarrai:ad OR Limerick:ad OR Luimneach:ad OR 
Luimnigh:ad OR Tipperary:ad OR 'Tiobraid Arann':ad OR 'Thiobraid Arann':ad OR Clare:ad OR 'An Clar':ad OR 'an Chlair':ad OR 
Galway:ad OR Gaillimh:ad OR 'na Gaillimhe':ad OR Mayo:ad OR 'Maigh Eo':ad OR 'Mhaigh Eo':ad OR Roscommon:ad OR 'Ros 
comain':ad OR Sligo:ad OR Sligeach:ad OR Shligigh:ad OR Leitrim:ad OR Liatroim:ad OR Liatroma:ad OR Donegal:ad OR 'Dhún 
na nGall':ad OR Dinnygal:ad OR Dunnyga:ad OR Leinster:ad OR Laighin:ad OR 'Cúige Laighean':ad OR Munster:ad OR 
Mumhain:ad OR 'Cúige Mumhan':ad OR Connacht:ad OR Connachta:ad OR Drogheda:ad OR 'Droichead Atha':ad OR Dundalk:ad 
OR 'Dún Dealgan':ad OR Swords:ad OR Sord:ad OR Bray:ad OR Bre:ad OR Navan:ad OR 'An Uaimh':ad OR Italy:ad OR Italia*:ad 
OR Abruzzo:ad OR Abruzzi:ad OR Basilicata:ad OR Lucania:ad OR Calabria:ad OR Campania:ad OR 'Emilia Romagna':ad OR 'friuli 
venezia giulia':ad OR Lazio:ad OR Latium:ad OR Liguria*:ad OR Lombardy:ad OR Lombardia:ad OR Marche:ad OR Marches:ad 
OR Molisano:ad OR Molise:ad OR Piedmont*:ad OR Piemonte:ad OR Bolzano:ad OR Bozen:ad OR Trentino:ad OR Trento:ad OR 
Puglia:ad OR Apulia:ad OR Sardinia:ad OR Sardegna:ad OR Sicily:ad OR Sicilia:ad OR Toscana:ad OR Tuscany:ad OR Umbria:ad 
OR 'Valle d Aosta':ad OR 'Vallee d Aoste':ad OR 'Aosta Valley':ad OR Veneto:ad OR Venetia:ad OR Triveneto:ad OR Rome:ad OR 
Roma:ad OR Milan:ad OR Milano:ad OR Naples:ad OR Napoli:ad OR Turin:ad OR Torino:ad OR Palermo:ad OR Genoa:ad OR 
Genova:ad OR Bologna:ad OR Florence:ad OR Firenze:ad OR Bari:ad OR Catania:ad OR Latvi*:ad OR Riga:ad OR Courland:ad OR 
Kurzeme:ad OR Kurland:ad OR Latgale:ad OR Lettgallia:ad OR Latgola:ad OR Latgalia:ad OR Vidzeme:ad OR Vidumo:ad OR 
Semigallia:ad OR Semigalia:ad OR Zemgale:ad OR Pieriga:ad OR Daugavpils:ad OR Dinaburg:ad OR Jekabpils:ad OR 
Jakobstadt:ad OR Jelgava:ad OR Jurmala:ad OR Liepaja:ad OR Libau:ad OR Rezekne:ad OR Rezne:ad OR Rositten:ad OR 
Valmiera:ad OR Wolmar:ad OR Ventspils:ad OR Windau:ad OR Ogre:ad OR Lithuania*:ad OR 'Lietuvos Respublika':ad OR 
Lietuva:ad OR lietuviu:ad OR Alytus:ad OR Alytaus:ad OR Kaunas:ad OR Kauno:ad OR Klaipeda:ad OR Klaipedos:ad OR 
Marijampoles:ad OR Marijampole:ad OR Panevezys:ad OR Panevezio:ad OR Siauliai:ad OR Siauliu:ad OR Taurages:ad OR 
Taurage:ad OR Telsiu:ad OR Telsiai:ad OR Utenos:ad OR Utena:ad OR Vilnius:ad OR Vilniaus:ad OR Mazeikiai:ad OR Jonava:ad 
OR Mazeikiu:ad OR Jonavos:ad OR Luxembourg*:ad OR Luxemburg:ad OR Letzebuerg:ad OR Diekirch:ad OR Grevenmacher:ad 
OR 'Esch sur Alzette':ad OR 'Esch Uelzecht':ad OR 'Esch an der Alzette':ad OR 'Esch an der Alzig':ad OR Dudelange:ad OR 
Diddeleng:ad OR Düdelingen:ad OR Duedelingen:ad OR Schifflange:ad OR Scheffleng:ad OR Schifflingen:ad OR Bettembourg:ad 
OR Beetebuerg:ad OR Bettemburg:ad OR Petange:ad OR Peiteng:ad OR Petingen:ad OR Ettelbruck:ad OR Ettelbreck:ad OR 
Ettelbrueck:ad OR Diekirch:ad OR Dikrech:ad OR Strassen:ad OR Stroossen:ad OR Bertrange:ad OR Bartreng:ad OR 
Bartringen:ad OR Malta:ad OR Maltese*:ad OR Maltin:ad OR Gozo:ad OR Ghawdex:ad OR Valletta:ad OR 'Ill Belt':ad OR 
Birkirkara:ad OR 'B Kara':ad OR Birchircara:ad OR Mosta:ad OR Qormi:ad OR 'St Paul s Bay':ad  OR 'Pawl il Bahar':ad OR 
Zabbar:ad OR Sliema:ad OR Naxxar:ad OR Gwann:ad OR 'St John':ad OR Zebbug:ad OR 'Citta rohan':ad OR Fgura:ad OR 
Netherlands:ad OR Nederland*:ad OR Dutch*:ad OR Drenthe:ad OR Flevoland:ad OR Friesland:ad OR Fryslan:ad OR Frisia:ad OR 
Gelderland:ad OR Guelders:ad OR Groningen:ad OR Limburg:ad OR Brabant:ad OR Holland:ad OR Overijssel:ad OR Overissel:ad 
OR Utrecht:ad OR Zeeland:ad OR Amsterdam:ad OR Rotterdam:ad OR Hague:ad OR 's-Gravenhage':ad OR 'Den Haag':ad OR 
Eindhoven:ad OR Tilburg:ad OR Almere:ad OR Breda:ad OR Nijmegen:ad OR Nimeguen:ad OR Poland:ad OR Polska:ad 
OR Polish:ad OR Pole:ad OR Poles:ad OR Polski:ad OR Polak:ad OR Polka:ad OR Polacy:ad OR Dolnoslaskie:ad OR Silesia*:ad 
OR Slask:ad OR Pomorskie:ad OR Pomerania*:ad OR Kujawsko:ad OR Kuyavian:ad OR Lodzkie:ad OR Lodz:ad OR Lubelskie:ad 
OR Lublin:ad OR Lubuskie:ad OR Lubusz:ad OR Lubus:ad OR Malopolskie:ad OR Mazowieckie:ad OR Mazowske:ad 
OR Masovia:ad OR Masovian:ad OR Opolskie:ad OR Opole:ad OR Podkarpackie:ad OR Subcarpathian*:ad 
OR Podlaskie:ad OR Podlachia:ad OR Podlasie:ad OR Slaskie:ad OR Swietokrzyskie:ad OR 'Varmia Mazuria':ad 
OR 'Varmian Mazurian':ad OR 'Varmia Masuria':ad OR 'Varmian Masurian':ad OR 'Warmia Mazury':ad 
OR 'Warminsko Mazurskie':ad OR 'Warmian Masurian':ad OR Wielkopolskie:ad OR Zachodniopomorskie:ad OR Warsaw:ad 
OR Warszawa:ad OR Krakow:ad OR Cracow:ad OR Wroclaw:ad OR Poznan:ad OR Gdansk:ad OR Szczecin:ad OR Bydgoszcz:ad 
OR Katowice:ad OR Portugal:ad OR Portugues*:ad OR Azores:ad OR Acores:ad OR Madeira:ad OR Alentejo:ad OR 
Algarve:ad OR Lisboa:ad OR Lisbon:ad OR 'Alto Tras-os-Montes':ad OR (Ave NEAR/3 (community OR intermunicipal 
OR comunidade)):ad OR Mondego:ad OR Vouga:ad OR Beira:ad OR Cavado:ad OR Lafoes:ad OR Douro:ad OR Porto:ad OR 
Oporto:ad OR Tejo:ad OR Minho:ad OR Setubal:ad OR Pinhal:ad OR 'Serra da Estrela':ad OR Tamega:ad OR Leira:ad OR 
Santarem:ad OR Beja:ad OR Faro:ad OR Evora:ad OR Portalegre:ad OR 'Castelo Branco':ad OR Guarda:ad OR Cimbra:ad 
OR Aveiro:ad OR Viseu:ad OR Braganca:ad OR Braganza:ad OR Braga:ad OR 'Vila real':ad OR 'Viana do Castelo':ad OR Gaia:ad 
OR Amadora:ad OR Funchal:ad OR Coimbra:ad OR Almada:ad OR (Agualva:ad AND Cacem:ad) OR Romania*:ad OR 
Rumania*:ad OR Roumania*:ad OR Romani:ad OR Rumani:ad OR Alba:ad OR Arad:ad OR Arges:ad OR Bacau:ad OR Bihor:ad 
OR 'Bistrita Nasaud':ad OR Botosani:ad OR Braila:ad OR Brasov:ad OR Kronstadt:ad OR Brasso:ad OR Brassovia:ad OR Coron:ad 
OR Bucharest:ad OR Bucuresti:ad OR Buzau:ad OR Calarasi:ad OR 'Caras-Severin':ad OR Cluj:ad OR Klausenburg:ad OR 
Kolozsvar:ad OR Constanta:ad OR Tomis:ad OR Konstantia:ad OR Kostence:ad OR Covasna:ad OR Dambovita:ad OR Dolj:ad OR 
Galati:ad OR Galatz:ad OR Galac:ad OR Kalas:ad OR Giurgiu:ad OR Gorj:ad OR Harghita:ad OR Hunedoara:ad OR Ialomita:ad OR 
Iasi:ad OR Jassy:ad OR Lassy:ad OR Ilfov:ad OR Maramures:ad OR Mehedinti:ad OR Mures:ad OR Neamt:ad OR (Olt:ad AND 
(river:ad OR county:ad OR region:ad OR judetul:ad OR Raul:ad)) OR Prahova:ad OR Salaj:ad OR 'Satu Mare':ad OR Sibiu:ad 
OR Suceava:ad OR Teleorman:ad OR Timis:ad OR Tulcea:ad OR Valcea:ad OR Vilcea:ad OR Vaslui:ad OR Vrancea:ad 
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OR Timisoara:ad OR Temeswar:ad OR Temeschburg:ad OR Temeschwar:ad OR Temesvar:ad OR Temisvar:ad OR Timisvar:ad 
OR Temesva:ad OR Craiova:ad OR Ploiesti:ad OR Ploesti:ad OR Oradea:ad OR Varad:ad OR Varat:ad OR Slovakia:ad 
OR Slovensk*:ad OR Slovak*:ad OR Slovaci:ad OR Slovenki:ad OR Bratislav*:ad OR Presporok:ad OR Pressburg:ad OR 
Preßburg:ad OR Posonium:ad OR Banskobystri*:ad OR 'Banska Bystrica':ad OR Neusohl:ad OR Besztercebánya:ad OR Kosic*:ad 
OR Kaschau:ad OR Kassa:ad OR Nitrian*:ad OR Nitra:ad OR Neutra:ad OR Nyitra:ad OR Nyitria:ad OR Trnav*:ad OR Tyrnau:ad 
OR Nagyszombat:ad OR Tyrnavia:ad OR Presov*:ad OR Trencian*:ad OR Trencin:ad OR Trentschin:ad OR Trencsén:ad OR 
Zilina:ad OR Sillein:ad OR Zsolna:ad OR Zylina:ad OR (Martin:ad AND (city:ad OR Svaty:ad)) OR Turócszentmárton:ad 
OR Poprad:ad OR Deutschendorf:ad OR Zvolen:ad OR Slovenia*:ad OR Slovenija:ad OR slovensk*:ad OR Slovenci:ad OR 
Slovene*:ad OR Gorenjska:ad OR Carniola:ad OR Goriska:ad OR Gorizia:ad OR Jugovzhodna:ad OR Koroska:ad OR Carinthia:ad 
OR 'Notranjsko kraska':ad OR 'Obalno kraska':ad OR 'Coastal karst':ad OR Osrednjeslovenska:ad OR Podravska:ad OR 
Drava:ad OR Pomurska:ad OR Mura:ad OR Savinjska:ad OR Savinja:ad OR Spodnjeposavska:ad OR Zasavska:ad OR 'Central 
Sava':ad OR Posavska:ad OR 'Lower Sava':ad OR Ljubljana:ad OR Laibach:ad OR Lubiana:ad OR Maribor:ad OR 'Marburg an der 
Drau':ad OR Kranj:ad OR Carnium:ad OR Creina:ad OR Chreina:ad OR Krainbur:ad OR Koper:ad OR Capodistria:ad OR Kopar:ad 
OR Celje:ad OR 'Novo mesto':ad OR Neustadtl:ad OR Domzale:ad OR Velenje:ad OR Wollan:ad OR Woellan:ad OR 'Nova 
Gorica':ad OR Kamnik:ad OR Spain:ad OR Espana:ad OR Spanish:ad OR Espanol*:ad OR Spaniard*:ad OR Andalucia:ad 
OR Andalusia:ad OR Aragon:ad OR Arago:ad OR Cantabria:ad OR Canarias:ad OR 'Canary Islands':ad OR (Canaries:ad AND 
island*:ad) OR 'Castile and leon':ad OR 'Castilla y Leon':ad OR 'Castile La Mancha':ad OR 'Castilla La Mancha':ad OR Cataluna:ad 
OR Catalonia:ad OR Ceuta:ad OR Madrid:ad OR Melilla:ad OR Navarra:ad OR Navarre:ad OR Valencia*:ad OR Extremadura:ad 
OR Galicia:ad OR Balears:ad OR 'Balearic Islands':ad OR 'Balear Islands':ad OR Baleares:ad OR 'La Rioja':ad OR 'Pais Vasco':ad 
OR 'Basque Country':ad OR 'Baske region':ad OR Euskadi:ad OR Asturias:ad OR Murcia:ad OR Coruna:ad OR Alava:ad 
OR Araba:ad OR Albacete:ad OR Alicante:ad OR Alacant:ad OR Almeria:ad OR Avila:ad OR Badajoz:ad OR Badajos:ad 
OR Barcelona:ad OR Burgos:ad OR Caceres:ad OR Cadiz:ad OR Castellon:ad OR Castello:ad OR 'Ciudad Real':ad OR Cordoba:ad 
OR Cuenca:ad OR Eivissa:ad OR Ibiza:ad OR Formentera:ad OR 'El Hierro':ad OR Fuerteventura:ad OR Galiza:ad OR Girona:ad 
OR Gerona:ad OR 'Gran Canaria':ad OR Granada:ad OR Guadalajara:ad OR Guipuzcoa:ad OR Gipuzkoa:ad OR Huelva:ad 
OR Huesca:ad OR Jaen:ad OR 'La Gomera':ad OR 'La Palma':ad OR Lanzarote:ad OR Leon:ad OR Lleida:ad OR Lerida:ad 
OR Lugo:ad OR Malaga:ad OR Mallorca:ad OR Majorca:ad OR Menorca:ad OR Minorca:ad OR Murcia:ad OR Ourense:ad OR 
Orense:ad OR Palencia:ad OR Pontevedra:ad OR Salamanca:ad OR Segovia:ad OR Sevilla:ad OR Seville:ad OR Soria:ad 
OR Tarragona:ad OR Tenerife:ad OR Teruel:ad OR Toledo:ad OR Valladolid:ad OR Vizcaya:ad OR Biscay:ad OR Zamora:ad 
OR Zaragoza:ad OR Saragossa:ad OR 'Las Palmas':ad OR Bilbao:ad OR Bilbo:ad OR Sweden:ad OR Sverige:ad OR 
Swedish:ad OR Svenska:ad OR svenskar:ad OR Swede:ad OR Swedes:ad OR Norrland:ad OR Mellansverige:ad 
OR Smaland:ad OR Stockholm*:ad OR Sydsverige:ad OR Vastsverige:ad OR Blekinge:ad OR Dalarna:ad OR Gavleborg*:ad OR 
Gotland*:ad OR Halland*:ad OR Jamtland*:ad OR Jonkoping*:ad OR Kalmar:ad OR Kronoberg*:ad OR Norrbotten*:ad OR 
Orebro:ad OR Ostergotland*:ad OR Skane:ad OR Sodermanlands:ad OR Uppsala:ad OR Varmland*:ad OR Vasterbotten*:ad OR 
Vasternorrland*:ad OR Vastmanland*:ad OR vastergotland*:ad OR Gotaland*:ad OR Gothenburg:ad OR Goteborg:ad 
OR Malmo:ad OR Vasteras:ad OR Linkoping:ad OR Helsingborg:ad OR Halsingborg:ad OR Norrkoping:ad OR 'GB':ad OR 'United 
kingdom':ad OR 'UK':ad OR Britain:ad OR British:ad OR England:ad OR English:ad OR Scotland:ad OR Scottish:ad OR Scots:ad 
OR Wales:ad OR Cymru:ad OR Welsh:ad OR 'North Ireland':ad OR 'Northern Ireland':ad OR Irish:ad OR Avon:ad OR 
Bedfordshire:ad OR Berkshire:ad OR Bristol:ad OR Buckinghamshire:ad OR Cambridgeshire:ad OR 'Isle  of  Ely':ad OR 
Cheshire:ad OR Cleveland:ad OR Cornwall:ad OR Cumberland:ad OR Cumbria:ad OR Derbyshire:ad OR Devon:ad OR Dorset:ad 
OR Durham:ad OR Essex:ad OR Gloucestershire:ad OR Hampshire:ad OR Southampton:ad OR (Hereford:ad AND Worcester:ad) 
OR Hertfordshire:ad OR Herefordshire:ad OR Humberside:ad OR Huntingdon:ad OR Huntingdonshire:ad OR 'Isle of Wight':ad OR 
Kent:ad OR Lancashire:ad OR Leicestershire:ad OR Lincolnshire:ad OR London:ad OR Manchester:ad OR Merseyside:ad OR 
Middlesex:ad OR Norfolk:ad OR Northamptonshire:ad OR Northumberland:ad OR Nottinghamshire:ad OR Oxfordshire:ad OR 
Peterborough:ad OR Rutland:ad OR Shropshire:ad OR Salop:ad OR Somerset:ad OR Yorkshire:ad OR Staffordshire:ad OR 
Suffolk:ad OR Surrey:ad OR Sussex:ad OR (Tyne:ad  AND  Wear:ad) OR Warwickshire:ad OR Midlands:ad OR Westmorland:ad 
OR Wiltshire:ad OR Worcestershire:ad OR 'Isle  of  Man':ad OR Jersey:ad OR Guernsey:ad OR 'Channel Islands':ad OR 
Aberdeen:ad OR Aberdeenshire:ad OR Angus:ad OR Forfarshire:ad OR Argyll:ad OR Ayrshire:ad OR Banffshire:ad OR 
Berwickshire:ad OR Bute:ad OR Caithness:ad OR Clackmannanshire:ad OR Cromartyshire:ad OR Dumfriesshire:ad OR 
Dunbartonshire:ad OR Dumbarton:ad OR Dundee:ad OR Lothian:ad OR Haddingtonshire:ad OR Edinburgh:ad OR Fife:ad OR 
Glasgow:ad OR Inverness-shire:ad OR Kincardineshire:ad OR Kinross-shire:ad OR Kirkcudbrightshire:ad OR Lanarkshire:ad OR 
Midlothian:ad OR Moray:ad OR Elginshire:ad OR Nairnshire:ad OR Orkney:ad OR Peeblesshire:ad OR Perthshire:ad OR 
Renfrewshire:ad OR (Ross:ad  AND  Cromarty:ad) OR Ross-shire:ad OR Roxburghshire:ad OR Selkirkshire:ad OR Shetland:ad OR 
Zetland:ad OR Stirlingshire:ad OR Sutherland:ad OR Linlithgowshire:ad OR Wigtownshire:ad OR Anglesey:ad OR 
Brecknockshire:ad OR Caernarfonshire:ad OR Carmarthenshire:ad OR Cardiganshire:ad OR Ceredigion:ad OR Clwyd:ad OR 
Denbighshire:ad OR Dyfed:ad OR Flintshire:ad OR Glamorgan:ad OR Gwent:ad OR Gwynedd:ad OR Merionethshire:ad OR 
Montgomeryshire:ad OR Monmouthshire:ad OR Pembrokeshire:ad OR Powys:ad OR Radnorshire:ad OR Antrim:ad OR 
Aontroim:ad OR 'Contae Aontroma':ad OR Anthrim:ad OR Antrìm:ad OR Entrim:ad OR Armagh:ad OR 'Ard Mhacha':ad OR 
Airmagh:ad OR Belfast:ad OR (Down:ad AND (district:ad OR council:ad OR County:ad)) OR 'An Dún':ad OR 'an Dúin':ad OR 
Doon:ad OR Doun:ad OR Fermanagh:ad OR 'Fear  Manach':ad OR 'Fhear Manach':ad OR Fermanay:ad OR Londonderry:ad OR 
Doire:ad OR Dhoire:ad OR Lunnonderrie:ad OR Derry:ad OR Birmingham:ad OR Leeds:ad OR Sheffield:ad OR Bradford:ad OR 
Liverpool:ad OR Albania*:ad OR Shqiperi*:ad OR Schqipt*:ad OR Berat:ad OR Beratit:ad OR Diber:ad OR Dibres:ad OR 
Durres:ad OR Durresit:ad OR Elbasan:ad OR Elbasanit:ad OR Fier:ad OR Fierit:ad OR Gjirokaster:ad OR Gjirokastres:ad OR 
Korce:ad OR Korces:ad OR Kukes:ad OR Kukesit:ad OR Lezhes:ad OR Lezhe:ad OR Shkodres:ad OR Shkoder:ad OR Tirana:ad OR 
Tirane*:ad OR Vlore:ad OR Vlores:ad OR Kamez:ad OR Beraz:ad OR Lushnje:ad OR Makedon*:ad OR Macedon*:ad OR Fyrom:ad 
OR Istocen:ad OR Severoistocen:ad OR Jugoistocen:ad OR Jugozapaden:ad OR Pelagonski:ad OR Pelagonia:ad OR Poloski:ad OR 
Polog:ad OR Skopski:ad OR Skopje:ad OR Ckonje:ad OR Vardar*:ad OR Bitola:ad OR Kumanovo:ad OR Prilep:ad OR Tetovo:ad 
OR Tetova:ad OR Tetove:ad OR Veles:ad OR Stip:ad OR Shtip:ad OR Ohrid:ad OR Gostivar:ad OR Gostivari:ad OR Strumica:ad 
OR Iceland:ad OR Icelandic*:ad OR islenska*:ad OR Icelander*:ad OR islendinga*:ad OR Islendigar:ad OR Inslenska:ad 
OR Reykjavík:ad OR Reykjavíkurborg:ad OR Hofudborgarsvaedi:ad OR Sudurnes:ad OR Vesturland:ad OR Vestfirdir:ad 
OR Westfjords:ad OR Nordurland:ad OR Austurland:ad OR Sudurland:ad OR Kopavogur:ad OR Hafnarfjordur:ad OR Akureyri:ad 
OR Gardabaer:ad OR Mosfellsbaer:ad OR Keflavik:ad OR Akranes:ad OR Selfoss:ad OR Seltjarnarnes:ad OR Montenegr*:ad OR 
TECHNICAL REPORT  Systematic review on the prevention and control of blood-borne viruses in prison settings 
78 
'Crna Gora':ad OR Crnogorci:ad OR Andrijevica:ad OR (Bar:ad AND (Opstina:ad OR municipality:ad OR city:ad OR town:ad)) OR 
Berane:ad OR 'Bijelo polje':ad OR Budva:ad OR Cetinje:ad OR Danilovgrad:ad OR Gusinje:ad OR 'herceg Novi':ad OR Kolasin:ad 
OR Kotor:ad OR Mojkovac:ad OR Niksic:ad OR Petnija:ad OR Plav:ad OR Pluzine:ad OR Pljevlja:ad OR Podgorica:ad OR 
Rozaje:ad OR Savnik:ad OR Tivat:ad OR Ulcinj:ad OR Zabljak:ad OR Serbia*:ad OR Srbija:ad OR Serb:ad OR Serbs:ad OR Srbi:ad 
OR Vojvodina:ad OR Belgrade:ad OR Beograd:ad OR Sumadija:ad OR Kolubara:ad OR Kolubarski:ad OR Macva:ad OR 
Macvanski:ad OR Moravica:ad OR Moravicki:ad OR Pomoravlje:ad OR Pomoravski:ad OR Rasinski:ad OR Rasina:ad OR Raska:ad 
OR Raski:ad OR Sumadijski:ad OR Zlatibor:ad OR Zlatiborski:ad OR Bor:ad OR Borski:ad OR Branicevo:ad OR Branicevski:ad OR 
Jablanica:ad OR Jablanicki:ad OR Nisava:ad OR Nisavski:ad OR Pcinja:ad OR Pcinjski:ad OR Pirot:ad OR Pirotski:ad OR 
Podunavlje:ad OR Podunavski:ad OR Toplica:ad OR Toplicki:ad OR Zajecar:ad OR Zajecarski:ad OR Banat:ad OR 
Srendjebanatski:ad OR Backa:ad OR Severnobacki:ad OR Severnobanatski:ad OR Juznobacki:ad OR Juznobanatski:ad OR 
Srem:ad OR Sremski:ad OR Zapadnobacki:ad OR 'Novi Sad':ad OR 'Novy Sad':ad OR Újvidék:ad OR Nis:ad OR Nish:ad OR 
Nissa:ad OR Kragujevac:ad OR Subotica:ad OR Szabadka:ad OR Zrenjanin:ad OR Pancevo:ad OR Cacak:ad OR Kraljevo:ad OR 
'Novi Pazar':ad OR 'Novy Pazar':ad OR Turkey:ad OR Turkiye:ad OR Turkish:ad OR Turk:ad OR Turkc*:ad OR Adana:ad OR 
Adiyaman:ad OR Ayfon*:ad OR Agri:ad OR Aksaray:ad OR Aksaray:ad OR Amasya:ad OR Ankara:ad OR Antalya:ad OR 
Ardahan:ad OR Artvin:ad OR Aydin:ad OR Balikesir:ad OR Bartin:ad OR Batman:ad OR Bayburt:ad OR Bilecik:ad OR Bingol:ad OR 
Bitlis:ad OR Bolu:ad OR Burdur:ad OR Bursa:ad OR Canakkale:ad OR Cannkiri:ad OR Corum:ad OR Denizli:ad OR Diyarbarkir:ad 
OR Duzce:ad OR Edirne:ad OR Elazig:ad OR Erzincan:ad OR Erzurum:ad OR Eskishir:ad OR Gaziantep:ad OR Giresun:ad OR 
Gumushane:ad OR Hakkari:ad OR Hatay:ad OR Igdir:ad OR Isparta:ad OR Istanbul:ad OR Izmir:ad OR Kahramanmaras:ad OR 
Karabuk:ad OR Karaman:ad OR Kars:ad OR Kastamonu:ad OR Kayseri:ad OR Kirikkale:ad OR Kirklarely:ad OR Kirklareli:ad OR 
Kirsheir:ad OR Kocaeli:ad OR Konya:ad OR Kutahya:ad OR Malatya:ad OR Manisa:ad OR Mardin:ad OR Mersin:ad OR Mugla:ad 
OR Mus:ad OR Nevsehir:ad OR Nigde:ad OR Ordu:ad OR Osmaniye:ad OR Rize:ad OR Sakarya:ad OR Samsun:ad OR 
Sanliurfa:ad OR Siirt:ad OR Sinop:ad OR Sivas:ad OR Sirnak:ad OR Tekirdag:ad OR Tokat:ad OR Trabzon:ad OR Tunceli:ad OR 
Usak:ad OR (Van:ad AND (province:ad OR ili:ad)) OR Yalova:ad OR Yozgat:ad OR Kilis:ad OR Bosnia*:ad OR Herzegov*:ad OR 
Herzegonine:ad OR Bosna:ad OR Bosne:ad OR Bosanski:ad OR Bosanac:ad OR Bosanci:ad OR Srpska:ad OR Brcko:ad OR 
Posavski:ad OR Posavina:ad OR posavska:ad OR Tuzlanski:ad OR Tuzla:ad OR Tuzlanska:ad OR 'Zenickho dobojski':ad OR 
'Zenicko dobojska':ad OR Zenica:ad OR 'Bosansko Podrinjski':ad OR 'Bosansko Podrinjska':ad OR Srednjobosanski:ad OR 
hercegovacko:ad OR Zapadnohercegovacki:ad OR Zapadnohercegovacka:ad OR Sarajevo:ad OR Sarajevska:ad OR 'Kanton 10':ad 
OR '10 kanton':ad OR Hercegbosanska:ad OR 'Unsko sanski':ad OR 'Una Sana':ad OR 'Banja Luka':ad OR bijeljina:ad OR 
Mostar:ad OR Prijedor:ad OR Cazin:ad OR Doboj:ad OR Zupanija:ad OR Kosov*:ad OR Ferizaj*:ad OR Urosevac*:ad OR 
Gjakov*:ad OR Dakovic*:ad OR Gjilan*:ad OR Gnjilan*:ad OR Mitrovic*:ad OR Pejes:ad OR Peja:ad OR Peje:ad OR Pecki:ad OR 
Pec:ad OR Pristin*:ad OR Prishtin*:ad OR Pristinski:ad OR Prizrenit:ad OR Prizrenski:ad OR Prizen:ad OR Prizren:ad OR Prizeni:ad 
OR Produjev*:ad OR Vucitrn:ad OR Vushtrri*:ad OR 'Suva reka':ad OR Suhareka:ad OR Besiana:ad OR Metohija:ad OR 
Dukagjini:ad OR Dukagjinit:ad OR Liechtenstein:ad OR Lienchtensteiner*:ad OR Balzers:ad OR Eschen:ad OR Gamprin:ad OR 
Mauren:ad OR Planken:ad OR Ruggell:ad OR Schaan:ad OR Schellenberg:ad OR Triesen:ad OR Triesenberg:ad OR Vaduz:ad OR 
Norway:ad OR Norwegian*:ad OR Norge:ad OR Noreg:ad OR Norgga:ad OR Akershus:ad OR 'Aust Agder':ad OR 
Buskerud:ad OR Finnmark:ad OR Hedmark:ad OR Hordaland:ad OR 'More og Romsdal':ad OR 'More and Romsdal':ad OR 
'More Romsdal':ad OR Nordland:ad OR Trondelag:ad OR Oppland:ad OR Oslo:ad OR Ostfold:ad OR Rogaland:ad OR 
'Sogn og fjordane':ad OR 'Sogn and fjordane':ad OR 'sogn fjordane':ad OR Telemark:ad OR Troms:ad OR Romsa:ad 
OR Romssa:ad OR 'Vest Agder':ad OR Vestfold:ad OR Bergen:ad OR Stavanger:ad OR Sandnes:ad OR 
Trondheim:ad OR Trondhjem:ad OR Kaupangen:ad OR Nidaros:ad OR Drammen:ad 
OR Fredrikstad:ad OR Skien:ad OR Tromso:ad OR Sarpsborg:ad OR Switzerland:ad OR Schweiz:ad OR Schweizerische:ad OR 
Swiss:ad OR Suisse*:ad OR Svizzera:ad OR Svizzeri:ad OR Svizzers:ad OR Svizra:ad OR Helvetica:ad OR Aargau:ad 
OR Argovia:ad OR Ausserrhoden:ad OR 'Outer Rhodes':ad OR Innerrhoden:ad OR 'Inner Rhodes':ad OR Basel:ad OR Bale:ad 
OR Basilea:ad OR Bern:ad OR Berne:ad OR Berna:ad OR Fribourg:ad OR Freiburg:ad OR Friburg:ad OR Geneva:ad 
OR Geneve:ad OR Genf:ad OR Ginevra:ad OR Genevra:ad OR Glarus:ad OR Graubunden:ad OR Graubuenden:ad OR Grisons:ad 
OR Grigioni:ad OR Grischun:ad OR jura:ad OR Lucerne:ad OR Luzern:ad OR Losanna:ad OR Neuchatel:ad OR Nidwalden:ad OR 
Nidwald:ad OR Obwalden:ad OR Obwald:ad OR Schaffhausen:ad OR Schaffhouse:ad OR Schwyz:ad OR Solothurn:ad OR 
Soleure:ad OR Thurgau:ad OR Thurgovia:ad OR Ticino:ad OR Tessin:ad OR Uri:ad OR Valais:ad OR Wallis:ad OR Vaud:ad OR 
Zug:ad OR Zurich:ad OR Zuerich:ad OR Zurigo:ad OR Lausanne:ad OR Losanna:ad OR Winterthur:ad OR Winterthour:ad 
OR 'St Gallen':ad OR 'Saint Gallen':ad OR 'Sankt Gallen':ad OR 'Saint Gall':ad OR 'San Gallo':ad OR 'Son Gagl':ad OR Turitg:ad OR 
Gibraltar:ti,ab OR Gibraltar:ad OR Hebrid*:ti,ab OR Hebrid*:ad OR Svalbard*:ti,ab OR Svalbard*:ad OR 'United States'/exp OR 
"United States":ad OR USA:ad OR US:ad OR U.S.A.:ad OR America*:ad OR “United States”:ti,ab OR USA:ti,ab OR US:ti,ab OR 
U.S.A.:ti,ab OR America*:ti,ab OR Alabama:ad OR Alaska:ad OR Arizona:ad OR Arkansas:ad OR California:ad OR Colorado:ad OR 
Connecticut:ad OR Delaware:ad OR Florida:ad OR Georgia:ad OR Hawaii:ad OR Idaho:ad OR Illinois:ad OR Indiana:ad OR 
Iowa:ad OR Kansas:ad OR Kentucky:ad OR Louisiana:ad OR Maine:ad OR Maryland:ad OR Massachusetts:ad OR Michigan:ad OR 
Minnesota:ad OR Mississippi:ad OR Missouri:ad OR Montana:ad OR Nebraska:ad OR Nevada:ad OR “New Hampshire”:ad OR 
“New Jersey”:ad OR “New Mexico”:ad OR “New York”:ad OR “North Carolina”:ad OR “North Dakota”:ad OR Ohio:ad OR 
Oklahoma:ad OR Oregon:ad OR Pennsylvania:ad OR “Rhode Island”:ad OR “South Carolina”:ad OR “South Dakota”:ad OR 
Tennessee:ad OR Texas:ad OR Utah:ad OR Vermont:ad OR Virginia:ad OR Washington:ad OR “West Virginia”:ad OR 
Wisconsin:ad OR Wyoming:ad OR Alabama:ti,ab OR Alaska:ti,ab OR Arizona:ti,ab OR Arkansas:ti,ab OR California:ti,ab OR 
Colorado:ti,ab OR Connecticut:ti,ab OR Delaware:ti,ab OR Florida:ti,ab OR Georgia:ti,ab OR Hawaii:ti,ab OR Idaho:ti,ab OR 
Illinois:ti,ab  OR Indiana:ti,ab OR Iowa:ti,ab OR Kansas:ti,ab OR Kentucky:ti,ab OR Louisiana:ti,ab OR Maine:ti,ab OR 
Maryland:ti,ab OR Massachusetts:ti,ab OR Michigan:ti,ab OR Minnesota:ti,ab OR Mississippi:ti,ab OR Missouri:ti,ab OR 
Montana:ti,ab OR Nebraska:ti,ab OR Nevada:ti,ab OR “New Hampshire”:ti,ab OR “New Jersey”:ti,ab OR “New Mexico”:ti,ab OR 
“New York”:ti,ab OR “North Carolina”:ti,ab OR “North Dakota”:ti,ab OR Ohio:ti,ab OR Oklahoma:ti,ab OR Oregon:ti,ab OR 
Pennsylvania:ti,ab OR “Rhode Island”:ti,ab OR “South Carolina”:ti,ab OR “South Dakota”:ti,ab OR Tennessee:ti,ab OR Texas:ti,ab 
OR Utah:ti,ab OR Vermont:ti,ab OR Virginia:ti,ab OR Washington:ti,ab OR “West Virginia”:ti,ab OR Wisconsin:ti,ab OR 
Wyoming:ti,ab OR 'Canada'/exp OR Canada:ad OR Canada:ti,ab OR Canadian:ti,ab OR Canadian:ad OR 'Australia'/exp OR 
Australia*:ti,ab OR Australia*:ad OR 'New Zealand'/exp OR “New Zealand”:ti,ab OR “New Zealand”:ad OR global:ti,ab OR 
world:ti,ab OR worldwide:ti,ab 
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Annex 3. Quality appraisal checklists other 
than NICE 
Cross-sectional study 
Code as - - / - / + - / + / ++ or NA if not 
applicable 
  
Author   
Countries   
    
Internal validity 
  
The study addresses an appropriate and clearly focused question 
  
The study population is clearly described  
  
The population is a representative sample of the source population 
  
The outcome measures are described 
  
The assessment of outcome is made blind to exposure status 
  
Where blinding was not possible, there is some recognition that knowledge of exposure status could 
have influenced the outcome assessment 
  
Exposure status is measured in a standard, valid and reliable way   
The measurement of outcome is clearly described (e.g., written questionnaire, face-to-face 
interview, internet survey)   
The main potential confounders are identified and taken into account in the design and analysis 
  
Comparison is made between participants and non-participants to establish their similarities/ 
differences 
  
Confidence intervals are provided 
  
If study is carried out at more than one site, results are comparable for all site 
  
  
  
Overall assessment of the study   
How well was study done to minimise confounding/ bias, and to establish a causal relationship?   
If coded + or -, what is the likely direction in which bias might affect the study results?   
Was the likelihood of bias due to measuring exposure and outcome at the same moment, taken into 
account by the authors? 
  
Are you certain that the overall effect is due to the exposure being investigated?   
Are the results of the study applicable to the patient group targeted in the search question?   
    
Comments   
    
Include or exclude   
    
If exclusion, give reason   
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Surveillance study 
Code as - - / - / + - / + / ++ or NA if not 
applicable 
  
Author 
  
Countries   
    
Internal validity 
  
The study addresses an appropriate and clearly focused question   
The population being studied is selected from a data source that is representative for the overall 
population of interest 
  
The outcomes are clearly defined   
The main potential confounders are identified and taken into account in the design and analysis   
    
Additional questions   
Are epidemiological outcomes described that can be used in this review, e.g. incidences or rates per 
100,000 or proportion of cases?  
  
Is the study population large enough to be a representative sample of the source population?   
Is the disease of interest the main subject of the paper?   
Are the outcomes of the study based on observed cases (and not on assumptions or models?)   
The surveillance period is long enough to detect new cases and to accurately calculate prevalence/ 
incidence rates 
  
  
Overall assessment of the study   
Are the results valid?   
Are the results applicable to the population targeted in the search question?   
 
  
Comments   
    
Include or exclude   
    
If exclusion, give reason   
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Other research (applied to outbreak studies) 
Code as - - / - / + - / + / ++ or NA if not 
applicable 
  
Author 
  
Countries   
    
Internal validity 
  
The study addresses an appropriate and clearly focused question   
The study population is clearly described   
The population is representative of the source population   
Exposure status is measured in a standard, valid and reliable way   
The outcomes are clearly defined  
Variation (e.g. range, SD) in outcome of interest is provided  
The diagnosis of interest the main subject of the paper  
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Annex 7. Report on field researchers for grey 
literature 
Field researchers  
A field researcher was appointed through HWBs in each of the following countries were the federation is active, 
namely UK, Germany, Spain, France and Italy. Several attempts have been made to find a field researcher for the 
Netherlands, through an e-mail exchange with Dr Michel Westra (member of HWBs) and Dr Kim van Rooy.  
The European field researchers appointed as responsible for each country were:  
• Ruth Gray, UK  
• Sofia Victoria Casado Hoces, Antonio Gonzalez Gomez, Spain  
• Leon Weichert, Germany  
• Deborah Iwanikow, France  
• Giordano Madeddu, Italy (coordinator) 
Materials 
The grey literature research officially started on 18th April 2016, with an official letter and call to the researchers 
sent by HWBs’ Secretariat. The definitive deadline for the collection of materials regarding the three macro areas 
(HIV, viral hepatitis, injecting-related infections) was settled on 31st July 2016. A call for paper (see below) was 
issued by HWBs and translated in the relevant language by the field researcher. It was up to the field researcher 
whether to work in team with any other expert they wished to involve, or to perform the research on their own. 
Results 
The following are the results concerning the three macro areas:  
1. UK  
The first batch of documents has been received on 10th May 2016. A total of 2 documents with related evidence 
tables has been sent to HWBs.  
2. Spain  
The first batch of documents has been received on 28th April 2016. A further batch was received from HWB on 
30th July 2016, and was sent to the coordinator on July 14th, 2017. A total of 57 documents with related evidence 
tables has been sent to HWBs.  
3. Germany  
The first batch of documents has been received on 24th May 2016. A further batch was received from HWB on 
30th July 2016. and sent to the coordinator on July 14th, 2017. A total of 4 documents with related evidence tables 
has been sent to HWBs. The number of documents might seem limited. This is due to the fact that the prison 
healthcare system in Germany is not managed by central headquarters, instead is handled by the single Länder, 
thus jeopardising the planning and introduction of general guidelines. This issue has affected negatively the 
research, which methodology has been described by Dr. Weichert in a specific document.  
4. France  
The first batch of documents has been received on 6th June 2016. A total of 2 documents not including the related 
evidence tables has been sent to HWBs.  
5. Italy 
The first batch of documents has been received on 24th May 2016. A further batch of documents was received by 
HWB on 9th June 2017 and a third batch on 12th July 2017 and was sent to the coordinator on 14th July 2017. A 
total of 28 documents were received. 
Call for papers 
This guidance will support field researchers work in researching an collecting relevant grey literature documents in 
the following prioritized macro areas: 
• Macro area 4: Prevention, care and treatment of HIV, including throughcare 
• Macro area 5: Prevention, care and treatment of viral hepatitis, with a focus on treatment for hepatitis C, 
including throughcare 
• Macro area 6: Prevention and control of injecting-related infections among current or former drug users, 
including throughcare. 
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Who is the focus? 
Prison population: adult people aged 18 years or older in prison settings (i.e. those detained or in remand and 
those ‘going through the gate’). 
Which is the setting? 
Prison setting: prisons and other custodial settings which function as prison excluding migrant centers and police 
detention rooms 
Key issues and scoping questions 
The key issues and scoping questions are useful to guide the systematic review of the grey literature. 
Macro area 4 
Key issue: prevention, care and treatment of HIV, including throughcare 
Scoping questions 
• Which prevention interventions for HIV are effective in prison settings? 
• Which care and/or treatment interventions aimed at control of HIV are effective in prison settings? 
• Which service models for prevention, care and/or treatment of HIV are effective in prison settings? 
• Which prevention interventions for HIV are cost-effective in prison settings? 
• Which care and/or treatment interventions aimed at control of HIV are cost-effective in prison settings? 
• Which service models for prevention, care and/or treatment of HIV are cost-effective in prison settings? 
• What is the acceptance/uptake/coverage of prevention, care and/or treatment of HIV in prison settings? 
• How to improve the acceptance/uptake/coverage of prevention, care and/or treatment of HIV in prison 
settings? 
• Who should be targeted for prevention, care and/or treatment of HIV in prison settings? 
Macro area 5 
Key issue: prevention, care and treatment of viral hepatitis, with a focus on treatment for hepatitis C, including 
throughcare 
Scoping questions 
• Which prevention interventions for viral hepatitis are effective in prison settings? 
• Which care and/or treatment interventions aimed at control of viral hepatitis are effective in prison settings? 
• Which service models for prevention, care and/or treatment of viral hepatitis are effective in prison settings? 
• Which prevention interventions for viral hepatitis are cost-effective in prison settings? 
• Which care and/or treatment interventions aimed at control of viral hepatitis are cost-effective in prison 
settings? 
• Which service models for prevention, care and/or treatment of viral hepatitis are cost-effective in prison 
settings? 
• What is the acceptance/uptake/coverage of prevention, care and/or treatment of viral hepatitis in prison 
settings? 
• How to improve the acceptance/uptake/coverage of prevention, care and/or treatment of viral hepatitis in 
prison settings? 
• Who should be targeted for prevention, care and/or treatment of viral hepatitis in prison settings? 
Macro area 6 
Key issue: prevention and control of injecting-related infections among current or former drug users, including 
throughcare 
Scoping questions 
• Which prevention interventions for injecting-related infections among current drug users are effective in prison 
settings? 
• Which interventions aimed at control of injecting-related infections among current or former drug users are 
effective in prison settings? 
• Which service models for prevention and control of injecting-related infections among current or former drug 
users are effective in prison settings? 
• Which prevention interventions for injecting-related infections among current or drug users are cost-effective 
in prison settings? 
• Which interventions aimed at control of injecting-related infections among current or former drug users are 
cost-effective in prison settings? 
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• Which service models for prevention and control of injecting-related infections among current or former drug 
users are cost-effective in prison settings? 
• What is the acceptance/uptake/coverage of prevention and control of injecting-related infections among 
current or former drug users in prison settings? 
• How to improve the acceptance/uptake/coverage of prevention and control of injecting-related infections 
among current or former drug users in prison settings? 
What kind of papers? 
National field researchers were asked to collect and summarise (in a short pre-defined format): 
Existing documents describing: 
• National guidelines 
• Institutional protocols 
• Unpublished research reports/national conference abstracts 
Summaries of: 
• Intervention case studies 
• Service models 
regarding the macro areas of this specific contract (prevention, care and treatment of HIV and viral hepatitis, and 
prevention and control of injecting-related infections among current or former drug users). 
Inclusion and exclusion criteria 
The following inclusion and exclusion criteria were applied for the grey literature search: 
Table A. Inclusion and exclusion criteria 
 Inclusion Exclusion 
Period of 
publication 
Conference abstracts: from 2010 onwards 
Other documents: from 2005 onwards 
 
Content of 
document 
• Conference abstracts 
• Guidelines  
• Intervention or clinical protocols 
• Unpublished research results 
• Case studies/service models, including 
measures of effectiveness 
 
Document 
quality 
Only grey literature documents with a 
methods section or an overview of sources. 
This means that when information relevant 
to our objectives is retrieved from a grey 
literature document, it must be clear what 
the source of this information is 
Document without a clear source/reference for 
the relevant information 
Document 
population 
Adults in prisons, jails and other custodial 
settings that function as a prison 
• Detained persons, including persons in 
remand 
• Persons ‘going through the gate’ (e.g. 
prison guards, healthcare workers, etc.) 
• Children (<18 years)  
• Persons in police custody 
• Persons in migrant centres 
Subject of the 
document 
• Prevention, care and treatment of HIV 
• Prevention, care and treatment of viral 
hepatitis 
• Prevention and control of injecting-
related infections among current or 
former drug users 
 
Geographical 
area 
• EU/EEA   
Specific 
outcomes of 
interest 
• Quantitative outcomes  
• Qualitative outcomes 
• No exclusion based on outcomes 
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Data extraction and summary 
Relevant data will be extracted from included documents in order to create evidence tables, or case studies/service 
models are summarised according to the template described below. The tables/summaries were compiled by each 
field researcher and reviewed by the HWBs researcher responsible for the grey literature.  
Ad 1. Existing national guidelines, institutional protocols and unpublished research reports/conference abstracts 
The included documents were summarised by collecting, per individual record, relevant information in a 
standardised data extraction format (Evidence table, see Annex below). 
Ad 2. Intervention case studies and service models 
Case studies and service models can be summarised according to pre-defined format, including: 
• Source 
• Setting 
• Target population(s) (country, prison setting, risk groups) 
• Clearly described accounts of their intervention/service model related to the relevant macro area (see also 
scoping questions above) 
• Elements of evaluation/monitoring or evidence of success (e.g. prevention intervention, pre- and post-
intervention infection rate) 
• Resource requirements 
• Linkage to care 
Case studies/service models can be included when at least the third and fourth item on the list are met.  
Table B: Evidence table for national guidelines, institutional protocol and unpublished research 
reports/conference abstracts 
  
Reference Source Type of document 
Setting, 
population Intervention Results Comments 
Author, title, 
year, web 
link (when 
available) 
Institute/ 
company, 
etc. that 
prepared 
the 
document 
National guideline, 
institutional protocol 
unpublished 
research, 
report/conferences 
abstract 
Country, prison 
setting, risk 
groups, etc. to 
which the 
results apply 
Type of 
intervention 
or service 
model: brief 
description 
Relevant results 
on the 
objectives given 
in the 
document: per 
objectives 
Any additional 
information that 
is relevant for 
interpreting the 
results 
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Annex 8. Exclusion table grey literature and 
corresponding reference list 
Exclusion table second selection step 
Exclusion reason (number of articles) References 
No data on objectives (n=60) [1-74] 
No country of interest (n=6) [75-81] 
More recent data available (n=1) [82] 
Duplicate with included in PRL (n=1) [83] 
Outside data range (n=1) [84] 
 
Reference list of excluded articles during second selection step 
1. Trattamento dell’Epatite cronica da HCV: esempi dalla pratica clinica. Primo volume. 2007.  
2. Trattamento dell’Epatite cronica da HCV: esempi dalla pratica clinica. Secondo volume. 2007.  
3. Progetto di Studio Osservazionale “Semplificazione a LPV/RTV+3TC in Pazienti Detenuti”. 2013.  
4. Acín E. Evolución de las Causas de Mortalidad en las Instituciones Penitenciarias Españolas, en la Primera 
Década del Siglo XXI. Revista Española de Sanidad Penitenciaria. 2012;S14:84. Presented at IX Congreso 
Nacional de Sanidad Penitenciaria y XVI Jornadas de la SESP Madrid, 15 y 17 de noviembre de 2012. 
5. Alonso‑Alcañiz M. Analisis de hepatitis C en un centro penitenciario. . Revista Española de Sanidad 
Penitenciaria. 2016;S18:90. Presented at XI Congreso Nacional y XIX Jornadasde la Sociedad Española de 
Sanidad Penitenciaria. 
6. Antón Basanta J. ¿Están desnutridos los infectados por el VIH en prisión? Situación en una de ellas. Revista 
Española de Sanidad Penitenciaria. 2012;S14:50. Presented at IX Congreso Nacional de Sanidad 
Penitenciaria y XVI Jornadas de la SESP Madrid, 15 y 17 de noviembre de 2012. 
7. Antón J. Respuesta viral Rápida en presos tratados de Hepatitis Crónica por VHC con Peginterferon alfa-2a 
más Ribavirina. Subanálisis del estudio PERSEO. Revista Española de Sanidad Penitenciaria. 2012;S14:38. 
Presented at IX Congreso Nacional de Sanidad Penitenciaria y XVI Jornadas de la SESP Madrid, 15 y 17 de 
noviembre de 2012. 
8. Ardita S. Incompatibilità con loo stato di detenzione dei pazienti con infezione da HIV. Rassegna 
penitenziaria e criminologica. 2003;3.  
9. Babudieri S. Studi in ambito penitenziario: ultime acquisizioni. 2009. Presented at X Congresso Nazionale 
S.I.M.S.Pe – onlus L’Agorà Penitenziaria. Napoli, 4 - 6 Giugno 2009. 
10. Babudieri S. Malattie infettive e detenzione: progetti nazionali ed internazionali. 2012. Presented at I 
conferenza regionale "prevenzione, tutela della salute e medicina di iniziativa", Lamezia Terme, 30 
novembre 2012. 
11. Babudieri S. Attualità e prospettive terapeutiche dell’epatite cronica da HCV. 2013. Presented at XIV^ 
Congresso Nazionale S.I.M.S.Pe. – onlus L’Agorà Penitenziaria. 
12. Bedoya A. HIV y uso de drogas vía inyectada en un Centro Penitenciario de Jóvenes. Análisis comparativo 
de los últimos 21 años. Revista Española de Sanidad Penitenciaria. 2010;S12:123. Presented at VIII 
Congreso de Sanidad Penitenciaria y XIV Jornada de la SESP. Sevilla, 11.,12 y 13 de noviembre de 2010. 
13. Blanco X. Uso de inhibidores de la proteasa en presos infectados por VIH de Cataluña en el periodo 2010‑
2013. Revista Española de Sanidad Penitenciaria. 2014;S16:99. Presented at X Congreso Nacional y XVIII 
Jornadas de la SESP Barcelona, 23, 24 y 25 de octubre de 2014. 
14. Cachafeiro A. Conocimiento y prácticas de riesgo en relación a la infección por vih/sida en la Prisión de 
Teixeiro. Revista Española de Sanidad Penitenciaria. 2012;S14:67. Presented at IX Congreso Nacional de 
Sanidad Penitenciaria y XVI Jornadas de la SESP Madrid, 15 y 17 de noviembre de 2012. 
15. Cecchini I. La Medicina in Carcere e l’epatite C: prima indagine sulle carceri italiane. 2007 (unpublished).  
16. Crespo R. Evaluación del programa de intercambio de jeringas (pij) en los Centros Penitenciarios de 
Catalunya: una mirada cualitativa. Revista Española de Sanidad Penitenciaria. 2014;S16:70. Presented at X 
Congreso Nacional y XVIII Jornadas de la SESP Barcelona, 23, 24 y 25 de octubre de 2014. 
17. Darriba G. Manifestaciones orales del SIDA en el medio oenitenciario. Estudio comparativo. Revista 
Española de Sanidad Penitenciaria. 2010;S12:106. Presented at VIII Congreso de Sanidad Penitenciaria y 
XIV Jornada de la SESP. Sevilla, 11 ,12 y 13 de noviembre de 2010. 
18. Darriba G. Efectos secundarios de la terapia antirretroviral a nivel de la cavidad oral. Revista Espanola de 
Sanidad Penitenciaria. 2010;S12:110-1. Presented at VIII Congreso de Sanidad Penitenciaria y XIV Jornadas 
de la SESP Sevilla, 11, 12 y 13 de noviembre de 2010. 
19. Deutsche AIDS Hilfe. Positiv in Haft. 2001.  
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20. Deutsche AIDS Hilfe. Risikominimierung im Strafvollzug: Arbeitsmaterialien zur HIV-Pravention fur 
Praktiker/innen. Berlin: Deutsche AIDS-Hilfe e.V., 2003. 
21. Deutsche AIDS Hilfe. Pravention zertifikat. Berlin: Deutsche-AIDS-Hilfe e.V., 2009. 
22. Esteban A. Estudio de la prevalencia de los factores de riesgo cardiovascular en pacientes con infección por 
VIH ingresados en un Centro Penitenciario Tipo. Revista Española de Sanidad Penitenciaria. 2010;S12:154. 
Presented at VIII Congreso de Sanidad Penitenciaria y XIV Jornada de la SESP. Sevilla, 11.,12 y 13 de 
noviembre de 2010. 
23. Federal State Nordrhein-Westfalen. Administrative instructions for the handling of infectious diseases in 
correctional facilities of Nordrheinwestfalen. 2012. 
24. Fernández‑Montesinos‑Aniorte P. Tratamiento del VHC en una cohorte de pacientes presos coinfectados 
VIH/VHC. Seguimiento conjunto por una unidad hospitalaria y los medicos de instituciones penitenciarias. 
Revista Espanola de Sanidad Penitenciaria. 2016;S18:95. Presented at XI Congreso Nacional y XIX 
Jornadasde la Sociedad Española de Sanidad Penitenciaria. 
25. Ferrer V. Indicadores de actividad del Programa de Intercambio de Jeringuillas (PIJ) en el Centro 
Penitenciario de Pereiro de Aguiar (Ourense). 2008. Presented at VII Congreso Nacional y XI Jornadas de la 
Sociedad Española de Sanidad Penitenciaria, Córdoba, 28, 29 y 30 de octubre de 2008. 
26. Gallego C. Grado de adaptación a las recomendaciones del grupo español sobre el SIDA/Plan Nacional sobre 
el SIDA de los tratamientos prescritos a los presos infectados por el VIH. Revista Española de Sanidad 
Penitenciaria. 2010;S12:150. Presented at VIII Congreso de Sanidad Penitenciaria y XIV Jornada de la 
SESP. Sevilla, 11.,12 y 13 de noviembre de 2010. 
27. Gallego C. Evolución en los últimos cuatro años de la prevalencia de infección por el VIH y del gasto en 
fármacos antirretrovirales en una prisión de Barcelona. Revista Española de Sanidad Penitenciaria. 
2012;S14:45. Presented at IX Congreso Nacional de Sanidad Penitenciaria y XVI Jornadas de la SESP 
Madrid, 15 y 17 de noviembre de 2012. 
28. Galli M. European in and out project: Confrontation and exchange of good practices among several 
european cities about experiences of support for seropositive people both in prison or after prison release. 
2008. 
29. Ginés C. Puesta en marcha de un programa de hepatitis C en un Centro Penitenciario. Evolución de la 
respuesta viral en pacientes infectados con el virus de la hepatitis C. Revista Española de Sanidad 
Penitenciaria. 2010;S12:100. Presented at VIII Congreso de Sanidad Penitenciaria y XIV Jornada de la 
SESP. Sevilla, 11.,12 y 13 de noviembre de 2010. 
30. Golf J. Estudio sobre la prevalencia de factores de riesgo cardiovascular en una población con infección por 
VIH-1 en Medio Penitenciario. Revista Española de Sanidad Penitenciaria. 2010;S12:156. Presented at VIII 
Congreso de Sanidad Penitenciaria y XIV Jornada de la SESP. Sevilla, 11.,12 y 13 de noviembre de 2010. 
31. Golf J. Estudio sobre riesgo cardiovascular y diferentes biomarcadores plasmáticos en una población con 
infecion por vih‑1 y por vhc en medio penitenciario. Revista Española de Sanidad Penitenciaria. 
2014;S16:114. Presented at X Congreso Nacional y XVIII Jornadas de la SESP Barcelona, 23, 24 y 25 de 
octubre de 2014. 
32. Golf J. Sintomatología ansiosa y depresiva en la población infectada por el vih‑1 de cuatro centros 
penitenciarios catalanes. Revista Española de Sanidad Penitenciaria. 2014;S16:115. Presented at X 
Congreso Nacional y XVIII Jornadas de la SESP Barcelona, 23, 24 y 25 de octubre de 2014. 
33. González-Tejedor D. VHB, otra epidemia olvidada. Revista Española de Sanidad Penitenciaria. 2012;S14:65. 
Presented at IX Congreso Nacional de Sanidad Penitenciaria y XVI Jornadas de la SESP Madrid, 15 y 17 de 
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Annex 9. Summary tables and guideline summaries – Prevention of BBVs 
General BBVs prevention 
Effectiveness 
Region  
Source 
Reference, 
country, 
study design 
Prison 
setting, 
time 
period 
Intervention description Sample, 
eligibility, 
comparator  
HIV 
prevalence 
/incidence  
Other outcomes of interest Sub-group 
considerations 
Level of 
evidence 
Intervention: condom distribution 
Non-
EU/EEA 
 
PRL 
Dolan, 2004 
[45] 
 
Australia 
 
Cross-sectional 
study 
23 NSW 
male 
correctional 
centres 
 
November 
1997 – 
September 
1998 
Installation of 150 condom 
vending machines  
- since November 1997 
- free use 
- boxes containing 1 
condom, 1 sachet of 
lubricant, 1 sealable 
disposal bag and an 
information card 
n=556 inmates and 
n=50 staff 
 
NR 
 
No comparator 
NR Use condom machine: 28% (n/N NR) 
- Every now and then: 52% 
- Once a week: 21% 
- Every couple of weeks: 9% 
- Only once: 15% 
 
40% used condoms for sex, 19% used the 
sealable disposal bags for storage of 
substances (e.g. tobacco), 25% used the 
contents of the box for self-masturbation 
(n/N NR) 
 
The frequency of condom use since 
programme introduction among sexually 
active inmates for anal and oral intercourse 
(n=44, n=54) was every time (52%, 28%), 
often (7%, 2%), sometimes (16%, 22%), 
never (21%, 44%) and no sex since 
condom availability (4%, 4%) 
 
294,853 condoms dispensed during study 
period; 24,571 per month 
NR Very low 
Intervention: safe tattooing programme 
EU/EAA 
 
GL 
Humet, 2012 
[46] 
 
Spain 
 
Correctional 
facilities in 
Catalunya 
 
September 
2011 – 
Safe tatooing programme n=86 inmates 
 
NR 
 
No comparator  
NR 66% (57/86) inmates requested safe 
tattoos  
 
68% (39/57) performed safe tattooing 
NR Conference 
abstract 
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Region  
Source 
Reference, 
country, 
study design 
Prison 
setting, 
time 
period 
Intervention description Sample, 
eligibility, 
comparator  
HIV 
prevalence 
/incidence  
Other outcomes of interest Sub-group 
considerations 
Level of 
evidence 
Retrospective 
study 
February 
2012 
 
- 30.5% (12/39) did not perform tattoos 
before and 69.5% (27/39) had previously 
been tattooed 
- Of the latter group 85% (23/27) were 
tattooed using uncontrolled equipment, 
43% (10/23) of these during imprisonment 
 
32% (18/57) did not perform safe tattoos 
- 50% (9/18) because of lack of money and 
50% (9/18) because of release from prison 
Group behaviour intervention vs. control 
Non-
EU/EEA 
 
PRL 
Lehman, 2015 
[47]  
 
USA 
 
RCT 
8 prison 
facilities in 2 
states 
 
NR 
WaySafe: 
- 6 weekly 1-hr sessions by 
a trained counsellor in 
groups of 10-20 inmates 
- Variety of group-based 
and participatory activities1 
- Added to TAU by focusing 
on decision making in an 
engaging and highly 
interactive format 
 
TAU: 
- Modified therapeutic 
community programming 
(group and individual) 
- Didactic, lecture format 
covering basic HIV 
information  
- Offenders were required 
to attend 20 hours in total 
 
 
n=653 WaySafe vs. 
n=604 TAU 
 
In last phase of 
prison-based 
substance abuse 
treatment; sufficient 
time left before 
release (from 2-3 
months) to complete 
the study 
 
WaySafe vs. TAU 
NR * WaySafe higher mean score at post-test 
(1 week after end of intervention, in prison) 
than TAU for all 5 measures (all p<0.001), 
effect sizes: 
- HIV knowledge confidence: 0.424  
- Avoiding risky sex: 0.416 
- Avoiding risky drug use: 0.270  
- HIV services and testing: 0.346  
- Risk reduction skills: 0.381  
*Significant pre-test to post-test (1 week 
after end of intervention) increases on all 5 
scales for both the TAU and WaySafe 
groups, although there were larger changes 
for the WaySafe group on each scale: 
- WaySafe: post-test/pre-test difference 
score ranges 2.7-5.3, effect sizes 0.491-
0.795 
- TAU: post-test/pre-test difference score 
ranges 1.3-2.6, effect sizes 0.232 to 0.352 
Study focuses 
solely on 
inmates 
receiving 
substance abuse 
treatment 
 
There were 
significant 
differences 
between 
WaySafe and 
TAU participants 
on all 5 scales in 
4 facilities, and 
significant 
differences for 
part of the 
scales in the 
other 4 facilities 
Low 
Group skills-building intervention vs. discussion intervention 
Non-
EU/EEA 
 
PRL 
St. Lawrence, 
1997 [50] 
 
USA 
 
RCT 
State 
women’s 
prison 
 
NR 
SCT intervention: 
- 4 sessions provided 
specific skills training using 
instruction, modelling and 
skill rehearsal 
 
n=90 inmates 
 
Females 
 
SCT vs. TGP 
NR - Greater improvements in acknowledging a 
partner's request in SCT group than in TGP 
group (p<0.02), directly post-intervention 
- Women in the TGP group showed greater 
improvements in commitment to change 
than women in the SCT group (p<0.02), 
NR Very low 
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Region  
Source 
Reference, 
country, 
study design 
Prison 
setting, 
time 
period 
Intervention description Sample, 
eligibility, 
comparator  
HIV 
prevalence 
/incidence  
Other outcomes of interest Sub-group 
considerations 
Level of 
evidence 
TGP intervention: 
- 4 sessions promoted 
unstructured discussion 
between participants and 
included no skill training or 
rehearsal of risk reduction 
skills 
 
- 4 cohort groups in each 
intervention condition with 
8-15 participants in each 
group 
- Group sessions for each 
condition met once a week 
for 6 weeks and lasted 90 
minutes 
- Sessions 1 and 2 were 
identical in both conditions 
and provided information 
about HIV/AIDS and other 
STIs, disease transmission, 
and local epidemiology; last 
4 sessions were parallel in 
their content emphasis but 
differed in format and 
methods, consistent with 
the theoretical models2 
both directly post-intervention and at 6 
months follow-up 
- Women in the SCT group showed greater 
increases in condom application skills than 
women in the TGP group (p<0.003) , both 
directly post-intervention and at 6 months 
follow-up 
- No significant difference in proposing a 
safe alternative, refusing unprotected 
sex/needle sharing, providing a reason for 
refusal, using ‘I’ messages, and overall 
behavioural skill effectiveness rating (all 
during role-play assessments), and 
furthermore no difference in perceived HIV 
risk, self-efficacy, self-esteem, attitudes 
towards prevention, AIDS knowledge, 
intentions to use condoms and condom 
communication 
 
 
AIDS: acquired immunodeficiency syndrome, GL: grey literature, HIV: human immunodeficiency virus, NR: not reported, NSW: New South Wales, PRL: peer-reviewed literature, RCT: randomised controlled trial, 
SCT: social cognitive theory, STI: sexually transmitted infection, TAU: treatment as usual, TGP: theory of gender and power, USA: United States of America 
1 Sessions: 1. Introduction to mapping, 2. Risk and reasons, 3. Information about the transmittal and prevention of HIV, 4. Should/want problem, 5. Risk scenes, 6. Planning for risks 
2 SCT: Session 3 - training in correct condom use, Sessions 4-5 - training in refusal, partner negotiation, and information provision skills, Session 6 - connection between drug use and HIV risk and training in 
correct needle-cleaning and drug refusal skills; TGP: Session 3 - women and condoms, Sessions 4-5 - discussion on sexual communication, Session 6 - discussion about the connection between drug use and 
high-risk sexual behaviour 
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Acceptability/barriers 
Region  
Source 
Reference, 
country, 
study design 
Prison setting, 
sample, time 
period 
Intervention 
description 
Eligibility/access Acceptance Intervention 
adherence 
Attrition Other outcomes 
of interest 
Sub-
group 
consider
ations 
Level of 
evidence 
Intervention: condom distribution 
Non-
EU/EEA 
 
PRL 
Dolan, 2004 
[45] 
 
Australia 
 
Cross-
sectional study 
23 NSW male 
correctional 
centres 
 
n=556 inmates 
and n=50 staff 
 
November 1997 
– September 
1998 
Installation of 150 
condom vending 
machines  
- since November 
1997 
- free use 
- boxes containing 1 
condom, 1 sachet of 
lubricant, 1 sealable 
disposal bag and an 
information card 
Location of machines 
(n/N NR): 
- Appropriate: 69% of 
inmates 
- Prefer alternative 
location: NR 
*More privacy: 65% 
of inmates  
*Improved access: 
16% of inmates 
*Preferred alternative 
locations: shower 
blocks, within 
accommodation wings 
and laundries 
Support condom 
provision: 
- Inmates: 84% 
(467/556) 
- Commissioned/ 
senior officers: 85% 
(11/13) 
- Prison officers: 
43% (16/37) 
 
 
NR NR Harassment for 
obtaining condoms 
(n/N NR): 
- No: 68% of 
inmates 
- Yes, other 
inmates: 15% of 
inmates 
- Yes, officers: 7% 
of inmates 
 
No incidents 
comprising prison 
safety/security or 
incidents of drug 
concealment  
 
Condom availability 
increases incidence 
of rape (n/N NR): 
- Yes: 14% of 
inmates 
- No: 72% of 
inmates 
NR Very low 
Non-
EU/EEA 
 
PRL 
May, 2002 
[49] 
 
USA 
 
Cross-
sectional study 
Central Deten-
tion Facility, city 
jail for 
Washington DC 
 
n=307 inmates 
and n=200 staff 
 
October 2000 – 
October 2001 
Condoms provided 
by public health and 
AIDS service 
organisations during 
weekly health 
education classes on 
HIV prevention, HIV 
pre- or post-test 
counselling, or upon 
request to 
healthcare staff 
- since 1993 
- free use 
11% (34/303) of 
inmates have been 
given a condom while 
being in jail 
 
200 condoms 
distributed each 
month 
55% (168/303) of 
inmates and 64% 
(126/197) of staff 
think distributing 
condoms is a good 
idea as condoms are 
an effective and 
low-risk method to 
prevent the 
transmission of HIV 
or STIs 
 
Those objecting 
mentioned: concern 
NR NR 42% of inmates 
believed condoms 
would increase 
likelihood of sex in 
jail 
 
13% (27/200) of 
staff reported 
occurrence of 
problems caused by 
condom distribution 
(not further defined) 
 
NR Very low 
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Region  
Source 
Reference, 
country, 
study design 
Prison setting, 
sample, time 
period 
Intervention 
description 
Eligibility/access Acceptance Intervention 
adherence 
Attrition Other outcomes 
of interest 
Sub-
group 
consider
ations 
Level of 
evidence 
of institutional and 
personal safety; 
intervention as an 
endorsement of 
same gender 
relationships; 
inconsistent 
message of condom 
availability given 
that sexual activity 
in the jail is 
prohibited by 
institutional policy  
No major security 
infractions involving 
condoms  
 
No evidence that 
sexual activity has 
increased on the 
basis of disciplinary 
reports and 
interviews with jail 
administrators 
Intervention: safe tattooing programme 
EU/EAA 
 
GL 
Humet, 2012 
[46] 
 
Spain 
 
Retrospective 
study 
Correctional 
facilities in 
Catalunya 
 
N=86 inmates 
 
September 2011 
– February 2012 
Safe tatooing 
programme 
NR 68% (39/57) of 
accepted requests 
performed safe 
tattooing  
 
NR NR 32% (18/57) did not 
perform safe 
tattoos: 50% (9/18) 
because of lack of 
money and 50% 
(9/18) because of 
release from prison 
NR 
 
Conference 
abstract 
Group behaviour intervention vs. control 
Non-
EU/EEA 
 
PRL 
Lehman, 2015 
[47] 
 
USA 
 
RCT 
8 prison facilities 
in 2 states 
 
n=653 WaySafe 
vs. n=604 TAU 
 
NR 
WaySafe: 
- 6 weekly 1-hr 
sessions by a 
trained counsellor in 
groups of 10-20 
inmates 
- Variety of group-
based and 
participatory 
activities1 
- Added to TAU by 
focusing on decision 
making in an 
engaging and highly 
interactive format 
 
TAU: 
In last phase of 
prison-based 
substance abuse 
treatment; sufficient 
time left before 
release (from 2-3 
months) to complete 
the study 
NR NR 9.8% 
(136/1393) of 
those who 
completed 
the pre-test 
survey did 
not complete 
a post-test 
survey  
(study 
includes only 
those 1257 
with ≥1 post-
test 
assessment) 
NR Study 
focuses 
solely on 
inmates 
receiving 
substance 
abuse 
treatment 
Low 
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Region  
Source 
Reference, 
country, 
study design 
Prison setting, 
sample, time 
period 
Intervention 
description 
Eligibility/access Acceptance Intervention 
adherence 
Attrition Other outcomes 
of interest 
Sub-
group 
consider
ations 
Level of 
evidence 
- Modified 
therapeutic 
community 
programming (group 
and individual) 
- Didactic, lecture 
format covering 
basic HIV 
information  
- Offenders were 
required to attend 
20 hours in total 
 
AIDS: acquired immunodeficiency syndrome, HIV: human immunodeficiency virus, NR: not reported, NSW: New South Wales, PRL: peer-reviewed literature, RCT: randomised controlled trial, STI: sexually 
transmitted infection, TAU: treatment as usual, USA: United States of America 
1 Sessions: 1. Introduction to mapping, 2. Risk and reasons, 3. Information about the transmittal and prevention of HIV, 4. Should/want problem, 5. Risk scenes, 6. Planning for risks 
Cost-effectiveness 
Region  
Source 
Reference, 
country, study 
design 
Prison setting, 
sample 
Perspective, 
time horizon 
Scenarios  Conclusions Sub-group specific 
considerations 
Level of 
evidence 
Intervention: condom distribution 
Non-EU/EEA 
 
PRL 
Leibowitz, 2013 
[48] 
 
USA 
 
Cost-effectiveness 
study 
K6G protective 
custody unit of 
the LA County 
Men’s Central 
Jail 
 
n=NR gay and 
transgender 
inmates 
Societal 
perspective 
 
32 years 
Condom distribution: staff 
visit the unit once a week, at 
which time inmates line up 
and may receive a single 
condom 
 
vs. 
 
No condom distribution 
- 25% of HIV transmissions 
averted, reducing the number of 
new infections from 0.8 to 0.6 per 
month 
- cost savings over the next 32 
years of $74,777 
This study focuses 
solely on gay and 
transgender inmates 
Low 
HIV: human immunodeficiency virus, LA: Los Angeles, NR: not reported, PRL: peer-reviewed literature, USA: United States of America 
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Guidelines 
Nine guidelines that reported on BBVs prevention were included, of which seven were specific to the prison setting (three supranational and four national guidelines) and two were 
supranational not specific to prison settings.  
Summary of guidelines on BBV prevention in prisons settings 
Guideline 
Specific to prison setting – supranational guidelines 
WHO, 2014 
[7] 
• Health education 
Information is not enough to prevent the transmission of HIV or hepatitis but it is an essential precondition to the implementation of HIV prevention measures in prisons. The 
main principle is that all information on blood borne diseases that is available to the community should be tailored to the needs, cultural and educational backgrounds and 
languages of the prison population, both staff and prisoners.  
• Prevention of sexual transmission and provision of condoms and lubricants 
Condoms and lubricant should be easily, discreetly and freely accessible. Staff in each prison should identify the best locations for making them accessible, taking into account 
the layout of the building, leadership and the movement of prisoners within the premises. In addition, it is essential to make condoms available in the intimate visit rooms. 
Measures to prevent sexual violence, such as proper classification, protection of the most vulnerable, rooms for conjugal visits and reporting systems must also be put in place 
by prison management. 
• Safe tattooing and piercing equipment 
Tattooing or piercing is highly prevalent in prisons and closely linked to the prison sub-culture. Research has demonstrated that injecting drug users tend to get tattooed in 
prison more frequently than other prisoners. Tattooing workshops, with professionals well-trained to give information and show how to operate safely, can be held. 
Alternatively, professional tattooists could be invited to offer their services. Information, needles and bleach can be distributed to the prisoners. Non-governmental 
organisations can also play an important role in the implementation of such programmes. 
• Prevention of mother-to-child transmission 
Prevention of the transmission of (HIV) virus to children begins with access to reproductive health and contraception. As with pregnant women outside prison, pregnant 
women in prisons need access to the full range of interventions for the prevention of mother-to-child transmission, including family planning and ART prophylaxis for pregnant 
and breastfeeding mothers. Children born to women living with HIV should be followed up according to national guidelines. 
• Universal precautions and safe health services 
Universal precautions are essential to ensure a safe workplace for staff and to prevent accidental or iatrogenic transmission of HIV and hepatitis in prisons. In addition to the 
transmission through blood transfusion of infected blood or through transplantations, HIV and hepatitis can be transmitted through used needles or dental and gynaecological 
equipment or any medical equipment that can be in contact with blood. Up-to-date sterilisation measures, the safe collection and disposal of sharps and disposal of medical 
waste, based on guidelines for health (and dental) settings in the community, apply in prisons. 
• Post-exposure prophylaxis 
Both prisoners and staff can be accidentally exposed to body fluids potentially infected by HIV. Post-exposure prophylaxis is short-term (one month) ART to reduce the 
likelihood of HIV infection after potential exposure, either through sexual activity or blood. Post-exposure prophylaxis should only be offered for exposure that has the 
potential for HIV transmission and must be initiated within 72 hours after exposure. It is, therefore, essential that clear guidelines and standard procedures to follow in case of 
suspected accidental exposure are produced and disseminated. These guidelines, based on national guidelines for post-exposure prophylaxis, should include first aid 
measures, reporting mechanisms, persons to contact, support and counselling measures. 
UNAIDS, 
2014 [51] 
Condoms need to be easily and discreetly available, ideally in areas such as toilets, shower areas, waiting rooms, workshops or day rooms where prisoners can pick up a 
condom without being seen by others. Distribution can be carried out by health staff, dispensing machines, trained prisoners (peers) or through a combination of any of these 
ways. Each prison should determine how best to make condoms available to ensure easy and discreet access. Prisoners should not have to ask for condoms, since few 
prisoners will do so because they do not want to disclose that they engage in same-sex sexual activity. Condoms should be provided free of charge, and can be made 
available to all prisoners in a health kit given to them upon entry to the facility. The health kit can also contain HIV and other health information, as well as other items such 
as a shaving kit, toothbrush, soap, etc. A water-based lubricant should also be provided since it reduces the probability of condom breakage and/or rectal tearing, both of 
which contribute to the risk of HIV transmission.  
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Gender-specific services are often unavailable. Reproductive and general health-care services should be available to all women and available from a female physician if so 
desired. Some women are pregnant or become pregnant while in detention. Some women give birth or are nursing infants while in prison. The needs related to HIV 
prevention, treatment, care and support for women and their children are often neglected. Similarly, transgendered people in prisons have special needs that should be 
addressed, including protection from sexual violence.  
 
Women in prisons are especially vulnerable to sexual abuse, including rape, by both male staff and male prisoners. The risks are particularly high when women are detained in 
facilities adjacent to or within male prisons or when women’s quarters are supervised by male prison staff. Women are also susceptible to sexual exploitation and may engage 
in sex in exchange for goods such as food, drugs, cigarettes and toiletries. In the case of sexual violence, women should have access to the full range of services, including 
emergency contraception, post-exposure prophylaxis and support.  
WHO, 2007 
[53] 
The proper (correct) and consistent (every time) use of condoms for sexual intercourse, vaginal, anal or oral can greatly reduce a person’s risk of acquiring or transmitting 
sexually transmitted infections, including HIV infection. 
To be comprehensive, HIV programmes in prisons should include the following components: 
• Preventing new infections through, in particular: (1) reducing sexual transmission by improving life-skills (especially among younger prisoners), providing easy, 
anonymous access to condoms and lubricants, controlling sexually transmitted infections, notifying partners and implementing measures aimed at reducing sexual 
abuse and rape; (2) ensuring blood safety by testing transfused blood for HIV, reducing the number of non-vital blood transfusions and enrolling donors at lower risk; and 
(3) reducing transmission through sharing contaminated injecting equipment by implementing needle and syringe programmes, substitution therapy and peer-based 
education. 
• Although tattooing is prohibited in prisons in many countries, it is a very common activity. Tattoos are often applied in unclean conditions using pencils, pens, straight pins 
or needles. The pigments injected can include carbon, soot, mascara, charcoal and dirt. Dirty tattooing equipment can act as an efficient vehicle for transmitting bloodborne 
infections. Tattooing is associated with the risk of acquiring HIV, HBV and HCV. 
• Piercing is also prevalent in many prisons. The body parts that are most commonly pierced are the earlobe and ear cartilage, eyebrow, lip, nose, tongue, nipple, navel and 
genitals. Preventing the transmission of bloodborne diseases through tattooing requires efforts at individual, institution and population level. 
Specific to prison setting – national guidelines 
NICE, 2016 
[54] 
Offer people in prison information about sexually transmitted infections and available sexual health services.  
Ensure that people in prison have discreet access to condoms, dental dams and water-based lubricants without the need to ask for them.  
The potential cost savings of preventing transmission of infectious diseases such as HIV and HCV are very high, and so the prevention of a single case of these diseases by 
the increased availability of condoms would offset the costs of providing tens of thousands of condoms.  
Given the prevalence of BBVs in UK prisons, an increase in condom use would be expected to prevent additional infections. 
Therefore the Guideline Development Group (GDG) considered that improved accessibility of free condoms, dental dams and lubricants, leading to increased use, would be 
quite likely to be cost saving, and very likely to be cost-effective at a threshold of GBP 20 000 per QALY gained. 
UK 
Department 
of Health, 
2011_a [55] 
HIV prevention advice for prisoners 
• Never share injecting drug equipment; this includes syringes, filters, spoons and water as well as needles. 
• Always use a condom during sex. 
• Never share tattooing or body piercing equipment. 
• Use disinfecting tablets to clean injecting equipment, razors etc. 
Post-exposure prophylaxis (PEP) 
If someone has been exposed to HIV, there is treatment available which can stop them from becoming infected. It is a four week course of antiretroviral drugs and should be 
taken as soon as possible (but no later than 72 hours) after potential exposure to HIV to have a chance of stopping infection occurring. It is important to note that PEP can 
have significant side effects. 
UK 
Department 
of Health, 
2011_b [56] 
Prevention 
• There is no vaccine available for the prevention of HIV infection. 
• The general guidance for prevention of BBVs should be followed to reduce the risk of infection. 
• Condoms should be used for all sexual contact with a partner whose HIV status is unknown. 
• Individuals who undergo body piercing/ tattooing should ensure that disposable sterile needles are used. 
• Sharing of personal items like toothbrushes, injecting equipment and razors should be avoided. 
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• In a healthcare setting, standard infection control precautions should be adhered to; all blood, body fluids and body tissues should be treated as potentially infectious at all 
times. 
• Post exposure prophylactic (PEP) antiviral drugs begun within hours (and certainly no later than 48 to 72 hours after exposure) of a significant 
exposure to HIV virus may prevent infection occurring. Information, support and advice can be obtained from genitourinary medicine clinics and the Health Protection 
Unit. Prison healthcare should have a policy for access to PEP and advice. 
• All pregnant women are now offered an HIV test during pregnancy which has greatly reduced the risk of children being born with HIV infection. 
SIMIT/Minist
ero della 
Salute 
(Italy), 2016 
[57] 
In order to reduce HIV transmission the panel recommends: 
• Free distribution of sterile tattooing equipment. 
• Free distribution of condoms and condoms vending machines in freely accessible but reserved areas within the prison. 
• Provide PEP by the prison Infectious Disease Specialist, if needed. 
• Assure the continuation of Opioid Substitution Treatment (OST) since it is highly effective in reducing HIV transmission among PWID. 
Other guidelines – supranational guidelines 
WHO, 2016 
[58] 
In addition to the recommended interventions for people in the community, interventions relevant to closed settings include: 
• Prevention of HIV transmission through medical and dental services. 
• Prevention of transmission of HIV and other bloodborne diseases through tattooing, piercing and other forms of skin penetration. 
Some other interventions are important and should not be overlooked, such as the distribution of toothbrushes and shavers in basic hygiene kits.  
The correct and consistent use of condoms with condom-compatible lubricants is recommended for all key populations to prevent sexual transmission of 
HIV and STIs.(strong recommendation, moderate quality level of evidence) 
Sexual activity takes place in prisons and other closed settings, but general access to condoms there is limited. It is important to introduce, and expand to scale, condom and 
lubricant distribution programmes in prisons and other closed settings, without quantity restriction, with anonymity and in an easily accessible manner (e.g. condom vending 
machines). 
It is important to provide people in prisons and other closed settings with prevention measures, such as condoms and clean injecting equipment, and not just with information 
about avoiding risks. People in prisons and other closed settings should have easy, confidential access to needle and syringe programmes. 
• Prison systems should pilot-test and evaluate safer tattooing initiatives to assess whether they reduce the sharing and re-use of tattooing equipment and, thereby, reduce 
infections. 
Oral PrEP (containing tenofovir disoproxil fumarate) should be offered as an additional prevention choice for key populations (including prisoners) at substantial risk for HIV 
infection as part of combination prevention approaches (strong recommendation, high quality of evidence) 
PEP is given to reduce the likelihood of acquiring HIV infection after possible exposure. WHO PEP guidelines were updated in 2014 and are relevant for all populations. The 
current recommended duration of PEP is 28 days; the first dose should be taken as soon as possible and within 72 hours after exposure. 
PEP should be made accessible to all people in prisons and other closed settings who have possibly been exposed to HIV, just as in non-prison settings. 
VMMC (voluntary medical male circumcision) is not one of the recommended interventions in the prison package. 
Special consideration should be given to ensuring that pregnant female prisoners have ready access to PMTCT services, as women often face greater barriers to HIV testing, 
counselling, care and treatment in prison than outside prison. 
European 
AIDS Clinical 
Society, 
2017 [30] 
 
Effective measures to reduce sexual transmission of HIV include: 
Male condom or female condom use 
• Effective in treated and untreated HIV-positive persons 
PEP 
• Consider after situations of unprotected anal or vaginal intercourse, if one partner has detectable HIV-VL and the other partner is seronegative 
• Start as soon as possible and within 48/72 hours post sexual exposure 
Pre-exposure prophylaxis (PrEP) 
• Effective in HIV-negative persons with high risk sexual behaviour 
ART for HIV-positive partner 
• Considered effective from 6 months of fully suppressive ART if no active STIs 
• Consider in e.g. sero-discordant couples 
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Prevention of injecting-related infections among PWID 
Effectiveness 
Region  
Source 
Reference, 
country, study 
design 
Prison 
setting, time 
period 
Intervention 
description  
Sample, eligibility, 
comparator 
Seroconversion  Adverse 
events 
Other outcomes Level of 
evidence 
Intervention: needles and syringes programmes 
EU/EEA 
 
PRL 
Stark, 2006 [62] 
 
Germany 
 
Longitudinal study 
 
 
1 male and 1 
female prison in 
Berlin 
 
October 1998 – 
June 2001 
- Female prison: 3 
automatic dispensers, 
providing a sterile 
syringe, needle and skin 
disinfection pad in 
exchange for a used 
syringe, or a dummy 
handed out to new 
entrants 
- Male prison: social 
workers from a NGO 
exchanged sterile 
syringes and needles 
for used equipment 3 
times a week 
n=174 inmates who 
had ever used illicit 
drugs 
 
Ever used illicit drugs 
(injection, inhalational 
or intranasal use of 
heroin or cocaine) 
 
No comparator 
During follow-up 
(median 12 months):  
- No HIV or HBV 
seroconversions 
- 4 out of 22 HCV 
seronegative at 
baseline developed 
HCV antibodies 
(incidence 18/100 
person-years) 
No adverse 
events possibly 
related to the 
project were 
observed (e.g. 
overall increase 
in injection 
drug use, 
violence 
involving 
needles against 
staff or other 
inmates) 
All IDUs who seroconverted denied 
tattooing, piercing, sexual risk 
behaviour or sharing syringes while in 
prison, but 3 reported ‘frontloading’ 
(dividing up drug doses between ≥2 
IDUs involving a used syringe) or 
sharing of spoons for drug 
preparation on several occasions in 
the months preceding seroconversion 
 
- 3383 syringes delivered to the 
female prison (October 1998 to June 
2001) 
- 4571 syringes delivered to the male 
prison (February 1999 to June 2001) 
Very low 
EU/EEA 
 
PRL 
Heinemann, 2001 
[61] 
 
Germany 
 
Cross-sectional study 
and longitudinal 
study 
 
 
 
 
 
1 prison for 
males and 
females 
 
April 1996 – 
July 1997 
Syringe vending 
machines, with 1:1 
exchange 
 
Several machines 
installed in different 
stations, partly in 
locations not accessible 
by staff 
Cross-sectional study: 
- n=191 intravenous 
drug using inmates 
questionnaire/n=22 
interview 
- n=81 prison 
employees 
questionnaire/n=9 
interview 
Longitudinal study: 
- n=231 intravenous 
drug using inmates 
 
No comparator 
- 12 HBV and 11 HCV 
seroconversions 
observed between M0 
(1-12 weeks before the 
start of the 
intervention) and M1 
(1-10 months after the 
start of the 
intervention), of which 
at least 5 HBV and 2 
HCV seroconversions 
probably occurred 
during imprisonment 
- No seroconversions 
were observed during 
the intervention period 
NR - Despite the installation of the 
machines, almost all subjects 
described the frequency of needle 
sharing as unchanged or only slightly 
decreased, so no clear success of the 
project could be recorded 
 
- 10,439 syringes were exchanged 
during the study period 
Very low 
EU/EAA 
 
GL 
Arroyo, 2015 [63] 
 
Spain 
 
Longitudinal study 
Spanish prison 
system 
 
1997-2014 
Needle exchange 
programme 
 
n=NR 
- Participating centres 
increased from 1 in 
1997 
Prevalence of HCV 
infection in Spanish 
prison system 
decreased from 48.6% 
in 1998 to 20% in 
2014. 
NR Number of syringes exchanged rose 
from 2,582 to nearly 23,000 in 2004 
and decreased since then to 4,393 in 
2014 
Conference 
abstract  
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Region  
Source 
Reference, 
country, study 
design 
Prison 
setting, time 
period 
Intervention 
description  
Sample, eligibility, 
comparator 
Seroconversion  Adverse 
events 
Other outcomes Level of 
evidence 
to 38 in 2003 and 
decreased since then to 
22 in 2014 
 
No comparator 
 
Prevalence of HIV 
infection in Spanish 
prison system 
decreased from 12.1% 
in 2003 to 5.8% in 
2014. 
Intervention: opioid substitution treatment 
Non-
EU/EEA 
 
PRL 
Dolan, 2005 [60] 
 
Australia 
 
4- year follow-up of 
RCT (Dolan, 2003) 
NSW prisons 
 
August 1997 – 
December 2002 
OST: methadone 
treatment immediately 
(30 mg with increase of 
5 mg/3 days until 60 
mg) 
 
Control: 4-month delay 
with guaranteed access 
after that period 
 
At end of RCT, all were 
offered OST (97% had 
received OST at some 
time during/since RCT) 
n=191 OST vs. n=191 
control in original RCT 
218 (57%) with follow-
up serostatus 
 
Males, suitable for OST 
according to medical 
staff confirming heroin 
problem, sentence >4 
months at baseline 
 
Direct OST versus 
delayed OST 
After median 4.2 years 
follow-up: 
- HCV: 39 of 95 HCV-
negative subjects 
seroconverted 
(incidence rate 
21.3/100 person-years, 
95% CI 15.6-29.2) 
p=ns between original 
RCT groups 
- HIV: 2 HIV 
seroconverters 
(seronegative at 
baseline NR; incidence 
rate 0.276/100 person-
years, 95% CI 0.033-
0.996) 
NR Periods of imprisonment of <2 
months (p≤0.001) and OST periods 
of <5 months (p=0.01) were 
significantly associated with 
increased risk of HCV seroconversion 
Very low 
Non-
EU/EEA 
 
PRL 
Dolan, 2003 [59] 
 
Australia 
 
RCT (4 months 
follow-up) 
NSW prisons 
 
August 1997 – 
October 1998 
OST: methadone 
treatment immediately 
(30 mg with increase of 
5 mg/3 days until 60 
mg) 
 
Control: 4-month delay 
with guaranteed access 
after that period 
n=191 OST vs. n=191 
control (follow-up data 
of 129 (67.5%) vs. 124 
(64.9%)) 
 
Males, suitable for OST 
according to medical 
staff confirming heroin 
problem, sentence >4 
months at baseline 
 
Direct OST versus 
delayed OST 
After ~4 months follow-
up: 
- HIV: 0 at baseline and 
follow-up 
- HCV: of 32 OST and 
35 control HCV-
negative subjects at 
baseline, 4 subjects in 
each group had 
seroconverted at 
follow-up (12.5% and 
11.4%, respectively, 
p=ns) 
NR NR Very low 
 
HBV: hepatitis B virus, HCV: hepatitis C virus, HIV: human immunodeficiency virus, IDU: injecting drug user, NGO: non-governmental organisation, NR: not reported, NSW: New South Wales, OST: opioid 
substitution treatment, PRL: peer-reviewed literature, RCT: randomised controlled trial 
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Acceptability/barriers 
Region  
Source 
Reference, 
country, study 
design 
Prison setting, 
sample, time 
period 
Intervention description Eligibility/access Acceptance Attrition Sub-group 
considerations 
Level of 
evidence 
Intervention: needles and syringes programmes 
EU/EEA 
 
PRL 
Stark, 2006 [62] 
 
Germany 
 
Longitudinal study 
 
 
1 male and 1 female 
prison in Berlin 
 
n=174 inmates who 
had ever used illicit 
drugs 
 
October 1998 – June 
2001 
- Female prison: 3 automatic 
dispensers, providing a sterile 
syringe, needle and skin 
disinfection pad in exchange for a 
used syringe, or a dummy 
handed out to new entrants 
- Male prison: social workers from 
a NGO exchanged sterile syringes 
and needles for used equipment 
3 times a week 
NR NR 28.7% lost to follow-
up (50/174), primarily 
due to pre-term 
release or transfer 
NR  Very low 
EU/EEA 
 
PRL 
Heinemann, 2001 
[61] 
 
Germany 
 
Cross-sectional study 
and longitudinal 
study 
 
1 prison for males 
and females 
 
Cross-sectional study: 
- n=191 intravenous 
drug using inmates 
questionnaire/n=22 
interview 
- n=81 prison emplo-
yees questionnaire 
/n=9 interview 
Longitudinal study: 
- n=231 intravenous 
drug using inmates 
 
April 1996 – July 1997 
Syringe vending machines, with 
1:1 exchange 
 
Several machines installed in 
different stations, partly in 
locations not accessible by staff 
Over 90% of the 
consumers 
reported 
unreliability of the 
syringe vending 
machines. Other 
challenges were: 
not enough 
needles, 
insufficient 
anonymity, poor 
supply of 
dummies, and lack 
of special cannulas 
(n/N NR) 
- In the survey, the 
acceptance (not defined) of 
the overall project among 
the drug-using inmates was 
significantly more positive 
than in the case of the non-
consuming inmates (p-value 
NR) 
- A stable proportion (58-
61%) of the prison 
employees evaluated the 
project ‘bad’ or ‘very bad’. 
At the end of the project, 
the majority of the 
employees is still not 
convinced of the need of an 
automatic spin-off device 
NR NR Very low 
Intervention: opioid substitution treatment 
Non-
EU/EEA 
 
PRL 
Dolan, 2003 [59] 
 
Australia 
 
RCT (4 months 
follow-up) 
NSW prisons 
 
n=191 OST vs. 
n=191 control 
(follow-up data of 129 
(68%) vs. 124 
(65%)) 
 
August 1997 – 
October 1998 
OST: methadone treatment 
immediately (30 mg with increase 
of 5 mg/3 days until 60 mg) 
 
Control: 4-month delay with 
guaranteed access after that 
period 
Male 
 
Assessed as 
suitable for OST by 
a detailed 
interview with 
medical staff  
 
Prison sentences 
>4 months at 
baseline 
OST group: 
- 68.2% (88/129) remained 
in treatment  
- 9.3% (12/129) did not 
start treatment (reasons 
NR) 
 
Control group: 
- 19% commenced OST 
during the study period; 
9% for the intended study 
22.5% (29/129) in 
OST and 26.6% 
(33/124) in control 
group were lost to 
follow-up due to 
release from prison 
NR Very low 
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Region  
Source 
Reference, 
country, study 
design 
Prison setting, 
sample, time 
period 
Intervention description Eligibility/access Acceptance Attrition Sub-group 
considerations 
Level of 
evidence 
period, 11% for part of the 
intended study period (n/N 
NR) 
Non-
EU/EEA 
 
PRL 
Dolan, 2005 [60] 
 
Australia 
 
4-year follow-up of 
RCT (Dolan, 2003) 
NSW prisons 
 
n=191 OST vs. 
n=191 control in 
original RCT; 218 
(57%) with follow-up 
serostatus; 341 
(89%) with follow-up 
OST status 
 
August 1997 – 
December 2002 
OST: methadone treatment 
immediately (30 mg with increase 
of 5 mg/3 days until 60 mg) 
 
Control: 4-month delay with 
guaranteed access after that 
period 
 
At end of RCT, all were offered 
OST (97% had received OST at 
some time during/since RCT) 
Male 
 
Assessed as 
suitable for OST by 
a detailed 
interview with 
medical staff  
 
Prison sentences 
>4 months at 
baseline 
97% had received OST at 
some time either during or 
since the original RCT (n/N 
NR) 
80.6% (275/341) 
dropped out of their 
first OST episode over 
436 person-years at 
risk (attrition rate 
63.1 per 100 person-
years, 95% CI 56.1–
71.0)  
- OST dropout risk 
was 10 times higher 
during short prison 
sentences (≤1 
month) compared to 
when subjects were in 
the community 
(p<0.001), although 
after 4 months 
imprisonment was 
significantly protective 
for OST dropout 
(p≤0.002) 
NR Very low 
IDU: injecting drug user, NGO: non-governmental organisation, NSW: New South Wales, OST: opioid substitution treatment, PRL: peer-reviewed literature, RCT: randomised controlled trial 
Cost-effectiveness 
Region  
Source 
Reference, 
country, study 
design 
Prison setting, 
sample 
Perspective, time 
horizon 
Scenarios  Conclusions Sub-group 
considerations 
Level of 
evidence 
Intervention: opioid substitution treatment 
Non-
EU/EEA 
 
PRL 
Warren, 2006 [64] 
 
Australia 
 
Cost-effectiveness 
study 
NSW prisons 
 
n=NR 
 
 
Provider/funder of 
prison services 
 
NR 
OST programme (see Dolan, 
2003 and 2005) for one year 
 
vs. 
 
No OST programme 
- Incremental cost per additional heroin-free day: AUD 
$38 
- Incremental cost per death avoided: AUD $458,074  
- Incremental cost per HCV case avoided: AUD $40,428 
- OST programme in prison is no more costly than 
community programmes 
NR Low 
AUD: Australian dollar, HCV: hepatitis C virus, NR: not reported, NSW: New South Wales, OST: opioid substitution treatment, PRL: peer-reviewed literature 
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Guidelines 
Six guidelines on prevention of BBVs infection in PWID were included, of which three were specific to prison settings (two supranational and one national guideline), and the other three 
were supranational guidelines not specific to prison setting.  
Summary of guidelines for injecting-related infections in prison settings 
Guideline 
Specific to prison setting – supranational guidelines 
WHO, 2014 [7] Prevention of transmission through needles shared by injecting drug users 
Different modalities have been adopted in several countries to make safe injection equipment available in prisons through health staff, by peers or through dispensing 
machines. There is evidence that these programmes are effective and not the source of security problems. To prevent hepatitis C, the injection kits should contain (in 
addition to the syringes) filters, water and cups. Bleach, especially in the prison context, is barely or not effective for disinfecting injection equipment and preventing 
the transmission of HIV and hepatitis. 
Whichever system is chosen to provide needles and syringes or kits, the method should include a component for the safe disposal of used needles and syringes. 
 
Drug dependence treatment 
Drug dependence treatment, including opioid substitution therapy for maintenance, is an essential component of the prevention of transmission through injection 
equipment. 
WHO, 2007 [53] Prevention is based on blocking transmission caused by using contaminated syringes. At the population level, adopting pragmatic policies to reduce risk creates the 
most favourable conditions for preventing transmission. If such policies are in place, the institutions can promote safe injecting practices by interventions ranging from 
health education to needle and syringe programmes. The individual drug user should avoid sharing injecting equipment and, when needle and syringe programmes are 
available, take part. If clean needles and syringes are not available, bleach should be used to reduce the risk of transmission, but this will not eliminate the risk. To 
prevent infection with HBV and HCV, PWID should avoid sharing any part of their injecting materials, including syringe, cotton, water and cooker. 
Specific to prison setting – national guidelines 
UK Department of 
Health, 2011 [55] 
HBV and HCV prevention advice for prisoners 
• Be vaccinated against HBV 
• Never share injecting drug equipment; this includes syringes, filters, spoons, tourniquets, swabs and water as well as needles 
• Never share tattooing or body piercing equipment 
• Use disinfecting tablets to clean injecting equipment, razors, and any other items that may have come into contact with blood or body fluids  
Other guidelines – supranational guidelines 
WHO, 2016 [58] All people from key populations who are dependent on opioids should be offered opioid substitution therapy in keeping with WHO guidance (strong 
recommendation, low quality of evidence), including those in prison and other closed settings. 
People in prisons should have access to the same evidence-based treatment options for substance dependence as people in the community. Prison authorities in 
countries where OST is available in the community should urgently introduce OST programmes and expand them to scale as soon as possible.  
Countries should affirm and strengthen the principle of providing treatment, education and rehabilitation as an alternative to conviction and punishment for drug-
related offences 
Care should be taken to see that people on OST before entering prisons or other closed settings can continue OST without interruption while imprisoned and when 
transferred between settings and can be linked to community-based OST upon release. 
Provision of OST before release can help reduce overdose-related mortality. 
ECDC/EMCDDA, 
2011 [25] 
Based on the most robust evidence available, expert opinion, and best practice used within the EU/EEA, the following key intervention components should be applied 
and, if possible, be combined to achieve the maximum prevention effect through synergy. 
• Injection equipment: Provision of, and legal access to, clean drug injection equipment, including sufficient supply of sterile needles and syringes, free of charge, as 
part of a combined multi-component approach, implemented through harm-reduction, counselling and treatment programmes. 
• Vaccination: Hepatitis A and B, tetanus, influenza vaccines, and, in particular for HIV-positive individuals, pneumococcal vaccine 
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• Drug dependence treatment: Opioid substitution treatment and other effective forms of drug dependence treatment 
• Testing: Voluntary and confidential testing with informed consent for HIV, hepatitis C (hepatitis B for unvaccinated) and other infections including TB should be 
routinely offered and linked to referral to treatment. 
• Infectious disease treatment: Antiviral treatment based on clinical indications for those who are HIV, HBV or HCV infected. Anti-TB treatment for active TB cases. 
TB prophylactic therapy should be considered for latent TB cases. Treatment for other infectious diseases should be offered as clinically indicated. 
• Health promotion: Health promotion focused on safer injecting behaviour; sexual health, including condom use; and disease prevention, testing and treatment. 
• Targeted delivery of services: Services should be organised and delivered according to user needs and local conditions; this includes the provision of services 
through outreach and fixed site settings, offering drug treatment, harm reduction, counselling and testing, and referrals to general primary health and specialist 
medical services. 
 
Whenever possible, interventions should be combined to achieve synergistic effects.  
EMCDDA, 2010 [65] Reducing or stopping the use of drugs is the safest way to prevent drug-related infectious 
diseases. This goal, however, may not always be realistic and counselling should therefore include information on how to reduce the risk of acquiring infections. 
 
In order to prevent the spread on the prevention of blood-borne and bacterial infections injecting drug users should: 
• Always use a new (sterile) needle and syringe every single time they inject. Syringes and needles are not designed to be used more than once. 
• Never share needles, syringes, water, cooker, filters or cotton with anyone. 
• Never re-use needles, syringes, water, cooker, filters or cotton. 
• If you are sometimes forced to re-use or share needles and syringes, clean them thoroughly each time.  
• If available, use treatment facilities and harm reduction measures such as: 
- needle exchange programmes and other sources of sterile injecting materials; 
- drug-assisted rehabilitation or opioid substitution programmes (e.g. methadone programmes or other drug treatment services); 
- medically supervised injection facilities. 
• Try to reduce or stop using drugs. Replace injecting practices with non-injecting practices such as smoking and sniffing, and if possible, reduce the frequency of 
injecting. 
 
Recommended vaccines for IDUs are: 
hepatitis A and B combination vaccine (or separate hepatitis A and hepatitis B vaccines) 
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Annex 10. Summary tables and guideline summaries – HIV treatment 
Effectiveness 
Region  
Source 
Reference, 
country, 
study 
design 
Prison 
setting, 
time period 
Description 
model of care 
Sample, 
eligibility, 
comparator 
Viral load, CD4 
count 
Treatment 
adherence 
Linkage to 
care post 
release 
Other 
outcomes of 
interest 
Other sub-
group 
conside-
rations 
Level of 
evidence 
HIV treatment in prison – usual care 
EU/EEA 
 
PRL 
Herraiz, 2008 
[68] 
 
Spain 
 
Longitudinal 
study 
Men’s Prison 
of Barcelona 
 
October 2003 
– January 
2005 
Provision of ART, 
not further 
specified 
 
n=75 HIV+ 
inmates receiving 
ART (convenience 
sample) 
 
Likely to be 
incarcerated for 
>6 months 
 
No comparator 
NR Definition 11 (n/N NR, 
p=ns): 
- At baseline: 72% 
- At 3 months: 68% 
- At 6 months: 77% 
Definition 22 (n/N NR, 
p=ns): 
- At baseline: 77% 
- At 3 months: 82% 
- At 6 months: 77% 
NR NR NR Very low 
EU/EEA 
 
PRL 
Inés, 2008 
[69] 
 
Spain  
 
Cross-
sectional 
study 
Topas Prison 
 
March 2001 – 
January 2002 
Provision of ART 
 
Drugs were 
dispensed on a 
monthly basis to 
each inmate and 
medication was 
self-administered 
without 
supervision  
n=50 HIV+ 
inmates starting 
ART during study 
period 
 
ART-naïve or 
receiving <3 
drugs, started 
ART over 10 
consecutive 
months within 
study period, and 
completed 6 
months of 
therapy 
 
No comparator 
Viral load: 
- 46.0% (23/50) 
achieved undetectable 
viral load after 6 
months of therapy 
- -1.43 log10 copies/ml 
change from baseline 
to 6 months (p<0.001) 
 
CD4 count: 
- +119.71 count/mm3 
change from baseline 
to 6 months (p<0.001) 
- this change differed 
significantly between 
adherent and non-
adherent inmates 
(p=0.48) 
42.0% (21/50)3 
 
 
NR Predictors 
undetectable 
viral load: 
- adherence (OR 
5.85, 95% CI: 
1.56-21.88; 
p=0.009) 
NR Very low 
EU/EEA 
 
PRL 
Orly de Labry 
Lima, 2007 
[70] 
 
Spain 
 
3 prisons 
(Córdoba, 
Huelva, 
Granada) 
 
Provision of ART, 
not further 
specified 
n=281 HIV+ 
inmates receiving 
ART 
 
NR 
 
Viral load – non-
significant difference 
in mean viral load 
between baseline, 6 
and 12 months  
 
- At baseline: 45.2% 
(127/281) 
- At 6 months: 43.5% 
(80/184) 
- At 12 months: 42.3% 
(58/137) 
NR Inmates without 
psychological 
morbidity 
showed a 
significant 
NR Very low 
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Region  
Source 
Reference, 
country, 
study 
design 
Prison 
setting, 
time period 
Description 
model of care 
Sample, 
eligibility, 
comparator 
Viral load, CD4 
count 
Treatment 
adherence 
Linkage to 
care post 
release 
Other 
outcomes of 
interest 
Other sub-
group 
conside-
rations 
Level of 
evidence 
Longitudinal 
study 
May 2002 – 
April 2003 
No comparator CD4 count – 
significant difference 
mean CD4 count at 
baseline vs. 6 months 
(p=0.014) 
(p=ns) 
 
At all 3 visits: 18% 
(n/N NR)4 
reduction in viral 
load (p=0.017) 
EU/EEA 
 
GL 
Prestileo, 
2006 [71] 
 
Italy 
 
Cross-
sectional 
study 
7 prisons in 
eastern Sicily 
 
NR 
Provision of ART, 
not further 
specified 
n=144 current or 
previous HIV+ 
PWID  
 
NR 
 
No comparator 
60% (21/35) had HIV 
RNA <400 copies/ml 
 
Inmates receiving ART 
showed a mean 
increase of 52 (range 
19-104) CD4 
cells/mm3 after 12 
weeks of treatment 
NR NR NR NR Conference 
abstract 
EU/EEA 
 
GL 
Gallego, 
2010 [67] 
 
Spain 
 
Cross-
sectional 
study 
5 prisons in 
Catalunya 
 
NR 
Provision of ART, 
not further 
specified 
n=769 HIV-
infected prisoners 
- 600 (78%) of 
these were 
receiving ART  
 
NR 
 
No comparator 
HIV RNA was <50 
copies/ml in 82.8% 
(497/600) 
 
HIV RNA was >1000 
copies/ml in 10.5% 
(63/600) of cases 
NR NR NR 
 
45% of ART 
treated inmates 
were receiving 
OST with 
methadone 
Conference 
abstract 
EU/EEA 
 
GL 
Botana 
Pazos, 2012 
[66] 
 
Spain 
 
Cross-
sectional 
study 
1 Penitentiary 
centre 
(Madrid VI de 
Aranjuez) 
 
NR 
Provision of ART, 
not further 
specified 
n=102 HIV-
infected prisoners  
- 85 (83.3%) 
received ART 
 
NR 
 
No comparator 
HIV RNA was: 
- <50 copies/ml in 
69.6% (71/102) 
- >50 and ≤200 
copies/ml in 2.9% 
(3/102) 
- >200 and ≤1,000 
copies/ml in 9.8% 
(10/102) 
- <1,000 and ≤10,000 
copies/ml in 5.9% 
(6/102) 
- >10,000 in 5.9% 
(6/102)  
 
CD4 cell count was: 
- ≥500 cells/mm3 in 
43.1% (44/102) 
NR NR NR NR Conference 
abstract 
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Region  
Source 
Reference, 
country, 
study 
design 
Prison 
setting, 
time period 
Description 
model of care 
Sample, 
eligibility, 
comparator 
Viral load, CD4 
count 
Treatment 
adherence 
Linkage to 
care post 
release 
Other 
outcomes of 
interest 
Other sub-
group 
conside-
rations 
Level of 
evidence 
- <500 and ≥350 
cells/mm3 in 23.5% 
(24/102) 
- <350 and ≥200 
cells/mm3 in 17.6% 
(18/102) 
- <200 cells/mm3 in 
12.7% 13/102 
HIV treatment in prison – usual care (partly DOT and/or transitional care) 
EU/EEA 
 
PRL 
Soto Blanco, 
2005 [77] 
 
Spain 
 
Cross-
sectional 
study 
2 prisons 
(Huelva, 
Granada) 
 
1 July 2000 – 
31 August 
2000 
Provision of ART 
 
ART freely 
provided on daily 
basis in sealed 
envelopes at 
prison pharmacy 
n=177 HIV+ 
inmates on ART 
 
No impairing 
physical/ 
psychological 
circumstances 
 
No comparator 
NR 75.7% (134/177)5  NR NR NR Very low 
Non-
EU/EEA 
 
PRL 
Altice, 2001 
[72] 
 
USA 
 
Cross-
sectional 
study 
2 minimum- 
and 2 
maximum-
security 
prisons 
 
April – 
October 1996 
Provision of ART 
 
Patients to 
choose between 
weekly pills 
packages or DOT 
 
On-site dedicated 
HIV nurse 
specialist ensures 
ART regimen is 
followed, 
continuity of 
care, discharge 
planning 
n=205 
consecutive HIV+ 
inmates receiving 
care by the HIV 
specialist 
 
Asymptomatic 
individuals eligible 
for ART 
(CD4<500; 
elevated viral 
load) 
 
No comparator 
 
NR 83.5% of those 
currently accepting 
ART (137/164)6 
NR NR NR Very low 
Non-
EU/EEA 
 
PRL 
Kirkland, 
2002 [73] 
 
USA 
 
Longitudinal 
study 
5 prisons 
 
April 1998 – 
March 2000 
Provision of ART 
(old combination 
treatment) 
 
Twice per day 
under DOT or at 
dispensing site 
n=108 HIV+ 
inmates 
 
Adult ART-naive 
with HIV-1 
infection (viral 
load >400 copies/ 
Viral load – After 24 
weeks therapy:  
- 62.0% (67/108) 
undetectable viral load 
- The median HIV-1 
RNA level was 2.41 
Overall self-reported: 
94.1% (n/N NR) 
Mean weeks 2-24: 
93.4-98.6% (n/N NR)7 
NR Significant 
predictors of 
virologic 
response: 
- baseline HIV-1 
RNA level 
(p<0.001) 
NR Very low 
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Region  
Source 
Reference, 
country, 
study 
design 
Prison 
setting, 
time period 
Description 
model of care 
Sample, 
eligibility, 
comparator 
Viral load, CD4 
count 
Treatment 
adherence 
Linkage to 
care post 
release 
Other 
outcomes of 
interest 
Other sub-
group 
conside-
rations 
Level of 
evidence 
for medication at 
specified times 
twice per day 
 
Change of 
treatment 
possible due to 
toxicity, 
hypersensitivity, 
or virologic 
failure 
ml, CD4 count 
≥50 cells/mm3 
within 14 days 
before study); no 
AIDS, pregnancy, 
breastfeeding, 
considering 
having a child, 
various clinical 
reasons, in 
another investiga-
tional drug study, 
non-compliant 
with study 
schedule 
 
No comparator 
log10 copies less than 
the baseline (p NR) 
 
CD4 count – During 
the 24 weeks, the 
median CD4 cell count 
remained at 377–441 
cells/mm3 
 
 
- black (vs. other 
races; p=0.049) 
- heterosexual 
contact (vs. other 
risk factors; 
p=0.039) 
- adherence 
(p=0.0037), after 
adjusting for 
baseline HIV-1 
RNA level 
(p=0.0002), CD4 
cell count 
(p=0.0339), and 
demographic 
covariates, such 
as ethnicity, sex, 
and age 
Non-
EU/EEA 
 
PRL 
Meyer, 2014 
[75] 
 
USA 
 
Longitudinal 
study 
CTDOC, an 
integrated 
system of 15 
male and 1 
female facility 
(pre-trial and 
sentenced) 
 
March 2005 – 
June 2012 
Provision of ART 
 
Managed by 
Infection Control 
nurse and 
provided by 
Infectious 
Diseases 
specialists  
 
DOT or SAT 
(based on 
patient/provider 
preference) 
 
Transitional case 
management 30 
days before 
release to 3 
months after 
release; 14 days 
of medication 
upon release 
n=882 HIV+ 
inmates on ART 
 
Confirmed HIV 
seropositive, in 
CTDOC for ≥90 
days, prescribed 
ART, ≥2 sets of 
laboratory data 
during 
incarceration 
available 90 days 
apart, pharmacy 
data available 
 
No comparator 
Viral load 
- HIV-1 RNA level 
(copies/ml): mean 
change -46379 
(p<0.0001) from 
baseline to release 
- Viral suppression 
<400 copies/ml: 
29.8% at baseline, 
70.0% at discharge (p 
NR) 
- Maximal viral 
suppression <50 
copies/ml: 6.2% at 
baseline, 23.1% at 
release (p NR) 
 
CD4 count 
- CD4 count (cells/μl): 
mean change +98.0 
(p<0.0001) from 
baseline to release 
- CD4 count <200 
cells/μl: 29.5% at 
NR NR Viral suppression 
at release 
correlated with:  
- Female sex 
(AOR 1.81; 
95%CI 1.26-
2.59) 
- Lower 
psychiatric 
disorder severity 
(AOR 1.50; 95% 
CI 1.12-1.99) 
NR Very low 
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Region  
Source 
Reference, 
country, 
study 
design 
Prison 
setting, 
time period 
Description 
model of care 
Sample, 
eligibility, 
comparator 
Viral load, CD4 
count 
Treatment 
adherence 
Linkage to 
care post 
release 
Other 
outcomes of 
interest 
Other sub-
group 
conside-
rations 
Level of 
evidence 
baseline, 16.5% at 
discharge (p NR) 
 
 
Non-
EU/EEA 
 
PRL 
Mostashari, 
1998 [76] 
 
USA 
 
Cross-
sectional 
study 
Connecticut’s 
sole 
correctional 
facility for 
women in 
Niantic 
 
July 1993 – 
January 1994 
& April 1995 – 
October 1995 
Provision of ART  
 
Comprehensive 
care from 
infectious disease 
specialist at 
regularly 
scheduled clinic 
visits 
 
Primarily through 
weekly package 
dispensation, 
minority through 
DOT 
n=102 HIV+ 
female inmates 
 
CD4 counts <500 
cells/μl 
 
No comparator 
NR 61.8% (47/76) of 
current ART users were 
adherent8, 27.6% 
(21/76) missed their 
prescribed doses for 
≥2 days/week and 
10.5% (8/76) reported 
taking some 
medication for ≥6 
days/week, but missing 
≥1 dose/day on 
average 
NR 63.7% (65/102) 
were first offered 
ART in prison 
NR Very low 
Non-
EU/EEA 
 
PRL 
Springer, 
2004 [78]  
 
USA 
 
Longitudinal 
study 
CTDOC, an 
integrated 
system of 15 
male and 1 
female facility 
(pre-trial and 
sentenced) 
 
January 1997 
– December 
2002 
Provision of ART  
 
HIV nurse 
specialist 
available at each 
facility 
 
Majority self-
administer 
medication, in 
select cases 
ordered as DOT 
by HIV specialist 
 
Transitional case 
management 3 
months before 
release to 
minimum of 30 
days after 
release; 2-week 
medication 
supply, medical 
appointment with 
n=1099 HIV+ 
inmates on ART 
 
Prescribed ART 
for ≥6 
consecutive 
months during 
prison sentence, 
available baseline 
and follow-up HIV 
RNA levels and 
CD4 counts, and 
with ART 
pharmacy 
prescriptions 
 
No comparator 
Viral load – Significant 
mean reduction from 
baseline to end of 
incarceration in HIV-1 
RNA level of 0.93 log10 
copies/ml (p<0.0001) 
 
CD4 count – 
Significant mean 
increase from baseline 
to end of incarceration 
in CD4 count of 74 
lymphocytes/ml 
(p<0.0001) 
 
 
NR NR Predictors of viral 
load: 
Women 
significantly 
greater 
reductions in viral 
load (p<0.0001) 
26.5% 
(292/1099) 
inmates were 
reincarcerated 
after having 
spent ≥3 
months in 
community): 
CD4 count was 
significantly 
lower and viral 
load 
significantly 
higher at re-
incarceration as 
compared to at 
time of release 
(p<0.0001) 
 
Very low 
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Region  
Source 
Reference, 
country, 
study 
design 
Prison 
setting, 
time period 
Description 
model of care 
Sample, 
eligibility, 
comparator 
Viral load, CD4 
count 
Treatment 
adherence 
Linkage to 
care post 
release 
Other 
outcomes of 
interest 
Other sub-
group 
conside-
rations 
Level of 
evidence 
HIV care 
provider, 
emergency 
housing and 
food, other 
assistance 
EU/EAA 
 
GL 
Manzano, 
2010 [74] 
 
Spain 
 
Cross-
sectional 
study 
Puerto II 
penitentiary 
center (Cadiz) 
 
2004 – 2009 
Provision of ART, 
Not further 
specified 
 
Evaluation of an 
ART 
implementation 
programme 
n=170  
- 73.5% 
(125/170) 
received ART 
 
No comparator 
HIV RNA: 
- <50 copies/ml in 
18.8% (32/170) at 
entry 
- <50 copies/ml In 
60.5% (103/170) at 
release  
 
CD4 cell count: 
- <200 cells/mm3 in 
27.6% (47/170) at 
entry and in 21.7% 
(37/170) at release  
- <350 cells/mm3 in 
57.0% (97/170) at 
entry and in 45.8% 
(78/170) at release  
- >350 cells/mm3 in 
42.9% (73/170) at 
entry and in 54.1% 
(92/170) at release  
NR NR NR NR Conference 
abstract 
HIV treatment in prison – usual care (comparison DOT vs SAT) 
EU/EEA 
 
PRL 
Babudieri, 
2000 [81] 
 
Italy 
 
Longitudinal 
observational 
study 
18 Italian 
prison 
facilities; 9 
offering DOT, 
9 not offering 
DOT 
 
April 1997-
September 
1998 
DOT: Every 
medication dose 
was administered 
by a nurse 
overseeing the 
intake 
 
SAT: nurse 
delivers 
medications to 
the patients daily 
but do not 
oversee intake 
84 patients 
consecutively 
enrolled on HIV 
treatment; 37 on 
DOT; 47 on SAT  
 
All individuals 
were injecting 
drug users 
All patients in the 
DOT group had 
significant decrease in 
viral load (>2 log) 
after therapy; and 23 
(62.1%) had viral 
load <400 copies/ml 
compared with 16 
patients (34.0%) in 
the SAT group (odds 
ratio, 3.18; 95% 
confidence interval, 
1.18-8.67; χ2=5.49; 
P=.01) 
NR NR 2 patients in the 
DOT group 
(5.4%), had a 
CD4 cell count 
that remained 
less than 200 × 
106/L vs 15 
patients in the 
SAT group 
(31.9%) (odds 
ratio, 0.12; 95% 
confidence 
interval, 0.02-
The cost of 
implementing 
DOT in this 
setting is low; 
no additional 
staff was 
required to 
administer this 
therapy 
Very low 
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Region  
Source 
Reference, 
country, 
study 
design 
Prison 
setting, 
time period 
Description 
model of care 
Sample, 
eligibility, 
comparator 
Viral load, CD4 
count 
Treatment 
adherence 
Linkage to 
care post 
release 
Other 
outcomes of 
interest 
Other sub-
group 
conside-
rations 
Level of 
evidence 
0.62; χ2=7.44; 
P<.001). 
Non-
EU/EEA 
 
PRL 
Wohl, 2003 
[80] 
 
USA 
 
Longitudinal 
study 
6 of 74 
NCDOC 
facilities 
 
September 
1999 – April 
2000 
DOT: patients 
visit medication 
window at 
specified times 
and swallow 
medication in 
sight of nurse or 
officer 
 
SAT: self-
administered 
 
Protease 
inhibitors always 
DOT, other 
medications DOT 
or SAT 
(according to 
preference of 
clinician) 
 
Medications 
dispensed to 
patient (SAT) or 
staff (DOT) in 30-
day allotments; 
pill bottles 
returned at end 
30-day period 
and refilled 
n=31 HIV+ 
inmates on ART 
(consecutive 
sample) 
 
Adults with 
documented HIV 
infection, no 
expected release 
during 4 study 
months, receiving 
≥3 ART of which 
≥1 administered 
via DOT, and 
having received 
ART for ≥3 
months prior to 
study start 
 
DOT vs SAT 
- 58% (18/31) all 
ART agents via 
DOT 
- 42% (13/31) 
one ART agent 
via DOT 
NR Median electronic 
monitoring caps 
adherence:  
- Overall: 86% (>90% 
in 32% of subjects) 
- 92% (range 0-100) in 
SAT vs. 82% (range 
16-100) in DOT 
(p=0.46) 
 
Median pill count 
adherence:  
- Overall: 90% 
- 90% (range 43-100) 
in SAT vs. 89% (range 
25-100) in DOT 
(p=0.82) 
 
Median self-reported 
adherence:  
- Overall: 100% 
- 100% (range 92-100) 
in SAT vs. 100% 
(range 52-100) in DOT 
(p=0.32) 
 
10 (n/N NR) 
NR NR Among 13 
subjects who 
received only 1 
of their 
medications by 
DOT (41.9%) 
- No adherence 
difference 
between DOT- 
and SAT-
provided 
medications 
irrespective of 
measurement  
- On 74% of 
days that any 
ART doses 
were missed, 
both DOT- 
based and SAT-
provided 
medications 
were not taken 
(n/N NR) 
Very low 
Intervention: DOT vs. SAT 
Non-
EU/EEA 
 
PRL 
White, 2015 
[79] 
 
USA 
 
Pilot of RCT 
3 prison-
based HIV 
clinics 
covering 11 of 
the largest 74 
North Caroline 
State prison 
system 
facilities 
DOT: prison staff 
observed and 
recorded each 
inmate ingest all 
ART medications; 
if missed >3 pills, 
they notify it 
 
n=20 DOT vs. 
n=23 SAT HIV+ 
inmates 
(consecutive 
sample) 
 
Adults with 
documented HIV 
infection, on ART, 
Viral load: 
- No difference in the 
proportion achieving 
viral suppression 
between the two 
study arms at week 24 
(p=0.21) or 48 
(p=0.48)  
 
Median (IQR) MEMS 
adherence1 
- 24 weeks: 99.0% 
(93.9-100) in DOT vs. 
98.3% (96.0-100) in 
SAT (p=0.82) 
- 48 weeks: 99.8% 
(96.3-100 in DOT vs. 
NR 45.0% (9/20) of 
the DOT 
participants 
60.9% (14/23) of 
the SAT 
participants 
opted to receive 
adherence 
counselling 
NR Very low 
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Region  
Source 
Reference, 
country, 
study 
design 
Prison 
setting, 
time period 
Description 
model of care 
Sample, 
eligibility, 
comparator 
Viral load, CD4 
count 
Treatment 
adherence 
Linkage to 
care post 
release 
Other 
outcomes of 
interest 
Other sub-
group 
conside-
rations 
Level of 
evidence 
 
August 2003 
– February 
2005 
SAT: monthly 
allotments of all 
ART medications 
and signing for 
each medication 
bottle; turn in 
any remaining 
medication at 
each monthly 
refill 
 
Protease 
inhibitors always 
DOT, other 
medications DOT 
or SAT 
 
After week 24, 
optional 
adherence 
counselling: 2 
motivational 
interview 
sessions 
no planned inter-
prison transfers, 
Karnofsky score 
≥70 to measure 
self-care, 
expected 
incarceration ≥6 
months, available 
CD4 count and 
HIV RNA level 
within 60 days of 
study entry 
 
DOT vs. SAT 
CD4 count: 
- No difference in CD4 
count change at 24 
weeks (p=0.69) and 
48 weeks (p=0.98) 
between DOT and SAT 
 
99.9% (85.2-100) in 
SAT (p=0.79) 
- Odds of achieving 
>95% adherence DOT 
vs SAT: OR 0.77 
(p=0.77) 
 
Median (IQR) pill count 
adherence7 
- 24 weeks: 97.1% 
(95.1-99.3) in DOT vs. 
98.5% (95.8-100) in 
SAT (p=0.40) 
- 48 weeks: 100% 
(94.8-100) in DOT vs. 
99.5% (97.0-100) in 
SAT (p=0.84) 
- Odds of achieving 
>95% adherence DOT 
vs SAT: OR 1.28 
(p=0.75) 
approximately 25 
and 26 weeks 
after 
randomisation 
Intervention: HIV care with telemedicine vs. usual care 
Non-
EU/EEA  
 
PRL 
Young, 2014 
[82] 
 
USA 
 
Before-after 
study 
IDOC, not 
further 
specified 
 
July 2009 – 
June 2010 
(pre-tele-
medicine) & 
July 2010 – 
June 2012 
(telemedicine) 
HIV care: visit 
every 3-month 
 
Pre-telemedicine: 
on-site 
management by 
correctional 
physician without 
subspecialty 
training 
 
Telemedicine: 
encrypted link to 
dedicated tele-
medicine suite; 
each visit with an 
infectious disease 
n=514 pre-
telemedicine vs. 
n=687 
telemedicine 
HIV+ inmates 
 
All known HIV+ 
adults who 
consented to 
medical care, 
with available 
date from ≥2 
visits 
 
Pre-telemedicine 
time period vs. 
Viral load: 
- Complete virologic 
suppression during the 
first 6 visits 
telemedicine vs. pre-
telemedicine: OR 7.0, 
95% CI 5.1–9.8; p< 
0.001 (when removing 
all subjects who were 
suppressed at the first 
visit: OR 10.5, 95% CI 
6.9–16.1; p< 0.001; 
when controlling for 
total number of clinic 
visits: OR 4.2, 95% CI 
2.5–7.0; p<0.001) 
 
NR NR NR NR Very low 
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Region  
Source 
Reference, 
country, 
study 
design 
Prison 
setting, 
time period 
Description 
model of care 
Sample, 
eligibility, 
comparator 
Viral load, CD4 
count 
Treatment 
adherence 
Linkage to 
care post 
release 
Other 
outcomes of 
interest 
Other sub-
group 
conside-
rations 
Level of 
evidence 
physician, 
infectious 
disease-trained 
pharmacist, a 
case manager 
and correctional 
nurse 
telemedicine time 
period 
CD4 count – Mean 
CD4 count higher in 
telemedicine group vs. 
pre-telemedicine 
group (p=0.032) 
Intervention: pharmacist-run HIV medication management model 
Non-
EU/EEA  
 
PRL 
Bingham, 
2012 [83] 
 
USA 
 
Longitudinal 
study 
BOP facilities 
 
December 
2004 – 
December 
2009 
 
 
Provision of ART 
by a 
multidisciplinary 
healthcare team 
including HIV 
clinical 
pharmacist 
consultant  
 
Patients’ care 
included 
consultation on 
treatment 
initiation, 
medication 
appropriateness/ 
interaction 
review, 
medication 
regimen 
complexity, 
adverse 
reactions, 
resistance 
review, 
opportunistic 
infection 
treatment, 
comorbid 
conditions 
n=135 HIV+ 
inmates on ART 
 
NR 
 
No comparator 
Viral load: 
- From April 2004 to 
December 2009, the 
overall percentage of 
patients with 
undetectable viral 
loads (<48 copies/ml) 
increased from 32% 
to 66% 
 
CD4 count – At 
December 2009, 76% 
of patients receiving 
ART achieved CD4 
counts of ≥200 
cells/mm3 
 
All n/N NR 
At December 2009, 
73% of patients 
receiving ART were 
taking ≥90% of the 
prescribed doses (n/N 
NR)11 
NR NR NR Very low 
Intervention: monthly nurse evaluation 
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Region  
Source 
Reference, 
country, 
study 
design 
Prison 
setting, 
time period 
Description 
model of care 
Sample, 
eligibility, 
comparator 
Viral load, CD4 
count 
Treatment 
adherence 
Linkage to 
care post 
release 
Other 
outcomes of 
interest 
Other sub-
group 
conside-
rations 
Level of 
evidence 
EU/EAA  
 
GL 
 
Martino, 
2010 [84] 
 
Spain 
 
Longitudinal 
study 
Penitentiary 
center Puerto 
III (Cadiz) 
 
November 
2008 – July 
2009 
Programmed 
monthly nurse 
visit including a 
structured 
interview 
n=54 inmates 
 
NR 
 
No comparator 
Mean CD4 count pre-
intervention 460.2 vs. 
464.1 cells/mm3 post-
intervention 
 
Mean HIV RNA pre-
intervention 8340.57 
vs. 4040.31 copies/ml 
post-intervention 
NR NR NR NR Conference 
abstract 
 
AIDS: autoimmune deficiency syndrome, ART: antiretroviral therapy, BOP: Bureau of Prisons, CI: confidence interval, CTDOC: Connecticut Department of Corrections, DOT: directly observed therapy, ER: 
emergency room, GL: grey literature, IDOC: Illinois Department of Corrections, IQR: interquartile range, NCDOC: North Carolina Department of Corrections, NNRTI: non-nucleoside reverse-transcriptase 
inhibitor, NR: not reported, NRTI: nucleoside reverse-transcriptase inhibitor, ns: not significant, OR: odds ratio, PI: protease inhibitor, PRL: peer-reviewed literature, RCT: randomized controlled trial, RNA: 
ribonucleic acid, SAT: self-administered therapy, SD: standard deviation, USA: United States of America 
1 Self-reported adherence as ‘very good’ (proportion indicates ≥95% adherence) 
2 Self-reported adherence according to number of pills not ingested in the last 4 days (proportion indicates ≥95% adherence) 
3 Self-reported adherence: 4 ‘no’ answers or 1 ‘yes’ answer (1 day) to 4 questions related to previous 5 days ‘did you forget to take a pill?’, ‘did you forget any dose of all the drugs?’, ‘did you take a tablet or a 
dose outside the timetable?’ and ‘did you take any tablet or the doses without realizing that you had to do so with or without meals?’ 
4 Self-reported non-adherence: answering yes to any qualitative question, >2 doses missed in the last week or >2 days without medication in the last 3 months 
5 Self-reported adherence: 4 ‘no’ answers or 1 ‘yes’ answer (1 day) to 4 questions related to previous 5 days ‘did you miss any pill?’, ‘did you miss any dose of all ART drugs?’, ‘did you take any pill out of 
scheduled time?’ and ‘did you take any pill/all doses without taking into account food requirements?’ 
6 Self-reported adherence: taken ≥80% of prescribed doses of medication during 7-day recall period 
7 Self-reported adherence, not further defined 
8 Self-reported adherence: taking medications for ≥6 days/week, and not missing any doses per day 
9 A HAART regimen strategy was defined by the type of regimen that was first initiated during the eligible incarceration period, including: a) PI-based regimens with 2 NRTIs and ≥1 PI (no NNRTI included); b) 
NNRTI-based regimens with 2 NRTIs and ≥1 NNRTI (no PI included); c) NRTI-only regimens with ≥3 NRTIs (no PI or NNRTI included); and d) 3-class regimens (multiple) with ≥1 NRTI and 1 NNRTI and 1 PI 
10 Assessed by electronic monitoring caps (eDEM), pill counts of returned medication, self-report (interviews at first clinical appointment after study entry [~3-4 months later]), and medication administration 
records completed by prison staff who dispensed medications for DOT; Adherence: proportion of prescribed doses taken 
11 Adherence not specified 
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Acceptability/barriers 
Region  
Source 
Reference, 
country, 
study 
design 
Prison 
setting, 
sample, time 
period  
Description 
model of care 
Eligibility/ 
access 
Acceptanc
e 
Treatment discontinuation/ 
non-adherence 
Attrition Other outcomes of 
interest 
Other 
sub-group 
conside-
rations 
Level of 
evidence 
HIV treatment in prison – usual care 
EU/EEA 
 
PRL 
Herraiz, 2008 
[68] 
 
Spain 
 
Longitudinal 
study 
Men’s Prison of 
Barcelona 
 
n=75 HIV+ 
inmates 
 
October 2003 – 
January 2005 
Provision of 
ART 
 
NR NR Reasons discontinuation/ 
change treatment (% NR): 
- Main reason: forgetting 
- Less common reasons: side 
effects, falling asleep, feeling 
nervous or depressed, having 
exhausted medication or not 
taking the medication with you 
 
Significant correlates of 
adherence at 6 months: 
Definition 11: 
- General self-efficacy (r=0.403, 
p=0.010), medication 
management self-efficacy 
(r=0.379, p=0.016), benefit 
perception (r=0.330, p=0.043) 
(all at baseline) 
- General self-efficacy (r=0.356, 
p=0.046), medication 
management self-efficacy 
(r=0.403, p=0.020), fatigue 
(r=-0.528, p=0.001), vigour 
(r=0.427, p=0.007) and viral 
load (r=0.418, p=0.017) (all at 
3 months) 
Definition 22: 
- Medication management self-
efficacy (r=0.377, p=0.014), 
vigour (r=0.378, p=0.014), 
depression (r=0.374, p=0.015) 
and CD4 level (r=-0.365, 
p=0.019) (all at baseline) 
- Fatigue (r=0.377, p=0.015), 
vigour (r=-0.324, p=0.039) and 
CD4 level (r=-0.39, p=0.014) 
(all at 3 months) 
45.3% (34/75) 
were lost to 
follow up at six 
months – no 
reason provided 
60% reported having 
received limited 
support from the 
healthcare staff (n/N 
NR)  
 
 
NR Very low 
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Region  
Source 
Reference, 
country, 
study 
design 
Prison 
setting, 
sample, time 
period  
Description 
model of care 
Eligibility/ 
access 
Acceptanc
e 
Treatment discontinuation/ 
non-adherence 
Attrition Other outcomes of 
interest 
Other 
sub-group 
conside-
rations 
Level of 
evidence 
EU/EEA 
 
PRL 
Inés, 2008 
[69] 
 
Spain  
 
Cross-
sectional 
study 
Topas Prison 
 
n=50 HIV+ 
inmates  
 
March 2001 – 
January 2002 
Provision of 
ART 
 
Drugs were 
dispensed on a 
monthly basis 
to each inmate 
and medication 
was self-
administered 
without 
supervision  
NR NR - 7.1% discontinued treatment 
(4/56) 
(study focuses on 50 inmates 
who completed 6 months of 
ART)  
 
Significant predictors of good 
adherence: 
- Active occupation inside 
prison (OR 5.56, 95% CI 1.12-
27.02; p=0.035) 
- Absence of HIV-related 
symptoms (OR 7.81, 95% CI 
1.01-62.5; p=0.049) 
- Good or average acceptance 
of treatment (OR 10.10, 95% 
CI 1.23-83.33; p=0.031)  
- Higher academic background 
(OR 5.20, 95% CI 1.05–26.31; 
p=0.044) 
Significant predictor of non-
adherence: 
- IDU as risk factor for HIV 
transmission (OR 8.86, 95% CI 
1.52–51.77; p=0.015) 
3.6% LTFU due 
to transfer (2/56) 
(study focuses 
on 50 inmates 
who completed 6 
months of ART) 
NR NR Very low 
EU/EEA 
 
PRL 
Orly de Labry 
Lima, 2007 
[70] 
 
Spain 
 
Longitudinal 
study 
3 prisons 
(Córdoba, 
Huelva, 
Granada) 
 
n=281 HIV+ 
inmates 
 
May 2002 – 
April 2003 
Provision of 
ART 
 
NR NR - At the 2nd visit (6 months), 
10.7% (30/281) did not 
continue taking ART 
(withdrawal, abandonment or 
intolerance) 
- At the 3rd visit (12 months), 
10.3% (29/281) were not on 
treatment anymore (reasons 
NR) 
 
- At the 2nd visit, 
23.8% (67/281) 
were not present 
(release or 
transfer)  
- At the 3rd visit, 
9.2% (17/184) 
of those at 
second visit were 
not present and 
0.54% (1/184) 
did not want to 
be interviewed 
NR NR Very low 
EU/EEA 
 
PRL 
Sordo-del-
Castillo, 2008 
[85] 
 
Spain 
3 prisons 
(Córdoba, 
Huelva, 
Granada) 
 
Provision of 
ART 
 
26.2% 
(153/585) not 
eligible for 
ART (no 
54.9% 
(321/585) 
on ART  
 
2.6% (15/585) discontinued 
ART due to adverse effects 
NR ART refusers vs. on 
ART or no ART 
indication:  
- more on methadone 
treatment (p=0.027) 
NR Very low 
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Region  
Source 
Reference, 
country, 
study 
design 
Prison 
setting, 
sample, time 
period  
Description 
model of care 
Eligibility/ 
access 
Acceptanc
e 
Treatment discontinuation/ 
non-adherence 
Attrition Other outcomes of 
interest 
Other 
sub-group 
conside-
rations 
Level of 
evidence 
 
Cross-
sectional 
study 
n=585 HIV+ 
inmates 
 
May – July 
2004 
reason 
specified) 
 
Those with 
physical/ 
psychological 
circumstances 
excluded from 
study 
 
 
16.4% 
(96/585) 
refused 
ART while 
indicated 
- more HCV co-
infection (p=0.003) 
- more heroin/cocaine 
use in prison 
(p=p=0.040) 
- more self-perceived 
health being worse 
compared to previous 
year (p<0.001) 
- more viral load 
>50,000 copies 
(p<0.001) 
- lower mean CD4 
count (p<0.001) 
- proportion with 
AIDS: those who were 
not indicated ART 
having the lowest 
proportion and those 
on ART the highest 
(p<0.001) 
- proportion previously 
treated with ART and 
number of times on 
ART: those who were 
not indicated ART 
having the lowest 
proportion and those 
on ART the highest 
(p<0.001) 
EU/EEA 
 
PRL 
Soto Blanco, 
2005 [86] 
 
Spain 
 
Cross-
sectional 
study 
3 prisons 
(Córdoba, 
Huelva, 
Granada) 
 
n=281 HIV+ 
inmates 
receiving ART 
 
2002 
Provision of 
ART 
Those with 
physical/ 
psychological 
circumstances 
excluded from 
study 
NR Main reasons non-adherence3:  
- forgetting: 43.4% (n/N NR) 
- side effects: 22.4% (n/N NR) 
 
Factors significantly associated 
with non-adherence3:  
- having flexible prison officials 
to open the cell (OR 0.47, 95% 
CI 0.26-0.84, p=0.01) 
- good quality of food (OR 5.65, 
95% CI 1.93-16.51, p<0.01) 
NR Opinions and beliefs 
on HIV treatment and 
care (% yes of 
n=281): 
- Prison official flexible 
in opening cell when 
medication forgotten: 
66.2% 
- Difficulty in taking 
medication: 33.2% 
- Very able to continue 
with treatment: 83.3% 
NR Very low 
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Region  
Source 
Reference, 
country, 
study 
design 
Prison 
setting, 
sample, time 
period  
Description 
model of care 
Eligibility/ 
access 
Acceptanc
e 
Treatment discontinuation/ 
non-adherence 
Attrition Other outcomes of 
interest 
Other 
sub-group 
conside-
rations 
Level of 
evidence 
- being anxious and/or 
depressed (OR 2.07, 95% CI 
1.18-3.66, p=0.01) 
- having no support outside 
prison (OR 3.97, 95% CI 1.19-
13.23, p=0.02) 
- having difficulty in taking 
medication (OR 1.94, 95% CI 
1.05-3.57, p=0.03) 
- being completely or largely 
unable to continue with 
treatment (OR 5.37, 95% CI 
2.06-13.94, p<0.001) 
- Trust in treatment: 
86.8% 
- Trust in doctors: 
68.7% 
- Receive necessary 
help from doctors: 
57.7% 
- Receive support in 
prison (professional, 
other inmates, 
NGOs/others): 44.4% 
EU/EEA 
 
GL 
Prestileo, 
2006 [71] 
 
Italy 
 
Cross-
sectional 
study 
7 prisons in 
eastern Sicily 
 
n=144 current 
or previous 
HIV+ PWID  
 
NR 
Provision of 
ART, 
Not further 
specified 
68.6% (35/51) 
HIV-infected 
inmates 
received ART 
 
NR 8.5% (3/35) discontinued ART 
due to prison-related problems 
(transfer to other institutions 
and new prescribed drug non 
available) 
NR NR NR Conference 
abstract 
EU/EEA 
 
GL 
Botana 
Pazos, 2012 
[66] 
 
Spain 
 
Cross-
sectional 
1 Penitentiary 
centre (Madrid 
VI de 
Aranjuez) 
 
N=102 HIV-
infected 
prisoners  
 
NR 
Provision of 
ART, 
Not further 
specified 
85 (83.3%) 
received ART 
 
 
NR NR NR Reasons for not having 
an HIV RNA<50 
copies/ml were: 
- Among the 5.9% 
(6/102) inmates with 
HIV RNA >1,000 and 
≤10,000 copies/ml: 4 
were CDC stage A1 
and 1 A2 without ART 
and 1 NR 
- Among the 5.9% 
(6/102) inmates with 
HIV RNA >10,000 
copies/ml:  
1.9% (2/102) showed 
low level of adherence, 
1.9% (2/102) refused 
ART, 1.9% (2/102) 
had started ART after 
the study started 
 
NR Conference 
abstract 
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Region  
Source 
Reference, 
country, 
study 
design 
Prison 
setting, 
sample, time 
period  
Description 
model of care 
Eligibility/ 
access 
Acceptanc
e 
Treatment discontinuation/ 
non-adherence 
Attrition Other outcomes of 
interest 
Other 
sub-group 
conside-
rations 
Level of 
evidence 
HIV treatment in prison – usual care (partly DOT and/or transitional care) 
EU/EEA 
 
PRL 
Soto Blanco, 
2005 [77] 
 
Spain 
 
Cross-
sectional 
study 
2 prisons 
(Huelva, 
Granada) 
 
n=177 HIV+ 
inmates on 
ART  
 
1 July 2000 – 
31 August 
2000 
Provision of 
ART 
 
Freely provided 
on daily basis in 
sealed 
envelopes at 
prison 
pharmacy 
ART provided 
to patients 
with acute HIV 
syndrome, 
seroconversio
n during 
previous 6 
months, 
clinical 
symptoms of 
HIV infection, 
asymptomatic 
patients with 
CD4 cell count 
<500 
cells/mm3 or 
viral load 
≤10,000 
copies/ml 
 
ART 
prescribed to 
54.2% 
(278/513) of 
HIV-positive 
inmates 
27.0% 
(75/278) of 
those 
prescribed 
ART 
refused 
ART while 
incarcerate
d, no 
reason 
provided  
 
66.5% 
(185/278) 
of those 
prescribed 
ART were 
receiving it 
(177 
participated 
in the 
study) 
 
27.0% (18/278) of those 
prescribed ART discontinued 
ART while incarcerated 
 
Reasons for non-adherence4 
(n=18):  
- side effects: 72.1% 
- missing pills: 20.9% 
- other: 7% 
 
Significant predictors of non-
adherence4:  
- poorly capable/incapable to 
follow the prescribed treatment 
regimen (OR 5.84, 95% CI 
2.27-15) 
- receiving no visits in a month 
(OR 2.76, 95% CI 1.22-6.24) 
- being anxious and/or 
depressed in the last week (OR 
2.40, 95% CI 1.02-5.60) 
NR Opinions and beliefs 
on HIV treatment and 
care (% yes of 
n=177): 
- Prison official flexible 
in opening cell when 
medication forgotten: 
31.6% 
- Difficulty in taking 
medication: 35% 
- Very capable to 
follow treatment 
schedule: 82.5% 
- Trust in treatment: 
87% 
- Trust in doctors: 
55.9% 
- Receive necessary 
help from doctors: 
57.7% 
- Receive support in 
prison (professional, 
other inmates, 
NGOs/others): 43.5% 
NR Very low 
Non-
EU/EEA 
 
PRL 
Altice, 2001 
[72] 
 
USA 
 
Cross-
sectional 
study 
2 minimum- 
and 2 
maximum-
security prisons 
 
n=205 HIV+ 
inmates 
 
April – October 
1996 
Provision of 
ART 
 
Weekly 
packages or 
DOT 
 
On-site HIV 
nurse specialist 
ensures ART 
regimen is 
followed, care 
plan, discharge 
planning 
NR 80.0% 
(164/205) 
accepted 
ART while 
incarcerate
d 
 
Significant 
factors of 
ART 
acceptance: 
- increased 
trust in 
physician 
Significant factors of ART 
adherence5:  
- Having had side effects from 
ART and having expressed 
willingness to stop medications 
if any side effect were to occur 
(OR 0.09, p<0.0001) 
- social isolation (OR 0.08, 
p=0.0005)  
- complexity of ART regimen 
(per step from monotherapy to 
dual nucleoside combination to 
protease inhibitor-containing 
combinations OR 0.33, p=0.01) 
NR Opinions on HIV 
treatment and care: 
- 82% of females and 
65% of males had 
high level of trust in 
their current HIV 
doctor 
- 55% of females and 
72% of males had 
high level of trust in 
current HIV nurse  
- 16% believed that 
taking medications for 
HIV was most 
NR Very low 
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Region  
Source 
Reference, 
country, 
study 
design 
Prison 
setting, 
sample, time 
period  
Description 
model of care 
Eligibility/ 
access 
Acceptanc
e 
Treatment discontinuation/ 
non-adherence 
Attrition Other outcomes of 
interest 
Other 
sub-group 
conside-
rations 
Level of 
evidence 
(OR 1.08, 
p=0.0001)  
- lower with 
increased 
mistrust in 
medication 
(OR 0.30, 
p<0.001) 
essential for remaining 
healthy 
- 83% had high level 
of trust in HIV 
medications 
Non-
EU/EEA 
 
PRL 
Kirkland, 
2002 [73] 
 
USA 
 
Longitudinal 
study 
5 prisons 
 
April 1998 – 
March 2000 
Provision of 
ART (old 
combination 
treatment) 
 
Twice per day 
under DOT or 
at dispensing 
site for 
medication at 
specified times 
twice per day 
 
Change of 
treatment 
possible due to 
toxicity, 
hypersensitivity, 
or virologic 
failure 
Adult ART-
naive with 
HIV-1 
infection (viral 
load >400 
copies/ml, 
CD4 count 
≥50 cells/mm3 
within 14 days 
before study); 
no AIDS, 
various clinical 
reasons, in 
another 
investigational 
drug study, 
non-compliant 
with study 
schedule 
 
NR 11.1% (12/108) withdrew 
prematurely for the following 
reasons (denominator n=108): 
- virologic failure: 3.6% 
- adverse events: 3.7% 
- withdrawal of consent: 1.9% 
- other: 1.9% 
 
The most frequently mentioned 
reasons for missing doses of the 
study medication were (n/N 
NR):  
- problems with dispensing or 
confusion (15.0%) 
- fatigue (13.3%) 
- illness (12.4%) 
 
5.6% lost to 
follow-up (6/108) 
83.3% (90/108) 
completed 24 weeks of 
therapy 
 
NR Very low 
Non-
EU/EEA 
 
PRL 
Meyer, 2014 
[75] 
 
USA 
 
Longitudinal 
study 
CTDOC, an 
integrated 
system of 15 
male and 1 
female facility 
(pre-trial and 
sentenced) 
 
n=882 HIV+ 
inmates on 
ART 
 
March 2005 – 
June 2012 
Provision of 
ART 
 
Managed by 
Infection 
Control nurse 
and provided by 
Infectious 
Diseases 
specialists  
 
DOT or SAT 
(based on 
patient/ 
Confirmed HIV 
seropositive, 
in CTDOC for 
≥90 days, 
prescribed 
ART, ≥2 sets 
of laboratory 
data during 
incarceration 
available 90 
days apart, 
pharmacy data 
available 
 
 
Type of 
medication 
at 
discharge:  
- 74.0% 
SAT  
- 26.0% 
DOT  
 
Type of 
medication 
overall from 
baseline to 
release:  
NR NR NR NR Very low 
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Region  
Source 
Reference, 
country, 
study 
design 
Prison 
setting, 
sample, time 
period  
Description 
model of care 
Eligibility/ 
access 
Acceptanc
e 
Treatment discontinuation/ 
non-adherence 
Attrition Other outcomes of 
interest 
Other 
sub-group 
conside-
rations 
Level of 
evidence 
provider 
preference) 
 
Transitional 
case 
management 
30 days before 
release to 3 
months after 
release; 14 
days of 
medication 
upon release 
- 2.4% 
continuous 
SAT 
- 1.6% 
change 
DOT to SAT 
- 2.5% 
continuous 
DOT 
- 23.5% 
change SAT 
to DOT 
 
Non-
EU/EEA 
 
PRL 
Mostashari, 
1998 [76] 
 
USA 
 
Cross-
sectional 
study 
Connecticut’s 
sole 
correctional 
facility for 
women in 
Niantic 
 
n=102 HIV+ 
female inmates 
 
July 1993 – 
January 1994 
& April 1995 – 
October 1995 
Provision of 
ART 
 
Comprehensive 
care from 
board-certified 
infectious 
disease 
specialist at 
regularly 
scheduled clinic 
visits 
 
Primarily 
through weekly 
package 
dispensation, 
minority 
through DOT 
CD4 counts 
<500 cells/μl 
 
First offered 
ART in prison: 
67% 
 
74.5% 
(76/102) 
accepted 
ART during 
current 
incarceratio
n  
 
Respondent
s were no 
less likely 
to accept 
ART offered 
in prison 
than 
outside (% 
and p NR) 
 
Factors 
significantly 
associated 
with 
acceptance: 
- Belief that 
ART 
extends life 
(AOR 3.2, 
95% CI 
1.2-8.6, 
p≤0.05) 
Factors significantly associated 
with adherence among current 
users: 
- Belief that HIV doctor always 
understands her (AOR 3.0, 95% 
CI 1.1-8.5, p≤0.05) 
- Talks to someone when ‘down’ 
(AOR 3.0, 95% CI 1.1-9.4, 
p≤0.05)  
NR Opinions HIV 
treatment and care (% 
yes, denominator NR): 
* Trust in ART 
- HIV medications 
increase survival 
(efficacy): 71% 
(72/102) 
- People I know who 
took HIV medications 
were not hurt by 
taking them (safety): 
82% (83/102) 
* Trust in healthcare 
system:  
- Healthcare offered to 
all inmates is 
excellent-outstanding: 
29% (30/102) 
- HIV-related 
healthcare I receive is 
excellent-outstanding: 
55% (53/102) 
*Relationship with 
doctor: 
- The HIV doctor 
always listens to me: 
71% (68/102) 
- The HIV doctors 
always understands 
NR Very low 
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Region  
Source 
Reference, 
country, 
study 
design 
Prison 
setting, 
sample, time 
period  
Description 
model of care 
Eligibility/ 
access 
Acceptanc
e 
Treatment discontinuation/ 
non-adherence 
Attrition Other outcomes of 
interest 
Other 
sub-group 
conside-
rations 
Level of 
evidence 
- Belief that 
ART did not 
harm a 
friend (AOR 
4.3, 95% 
CI 1.4-12.9, 
p≤0.01) 
what I am saying: 
59% (56/102) 
EU/EAA 
 
GL 
Manzano, 
2010 [74] 
 
Spain 
 
Cross-
sectional 
Puerto II 
penitentiary 
center (Cadiz) 
 
n=170  
 
2004 – 2009 
Provision of 
ART, not 
further 
specified 
 
 
73.5% 
(125/170) 
received ART 
 
 
 
DOT was 
used in 
29.6% 
(37/125) of 
ART treated 
patients 
- 13.5% 
(5/37) of 
DOT 
receiving 
patients 
self-
administere
d ART after 
some 
months 
during the 
programme 
NR NR Virological failure 
occurred in 8.0% 
(10/125) patients: 
- 4% (5/125) due to 
voluntary interruption 
of ART 
- 2.4% (3/125) due to 
low adherence 
- 1.6% (2/125) due to 
resistance 
development 
NR Conference 
abstract 
HIV treatment in prison – usual care (comparison DOT vs SAT) 
Non-
EU/EEA 
 
PRL 
Wohl, 2003 
[80] 
 
USA 
 
Longitudinal 
study 
6 of 74 NCDOC 
facilities 
 
n=31 HIV+ 
inmates 
(consecutive 
sample) 
- 58% (18/31) 
all ART agents 
via DOT 
- 42% (13/31) 
one ART agent 
via DOT 
 
Provision of 
ART 
 
DOT: patients 
visit medication 
window at 
specified times 
and swallow 
medication in 
sight of nurse 
or officer 
 
SAT: self-
administered 
 
Adults with 
documented 
HIV infection, 
no expected 
release during 
4 study 
months, 
receiving ≥3 
ART of which 
≥1 
administered 
via DOT, and 
having 
received ART 
for ≥3 months 
NR Of 41 subjects enrolled, 8 
(19.5%) discontinued DOT soon 
after study entry 
(study focused on 31 inmates 
with full data) 
 
 
Of 41 subjects 
enrolled, 2 
(4.9%) 
transferred from 
prison during 
study 
(study focused 
on 31 inmates 
with full data) 
68% (n/N NR) would 
prefer to take 
medications on their 
own, rather than 
provided via DOT 
 
8% (n/N NR) expected 
that DOT replaced by 
SAT would lead to an 
increase in number of 
missed doses 
NR Very low 
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Region  
Source 
Reference, 
country, 
study 
design 
Prison 
setting, 
sample, time 
period  
Description 
model of care 
Eligibility/ 
access 
Acceptanc
e 
Treatment discontinuation/ 
non-adherence 
Attrition Other outcomes of 
interest 
Other 
sub-group 
conside-
rations 
Level of 
evidence 
September 
1999 – April 
2000 
Protease 
inhibitors 
always DOT, 
other 
medications 
DOT or SAT 
(according to 
preference of 
clinician) 
 
Medications 
dispensed to 
patient (SAT) or 
staff (DOT) in 
30-day 
allotments; pill 
bottles returned 
at end 30-day 
period and 
refilled 
prior to study 
start 
Intervention: DOT vs SAT 
Non-
EU/EEA 
 
PRL 
White, 2015 
[79] 
 
USA 
 
Pilot of RCT 
3 prison-based 
HIV clinics 
covering 11 of 
the largest 74 
North Caroline 
State prison 
system 
facilities 
 
n=20 DOT vs. 
n=23 SAT 
HIV+ inmates 
(consecutive 
sample) 
 
August 2003 – 
February 2005 
DOT: prison 
staff observed 
and recorded 
each inmate 
ingest all ART 
medications; if 
missed >3 pills, 
they notify it 
 
SAT: monthly 
allotments of all 
ART 
medications 
and signing for 
each 
medication 
bottle; turn in 
any remaining 
medication at 
each monthly 
refill 
Adults with 
documented 
HIV infection, 
on ART, no 
planned inter-
prison 
transfers, 
Karnofsky self-
care score 
≥70, expected 
incarceration 
≥6 months, 
available CD4 
count and HIV 
RNA level 
within 60 days 
of study entry 
 
 
NR DOT:  
- Week 24: 10.0% (2/20) 
withdrew 
- Week 48: 6.3% (1/16) 
discontinued medication, 
reasons NR 
 
SAT:  
- Week 24 and week 48: 0% 
 
DOT: 
- Week 24: 
10.0% (2/20) 
transfer  
- Week 28: 6.3% 
(1/16) release, 
6% (1/16) 
incomplete data, 
6.3% (1/16) 
study ended  
 
SAT: 
- Week 24: 4.3% 
(1/23) release, 
4.3% (1/23) 
hospitalised  
- Week 28: 4.8% 
(1/21) release, 
28.6% (6/21) 
incomplete data, 
45.0% of DOT 
participants (9/20) and 
60.9% of SAT 
participants (14/23) 
opted to receive 
adherence counselling 
approximately 25 and 
26 weeks after 
randomisation 
 
NR Very low 
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Region  
Source 
Reference, 
country, 
study 
design 
Prison 
setting, 
sample, time 
period  
Description 
model of care 
Eligibility/ 
access 
Acceptanc
e 
Treatment discontinuation/ 
non-adherence 
Attrition Other outcomes of 
interest 
Other 
sub-group 
conside-
rations 
Level of 
evidence 
 
Protease 
inhibitors 
always DOT, 
remaining 
medications 
DOT or SAT 
 
After week 24, 
optional 
adherence 
counselling: 2 
motivational 
interview 
sessions 
14.3% (3/21) 
study ended 
ART: antiretroviral therapy, CI: confidence interval, DOT: directly observed therapy, GL: grey literature, HCV: hepatitis C virus, HIV: human immunodeficiency virus, NCDOC: North Carolina 
Department of Corrections, NGO: non-governmental organisation, NR: not reported, OR: odds ratio, PRL: peer-reviewed literature, PWID: People who inject drugs, RCT: randomised 
controlled trial, RNA: ribonucleic acid, RR: relative risk, SAT: self-administered therapy, USA: United States of America 
1 Self-reported adherence as ‘very good’ (proportion indicates ≥95% adherence) 
2 Self-reported adherence according to number of pills not ingested in the last 4 days (proportion indicates ≥95% adherence) 
3 Self-reported non-adherence: answering yes to any qualitative question, >2 dopes missed in last week or >2 days without medication in the last 3 months 
4 Self-reported adherence: 4 ‘no’ answers or 1 ‘yes’ answer (1 day) to 4 questions related to previous 5 days ‘did you miss any pill?’, ‘did you miss any dose of all ART drugs?’, ‘did you take 
any pill out of scheduled time?’ and ‘did you take any pill/all doses without taking into account food requirements?’ 
5Self-reported adherence: taken ≥80% of prescribed doses of medication during 7-day recall period 
Cost-effectiveness 
No cost-effectiveness studies were included on HIV care and treatment. 
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Guidelines 
Six guidelines on HIV treatment were included, of which four were specific to prison setting (two supranational and two national guidelines), and the other two were supranational 
guidelines not specific to prison setting 
Summary of guidelines on HIV treatment in prison settings 
Guideline 
Specific to prison setting – supranational guidelines 
WHO, 2014 [7] There is evidence that ART is feasible in prison settings. One of the problems of ART is resistance to some of the drugs that can be caused by the interruption of 
treatment. It is, therefore, most important to avoid any interruption of treatment when individuals are admitted to pre-trial detention centre or prison, when they are 
transferred from one prison or pre-trial detention centre to another, and when people under treatment are released into the community. In addition, specific attention 
should be paid to adherence to the treatment. 
‘Clinical and laboratory follow-up is needed to monitor the response to treatment. The minimum requirement is to monitor the level of CD4. All ART drugs have numerous 
adverse effects and the treatment requires monitoring for these effects.’ 
Prevention of opportunistic infections 
Prevention of opportunistic infections is part of the treatment for HIV. In view of the higher risk in prison settings, this component is essential to prevent mortality linked 
to HIV. Please refer to the WHO website for detailed information. 
WHO, 2007 [53] 
 
 
Providing access to ART for those in need in the context of prisons, particularly in resource-constrained settings, is a challenge, but it is necessary and feasible. 
Studies have documented that, when prisoners are provided care and access to ART, they respond well. Adherence rates in prisons can be as high or higher than 
among people in the community, but the gains in health status made during the term of incarceration may be lost unless careful discharge planning and links to 
community care are undertaken. 
ART requires clinical and laboratory assessments at baseline and regularly during therapy. Stage of HIV disease, concomitant conditions (TB and pregnancy), concomitant 
medication use (including traditional therapy), body weight and the patient’s readiness for therapy are evaluated at baseline. While on therapy, signs and symptoms 
of potential drug toxicity, body weight, response to therapy and adherence are assessed and, when clinically indicated, depending on the 
antiretroviral drug regimen used, laboratory evaluation is performed. 
Specific to prison setting – national guidelines 
UK Department 
of Health, 2011 
[55] 
All prisoners with HIV will require referral for specialist care. ART is the main type of treatment for HIV.  
The aim of ART is to stop HIV reproducing and allows the immune system to recover from any damage that HIV might have previously caused. 
SIMIT/Ministero 
della Salute 
(Italy), 2016 [57] 
 
ART should be offered to every HIV-infected prisoner, independently of CD4 cell count. Early treatment, apart from individual benefit, could result in better 
linkage to care of the prisoner and the HIV RNA reduction reduces the possibility of HIV transmission during prison stay and after release. 
- Offer ART to HIV-infected prisoners according to national and international guidelines 
- Offer a specific counselling on the efficacy, safety and adherence issues before starting ART 
- Assure the delivery of ART according to the specialist prescription 
- Directly Observed Therapy (DOT) 
- Offer of DAAs treatment for HIV/HCV co-infected prisoners 
- Monitor adherence to ART 
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Other guidelines – supranational guidelines 
WHO, 2016 [58] The use of ART for HIV in key populations should follow the same general principles and recommendations as for all adults. 
HIV treatment adherence can be increased by addressing HIV stigma and discrimination, ensuring the confidentiality of a prisoner’s HIV status, and allowing people in 
prisons and other closed settings access to care and treatment without discrimination by prison officials. 
 
ART initiation 
• As a priority ART should be initiated in all individuals with severe or advanced 
HIV clinical disease (WHO clinical stage 3 or 4) and individuals with CD4 counts 
of ≤350 cells/mm3 (strong recommendation, moderate quality of evidence). 
• ART should be initiated in all individuals with HIV regardless of WHO clinical 
stage (strong recommendation, moderate quality of evidence) (4). 
• ART should be initiated in all individuals with HIV, regardless of WHO clinical 
stage or CD4 count, with priority for the following people (4) : 
– individuals with HIV and active TB disease (strong recommendation, low quality 
of evidence) ; 
– individuals co-infected with HIV and HBV with evidence of severe chronic liver 
disease (strong recommendation, low quality of evidence) ; 
– partners with HIV in serodiscordant couples, to reduce HIV transmission to 
uninfected partners (strong recommendation, high quality of evidence) ; 
– pregnant and breastfeeding women (strong recommendation, moderate quality of evidence) 
 
All pregnant and breastfeeding women living with HIV should initiate triple antiretrovirals (ARV), which should be maintained at least for the duration of risk of mother-to-
child transmission. Women meeting treatment eligibility criteria should continue ART for life (CD4 <500 cells/mm3) (strong recommendation, moderate quality of 
evidence). 
Special consideration should be given to ensuring that pregnant female prisoners have ready access to PMTCT services, as women often face greater barriers to HIV 
testing, counselling, care, and treatment in prison than outside prison. 
European AIDS 
Clinical Society, 
2017 [30] 
 
ART is recommended in all adults with chronic HIV infection, irrespective of CD4 counts 
ART should always be recommended irrespective of the CD4 count, but the lower the CD4 count, the greater the urgency to start ART immediately. 
Genotypic resistance testing is recommended prior to initiation of ART, ideally at the time of HIV diagnosis; otherwise before initiation of ART. 
If ART needs to be initiated before genotypic testing results are available, it is recommended to include a drug with high genetic barrier to resistance in the first-line 
regimen (e.g. a PI/r, PI/c or DTG). Ideally, before starting treatment, the HIV-VL level and CD4-count should be repeated to obtain a baseline to assess subsequent 
response. 
Use of ART should also be recommended with any CD4-count in order to reduce sexual transmission, risk of AIDS event and mother-to-child transmission of HIV (before 
third trimester of pregnancy). 
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Annex 11. Summary tables and guideline summaries – Viral hepatitis 
treatment 
Effectiveness 
Regio
n  
Source 
Reference, 
country, 
study design 
Prison 
setting, 
time 
period 
Description 
model of 
care 
Sample, eligibility, 
comparator 
SVR in ITT population 
Significant non-
biological predictors of 
SVR 
Treatment 
completion 
Linkage 
to care 
post 
release 
Other outcomes 
of interest 
Sub-group 
considerati
ons 
Level of 
evidence 
HCV treatment in prison – usual care 
EU/EEA 
 
PRL 
Strock, 2009 
[112] 
 
Luxembourg 
 
Longitudinal 
study 
Centre 
Pénitentiaire 
de 
Luxembourg 
 
January 
2003 – 
December 
2006 
Provision of 
pegylated IFN 
+ RBV 
 
All HCV+ 
inmates are 
offered a 
specialist 
consultation 
(delay after 
blood tests 2-4 
weeks); liver 
biopsy offered 
but not 
mandatory 
n=268 HCV+ inmates seen by 
specialist consultant to 
evaluate treatment initiation 
- Positive viral load associated 
with elevated ALT, expressed 
in multiples of upper limit of 
normal or an isolated high 
viral load or a positive viral 
load associated with HIV 
infection 
- Decision to start therapy 
finally made in case-by-case 
discussion between 
practitioner and inmate 
 
No comparator 
6 months after end 
treatment: 
- SVR: 52.3% (45/86)  
 
65.1% (56/86) NR NR NR Very low 
EU/EEA 
 
PRL 
De Juan, 
2014 [92] 
 
Spain 
 
Longitudinal 
study 
26 prisons 
throughout 
Spain 
 
October 
2007 – July 
2008 
Provision of 
pegylated IFN 
+ RBV 
n=431 treated HCV+ inmates 
who were treatment-naïve.  
Meeting chronic HCV 
treatment criteria, following 
standard clinic practice (not 
further specified), penalty 
length ≥2 years and no 
possibility of being transferred 
to another institute or any 
other incident that could alter 
treatment persistence 
 
No comparator 
24 weeks after end of 
treatment:  
- SVR: 52.0% (224/431) 
77.5% 
(334/431) 
NR NR NR Very low 
EU/EEA 
 
PRL 
Marco 
Mouriño, 
2010 [102] 
4 prisons in 
Barcelona 
 
Provision of 
pegylated IFN 
+ RBV 
n=162 HCV+ treated inmates 
with history of drug use 
NR 
NR 91.4% 
(148/162) 
NR NR Treatment 
completion 
in those with 
Very low 
TECHNICAL REPORT  Systematic review on the prevention and control of blood-borne viruses in prison settings 
141 
Regio
n  
Source 
Reference, 
country, 
study design 
Prison 
setting, 
time 
period 
Description 
model of 
care 
Sample, eligibility, 
comparator 
SVR in ITT population 
Significant non-
biological predictors of 
SVR 
Treatment 
completion 
Linkage 
to care 
post 
release 
Other outcomes 
of interest 
Sub-group 
considerati
ons 
Level of 
evidence 
Spain 
 
Cross-
sectional 
study 
January 
2003 – 
December 
2007 
IFN 
administered 
by clinical 
nurse, RBV 
delivered to 
inmate weekly 
for SAT 
 
Treatment co-
ordinated with 
Internal Medi-
cine Service of 
a Barcelona 
hospital 
No comparator history IDU: 
88% (n/N 
NR) 
Non-
EU/EEA 
 
PRL 
Bate, 2010 
[89] 
 
Australia 
 
Longitudinal 
study 
Royal 
Adelaide 
Hospital 
Viral 
Hepatitis 
Centre 
(where 
inmates are 
treated) 
 
January 
1997 – 
December 
2008 
Provision of 
standard IFN 
(with or 
without RBV) 
or pegylated 
IFN + RBV 
 
Patients 
management 
was via a 
shared-care 
programme 
between the 
Royal Adelaide 
Hospital Viral 
Hepatitis 
Centre and the 
South 
Australian 
Prison Health 
Service 
n=79 treated HCV+ inmates 
 
To be incarcerated for the 
entire planned duration of 
therapy 
 
No comparator 
6 months after end of 
treatment: 
- SVR: 67.1% (53/79) 
 
NR NR 6.3% re-infected 
after completion 
of treatment 
(5/79; 1 following 
ETR and 4 
following SVR) 
 
NR Very low 
Non-
EU/EEA 
 
PRL 
Farley, 2005 
[93] 
 
Canada 
Longitudinal 
study 
10 federal 
prisons in 
British 
Columbia 
November 
2000 – April 
2003 
Provision of 
standard IFN 
+ RBV 
n=114 HCV+ treated inmates 
 
Positive test result for HCV, 
not taking illicit drugs for ≥6 
months 
6 months after end of 
treatment:  
- SVR: 51.8% (59/114) 
 
Significant non-biological 
predictors of SVR: 
- Self-reported HCV risk 
factors (p<0.01 with IDU 
78.7% (63/80) NR NR NR Very low 
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Regio
n  
Source 
Reference, 
country, 
study design 
Prison 
setting, 
time 
period 
Description 
model of 
care 
Sample, eligibility, 
comparator 
SVR in ITT population 
Significant non-
biological predictors of 
SVR 
Treatment 
completion 
Linkage 
to care 
post 
release 
Other outcomes 
of interest 
Sub-group 
considerati
ons 
Level of 
evidence 
highest % SVR, followed by 
non-IDU, and lowest % SVR 
in those with unknown risk 
factors) 
Non-
EU/EEA 
 
PRL 
Farley, 2005 
[94] 
 
Canada 
 
Longitudinal 
study 
6 federal 
prisons in 
British 
Columbia 
 
March 2001 
– October 
2002 
Provision of 
standard IFN 
+ RBV 
 
Treatment 
supervised by 
a Correctional 
Service 
Canada 
Medical 
Infectious 
Diseases 
Consultant; 
ongoing care 
delivered by 
correctional 
nursing staff 
n=90 treated HCV+ inmates 
 
Screening for history of 
psychiatric diseases; standard 
liver biochemistry, hematology 
profiles, HCV-RNA with 
genotyping and, in the 
majority of cases, liver biopsy 
 
No comparator 
6 months after end of 
treatment: 
- SVR: 47.7% (43/90) 
NR NR All inmates who 
completed 
treatment 
achieved at least 
80% adherence of 
the doses and 
duration of IFN + 
RBV therapy 
(definition 
adherence NR) 
NR Very low 
Non-
EU/EEA  
 
PRL 
Simonović 
Babić, 2016 
[110] 
 
Serbia 
 
Longitudinal 
study 
Special 
Hospital for 
Prisoners in 
Belgrade 
 
2007 – 
2013  
Provision of 
pegylated IFN 
+ RBV 
n=32 treated HCV+ inmates 
who were IFN-naïve 
 
HCV RNA level >100,000 
copies/ml, elevated ALT level 
on ≥2 visits during preceding 
6 months, and a liver biopsy 
performed within 3 years 
before treatment 
 
No comparator 
24 weeks after end of 
treatment:  
- SVR : 62.5% (20/32) 
87.5% (28/32) NR NR NR Very low 
Non-
EU/EEA 
 
PRL 
Boonwaat, 
2010 [90] 
 
Australia 
 
Nested case-
control study 
Correctional 
centres in 
NSW 
 
January 
1996 – 
December 
2005 
Provision of 
standard IFN 
(with or 
without RBV) 
or pegylated 
IFN + RBV 
 
Hepatitis 
clinical service 
- Initiated in 
1995; monthly 
n=185 treated HCV+ inmates 
who attended the hepatitis 
clinics 
 
- During 1995–1998 
individuals should have had a 
fibrosis score of ≥1 and 
current IDUs were ineligible; 
in May 2001, the exclusion of 
IDUs was removed 
- Sentence of ≥6 months 
Timing NR: 
- SVR: 27.6% (51/185) 
NR NR 62.2% (115/185) 
treatment 
adherence 
(definition NR; 
assuming those 
without complete 
follow-up data 
available have 
been non-
adherent); 100% 
adherence among 
NR Very low 
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Regio
n  
Source 
Reference, 
country, 
study design 
Prison 
setting, 
time 
period 
Description 
model of 
care 
Sample, eligibility, 
comparator 
SVR in ITT population 
Significant non-
biological predictors of 
SVR 
Treatment 
completion 
Linkage 
to care 
post 
release 
Other outcomes 
of interest 
Sub-group 
considerati
ons 
Level of 
evidence 
clinic held at 1 
correctional 
centre with 1 
visiting 
specialist 
- By 2005: 12 
additional 
clinics 
- Clinics 
supported by 
public health 
nurses who 
were major 
referral source 
following 
screening  
 
No comparator 
patients with 
complete follow 
up (115/115) 
Non-
EU/EEA  
 
PRL 
Chew, 2009 
[91] 
 
USA 
 
Longitudinal 
study 
Rhode 
Island 
Department 
of 
Corrections 
(both jail 
and prison) 
 
October 
2000 – April 
2004 
Provision of 
pegylated IFN 
+ RBV 
 
On-site 
evaluation and 
management  
n=71 HCV+ inmates who 
started treatment 
 
All patients with detectable 
virus were potential 
candidates, although 
treatment was not generally 
recommended for earlier 
stages of disease; patients 
with addiction history were 
counselled and referred to 
addiction treatment 
programmes and those with 
psychiatric 
disorders/depression were 
referred to on-site psychiatrist 
for evaluation and clearance 
and were closely monitored 
(both groups were eligible 
under these circumstances); 
biopsy was recommended but 
not required to initiate 
treatment 
 
No comparator 
6 months after end of 
treatment:  
- SVR: 28.2% (20/71) 
46.5% (33/71) NR NR NR Very low 
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Regio
n  
Source 
Reference, 
country, 
study design 
Prison 
setting, 
time 
period 
Description 
model of 
care 
Sample, eligibility, 
comparator 
SVR in ITT population 
Significant non-
biological predictors of 
SVR 
Treatment 
completion 
Linkage 
to care 
post 
release 
Other outcomes 
of interest 
Sub-group 
considerati
ons 
Level of 
evidence 
EU/EAA 
 
GL 
Marco, 2010 
[99] 
 
Spain 
 
Retro-
spective 
study 
Correctional 
facilities in 
Catalunya 
 
2002 – 
2008 
Provision of 
pegylated 
IFN+RBV 
n=513 inmates with HCV 
infection 
 
NR 
 
No comparator 
24 weeks after end of 
treatment: 
- SVR: 65.9%  
NR NR NR NR Conference 
abstract 
EU/EAA 
 
GL 
Pallás, 2010 
[105] 
 
Spain 
 
Cross-
sectional 
study 
Penitentiary 
center El 
Dueso 
(Cantabria) 
 
2003 – 
2010 
 
Provision of 
pegylated 
IFN+RBV 
 
 
n=41 inmates with HCV 
infection receiving methadone 
 
NR 
 
No comparator 
NR 80.5% (33/41) NR NR Only 
inmates on 
methadone 
were 
included 
Conferenc
e abstract 
HCV treatment in prison – usual care (fully or partly DOT) 
EU/EEA 
 
PRL 
Iacomi, 
2013 [96] 
 
Italy 
 
Longitudinal 
study 
5 
correctional 
facilities in 
Rome 
 
January 
2008 – 
December 
2009 
Provision of 
pegylated IFN 
+ RBV 
 
Administration 
of IFN via 
DOT, RBV via 
SAT 
 
Specialist 
medical 
consultations 
in local 
hospital 
n=50 inmates HCV+ at 
entry who were sent for 
consultation to National 
Institute for Infectious 
Diseases 
 
Liver biopsy consistent with 
chronic hepatitis and 
fibrosis stage F1/4, alcohol 
or drug abusers on 
rehabilitation/ OST 
 
No comparator 
24 weeks after end treatment: 
- SVR: 50.0% (25/50) 
60.0% (30/50) 
 
NR NR Only PWID 
on rehabili-
tation/stable 
OST were 
included 
(68% of the 
participants 
had history 
of IDU), IDU 
was not 
associated 
with 
treatment 
outcome 
Very low 
Non-
EU/EEA 
 
PRL 
Allen, 2003 
[87] 
 
USA 
 
Longitudinal 
study 
Rhode 
Island 
Department 
of 
Corrections 
(both jail 
and prison) 
 
1997 – 
2001  
Provision of 
standard IFN 
+ RBV 
 
Therapy was 
DOT, with 
nurses 
administering 
all injections 
and some RBV 
doses; SAT 
n=90 treated HCV+ 
inmates  
 
Sentences of ≥15 months; 
patients with addiction 
history strongly encouraged 
to enrol in prison substance 
abuse treatment 
programmes (for some a 
documented 1-year sobriety 
period was required); 
6 months after end of 
treatment: 
- SVR: 28.9% (26/90) 
12 months after end of 
treatment: 
- SVR: 18.9% (17/90) 
45.6% (41/90) NR Adherence to 
treatment >90% 
NR Very low 
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Regio
n  
Source 
Reference, 
country, 
study design 
Prison 
setting, 
time 
period 
Description 
model of 
care 
Sample, eligibility, 
comparator 
SVR in ITT population 
Significant non-
biological predictors of 
SVR 
Treatment 
completion 
Linkage 
to care 
post 
release 
Other outcomes 
of interest 
Sub-group 
considerati
ons 
Level of 
evidence 
RBV dosing 
was monitored 
by random 
spot checks of 
medication 
kept by the 
patient 
during course of study the 
requirement of liver biopsy 
was lifted, but still 
recommended 
No comparator 
Non-
EU/EEA 
 
PRL 
Maru, 2008 
[103] 
 
USA 
 
Longitudinal 
study 
20 facilities 
of the 
Connecticut 
Department 
of 
Corrections 
 
September 
2002 – 
October 
2006 
Provision of 
pegylated IFN 
+ RBV 
 
Primary care 
provider refers 
eligible 
inmates to 
infectious 
diseases 
specialist; 
treatment 
initiated in 
conjunction 
with an 
infectious 
disease nurse 
 
DOT 
n=68 treated HCV+ 
inmates who were 
treatment-naïve  
Referred to infectious 
diseases specialist if 
persistently elevated 
transaminase levels for ≥6 
months; eligible for 
treatment if fulfils criteria1 
including laboratory testing 
and liver biopsy (for 
genotypes 1/4) 
No comparator 
6 months after end of 
treatment: 
- SVR: 47.1% (32/68) 
69.1% (47/68) NR NR NR Very low 
Non-
EU/EEA 
 
PRL 
Sterling, 
2004 [111] 
 
USA 
 
Longitudinal 
study 
Virginia 
Department 
of 
Corrections 
 
March 1998 
– October 
2000 
Provision of 
standard IFN 
+ RBV 
 
Telemedicine, 
using real-time 
video 
conferencing 
between 
correctional 
facilities and 
Virginia 
University, 
was utilised 
for all 
treatment 
visits 
n=59 treated HCV+ 
inmates (out of consecutive 
sample of evaluated 
inmates) 
HCV-RNA positive and 
negative for HBV surface 
antigen and HIV antibodies; 
patients with ≥2 years of 
incarceration without 
contraindication for therapy, 
if they had evidence of 
histologically significant 
HCV as defined by a total 
HAI ≥5 or the presence of 
any degree of fibrosis 
(score ≥1); all HCV+ 
receive liver biopsy; 
24 weeks after end of 
treatment: 
- SVR: 35.6% (21/59) 
98.3% (58/59) NR NR NR Very low 
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Regio
n  
Source 
Reference, 
country, 
study design 
Prison 
setting, 
time 
period 
Description 
model of 
care 
Sample, eligibility, 
comparator 
SVR in ITT population 
Significant non-
biological predictors of 
SVR 
Treatment 
completion 
Linkage 
to care 
post 
release 
Other outcomes 
of interest 
Sub-group 
considerati
ons 
Level of 
evidence 
 
DOT (by 
prison nurses) 
patients with anaemia, 
renal failure, HIV infection 
or significant co-morbid or 
psychiatric diseases were 
not eligible; final decision 
on receiving therapy was 
left to the correctional 
facility 
No comparator 
HCV treatment in prison – provision of first generation DAAs 
EU/EAA 
 
GL 
Marco, 2014 
[100] 
 
Spain 
 
Retrospec-
tive study 
7 
correctional 
institutions 
in Spain 
 
2013 
Provision of 
Telaprevir + 
pegylated IFN 
+ RBV 
n=24 HCV infected inmates 
NR 
No comparator 
62.5% (15/24) eRVR (time 
period NR) 
 
 
 87.5% (21/24) 
 
 
NR Virological failure: 
9.5% (2/21)  
NR Conferenc
e abstract 
EU/EAA 
 
GL 
Marco, 2014 
[101] 
 
Spain 
 
Retrospec-
tive study 
Correctional 
facilities in 
Catalunya 
 
January 
2013 – June 
2014 
Provision of 
Telaprevir or 
Boceprevir + 
pegylated IFN 
+ RBV  
n=32 HCV infected inmates 
- n=27 received Telaprevir  
- n=5 received Boceprevir 
No comparator 
Time period NR: 
85.7% (9/11) as treated 
analysis 
NR NR NR 
 
NR Conferenc
e abstract 
HCV treatment in prison – provision of second generation DAAs 
EU/EAA 
 
GL 
Touzòn-
Lòpez, 2016 
[113] 
 
Spain 
Longitudinal 
study 
5 
correctional 
facilities in 
Catalunya 
 
October 
2014 – April 
2016 
Provision of  
DAA s 
 
n=207 inmates with HCV  
- 18 received pegylated IFN 
+DAA and  
- 189 DAA without 
pegylated IFN 
-58.8% of patients also 
received RBV 
NR. No comparator. 
12 weeks after end of 
treatment: 
- SVR: 91.1% (123/135)  
 
95.5 % 
(199/207)  
 
NR 5.2% (7/135) 
failures without 
SVR at 12 weeks 
post-treatment 
There were 
more 
failures in 
genotype 3 
but this 
difference 
was not 
significant 
Conference 
abstract 
EU/EAA 
 
GL 
Jimènez-
Galàn, 2016 
[97] 
 
Spain 
 
1 
correctional 
facility in 
Madrid 
 
Provision of 
DAAs 
n=50 inmates with HCV 
- 38 
(Sofosbuvir+Ledipasvir) 
- 28 with and 10 without 
RBV 
- 7 paritaprevir/ritonavir/ 
ombitasvir/dasabuvir + RBV 
12 weeks after end of 
treatment: 
- SVR: 92% 
 
 
 
NR NR Virological failure: 
2 (4%)  
 
Significant fibrosis 
reduction in 32 
evaluable patients 
NR 
 
Conference 
abstract 
TECHNICAL REPORT  Systematic review on the prevention and control of blood-borne viruses in prison settings 
147 
Regio
n  
Source 
Reference, 
country, 
study design 
Prison 
setting, 
time 
period 
Description 
model of 
care 
Sample, eligibility, 
comparator 
SVR in ITT population 
Significant non-
biological predictors of 
SVR 
Treatment 
completion 
Linkage 
to care 
post 
release 
Other outcomes 
of interest 
Sub-group 
considerati
ons 
Level of 
evidence 
Longitudina, 
retrospective 
study 
February 
2015 – June 
2016 
 
 
 
NR 
No comparator 
EU/EAA 
 
GL 
Mìnguez-
Gallego 
2016 [104] 
 
Spain 
 
Longitudinal 
retrospective 
study  
 
1 
correctional 
institution 
(Albocasser, 
Castellòn) 
 
2015 – 
2016 
Provision of 
DAAs 
n=40 inmates with HCV 
infection 
 
NR 
 
No comparator 
Time period NR: 
- SVR: 85.0% (34/40) 
90.0% (36/40) NR Virological failure: 
2 (5%) 
 
 
HIV/HCV no 
difference in 
efficacy 
(93.7% vs. 
95% at on 
treatment 
analysis) 
Conferenc
e abstract 
EU/EAA 
 
GL 
Fernàndez-
Gonzàlez, 
2016 [95] 
 
Spain 
 
Prospective 
longitudinal 
study 
Spanish 
correctional 
facilities 
 
NR 
Provision of 
DAAs 
n=83 inmates with HCV 
infection 
- 92.8% (77/83) received 
RBV 
 
NR 
 
No comparator 
 
12 weeks after end of 
treatment: 
- SVR: 94.7 % (36/38) 
 
 
NR NR NR 
 
NR Conferenc
e abstract 
EU/EAA 
 
GL 
Pontali, 
2017 [106] 
 
Italy 
 
Prospective 
longitudinal 
study 
25 Italian 
correctional 
facilities 
 
May 2015 – 
October 
2016 
Provision of 
DAAs 
n=142 inmates with HCV 
infection 
- Sofosbuvir/daclatasvir/ 
RBV= 25.4% 
- Sofodbuvir/ledipasvir/RBV 
21.1% 
- Sofosbuvir/ledipasvir  
14.1% 
 
NR 
No comparator 
12 weeks after end of 
treatment: 
- SVR: 90% 
 
 
 
 
94.4% 
(134/142) 
 
 
NR NR 
 
 
 
 
 
NR Conferenc
e abstract 
EU/EAA 
 
GL 
Michel, 2017 
[114] 
 
France 
 
Prospective 
study 
Ile de 
France 
prisons, 
 
October 
2016-April 
2017 
Privsion of 
DAAs 
45 patients with HCV 
infection (38% newly 
diagnosed, 62% already 
known to be HCV infected) 
 
NR 
 
No comparator 
NR 69.5% (16/23), 
of these, 68.7%  
(11/16) in 
prison  
 
 
31.3% 
(5/16) 
complete
d 
treatment 
outside of 
prison  
 
In 30.4% (7/23) 
treatment still 
ongoing 
 Unpublish
ed 
research 
report 
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Regio
n  
Source 
Reference, 
country, 
study design 
Prison 
setting, 
time 
period 
Description 
model of 
care 
Sample, eligibility, 
comparator 
SVR in ITT population 
Significant non-
biological predictors of 
SVR 
Treatment 
completion 
Linkage 
to care 
post 
release 
Other outcomes 
of interest 
Sub-group 
considerati
ons 
Level of 
evidence 
EU/EAA 
 
GL 
Meroueh, 
2017 [115] 
 
France 
 
Prospective 
study 
Villeneuve 
Les 
Maguleon 
prison 
 
2010-2016 
Provision of 
pegylated IFN 
+ RBV (2010-
2013) 
 
Provision of 
DAAs 
(2014-206) 
287 patiens with HCV 
infection 
 
After 2016 all HCV infected 
prisoners regardless of 
fibrosis 
No comparator 
62% (29/47) in 2010 
65% (19/29) in 2011 
65% (24/37) in 2012 
68% (22/33) in 2013 
90% (48/53) in 2014 
98% (58/59) in 2015 
98% (28/29) in 2016 
 
NR NR NR NR Unpublish
ed 
research 
report 
HCV treatment in prison vs. community – usual care 
EU/EEA 
 
PRL 
Aspinall, 
2016 [88] 
 
Scotland 
 
Matched 
cohort study 
Health 
Boards with 
compre-
hensive 
data on 
prison and 
community 
treatment 
initiations  
 
2 June 2009 
– 31 May 
2012 
Provision of 
pegylated IFN 
+ RBV with or 
without a 
protease 
inhibitor 
Inmates and community 
patients who initiated HCV 
treatment at NHS clinics in 
Scotland: n=291 inmates/ 
n=1137 community patients 
(part 1); n=200 inmates 
(part 2) 
 
- Part 1: treatment-naïve 
adults aged ≥20 years 
infected with GT 1-4, 
treated with pegylated IFN 
+ RBV with or without a 
protease inhibitor, initiated 
treatment after 1 June 2009 
and before 1 December 
2011 (GT 1 & 4) and 1 June 
2012 (GT 2 & 3) 
- Part 2: inclusion criteria 
Part 1 & initiated treatment 
in prisons in Forth Valley, 
Greater Glasgow and Clyde, 
or Lothian 
- Part 1: inmates vs. 
community patients 
- Part 2: inmates treated 
fully in prisons (n=125) vs. 
inmates transferred but not 
released (n=37) vs. inmates 
released during treatment 
(n=38) 
Part 1 
24 weeks after end treatment: 
- SVR in inmates: 60.5% 
(176/291; 95% CI 55-66%) 
- SVR in community: 62.9% 
(715/1137; 95% CI 60-66%) 
Part 2 
24 weeks after end treatment: 
- SVR in inmates treated in 
prison: 73.6% (92/125; 95% 
CI 65-81%) 
- SVR in transferred inmates: 
59.4% (22/37; 95% CI 42-
75%) 
- SVR in released inmates: 
44.7% (17/38; 95% CI 29-
62%) for those released during 
treatment 
Significant non-biological 
predictors of SVR:  
Part 1: NR 
Part 2 
- Being released from prison 
during treatment (OR 0.33; 
95% CI 0.15-0.71; p<0.01), 
but not transfer during 
treatment (p=0.18) 
Part 1 
NR 
 
Part 2 
73.5% 
(147/200; 95% 
CI 67-80%)  
NR 
 
Part 1 
- Achieving SVR 
not significantly 
associated with 
prisoner status at 
treatment 
initiation in ITT 
analysis (OR 0.87, 
95% CI 0.67-
1.15; p=0.33); 
nor in PP analysis 
(OR 1.18, 95% CI 
0.76-1.83, 
p=0.46) 
- The same 
findings were 
observed when 
stratifying by 
genotype 
 
Part 2 
NR 
 
NR Moderate  
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Regio
n  
Source 
Reference, 
country, 
study design 
Prison 
setting, 
time 
period 
Description 
model of 
care 
Sample, eligibility, 
comparator 
SVR in ITT population 
Significant non-
biological predictors of 
SVR 
Treatment 
completion 
Linkage 
to care 
post 
release 
Other outcomes 
of interest 
Sub-group 
considerati
ons 
Level of 
evidence 
Non- 
EU/EEA 
 
PRL 
Rice, 2012 
[107] 
 
USA 
 
Comparative 
study 
University 
of 
Wisconsin 
Hepatology 
or 
Infectious 
Diseases 
clinic 
 
January 
2002 – 
December 
2007 
 
Provision of 
pegylated IFN 
+ RBV 
n=234 HCV-infected 
inmates and n=319 
community patients 
- Incarcerated patients: 
expected release date after 
proposed treatment 
completion data 
- Patients with genotype 
1/4: at least Metavir stage 2 
fibrosis on liver biopsy, 
medically/psychiatrically 
appropriate for treatment 
- All medically and 
psychiatrically appropriate 
patients with genotypes 2/3 
eligible for treatment 
without a staging biopsy 
 
Inmates vs. community 
patients 
- SVR in incarcerated and non-
incarcerated patients: 42.9% 
(97/226) vs. 38.0% (115/303) 
(p=0.282) (reported for the 
per-protocol population only) 
- When stratifying by 
genotype: SVR for genotype 1 
(30.4% vs. 28.2%; p=0.644); 
SVR for genotypes 2 and 3 
virus (61.3% vs. 64.4%; 
p=0.749) 
 
- Inmates: 
75.0% 
(174/234)  
- Community 
patients: 68.6%  
p=0.124 
 
NR Incarcerated 
patients were as 
likely to be 
treated for HCV 
and as likely to 
achieve an SVR as 
non-incarcerated 
patients (25.0% 
vs. 22.1%; 
p=0.304) 
Incarcerated 
patients 
were more 
likely to be 
younger at 
time of 
treatment 
initiation 
(p<0001), 
and to have 
a history of 
previous 
alcohol or 
IDU 
(p<0.001) 
Low 
Intervention: DOT vs SAT 
EU/EEA 
 
PRL 
Saiz de la 
Hoya, 2014 
[109] 
 
Spain 
 
RCT 
Healthcare 
centres of 
25 prisons 
in Spain 
 
 
July 2006 – 
April 2007 
Provision of 
pegylated IFN 
+ RBV 
 
DOT: RBV 
given by study 
nurse on on-
going basis (1 
or 3 
times/week) 
 
SAT: RBV was 
self-
administered 
n=109 DOT vs. n=135 SAT 
treatment-naive HCV+ 
inmates 
 
Adults with child Pugh score 
of 5, cirrhotic patients 
should not have 
hepatocellular carcinoma 
and should have alpha-
fetoprotein level <100 
ng/ml; exclusion criteria2 
 
DOT vs. SAT 
24 weeks after end of 
treatment: 
- Overall SVR: 63.5% 
(155/244) 
- SVR in DOT: 60.6% (66/109; 
95% CI, 51.17-69.22) 
- SVR in SAT: 65.9% (89/135, 
95% CI, 57.59-73.38)  
- SVR in DOT vs. SAT: RR 
0.918, 95% CI 0.746-1.125 
 
Significant non-biological 
predictors of SVR: 
- No HIV co-infection and low 
viral load (p<0.05) 
83.0% 
(186/224) 
NR Mean proportion 
administered 
doses (n/N NR)3: 
- Overall: 97.9% 
(SD 6.5) 
- DOT: 97.6% (SD 
8.1)  
- SAT: 98.2% (SD 
4.9) 
- DOT vs. SAT 
p=0.117 
 
Mean treatment 
continuance 
proportion (n/N 
NR)4: 
- Overall: 82.9% 
(SD 30.5) 
- DOT: 81.3% (SD 
29.6) 
NR Very low 
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Regio
n  
Source 
Reference, 
country, 
study design 
Prison 
setting, 
time 
period 
Description 
model of 
care 
Sample, eligibility, 
comparator 
SVR in ITT population 
Significant non-
biological predictors of 
SVR 
Treatment 
completion 
Linkage 
to care 
post 
release 
Other outcomes 
of interest 
Sub-group 
considerati
ons 
Level of 
evidence 
- SAT: 84.2% (SD 
31.3) 
- DOT vs. SAT 
p=0.091 
EU/EEA 
 
GL 
Saiz de la 
Hoya, 2010 
[108] 
 
Spain 
 
Prospective, 
randomised 
study 
3 
correctional 
facilities in 
Spain 
 
July 2006 –
September 
2008 
Provision of 
pegylated 
IFN+RBV 
 
n=244 inmates with HCV 
infection 
 
NR 
 
DOT-RBV vs. SAT-RBV 
(both plus DOT pegylated-
IFN) 
24 weeks after end of 
treatment:  
- SVR: 62.2% 
 
58.5% in DOT arm vs 
65.9% in SAT arm; p=0.27 
 
No difference in SVR between 
PWID vs non-injecting inmates; 
HIV co-infected showed a 
lower response rate (46.2% vs 
66.7%) 
79.8% NR NR NR Conferenc
e abstract 
Intervention: nurse-led and specialist-supported telemedicine model 
Non-
EU/EEA 
 
PRL 
 
 
 
 
Lloyd, 2013 
[98] 
 
Australia 
 
Longitudinal 
study 
3 
correctional 
centres 
 
January 
2009 – 
December 
2010 
Provision of 
therapy, not 
specified 
 
- 3 nurses 
followed 
extensive HCV 
training 
- Nurses 
independently 
triaged 
inmates, 
following 
blood 
investigations, 
structured, 
hepatitis- and 
IDU-focused 
history and 
physical 
examination, 
and further 
investigations 
(if necessary), 
taking into 
n=108 treated inmates 
(out of 391 inmates 
consecutively assessed by 
nurse) 
 
NR 
 
No comparator 
24 weeks after end of 
treatment: 
- SVR: 43.5% (47/108) 
69.4% (75/108) NR NR NR Very low 
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Regio
n  
Source 
Reference, 
country, 
study design 
Prison 
setting, 
time 
period 
Description 
model of 
care 
Sample, eligibility, 
comparator 
SVR in ITT population 
Significant non-
biological predictors of 
SVR 
Treatment 
completion 
Linkage 
to care 
post 
release 
Other outcomes 
of interest 
Sub-group 
considerati
ons 
Level of 
evidence 
account 
comorbidities, 
motivation, 
psychosocial 
supports, and 
risk of adverse 
events 
- Specialist 
prescribed 
treatment 
after 
consultation 
with nurse, via 
a discussion 
only (A), 
teleconference 
(B), or face-
to-face 
assessment 
(C) 
ALT: alanine aminotransferase, CI: confidence interval, DAA: direct-acting antiviral, DOT: directly observed therapy, eRVR: extended rapid virologic response - HCV RNA not detected at week 4 and 12, ETR: end 
of treatment response, GL: grey literature, GT: genotype, HCV: hepatitis C virus, HIV: human immunodeficiency virus, IDU: injecting drug use, IFN: interferon, ITT: intention-to-treat, NHS: National Health 
Service, NSW: New South Wales, OR: odds ratio, OST: opioid substitution therapy, PP: per-protocol, PRL: peer-reviewed literature, RBV: ribavirin, RCT: randomised controlled trial, RR: relative risk, SAT: self-
administered therapy, SVR: sustained viral response, USA: United States of America 
1 Detectable HCV RNA, persistent elevations in hepatic transaminase levels ≥6 months, not treated with IFN therapy before, no evidence of another aetiology of chronic liver disease, stability of other chronic 
illnesses, no evidence of decompensated cirrhosis or chronic renal insufficiency, pre-treatment mental health screening with evidence of stable mental health, with findings confirmed by a psychiatrist, 
sufficiently long prison sentence to obtain liver biopsy (~3 months) and complete treatment while incarcerated (9 months for genotypes 2/3, 15 months for all others), willing to defer any early-release 
programmes until treatment is fully completed, willing to be transferred to and remain at a correctional facility where 24-h nursing is available, willing to sign a treatment contract regarding adherence with 
treatment and recommendations by the infectious diseases specialist, HIV-HCV-coinfected patients are eligible for treatment, chemical dependence is assessed but enrolment in a treatment programme not 
required 
2 Patients who had undergone any systemic antiviral, antineoplastic or immunomodulator therapy in the 6 months prior to the 1st dose of study treatment or any investigational therapy in the 6 weeks prior to 
the 1st dose of study treatment; patients with the following comorbidities: hepatic disease of an etiology other than HCV; positive IgM anti-HAV test; decompensated hepatic disease (Child-Pugh >6); prior 
transplantation with a current functional graft; high risk of aneamia, coronary disease or cerebrovascular disease that, according to investigator criteria, were unlikely to tolerate an acute hemoglobin reduction 
(down to 4 g/dL); history of severe cardiac disease, thyroid disorder or abnormalities in thyroid function tests, unless it could be controlled with conventional treatment; and other severe comorbid conditions, 
such as chronic respiratory disease, immunological disease, severe retinopathy, severe psychiatric disorders or convulsive disorder; pregnant or lactating women, and men whose partner was pregnant; patients 
with neutropenia (neutrophil count <1500 cells/mm3), thrombocytopenia (platelet count <90,000 cells/mm3), anaemia (hemoglobin concentration <12 g/dL) or serum creatinine level >1.5 times the upper limit 
of normal; patients with a history of drug use (including alcohol) in the previous year, except those who were already on methadone maintenance programmes 
3 Treatment compliance: number of doses that were actually administered divided by the number of doses that were prescribed 
4 Treatment continuance: the number of days that the treatment was actually administered divided by the number of days that the treatment was prescribed 
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Acceptability/barriers 
Region  
Source 
Reference, 
country, 
study 
design 
Prison 
setting, 
sample, time 
period  
Description 
model of 
care 
Eligibility/access Treatment 
discontinuation/ non-
adherence 
Attrition Other outcomes 
of interest 
Sub-group 
conside-
rations 
Level of 
evidence 
HCV treatment in prison – usual care 
EU/EEA 
 
PRL 
Strock, 2009 
[112] 
 
Luxembourg 
 
Longitudinal 
study 
Centre 
Pénitentiaire de 
Luxembourg 
 
n=268 HCV+ 
inmates seen 
by specialist 
consultant to 
evaluate 
treatment 
initiation 
 
January 2003 – 
December 2006 
Provision of 
pegylated IFN 
+ RBV 
 
All HCV+ 
inmates are 
offered a 
specialist 
consultation 
(delay after 
blood tests 2-
4 weeks) 
- Positive viral load associated 
with elevated ALT, expressed 
in multiples of upper limit of 
normal or an isolated high 
viral load or a positive viral 
load associated with HIV 
infection 
- Decision to start therapy 
finally made in case-by-case 
discussion between 
practitioner and inmate 
 
32.1% (86/268) of evaluated 
HCV+ inmates started 
treatment  
 
Reasons not initiating 
treatment (n=182): 
- Negative PCR results: 31.3% 
- Deceased: 0.5% 
- Medical contraindication: 
3.3% 
- Spontaneous viral clearance: 
2.7% 
- Mild disease on liver biopsy: 
6.0% 
- Normal transaminases: 
15.9% 
- Released while in work-up: 
13.7% 
- Still in work-up/waiting for 
biopsy: 6.6% 
- Refusal of therapy: 8.2% 
- Wanting to wait until after 
release: 11.5%  
In genotype 2/3 group, 50% 
started therapy vs. 33% with 
other genotypes (p=0.01) 
16.3% (14/86) inmates 
stopped therapy early  
 
Reasons discontinuation 
(n=14): 
- non-compliance: 35.7% 
- non-responding: 21.4% 
- side-effects: 42.9% 
 
18.6% (16/86) 
inmates were 
released from 
prison while 
under therapy 
 
6 months after 
end of treatment: 
- 1.2% (1/86) 
refused blood 
test  
- 31.4% (27/86) 
lost to follow-up 
6 months after 
the end of 
therapy 
NR NR Very low 
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Region  
Source 
Reference, 
country, 
study 
design 
Prison 
setting, 
sample, time 
period  
Description 
model of 
care 
Eligibility/access Treatment 
discontinuation/ non-
adherence 
Attrition Other outcomes 
of interest 
Sub-group 
conside-
rations 
Level of 
evidence 
(due to waiting period for 
biopsy in non-genotype 2/3; 
other reasons for not treating 
were similar in both groups) 
EU/EEA 
 
PRL 
De Juan, 
2011 [116] 
 
Spain 
 
Cross-
sectional 
study 
26 prisons 
throughout 
Spain 
 
n=195 
untreated 
HCV+ inmates 
 
October 2007 – 
July 2008 
Provision of 
pegylated IFN 
+ RBV 
Meeting chronic HCV 
treatment criteria, following 
standard clinic practice (not 
further specified) 
 
Reasons not initiating 
treatment (n=195 for main 
group reasons*): 
* Medical reasons: 30.8% 
- Immunological status: 35.0% 
- Psychiatric/ neurological: 
28.3% 
- Other pathology: 21.7% 
- Mild fibrosis/ low viral load: 
8.3% 
- Drug use: 5.0% 
- Pregnancy: 1.7% 
* Patient reasons: 41.0% 
- Lack of motivation/ 
awareness only: 47.5% 
- Fear of adverse events only: 
18.8% 
- Former 2 combined: 20.0% 
- Influence by relatives/ 
others: 6.3% 
- Lack of motivation/ 
awareness + influence by 
relatives/others: 3.8% 
- Lack of confidence in health 
professionals: 2.5% 
- Other: 1.3% 
* Prison reasons: 24.6% 
- Impending release/transfer 
to another centre: 64.6% 
- Lack of material resources: 
2.1% 
- Delayed diagnostic tests: 
33.3%  
NR NR NR NR Very low 
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Region  
Source 
Reference, 
country, 
study 
design 
Prison 
setting, 
sample, time 
period  
Description 
model of 
care 
Eligibility/access Treatment 
discontinuation/ non-
adherence 
Attrition Other outcomes 
of interest 
Sub-group 
conside-
rations 
Level of 
evidence 
* Patient and prison reasons: 
3.6% 
EU/EEA 
 
PRL 
De Juan, 
2014 [92] 
 
Spain 
 
Longitudinal 
study 
26 prisons 
throughout 
Spain 
 
n=431 treated 
HCV+ inmates 
 
October 2007 – 
July 2008 
Provision of 
pegylated IFN 
+ RBV 
Meeting chronic HCV 
treatment criteria, following 
standard clinic practice (not 
further specified)  
 
68.8% (431/626) started 
treatment 
22.5% (97/431) discontinued 
treatment 
- Most treatment discontinua-
tions occurred in the 1st 
trimester of treatment 
(p<0.05) 
 
Reasons discontinuation (n=97 
for main group reasons*): 
* Medical reasons: 20.6% 
- Adverse events: 75.0% 
- Drug-addiction relapse: 
10.0%  
- Other: 15.0% 
* Patient reasons: 37.1% 
- Lack of motivation/ 
awareness only: 41.7% 
- Fear of adverse events only: 
11.1% 
- Former 2 combined: 41.7% 
- Influence by relatives/ 
others: 5.6% 
* Other causes: 42.3% 
- Release from prison: 85.4% 
- Transfer to another prison: 
14.4% 
 
Release from prison was the 
most frequent cause for 
treatment discontinuation for 
all trimesters except the 1st, 
during which the main cause 
was lack of motivation 
NR NR NR Very low 
EU/EEA 
 
PRL 
Marco 
Mouriño, 
2010 [102] 
 
Spain 
 
4 prisons in 
Barcelona 
 
n=162 HCV+ 
treated inmates 
with history of 
drug use 
 
Provision of 
pegylated IFN 
+ RBV 
 
IFN 
administered 
by clinical 
nurse, RBV 
NR 5.4% discontinued treatment 
(9/168) 
 
Reasons discontinuation 
(n=9): 
- Voluntary withdrawal: 33.3% 
- Adverse effects: 33.3% 
- Lack of response: 33.3% 
3.0% was 
released or 
transferred 
during 
treatments 
(5/168) 
NR NR Very low 
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Region  
Source 
Reference, 
country, 
study 
design 
Prison 
setting, 
sample, time 
period  
Description 
model of 
care 
Eligibility/access Treatment 
discontinuation/ non-
adherence 
Attrition Other outcomes 
of interest 
Sub-group 
conside-
rations 
Level of 
evidence 
Cross-
sectional 
study 
January 2003 – 
December 2007 
delivered to 
inmate weekly 
for SAT 
 
Treatment co-
ordinated with 
Internal Medi-
cine Service of 
a Barcelona 
hospital 
 
Predictors discontinuation 
(including those 
released/transferred): 
- IDU in and out of prison: OR 
10.39, 95% CI 1.93-55.88, 
p=0.006 
Non-
EU/EEA 
 
PRL 
Bate, 2010 
[89] 
 
Australia 
 
Longitudinal 
study 
Department of 
Gastro-
enterology and 
Hepatology of 
the Royal 
Adelaide 
Hospital 
 
n=86 treated 
HCV+ inmates 
 
January 1997 – 
December 2008 
Provision of 
standard IFN 
(with or 
without RBV) 
or pegylated 
IFN + RBV 
To be incarcerated for the 
entire planned duration of 
therapy 
1.3% (1/79) discontinued 
therapy because of adverse 
events 
 
 
5.8% (5/86) 
LTFU before 6 
months after end 
of treatment 
NR NR Very low 
Non-
EU/EEA 
 
PRL 
Farley, 2005 
[93] 
 
Canada 
 
Longitudinal 
study 
10 federal 
prisons in 
British 
Columbia 
 
n=114 HCV+ 
treated inmates 
 
November 
2000 – April 
2003 
Provision of 
standard IFN 
+ RBV 
Positive test result for HCV, 
not taking illicit drugs for ≥6 
months 
14.9% (17/114) discontinued 
therapy - mostly because of 
side effects or failure to 
achieve early response 
29.8% (34/114) 
had no treatment 
outcome data – 
reasons NR 
NR NR Very low 
Non-
EU/EEA 
 
PRL 
Farley, 2005 
[94] 
 
Canada 
 
Longitudinal 
study 
6 federal 
prisons in 
British 
Columbia 
 
n=214 HCV+ 
inmates 
evaluated for 
treatment 
Provision of 
standard IFN 
+ RBV 
 
Treatment 
supervised by 
a Correctional 
Service 
Canada 
42.1% (90/214) eligible for 
treatment 
 
Reasons not eligible (n=124): 
- Undetectable serum HCV-
RNA: 19% 
- Normal serum 
aminotransferase levels during 
incarceration follow-up: 8% 
18.9% (17/90) discontinued 
treatment 
 
Reasons discontinuation 
(n=17): 
- Adverse events: 47.1% 
- Non-response: 52.9% 
14.4% (13/90) of 
treated patients 
were lost to 
follow-up before 
assessment of 
SVR 
NR NR Very low 
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Region  
Source 
Reference, 
country, 
study 
design 
Prison 
setting, 
sample, time 
period  
Description 
model of 
care 
Eligibility/access Treatment 
discontinuation/ non-
adherence 
Attrition Other outcomes 
of interest 
Sub-group 
conside-
rations 
Level of 
evidence 
 
March 2001 – 
October 2002 
Medical 
Infectious 
Diseases 
Consultant; 
ongoing care 
delivered by 
correctional 
nursing staff 
- Inmate preference not to be 
treated including those 
awaiting future therapies: 8% 
- Psychiatric disease: 3% 
- Comorbid medical conditions: 
1.6% 
- Normal liver biopsy: 0.8% 
- Released before start of 
treatment: 4% 
- No specified reason for non-
treatment: 52% (on review, it 
was thought that the most 
likely reason was because of 
unremarkable serum liver 
enzymes) 
Non-
EU/EEA  
 
PRL 
Simonović 
Babić, 2016 
[110] 
 
Serbia 
 
Longitudinal 
study 
Special Hospital 
for Prisoners in 
Belgrade 
 
n=32 IFN-naïve 
HCV+ inmates 
who were 
treated 
 
2007 – 2013  
Provision of 
pegylated IFN 
+ RBV 
HCV RNA level >100,000 
copies/ml, elevated ALT level 
on ≥2 visits during preceding 
6 months, and a liver biopsy 
performed within 3 years 
before treatment 
 
42.1% (32/76) of screened 
inmates started treatment 
 
Reasons ineligible (n=44): 
- Frequent transfer: 27.2% 
- Normal biopsy finding: 
24.9% 
- Normal ALT level: 22.7% 
- Patient discharged too early: 
6.8% 
- Non-compliant patient: 2.2% 
- Uncontrolled psychiatric 
disease: 2.2% 
- Refused therapy: 4.4% 
- Other: 9.0% 
12.5% (4/32) discontinued 
therapy 
 
Reasons discontinuation 
(n=4): 
- Tuberculosis relapse: 25.0% 
- Drug overdose: 25.0% 
- Gave up on therapy: 25.0% 
(not further specified) 
- No early virologic response: 
25.0% 
 
No follow-up data 
available 24 
weeks after end 
treatment: 
15.6% (5/32) 
NR NR Very low 
Non-
EU/EEA 
 
PRL 
Boonwaat, 
2010 [90] 
 
Australia 
 
Correctional 
centres in NSW 
 
n=185 treated 
vs. n=186 
untreated 
Provision of 
standard IFN 
(with or 
without RBV) 
or pegylated 
IFN + RBV 
- During 1995–1998 
individuals should have had a 
fibrosis score of ≥1 and 
current IDUs were ineligible; in 
May 2001, the exclusion of 
IDUs was removed 
NR 38% (70/185) of 
treated inmates 
LTFU before 
assessment of 
SVR (timing NR) 
Compared to 
treated inmates, 
untreated inmates 
were more often 
IDU in the 
community 
NR Very low 
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Region  
Source 
Reference, 
country, 
study 
design 
Prison 
setting, 
sample, time 
period  
Description 
model of 
care 
Eligibility/access Treatment 
discontinuation/ non-
adherence 
Attrition Other outcomes 
of interest 
Sub-group 
conside-
rations 
Level of 
evidence 
Nested case-
control study 
HCV+ inmates 
who attended 
the hepatitis 
clinics 
 
January 1996 – 
December 2005 
 
Hepatitis 
clinical service 
- Initiated in 
1995; monthly 
clinic held at 1 
correctional 
centre with 1 
visiting 
specialist 
- By 2005: 12 
additional 
clinics 
- Clinics 
supported by 
public health 
nurses who 
were major 
referral source 
following 
screening  
- Sentence of ≥6 months 
 
50.1% (186/371) initiated 
treatment 
 
Reasons not initiating 
treatment (n=186): 
- Imminent release from 
prison: 59.7% 
- Ineligible according to 
Pharmaceutical Benefits 
Scheme: 20.4% 
- Free of hepatitis C viraemia 
on follow-up: 12.9% 
- Patient refusal: 3.8% 
- Not specified: 3.2% 
– all released 
from prison 
(p=0.01), co-
infected with HBV 
(p=0.001), or had 
either genotype 
1/4 or untypeable 
genotype, and less 
often had a biopsy 
performed 
(p<0.001) or HCV 
genotyping results 
available 
(p<0.001) 
Non-
EU/EEA  
 
PRL 
Chew, 2009 
[91] 
 
USA 
 
Longitudinal 
study 
Rhode Island 
Department of 
Corrections 
(both jail and 
prison) 
 
n=71 HCV+ 
inmates who 
started 
treatment 
 
October 2000 – 
April 2004 
Provision of 
pegylated IFN 
+ RBV 
 
On-site 
evaluation 
and 
management 
All patients with detectable 
virus were potential 
candidates, although 
treatment was not generally 
recommended for earlier 
stages of disease; patients 
with addiction history referred 
to addiction treatment 
programmes and those with 
psychiatric 
disorders/depression were 
closely monitored (both 
groups were eligible under 
these circumstances); biopsy 
was recommended but not 
required to initiate treatment 
43.7% (31/71) discontinued 
treatment 
 
Reasons discontinuation 
(n=31): 
- Side effects: 83.9% 
- Non-responder: 16.1% 
 
- 9.9% (7/71) 
LTFU before end 
of treatment 
- 5.6% (4/71) 
LTFU between 
end of treatment 
and SVR 
assessment 
NR NR Very low 
EU/EAA  
 
GL 
Marco, 2010 
[99] 
 
Spain 
 
4 correctional 
facilities 
 
n=513 inmates 
with HCV 
infection 
Provision of 
pegylated IFN 
+ RBV 
 
NR 20.1% (104/513) discontinued 
treatment 
 
Reasons discontinuation 
(n=104): 
- Release from prison: 53.8% 
NR NR NR 
 
Conference 
abstract 
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Region  
Source 
Reference, 
country, 
study 
design 
Prison 
setting, 
sample, time 
period  
Description 
model of 
care 
Eligibility/access Treatment 
discontinuation/ non-
adherence 
Attrition Other outcomes 
of interest 
Sub-group 
conside-
rations 
Level of 
evidence 
Retrospective 
study 
 
2002-2008 
 
EU/EAA 
 
GL 
Pallás, 2010 
[105] 
 
Spain 
 
Cross-
sectional 
study 
Penitentiary 
centre El Dueso 
(Cantabria) 
 
n=41 inmates 
with HCV 
infection 
receiving 
methadone 
 
2003 – 2010 
Provision of 
pegylated 
IFN+RBV 
 
 
NR 
 
 
19.5% (8/41) discontinuations 
 
Reason for discontinuation 
(n=8): 
- Patient’s decision: 37.5% 
NR NR Only inmates 
on methadone 
were included 
Conference 
abstract 
HCV treatment in prison – usual care (fully or partly DOT) 
EU/EEA 
 
PRL 
Iacomi, 2013 
[96] 
 
Italy 
 
Longitudinal 
study 
5 correctional 
facilities in 
Rome 
 
n=50 inmates 
HCV+ at entry 
who were sent 
for consultation 
to National 
Institute for 
Infectious 
Diseases and 
were treated 
 
January 2008 – 
December 2009 
Provision of 
pegylated 
IFN-α2a + 
RBV 
 
Administration 
of IFN via 
DOT, RBV via 
SAT 
Liver biopsy consistent with 
chronic hepatitis and fibrosis 
stage F1/4, alcohol or drug 
abusers should be on 
rehabilitation/ OST 
 
37.1% (59/159) of HCV+ 
inmates evaluated at the 
institute were eligible 
- 15.3% (9/59) of eligible 
inmates refused therapy 
 
Reasons not initiating 
treatment (n=100): 
- length of detention: 69.0% 
- contraindicated due to 
psychiatric problems: 14.0% 
- contraindicated due to 
substance abuse: 12.0% 
- Absence of HCV replication: 
4.0% 
- Decompensated cirrhosis: 
1.0%  
40.0% (20/50) did not 
complete treatment 
 
Reasons discontinuation 
(n=20):  
- No response: 75% (9 null 
and 6 non-responder) 
- Side effects: 25% 
NR NR NR Very low 
Non-
EU/EEA 
 
PRL 
Allen, 2003 
[87] 
 
USA 
 
Rhode Island 
Department of 
Corrections 
(both jail and 
prison) 
Provision of 
standard IFN 
+ RBV 
 
Sentences of ≥15 months; 
patients with addiction history 
strongly encouraged to enrol 
in prison substance abuse 
treatment programmes (for 
45.6% (41/90) discontinued 
treatment 
 
Reasons discontinuation 
(n=41) 
- 8.9% (8/90) 
LTFU before 
treatment 
completion 
NR NR Very low 
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Region  
Source 
Reference, 
country, 
study 
design 
Prison 
setting, 
sample, time 
period  
Description 
model of 
care 
Eligibility/access Treatment 
discontinuation/ non-
adherence 
Attrition Other outcomes 
of interest 
Sub-group 
conside-
rations 
Level of 
evidence 
Longitudinal 
study 
 
n=90 treated 
HCV+ inmates  
 
1997 – 2001  
Therapy was 
essentially 
DOT, with 
nurses 
administering 
all injections 
and some RBV 
doses; SAT 
RBV dosing 
was 
monitored by 
random spot 
checks of 
medication 
kept by the 
patient 
some a documented 1-year 
sobriety period was required) 
 
25.8% (90/349) of evaluated 
inmates started therapy 
 
Reasons nog initiating 
treatment (n=259): 
- Duration of sentence criteria: 
75.7% 
- Spontaneous virus clearance: 
11.6% 
- Decision to decline/defer 
after informed consent 
discussions: 11.6% 
- Exclusion by psychiatrist: 
1.2% 
- Side effects: 26.8% 
- Death: 2.4% 
- Non-response: 70.7%  
 
- 5.6% (5/90) 
LTFU between 
treatment 
completion and 
6-month SVR 
assessment 
- 8.9% (8/90) 
LTFU between 6- 
and 12-month 
SVR assessment  
Non-
EU/EEA 
 
PRL 
Maru, 2008 
[103] 
 
USA 
 
Longitudinal 
study 
20 facilities of 
the Connecticut 
Department of 
Corrections 
 
n=68 treated 
HCV+ inmates 
who were 
treatment-
naïve  
 
September 
2002 – October 
2006 
Provision of 
pegylated IFN 
+ RBV 
 
Primary care 
provider 
refers eligible 
inmates to 
infectious 
diseases 
specialist; 
treatment 
initiated in 
conjunction 
with an 
infectious 
disease nurse 
 
DOT 
Referred to infectious diseases 
specialist if persistently 
elevated transaminase levels 
for ≥6 months; eligible for 
treatment if fulfils criteria1 (for 
genotypes 1/4) 
 
49.3% (68/138) evaluated 
treatment-naïve patients were 
eligible to receive therapy 
 
Reasons not initiating 
treatment (n=70): 
- Release too soon: 57.1% 
- Normal liver function test 
results: 11.4% 
- Normal biopsy findings: 
10.0% 
- Patient refused 
consent/change of facilities: 
2.9% 
- Patient refused 
consent/other: 7.1% 
- Hepatic decompensation: 
2.9% 
30.9% (21/68) discontinued 
treatment 
 
Reasons discontinuation 
(n=21): 
- Lack of EVR: 57% 
- Mental health issues: 14.3% 
- Adverse effects: 9.5% 
- Early release/patient 
discontinuation of treatment/ 
missing chart: 19% 
 
NR NR NR Very low 
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Region  
Source 
Reference, 
country, 
study 
design 
Prison 
setting, 
sample, time 
period  
Description 
model of 
care 
Eligibility/access Treatment 
discontinuation/ non-
adherence 
Attrition Other outcomes 
of interest 
Sub-group 
conside-
rations 
Level of 
evidence 
- Patient deemed to be non-
compliant: 1.4% 
- Uncontrolled HIV disease: 
4.3% 
- Uncontrolled diabetes: 1.4% 
- Unclear: 1.4% 
Non-
EU/EEA 
 
PRL 
Sterling, 2004 
[111] 
 
USA 
 
Longitudinal 
study 
Virginia 
Department of 
Corrections 
 
n=59 treated 
HCV+ inmates 
(out of 
consecutive 
sample of 
evaluated 
inmates) 
 
March 1998 – 
October 2000 
Provision of 
standard IFN 
+ RBV 
 
Telemedicine, 
using real-
time video 
conferencing 
between 
correctional 
facilities and 
Virginia 
University, 
was utilised 
for all 
treatment 
visits 
DOT (by 
prison nurses) 
HCV-RNA positive and 
negative for HBV surface 
antigen and HIV antibodies; 
patients with ≥2 years of 
incarceration without 
contraindication for therapy, if 
they had evidence of 
histologically significant HCV 
as defined by a total HAI ≥5 
or the presence of any degree 
of fibrosis (score ≥1); all 
HCV+ receive liver biopsy; 
patients with anaemia, renal 
failure, HIV infection or 
significant co-morbid or 
psychiatric diseases were not 
eligible; final decision on 
receiving therapy was left to 
the correctional facility 
 
- 73.1% (87/119 NR) of 
consecutive inmates who 
underwent liver biopsy, were 
eligible for treatment 
- 49.6% (59/119) of inmates 
who underwent liver biopsy 
received therapy 
1.7% (1/59) stopped 
treatment for unclear reasons 
13.6% (8/59) 
LTFU between 
completion of 
treatment and 
SVR assessment 
(unclear if some 
inmates LTFU 
before 
completion of 
treatment) 
NR NR Very low 
HCV treatment in prison – provision of first generation DAA 
EU/EAA 
 
GL 
Marco, 2014 
[100] 
 
Spain 
 
Retrospective 
study 
7 correctional 
institutions in 
Spain 
 
n=24 HCV 
infected 
inmates 
 
Provision of 
Telaprevir + 
pegylated IFN 
+ RBV 
NR 12.5% (3/24) discontinuations 
 
Reasons discontinuation 
(n=3): 
- LTFU after release from 
prison: 33.3% 
- Adverse events: 33.3% 
NR NR NR Conference 
abstract 
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Region  
Source 
Reference, 
country, 
study 
design 
Prison 
setting, 
sample, time 
period  
Description 
model of 
care 
Eligibility/access Treatment 
discontinuation/ non-
adherence 
Attrition Other outcomes 
of interest 
Sub-group 
conside-
rations 
Level of 
evidence 
2013 - Rash (telaprevir only): 
33.3% 
EU/EAA 
 
GL 
Marco, 2014 
[101] 
 
Spain 
 
Retrospective 
study 
Correctional 
facilities in 
Catalunya 
 
n=32 HCV 
infected 
inmates 
 
January 2013 – 
June 2014 
Provision of 
Telaprevir or 
Boceprevir + 
pegylated IFN 
+ RBV  
 
 
 
NR 21.9% (7/32) discontinuations 
 
Reasons discontinuation 
(n=7): 
- Lack of virologic response: 
28.6% 
- Adverse events: 28.6% 
- Release from prison: 28.6%  
- Unknown (telaprevir only): 
14.3%  
NR NR NR Conference 
abstract 
HCV treatment in prison – provision of second generation DAA 
EU/EAA 
 
GL 
Touzòn-
Lòpez, 2016 
[113] 
 
Spain 
 
Longitudinal 
study 
 
5 correctional 
facilities in 
Catalunya 
 
n=207 inmates 
with HCV  
October 2014 – 
April 2016 
Provision of 
DAAs 
NR 5.9% (8/135) discontinuations 
 
Reasons discontinuation 
(n=8): 
- Release from prison: 62.5% 
- Adverse events: 12.5% 
- NR: 25.0% 
NR NR NR Conference 
abstract 
EU/EAA 
 
GL 
Jimènez-
Galàn, 2016 
[97] 
 
Spain 
 
Longitudinal 
Retrospective 
Study 
1 correctional 
facility in 
Madrid 
 
n=50 inmates 
with HCV 
 
February 2015 
– June 2016 
 
 
Provision of 
DAA 
NR Voluntary discontinuation: 2% 
(1/50) 
 
NR NR NR Conference 
abstract 
EU/EAA 
 
GL 
Mìnguez-
Gallego, 2016 
[104] 
 
Spain 
 
Longitudinal 
retrospective 
Study 
1 correctional 
institution 
(Albocasser, 
Castellòn) 
 
n=40 inmates 
with HCV 
infection 
 
Provision of 
DAAs 
NR NR 10% (4/40) LTFU NR NR Conference 
abstract 
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Region  
Source 
Reference, 
country, 
study 
design 
Prison 
setting, 
sample, time 
period  
Description 
model of 
care 
Eligibility/access Treatment 
discontinuation/ non-
adherence 
Attrition Other outcomes 
of interest 
Sub-group 
conside-
rations 
Level of 
evidence 
 
 
2015 – 2016 
EU/EAA 
 
GL 
Fernàndez-
Gonzàlez, 
2016 [95] 
 
Spain 
 
Prospective 
longitudinal 
study 
Spanish 
correctional 
facilities 
 
n=83 inmates 
with HCV 
infection 
 
NR 
Provision of 
DAAs 
NR 2.4% (2/83) discontinuations 
(reasons NR) 
 
No discontinuation due to 
adverse events 
NR NR NR Conference 
abstract 
EU/EAA 
 
GL 
Pontali, 2017 
[106] 
 
Italy 
 
Prospective 
longitudinal 
study 
25 Italian 
correctional 
facilities 
 
n=142 inmates 
with HCV 
infection 
 
May 2015 – 
October 2016 
Provision of 
DAAs 
NR 5.6% (8/142) patients 
discontinued 
 
Reasons discontinuation 
(n=8): 
- Adverse events: 12.5%  
 
NR NR NR Conference 
abstract 
EU/EAA 
 
GL 
Marco-
Mourino, 
2016 [117] 
 
Spain 
 
Prospective 
longitudinal 
study 
Prisons in 
Catalunya 
 
N=212 inmates 
with HCV 
infection 
 
October 2014-
April 2016 
 
 
Provision of 
DAAs 
NR 3.8% (8/212) discontinuations 
 
Reasons for discontinuation 
(n=8): 
-37.5% (3/8) release from 
prison 
-25% (2/8) other concomitant 
diagnosis 
-12.5% (1/8) patient’s decision 
-12.5% (1/8) adverse events 
-12.5% (1/8) death 
NR NR NR Coference 
abstract 
HCV treatment in prison vs. community – usual care 
EU/EEA 
 
PRL 
Aspinall, 
2016 [88] 
 
Scotland 
 
Matched 
cohort study 
Health Boards 
with compre-
hensive data 
on prison and 
community 
treatment 
initiations  
 
Provision of 
pegylated IFN 
+ RBV with or 
without a 
protease 
inhibitor 
NR 
 
Part 1 
NR 
 
Part 2 
- 17.5% (35/200) did not 
complete treatment – no 
reasons reported 
- 9.0% (18/200) unknown if 
completed or not (for the 
NR NR NR Moderate 
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Region  
Source 
Reference, 
country, 
study 
design 
Prison 
setting, 
sample, time 
period  
Description 
model of 
care 
Eligibility/access Treatment 
discontinuation/ non-
adherence 
Attrition Other outcomes 
of interest 
Sub-group 
conside-
rations 
Level of 
evidence 
Inmates and 
community 
patients who 
initiated HCV 
treatment at 
NHS clinics in 
Scotland: 
n=291 
inmates/ 
n=1137 
community 
(part 1; 
treatment-
naïve); n=200 
inmates (part 
2) 
 
2 June 2009 – 
31 May 2012 
logistic regression, it was 
assumed that they had not 
completed treatment) 
 
Predictors of completion: 
- Having cirrhosis (OR 0.16; 
95% CI 0.03-0.81; p=0.03) 
- Being transferred during 
treatment (OR 0.41; 95% CI 
0.17-1.00; p=0.05) 
- Being released during 
treatment (OR 0.10; 95% CI 
0.04- 0.24; p<0.01) 
Non-
EU/EEA 
 
PRL 
Rice, 2012 
[107] 
 
USA 
 
Comparative 
study 
University of 
Wisconsin 
Hepatology or 
Infectious 
Diseases clinic 
 
n=234 HCV-
infected 
inmates and 
n=319 
community 
patients 
 
 
January 2002 – 
December 2007 
 
Provision of 
pegylated IFN 
+ RBV 
- Incarcerated patients: 
expected release date after 
proposed treatment 
completion data 
- Patients with genotype 1/4: 
at least Metavir stage 2 
fibrosis on liver biopsy, 
medically/psychiatrically 
appropriate for treatment 
- All medically and 
psychiatrically appropriate 
patients with genotypes 2/3 
eligible for treatment without a 
staging biopsy 
 
- 60.3% (234/388) 
incarcerated and 61.2% 
(319/521) non-incarcerated 
patients started treatment 
 
Reasons for not treating HCV-
infected inmates (n=154):  
- Failure to meet DOC 
requirements: 43.5% (most 
NR NR NR  Low 
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Region  
Source 
Reference, 
country, 
study 
design 
Prison 
setting, 
sample, time 
period  
Description 
model of 
care 
Eligibility/access Treatment 
discontinuation/ non-
adherence 
Attrition Other outcomes 
of interest 
Sub-group 
conside-
rations 
Level of 
evidence 
common reason being 
expected release date before 
anticipated treatment 
completion)  
- Medical: 15.6% 
- Psychiatric: 3.9% 
- Medical and psychiatric: 
1.3% 
- Patient declined: 3.2% 
- Other: 3.2% 
- Unknown: 29.2% 
 
Reasons for not treating HCV-
infected community members 
(n=202):  
- Medical: 26.2% 
- Psychiatric: 6.9% 
- Medical and psychiatric: 
4.5% 
- Substance abuse: 6.9% 
- Patient declined: 22.8% 
- Payment issue: 3.5% 
- Other: 7.9% 
- Unknown: 28.2% 
 
- Significant differences 
between both groups in the 
percentage of reasons for not 
initiating treatment were 
found for meeting DOC 
requirements (p<0.0001), 
medical and psychiatric issues 
(p=0.0007), active substance 
use (p=0.0004), and patient 
declining (p<0.0001) 
Intervention: DOT vs SAT 
EU/EEA 
 
PRL 
Saiz de la 
Hoya, 2014 
[109] 
 
Spain 
 
Healthcare 
centres of 25 
prisons in Spain 
 
n=109 DOT vs. 
n=135 SAT 
Provision of 
pegylated IFN 
+ RBV 
 
DOT: RBV 
given by study 
Child Pugh score of 5, cirrhotic 
patients should not have 
hepatocellular carcinoma and 
should have alpha-fetoprotein 
level <100 ng/ml; exclusion 
criteria2 
9.4% (21/244) discontinued 
treatment 
 
Reasons discontinuation 
(n=21): 
- Treatment failure: 66.7% 
4.9% (11/224) 
lost to follow-up 
before 
completion of 
treatment 
 
NR NR Moderate 
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Region  
Source 
Reference, 
country, 
study 
design 
Prison 
setting, 
sample, time 
period  
Description 
model of 
care 
Eligibility/access Treatment 
discontinuation/ non-
adherence 
Attrition Other outcomes 
of interest 
Sub-group 
conside-
rations 
Level of 
evidence 
RCT treatment-
naive HCV+ 
inmates 
 
July 2006 – 
April 2007 
nurse on on-
going basis (1 
or 3 
times/week) 
 
SAT: RBV was 
self-
administered 
 
No treatment was initiated in 
3.3% (4/122) of randomised 
inmates in original DOT group 
- LTFU: 25.0% 
- Voluntary withdrawal: 25.0% 
- Withdrawal due to 
assignment to DOT: 50.0% 
 
No treatment was initiated in 
3.1% (4/130) of randomised 
inmates in original SAT group 
- LTFU: 25.0% 
- Voluntary withdrawal: 50.0% 
- Delayed biopsy: 25.0% 
 
7.4% (9/122) of inmates who 
had been randomly allocated 
to DOT, rejected to follow 
DOT and followed SAT instead 
- Patient decision: 19.0% 
- Adverse event: 14.3% 
EU/EEA 
 
GL 
Saiz de la 
Hoya, 2010 
[108] 
 
Spain 
 
Prospective, 
randomised 
study 
3 correctional 
facilities in 
Spain 
 
n=244 inmates 
with HCV 
infection 
 
July 2006 –
September 
2008 
Provision of 
pegylated 
IFN+RBV 
 
NR Reasons discontinuation: 
- 2.8% transfer to centre not 
involved in the study 
- 9.4% release from prison  
- 4.5% voluntary decision 
- 3.6% adverse events 
NR NR NR Conference 
abstract 
Intervention: nurse-led and specialist-supported telemedicine model 
Non-
EU/EEA 
 
PRL 
Lloyd, 2013 
[98] 
 
Australia 
 
Longitudinal 
study 
3 correctional 
centres 
 
n=108 treated 
inmates 
(out of 391 
inmates 
consecutively 
seen by nurse) 
 
Provision of 
therapy, not 
specified 
 
- 3 nurses 
followed 
extensive HCV 
training 
- Nurses 
independently 
- 55.5% (217/391) completed 
the nurse-led assessments 
- 36.1% (141/391) completed 
the specialist physician review 
- 27.6% (108/391) initiated 
treatment 
 
Reasons not initiating 
treatment (n=283): 
- IDU: 3.2% 
12.0% (13/108) discontinued 
treatment 
 
Reasons discontinuation 
(n=13) 
- IDU: 7.7% 
- Adverse events: 61.5% 
- Non-response: 30.8% 
 
9.3% (10/108) 
LTFU before 
treatment 
completion due 
to release 
 
13.0% (14/108) 
LTFU between 
treatment 
completion and 
- The timelines for 
completion of each 
clinical milestone 
varied widely with 
a mean of 58 days 
from enrolment to 
nurse-led 
assessment 
completion (95% 
CI, 44–72 days); a 
NR Very low 
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Region  
Source 
Reference, 
country, 
study 
design 
Prison 
setting, 
sample, time 
period  
Description 
model of 
care 
Eligibility/access Treatment 
discontinuation/ non-
adherence 
Attrition Other outcomes 
of interest 
Sub-group 
conside-
rations 
Level of 
evidence 
January 2009 – 
December 2010 
triaged 
inmates, 
following 
blood 
investigations, 
structured, 
hepatitis- and 
IDU-focused 
history and 
physical 
examination, 
and further 
investigations 
(if necessary), 
taking into 
account 
comorbidities, 
motivation, 
psychosocial 
supports, and 
risk of adverse 
events 
- Specialist 
prescribed 
treatment 
after 
consultation 
with nurse, 
via a 
discussion 
only (A), 
teleconference 
(B), or face-
to-face 
assessment 
(C) 
- Transfer: 6.4% 
- PCR-negative: 11.7% 
- Released: 33.6% 
- Refusal of therapy: 31.4% 
- Adverse events: 2.1% 
- Treatment non-response: 
1.4% 
- Still in progress towards 
initiating treatment: 10.2% 
9.3% (10/108) treatment not 
yet completed 
 
 
SVR assessment 
due to release 
 
4.6% (5/108) 
were still in 
follow-up (no 
post-treatment 
outcomes 
reported) 
mean of 67 days 
from nurse-led 
assessments to 
specialist review 
(95% CI, 51–84 
days); and a mean 
of 54 days from 
specialist review to 
treatment initiation 
(95% CI, 42–65 
days) 
- Longer lead time 
from assessment to 
treatment initiation 
among those 
patients who 
needed a 
consultation with 
the specialist either 
via telemedicine or 
face-to-face (p-
value NR) 
 
 
CI: confidence interval, DAA: Direct-acting antiviral agents; DOT: directly observed therapy, EVR: early viral response, GL: grey literature, GT: genotype, HCV: hepatitis C virus, IDU: injecting drug use, IFN: 
interferon, LTFU: lost to follow-up, NHS: National Health Service, OR: odds ratio, OST: opioid substitution therapy, PRL: peer-reviewed literature, RBV: ribavirin, RCT: randomised controlled trial, RR: relative 
risk, RVR: rapid viral response, SAT: self-administered therapy, SVR: sustained viral response, USA: United States of America 
1 Detectable HCV RNA, persistent elevations in hepatic transaminase levels ≥6 months, not treated with IFN therapy before, no evidence of another aetiology of chronic liver disease, stability of other chronic 
illnesses, no evidence of decompensated cirrhosis or chronic renal insufficiency, pre-treatment mental health screening with evidence of stable mental health, with findings confirmed by a psychiatrist, 
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sufficiently long prison sentence to obtain liver biopsy (~3 months) and complete treatment while incarcerated (9 months for genotypes 2/3, 15 months for all others), willing to defer any early-release 
programmes until treatment is fully completed, willing to be transferred to and remain at a correctional facility where 24-h nursing is available, willing to sign a treatment contract regarding adherence with 
treatment and recommendations by the infectious diseases specialist, HIV-HCV-coinfected patients are eligible for treatment, chemical dependence is assessed but enrolment in a treatment programme not 
required 
2 Patients who had undergone any systemic antiviral, antineoplastic or immunomodulator therapy in the 6 months prior to the 1st dose of study treatment or any investigational therapy in the 6 weeks prior to 
the 1st dose of study treatment; patients with the following comorbidities: hepatic disease of an aetiology other than HCV; positive IgM anti-HAV test; decompensated hepatic disease (Child-Pugh >6); prior 
transplantation with a current functional graft; high risk of anaemia, coronary disease or cerebrovascular disease that, according to investigator criteria, were unlikely to tolerate an acute haemoglobin reduction 
(down to 4 g/dL); history of severe cardiac disease, thyroid disorder or abnormalities in thyroid function tests, unless it could be controlled with conventional treatment; and other severe comorbid conditions, 
such as chronic respiratory disease, immunological disease, severe retinopathy, severe psychiatric disorders or convulsive disorder; pregnant or lactating women, and men whose partner was pregnant; patients 
with neutropenia (neutrophil count <1500 cells/mm3), thrombocytopenia (platelet count <90,000 cells/mm3), anaemia (haemoglobin concentration <12 g/dL) or serum creatinine level >1.5 times the upper limit 
of normal; patients with a history of drug use (including alcohol) in the previous year, except those who were already on methadone maintenance programmes. 
Cost-effectiveness 
Region  
Source 
Reference, 
country, 
study design 
Prison 
setting, 
sample 
Perspective, 
time 
horizon 
Scenarios  Conclusions Sub-group considerations Level of 
evidence 
Intervention: no treatment vs. 2 drug therapy vs. 3-drug therapy 
Non-
EU/EEA  
 
PRL 
Liu, 2014 [118] 
 
USA 
 
Cost-
effectiveness 
study 
Correctional 
facilities in 
USA 
 
n=NR 
 
Societal 
 
Lifetime 
No treatment 
 
vs. 
 
2-drug therapy (pegylated 
IFN and RBV for 48 weeks) 
 
vs. 
 
3-drug therapy with either 
boceprevir or sofosbuvir (4 
weeks of pegylated IFN and 
RBV followed by 24 weeks of 
triple therapy) 
Short sentences (<1.5 years) 
- Costs no treatment vs. sofosbuvir 3-drug therapy: 
$174,174 vs. $228,316 
- QALY yields no treatment vs. sofosbuvir 3-drug therapy: 
13.21 vs. 15.31 QALYs 
- Sofosbuvir cost $25,700 per QALY gained compared with 
no treatment  
Long sentences (≥1.5 years) 
- Costs no treatment vs. 2-drug therapy vs. 3-drug therapy 
with boceprevir vs. with sofosbuvir: $182,596 vs. $227,832 
vs. $235,151 vs. $241,948 
- QALY yields no treatment vs. 2-drug therapy vs. 3-drug 
therapy with boceprevir vs. with sofosbuvir: 13.12 vs. 13.57 
vs. 14.43 vs. 15.18 QALYs 
- Sofosbuvir 3-drug therapy dominated other treatments, 
costing $28 800 per QALY gained compared with no 
treatment 
 
Sofosbuvir-based treatment is cost-effective for incarcerated 
persons. Given the high price of sofosbuvir, affordability is an 
important consideration 
NR Moderate 
Intervention: treatment with or without liver biopsy 
Non-
EU/EEA 
 
PRL 
Sterling, 2005 
[119] 
 
USA 
 
Virginia 
DOC 
 
n=302 
inmates 
Virginia DOC 
 
Until 24 
months after 
Treating (IFN and RBV) all 
patients without a liver 
biopsy 
 
vs. 
- Costs to simply treat 100 representative patients without a 
biopsy: $1,775,900; cost per SVR: $35,517 
- Costs to treat only those patients with an elevated serum 
ALT (51% of the cohort): $905,709; cost per SVR would be 
unaffected 
NR Low 
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Region  
Source 
Reference, 
country, 
study design 
Prison 
setting, 
sample 
Perspective, 
time 
horizon 
Scenarios  Conclusions Sub-group considerations Level of 
evidence 
Cost-
effectiveness 
study 
end of 
treatment 
 
Treating (IFN and RBV) only 
those patients with an 
elevated ALT without 
performing a liver biopsy 
 
vs. 
 
Liver biopsy and examination 
of liver histology utilised to 
define which patients had 
sufficient liver injury from 
chronic HCV (Knodell score 
<5 and no fibrosis) to 
warrant treatment (IFN and 
RBV) 
- Costs to treat 100 inmates after performing liver biopsy 
(85% of the cohort): $1,651,200; cost per SVR: $38,851 
- Cost savings biopsy-directed strategy: $124,700 for 100 
patients; incremental cost associated with treating all 
patients: $3,334 for each additional SVR. Cost savings would 
increase to $408,857 when only those with fibrosis were 
treated (69% of the cohort) 
- Cost savings ALT-directed strategy: $870,191 for the 100 
patients; incremental cost associated with treating all 
patients: $0 for each additional SVR 
 
A strategy in which inmates with chronic HCV undergo liver 
biopsy and only those with a histologically significant liver 
disease undergo therapy with standard IFN and RBV is cost-
effective compared to treating all inmates without a biopsy 
or elevated ALT 
Non-
EU/EEA 
 
PRL 
Tan, 2008 
[120] 
 
USA 
 
Cost-
effectiveness 
study 
US prisons 
 
n=NR 
 
US prison 
healthcare 
system 
 
Lifetime 
Prisoners did not undergo a 
liver biopsy prior to starting 
treatment (pegylated IFN 
and RBV) 
 
vs. 
 
All prisoners underwent a 
liver biopsy prior to 
beginning therapy 
(pegylated IFN and RBV) in 
order to determine stage of 
fibrosis 
First strategy 
- Treatment was cost-effective compared to no treatment in 
prisoners of all age ranges and genotypes when liver biopsy 
was not a prerequisite to starting ART (first strategy)  
Second strategy 
- Treatment after pre-treatment biopsy was cost-effective 
compared to no treatment in prisoners of all age ranges and 
genotypes with portal fibrosis, bridging fibrosis or 
compensated cirrhosis (second strategy)  
 
Pegylated IFN and RBV combination therapy is cost-effective 
in the prison population. The strategy with pre-treatment 
biopsy was the most cost-effective, however not for inmates 
between 40 and 49 years old with genotype 1 and no fibrosis 
First strategy 
- In prisoners 40-49 years, 
treatment saved $41,321 & 
increased QALYs by 0.75 
- In prisoners 50-59 years, 
treatment saved $33,445 & 
increased QALYs by 0.69 
- In prisoners 60-69 years, 
treatment saved $11,637 & 
increased QALYs by 0.5  
Second strategy 
- Patients with no fibrosis:  
o In prisoners 40-49 years, 
treatment increased costs by 
$300 & increased QALYs by 
0.02 
o In prisoners 50-59 years, 
treatment saved $5,937 & 
increased QALYs by 0.22 
o In prisoners 60-69 years, 
treatment increased costs by 
$1,022 & increased QALYs by 
0.15  
- Patients with portal fibrosis: 
o In prisoners 40-49 years, 
treatment saved $18,516 & 
increased QALYs by 0.58 
Moderate 
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Region  
Source 
Reference, 
country, 
study design 
Prison 
setting, 
sample 
Perspective, 
time 
horizon 
Scenarios  Conclusions Sub-group considerations Level of 
evidence 
o In prisoners 50-59 years, 
treatment saved $25,261 & 
increased QALYs by 0.70 
o In prisoners 60-69 years, 
treatment saved $7,714 & 
increased QALYs by 0.45 
- Patients with bridging fibrosis:  
o In prisoners 40-49 years, 
treatment saved $102,513 & 
increased QALYs by 1.60 
o In prisoners 50-59 years, 
treatment saved $85,454 & 
increased QALYs by 1.64 
o In prisoners 60-69 years, 
treatment saved $34,773 & 
increased QALYs by 0.96 
- Patients with compensated 
cirrhosis: 
o In prisoners 40-49 years, 
treatment saved $262,313 and 
increased QALYs by 4.07 
o In prisoners 50-59 years, 
treatment saved $155,974 & 
increased QALYs by 2.91 
o In prisoners 60-69 years, 
treatment saved $61,542 & 
increased QALYs by 1.54 
- Treatment was not cost-effective 
compared to no treatment in 
patients 40-49 years with no 
fibrosis and genotype 1 
- Treatment was cost-effective but 
not dominant compared to no 
treatment in patients between 40-
49 years with no fibrosis (ICER 
$15,000/QALY), and in patients 
60-69 years with no fibrosis (ICER 
$6,813/QALY) 
 
ALT: alanine aminotransferase, DOC: Department of Corrections, IFN: interferon, NR: not reported, PRL: peer-reviewed literature, QALY: quality-adjusted life year, RBV: ribavirin, SVR: sustained viral response, 
US(A): United States (of America) 
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Guidelines 
Four guidelines on HCV treatment were included, of which three were specific to prison settings (one supranational and two national guidelines), and the other one was a supranational 
guidelines not specific to prison setting 
Summary of guidelines on HCV treatment 
Guideline 
Specific to prison setting – supranational guidelines 
WHO, 2014 [7] As with HBV, diagnosis and treatment for HCV are expensive and not available in all countries. 
Assessment for HCV is very similar to assessment for HBV. In addition to assessment of the severity of liver disease, it includes the determination of the genotype of the 
virus. Both components are critical to treatment decisions. It consists of the following steps: 
• Assess the severity of the liver disease (see HBV); 
• Investigate other causes of liver disease and coinfection with HBV or with HIV; 
• Determine HCV genotype (1 to 6) prior to antiviral treatment, as the genotype will determine the treatment; 
• Vaccinate for hepatitis A-B to prevent co-infection with these hepatitis viruses and protect the liver  
Specific to prison setting – national guidelines 
National Hepatitis 
C Strategy 2011-
2014 (Ireland) 
[121] 
• The principle that treatment should be available in an equitable manner for all those infected with HCV, irrespective of mode of acquisition, has been firmly agreed by 
the treatment sub-group and endorsed by the main working group. 
• Improving access to treatment and supporting patients through treatment will reduce the progression from viral infection to liver damage for many patients. It should 
also contribute to a reduction in the prevalence of HCV infection, thus reducing the associated clinical and social burden of the disease. 
• The prevalence of HCV amongst prisoners with a history of injecting drug use is particularly high. Those serving custodial sentences should be offered HCV care in line 
with best practice models. 
• Recommendation 33: Develop, implement and evaluate a treatment model appropriate to the prison setting on a national basis. 
Technical Group 
of Italian experts 
on Hepatitis 
management 
(Italy), 2009 
[122] 
 
• Is advisable that the prison stay could represent a unique occasion to inform about health and hepatitis in particular a population of ‘hard-to-reach’ subjects when they 
are outside the prison walls. 
• Start antiviral therapy only in prisoners with an imprisonment duration that allows the completion of treatment or when the linkage and continuity of care is guaranteed. 
• Apply Directly Observed Therapy (DOT) strategy as already done for HIV infection 
• Start or maintain OST with methadone or buprenorphine in active PWID in order to limit Hepatitis transmission and reinfection. 
• Adopt a multidisciplinary approach including hepatologists, infectious disease specialists, psychiatrists, psychologists, nurses, penitentiary physicians. 
• Establish a clinical and social link between hospital, general practitioners and penitentiary institutions in order to maintain the linkage to care after release from prison. 
• Start alcohol abuse cessation programmes. 
• It is advisable to increase the participation to Hepatitis therapy randomized clinical trials in prison setting. 
  
TECHNICAL REPORT  Systematic review on the prevention and control of blood-borne viruses in prison settings 
171 
Other guidelines – supranational guidelines 
European 
Association for 
the Study of the 
Liver (EASL), 
2016 [34] 
Recommendations 
• The goal of therapy is to cure HCV infection to prevent hepatic cirrhosis, decompensation of cirrhosis, hepatocellular carcinoma (HCC), severe extrahepatic 
manifestations and death. 
• The endpoint of therapy is undetectable HCV RNA in blood by a sensitive assay (lower limit of detection ≤15 IU/ml) 12 weeks (SVR12) and/or 24 weeks (SVR24) after 
the end of treatment. 
• Undetectable HCV core antigen 12 weeks (SVR12) and/or 24 weeks (SVR24) after the end of treatment is an alternative endpoint of therapy in patients with detectable 
HCV core antigen prior to therapy if HCV RNA assays are not available or not affordable. 
• In patients with advanced fibrosis and cirrhosis, HCV eradication reduces the rate of decompensation and will reduce, albeit not abolish, the risk of HCC. In these 
patients surveillance for HCC should be continued. 
• All treatment-naive and treatment-experienced patients with compensated or decompensated chronic liver disease due to HCV must be considered for therapy. 
• Treatment should be considered without delay in patients with significant fibrosis or cirrhosis (METAVIR score F2, F3 or F4), including decompensated (Child-Pugh B or 
C) cirrhosis, in patients with clinically significant extra-hepatic manifestations (e.g. symptomatic vasculitis associated with HCV-related mixed cryoglobulinaemia, HCV 
immune complex-related nephropathy and non-Hodgkin B cell lymphoma), in patients with HCV recurrence after liver transplantation, and in individuals at risk of 
transmitting HCV (active injection drug users, men who have sex with men with high-risk sexual practices, women of child-bearing age who wish to get pregnant, 
haemodialysis patients, incarcerated individuals). 
• Patients with decompensated cirrhosis and an indication for liver transplantation with a MELD score ≥18-20 should be transplanted 6 months, these patients can be 
treated before transplantation. 
• Treatment is not recommended in patients with limited life expectancy due to non-liver-related comorbidities. 
• National elimination plans require the development of economic partnerships and planning to expedite unrestricted access to treatment. 
In 2016 and onwards, IFN-free regimens are the best options in treatment-naïve and treatment-experienced, DAA-naïve patients with compensated and decompensated 
liver disease, because of their virological efficacy, ease of use and tolerability. Indications depend on the HCV genotype/subtype, the severity of liver disease, and/or the 
results of prior therapy. The indications are the same in HCV-mono-infected and HIV-co-infected patients. 
The panel recognises the heterogeneity of per capita incomes and health insurance systems across Europe and in other regions, and therefore the imposition to continue 
to utilise regimens with pegylated IFN-a and ribavirin, with or without DAAs, such as telaprevir, boceprevir, simeprevir or sofosbuvir. However, the advent of new DAAs 
implies that these regimens are not recommended in 2016. It is hoped that the publication of up-to-date recommendations will guide reimbursement and discounting of 
drug costs in order to harmonize treatments across different countries and regions. 
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Annex 12. Summary tables and guideline summaries – Throughcare 
Region  
Source 
Reference, 
country, 
study design 
Prison 
setting, 
time 
period 
Intervention description Sample, eligibility, 
comparator  
HIV 
prevalence 
/incidence  
Other outcomes of interest Sub-group 
considerations 
Level of 
evidence 
Intervention: pre-release individual intervention 
Non-
EU/EEA 
 
PRL 
Bauserman, 
2003 [123] 
 
USA 
 
Longitudinal 
study 
Local jails in 
Maryland 
counties, 
Baltimore 
city, and in 
some 
facilities of 
the 
Maryland 
Department 
of 
Corrections 
 
July 1996 – 
May 2000 
PCM intervention: 
- Individual counselling and 
case management services 
- Skills-building for personal 
HIV risk, condom use, 
substance abuse, transitioning 
into community 
- Post-release plans, including 
referrals 
- Combined with group 
educational sessions covering 
variety of topics 
- Mandatory and optional 
modules1  
n=745 PCM completer 
inmates 
 
Inmates within 6 months 
of expected release date 
 
No comparator 
NR Change from pre- to post-test (time after 
release NR): 
- Increase attitude towards condoms (p<0.001, 
d=0.27) 
- Increase self-efficacy to use condoms 
(p<0.001, d=0.27) 
- Increase self-efficacy to reduce IDU risk 
(p=0.05, d=0.16) 
- Decrease self-efficacy to reduce other 
substances risk (p<0.001, d=0.27) 
- Increase safer sex intentions (p<0.001, 
d=0.15) 
- Increase likelihood that you have HIV/AIDS 
(p=0.001, d=NR) 
- Same likelihood that you will get HIV/AIDS 
(p=0.54, d=NR) 
Some participants 
showed greater 
changes than 
others. Data 
suggested those 
who initially 
scored lowest - 
and consequently 
more likely to be 
at risk - showed 
the greatest 
improvements 
Very low 
Non-
EU/EEA 
 
PRL 
Grinstead, 
1999 [126] 
 
USA 
 
RCT 
A large state 
prison for 
men 
 
October 
1994 – July 
1996 
Intervention:  
- 30-minute session with 
trained inmate peer educator 
- Assess post-release HIV risk 
and make risk reduction plan; 
provide referrals  
- Appointments for follow-up 
survey, for which they receive 
reimbursements  
 
Control: no intervention, not 
further specified 
 
Access to HIV educational 
materials and informal 
consultation with staff for all 
inmates 
n=199 intervention vs. 
n=205 control inmates 
 
Males; within 14 days of 
release 
 
Intervention vs. control 
NR Comparison intervention vs. control at follow-up 
2 weeks after release: 
- Significant difference condom use during first 
time oral, vaginal or anal sex after release 
(p=0.05) 
- Non-significant difference drug use since 
release (p=ns) 
- Non-significant difference IDU since release 
(p=ns) 
- Non-significant difference sharing needles 
among IDUs since release (p=ns) 
 
NR Very low 
Non-
EU/EEA 
 
PRL 
Wolitski, 2006 
[130] 
 
USA 
8 state 
prisons in 4 
states 
 
EI: 
- 2 individual sessions before 
release (60-90 minutes) and 4 
sessions at 1, 3, 6 and 12 
n=263 EI vs. n=259 SSI 
 
Aged 18-29 years; 
incarcerated ≥90 days, 
NR At week 1 and 12 post-release: 
- No statistically significant differences in any 
sexual behaviour between SSI and EI groups 
At week 24 post-release, EI vs. SSI: 
Given the low 
prevalence of IDU 
in both groups at 
week 1 (1.8% 
Low 
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Region  
Source 
Reference, 
country, 
study design 
Prison 
setting, 
time 
period 
Intervention description Sample, eligibility, 
comparator  
HIV 
prevalence 
/incidence  
Other outcomes of interest Sub-group 
considerations 
Level of 
evidence 
RCT 2001 – 2002  weeks after release (30-60 
minutes) 
- 1st in-prison sessions same 
as SSI session 
- 2nd in-prison session: 
community re-entry needs, 
including referrals 
- Post-release sessions: 
review and update of risk-
reduction plan 
- Additional sessions if needed 
 
SSI: 
- 60-90 individual session ~2 
weeks before release 
- Based on brief HIV-risk 
assessment and reduction 
planning intervention (Project 
START) 
- Assessment HIV, hepatitis 
and STI knowledge and risk 
behaviour, personal risk-
reduction plan, provision of 
information, skills training and 
referrals 
scheduled for release 
within 14-60 days; able to 
provide informed consent 
and speak English; willing 
to provide post-release 
contact information; 
released to unrestricted 
environment in site-
specific catchment areas 
 
EI vs. SSI 
- Significantly less unprotected vaginal/anal sex 
at last sexual intercourse with any partner 
(adjusted OR 0.48, 95% CI 0.24-0.95) 
- Significantly less unprotected vaginal/anal sex 
overall with any partner (adjusted OR 0.40, 
95% CI 0.18-0.88) 
- Significantly less unprotected vaginal/anal sex 
overall with a main partner (adjusted OR 0.30, 
95% CI 0.13-0.71) 
- No significant difference in unprotected 
vaginal/anal sex at last sexual intercourse with 
an at-risk partner and overall with a non-main 
partner 
 
EI at week 24 vs. SSI at week 12 after release 
(same time elapsed since end of intervention): 
- Significantly less unprotected vaginal/anal sex 
at last sexual intercourse with any partner 
(adjusted OR 0.45, 95% CI 0.22-0.91) 
- Significantly less unprotected vaginal/anal sex 
overall with any partner (adjusted OR 0.45, 
95% CI 0.20-0.98) 
- Significantly less unprotected vaginal/anal sex 
overall with a main partner (adjusted OR 0.43, 
95% CI 0.19-0.99) 
- Significantly less unprotected vaginal/anal sex 
at last sexual intercourse with an at-risk partner 
(adjusted OR 0.42, 95% CI 0.20-0.90)  
- No significant difference in unprotected 
vaginal/anal sex overall with a non-main partner 
2 
SSI, 0.9% EI), 12 
(3.6% SSI, 2.4% 
EI), and 24 (3.6% 
SSI, 3.9% EI), no 
outcome analyses 
were performed 
 
Intervention: pre-release group intervention 
Non-
EU/EEA 
 
PRL 
El-Bassel, 
1995 [124] 
 
USA 
 
RCT 
New York 
City’s Rikers 
Island Jail 
 
NR 
SS:  
- 16 2-hour group sessions 
twice weekly in prison and 6 
group booster sessions 
monthly in the community  
- Group size n=10, led by 2 
group facilitators3 
 
AI:  
n=67 SS vs. n=78 AI 
inmates 
 
Females, aged 18-55 
years, convicted and 
serving a sentence of 3-
12 months, who used 
cocaine, crack or heroin 
≥3 times/week during 3 
NR Change from pre-test to 1-month post-release 
test in the SS group compared to AI group for: 
- Safer sex behaviour: OR 3.83 (p<0.09) 
- Coping skills: OR 2.83 (p=0.02) 
- Perceived emotional support: OR 2.71 
(p=0.03) 
 
Study focuses 
solely on 
incarcerated 
women with 
recent histories of 
significant drug 
abuse  
 
Very low 
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Region  
Source 
Reference, 
country, 
study design 
Prison 
setting, 
time 
period 
Intervention description Sample, eligibility, 
comparator  
HIV 
prevalence 
/incidence  
Other outcomes of interest Sub-group 
considerations 
Level of 
evidence 
- 3 2-hour group sessions 
- HIV/AIDS information 
primarily focussed on 
transmission-related issues 
and safer sex and drug 
alternatives 
months before arrest, and 
are within 10 weeks of 
scheduled release to New 
York City boroughs 
(excluding Staten Island) 
 
SS vs. AI 
No significant difference between intervention 
groups in perceived vulnerability to HIV, sexual 
self-efficacy and AIDS knowledge 
 
Participants who 
were married or 
living with their 
partner were 
significantly less 
likely to report 
improving safer 
sex behaviour 
(OR 0.229, 
p=0.02) 
Non-
EU/EEA 
 
PRL 
Fogel, 2015 
[125] 
 
USA 
 
RCT 
2 prisons for 
women in 
North 
Carolina (1 
is primary 
processing 
facility) 
 
September 
2010 – 
November 
2011 
Power 
- 8 interactive group sessions 
(1.5 hours) delivered over 4 
weeks provided by nurse and 
social worker4 
- 1 booster session 1 month 
after session 8 and prior to 
release; 3 5-minute booster 
phone calls after release 
 
Control 
- 1 1-h standard-of-care STI 
education session by prison 
nurse, including information 
on STI transmission, sexual 
abstinence, and condom use 
- During 1st 3 months of 
incarceration 
- Provided to all women, also 
POWER participants 
n=265 Power vs. n=256 
control newly incarcerated 
inmates 
 
Females; 18-60 years; 
total sentence length ≤12 
months; speaking English; 
able to provide verbal and 
written consent; planning 
to live in North Carolina 
during study; having had/ 
expecting to have sexual 
activity with a man; HIV-
negative; <6 months left 
of sentence 
 
POWER vs. control 
NR * POWER vs. control at 3 months after release: 
- Significantly more HIV knowledge (p<0.001) 
- Significantly more health-protective 
communication (p<0.05) 
- Significantly fewer motivational barriers to 
condoms (p<0.05) 
- Significantly fewer physical spousal abuse 
(p<0.01) 
* POWER vs. control 6 months after release: 
- Significantly less unprotected vaginal sex 
outside of monogamous relationships (adjusted 
OR 0.57, 95% CI 0.35-0.92) 
- Significantly more condom use during vaginal 
intercourse with main male partner (adjusted 
OR 2.06, 95% CI 1.14-3.72) 
- Significantly more HIV knowledge (p<0.001) 
- Significantly fewer motivational barriers to 
condoms (p<0.05) 
- Significantly fewer partner and physical effect 
barriers to condoms (p<0.05) 
- Significantly more tangible social support 
(p<0.05) 
 
No significant difference in:  
- Both time points in: access barriers to condom 
use, condom self-efficacy, sexual protective 
practices barriers, depression, social support, 
emotional/informational/affectionate support, 
positive social interaction, social network risk, 
number of stressors, non-physical spouse 
abuse, power and attitudes in relationships 
NR Moderate 
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Region  
Source 
Reference, 
country, 
study design 
Prison 
setting, 
time 
period 
Intervention description Sample, eligibility, 
comparator  
HIV 
prevalence 
/incidence  
Other outcomes of interest Sub-group 
considerations 
Level of 
evidence 
- 3 months only: condom barriers overall and 
partner and physical effect barriers to condoms, 
tangible support  
- 6 months only: health-protective 
communication, physical spousal abuse, and 
(measured only at 6 months) condom use with 
non-main male partner, partner concurrency, 
number of male sexual partners, drug use 
before sexual intercourse, trading sex, incidence 
of non-viral STIs 
Non-
EU/EEA 
 
PRL 
Knudsen, 
2014 & 
Leukefeld, 
2012 
[127,128] 
 
USA 
 
RCT 
4 state 
prisons 
 
March 2007 
– December 
2008 
RRR-HIV: 
- 5 90-minute prison-based 
group sessions starting ~6 
weeks before release 
- 1 telephone/face-to-face 
booster session after release 
- Didactic and interactive skill-
building exercises focused on 
7 relationship thinking myths5 
to make healthier and safer 
decisions about risky sexual 
behaviour and drug use 
- Receive also control 
intervention in session 1 
 
Control: 
- 17-minute HIV/AIDS risk 
reduction information and 
awareness video 
n=378 inmates 
(Knudsen), n=344 
inmates (Leukefeld)  
- The 34 inmates without 
follow-up data are 
included in the study of 
Knudsen et al by using 
imputation) 
 
Females; ≥18 years old; 
being scheduled to appear 
before the parole board or 
complete one’s sentence 
within 6 weeks; 
consenting to participate; 
reporting at least weekly 
substance use before 
incarceration; no past-
month psychotic features 
or having specific 
parole/probation 
conditions that would 
prohibit participation 
 
RRR-HIV vs. control 
NR Knudsen et al.: 
- At 90 days follow-up (post-release), women in 
RRR-HIV reported significantly fewer past-
month unprotected sexual behaviours than 
women assigned to the control condition 
(p=0.007) 
 
Leukefeld et al.: 
90-day change (pre-release to post-release) 
RRR-HIV vs. control: 
- Greater increase in overall HIV knowledge of 
HIV risk behaviours (p=0.024) 
- Greater increase in self-esteem (p=0.032) 
- Greater increase sexual relationship power 
(p=0.018) 
- Greater increase relationship control 
(p=0.019) 
- Greater improvement in specific HIV risk 
knowledge items: can get HIV through sharing 
works (p=0.008), female/male condom not 
used together (p<0.001), women who use 
drugs do not make healthier choices (p=0.011) 
- Greater improvement in specific thinking 
myths: use drugs and make healthy choices 
regarding protection (p=0.002), unhealthy 
choices regarding protection when using drugs 
(p=0.009), know partner safe from HIV by how 
talks (p=0.014) and how acts (p=0.032), will 
not get HIV because not at risk (p=0.048) 
- For non-significant changes, see 
corresponding evidence table 
Study focuses 
solely on inmates 
with at least 
weekly substance 
use before 
incarceration 
 
Knudsen et al.: 
Re-incarceration 
(p=0.005) during 
90 days follow-up 
and older age 
(p=0.001) were 
negatively 
associated with 
unprotected 
sexual behaviours 
Low 
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Region  
Source 
Reference, 
country, 
study design 
Prison 
setting, 
time 
period 
Intervention description Sample, eligibility, 
comparator  
HIV 
prevalence 
/incidence  
Other outcomes of interest Sub-group 
considerations 
Level of 
evidence 
Non-
EU/EEA 
 
PRL 
Magura, 1995 
[129] 
 
USA 
 
Comparative 
study 
New York 
City’s 
central jail 
facility for 
women at 
Rikers 
Island 
 
1991 (not 
further 
specified) 
Health education curriculum: 
- 4 alternate-day, 1-hr small-
group (n=8) educational 
sessions 
- Focusing on drug use, 
sexual behaviour and 
HIV/AIDS knowledge and risk 
reduction and how to seek 
health and social services in 
the community 
- Led by counsellor 
 
Control: 
- No health education, not 
further specified 
n=53 educations vs. n=48 
control inmates 
 
- At start study: women 
who were detoxified for 
heroin or were being 
maintained on methadone 
in jail, and who were not 
in drug dependency 
treatment at arrest 
- Later in study: eligibility 
extended to women who 
were in drug dependency 
treatment at arrest and 
female drug users who 
were not injecting 
 
Health education vs. 
control 
NR None of the following outcomes measured at 
median 7 months after release were 
significantly associated with AIDS education in 
jail (p>0.05): 
- Drug injection 
- Needle/syringe sharing 
- Needle/syringe sterilisation 
- Heroin use 
- Crack use 
- Multiple sexual partners 
- High-risk sexual partners 
- Condom use 
- Enrolling or remaining in drug dependency 
treatment 
Study focuses 
solely on drug 
users 
 
Being in drug 
dependency 
treatment at the 
time of follow-up 
was associated 
with reductions in 
heroin use 
(p<0.01) and 
drug dealing 
(p<0.05) 
Very low 
AI: standard AIDS information intervention, AIDS: acquired immunodeficiency syndrome, EI: enhanced intervention, HIV: human immunodeficiency virus, IDU: injecting drug use, NR: not reported, OR: odds 
ratio, PCM: prevention case management, PRL: peer-reviewed literature, RCT: randomised controlled trial, RRR-HIV: reducing risky relationships for HIV, SS: skills building and social support enhancement 
intervention, SSI: single-session intervention, STI: sexually transmitted infection, USA: United States of America 
1 The initial PCM curriculum in 1996 included 2 mandatory modules (Personalizing HIV/AIDS Risk and Risk Reduction and Transitioning Into the Community) and 5 optional modules (Condoms and Other Devices, 
Substance Abuse, Self-Esteem, Relationships, and Employment and Career Goals). In 1998 the Condoms and Substance Abuse modules became mandatory. Additional optional modules have been developed by 
counsellors to meet client needs, e.g. Personal Responsibility, Coping, Communication, and Decision-Making. Methods for each module include activities such as informational lecturing by counsellors; individual 
or group discussion, according to the format of particular sessions; practice exercises and role play; and homework activities to be completed between sessions 
2 Main partner: someone the inmate feels a special emotional attachment or commitment to; at-risk partner: a partner who 1) had ever injected drugs, 2) had ever smoked crack, 3) had ever traded sex for 
money or drugs, 4) had ever had an STI, 5) currently had other sexual partners, or 6) was HIV seropositive 
3 Aims to bolster participants’ awareness of HIV/AIDS risk behaviours and their ability to anticipate high-risk situations; to enhance their self-efficacy, problem-solving, and coping skills in high-risk and other life 
problem situations; to enable participants to assess their social networks, strengthen ties to drug-free support networks, and use supportive individuals in reducing HIV/AIDS risk behaviour and solving life 
problems; and to help participants gain access to formal and informal help to support their efforts to acquire and sustain protective behaviours 
4 Session 1: purpose intervention, HIV-STIs facts; Session 2: self-protection/individual strength, signs and symptoms of HIV-STIs; Session 3: substance abuse, HIV-STI prevention practices, partner information, 
condoms, cleaning drug paraphernalia; Session 4: female sexuality/ roles, sexual decision-making; Session 5: male-female interaction/relationships, identifying triggers to unsafe sex; Session 6: violence, 
strategies for decreasing risk; Session 7: preparing for the life after release; Session 8: condom negotiation/use, setting goals for oneself, graduation ceremony 
5 7 risky relation thinking myths: 1) Fear of rejection: ‘Having sex without protection will strengthen my relationship’; 2) Self-worth/self-esteem: ‘I only think good things about myself when I am in a 
relationship, even if it is risky’; 3) Drug use: ‘I can use drugs and still make healthy decisions about sex’; 4) Safety: ‘I know my partner is safe by the way my partner looks, talks and/or acts’; 5) Trust: I’ve been 
with this partner for a long time so there’s no need to practice safe sex; 6) Invincibility: I will not get HIV because I’m not really at risk; 7) Strategy/power: ‘I have to use sex to get what I want’ 
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Acceptability/barriers 
Region  
Source 
Reference, 
country, 
study 
design 
Prison 
setting, 
sample, time 
period 
Intervention description Eligibility/ access Acceptance Intervention 
adherence 
Attrition Other 
outcomes 
of interest 
Sub-group 
conside-
rations 
Level of 
evidence 
Intervention: pre-release individual intervention 
Non-
EU/EEA 
 
PRL 
Bauserman, 
2003 [123] 
 
USA 
 
Longitudinal 
study 
Local jails in 
Maryland 
counties, 
Baltimore city, 
and in some 
facilities of the 
Maryland 
Department of 
Corrections 
 
n=745 PCM 
completers 
 
July 1996 – 
May 2000 
PCM intervention: 
- Individual counselling and 
case management services 
- Skills-building for personal 
HIV risk, condom use, 
substance abuse, transitioning 
into community, optional 
- Post-release plans, including 
referrals 
- Combined with group 
educational sessions covering 
variety of topics 
- Mandatory and optional 
modules1 
Within 6 months of expected 
release date 
NR Completion rates 
per mandatory 
module varied 
from 21.2% to 
95.8%  
 
88% completed 
≥2 mandatory 
modules, but only 
39% completed 3 
or 4  
 
Participants 
completed a 
median of 6 
modules and 9 
sessions in about 
11 hours total 
NR Despite the 
goal of 
individualised 
attention, 
participants 
completed 
more 
modules and 
spent more 
programme 
time in group 
sessions 
NR Very low 
Non-
EU/EEA 
 
PRL 
Grinstead, 
1999 [126] 
 
USA 
 
RCT 
A large state 
prison for men 
 
n=199 
intervention 
vs. n=205 
control 
inmates 
 
October 1994 
– July 1996 
Intervention:  
- 30-minute session with 
trained inmate peer educator 
- Assess post-release HIV risk 
and make risk reduction plan; 
provide referrals  
- Appointments for follow-up 
survey, when they receive 
reimbursements  
Control: no intervention, not 
further specified 
Access to HIV educational 
materials and informal 
consultation with staff for all 
inmates 
Males; within 14 days of 
release 
 
97.6% of inmates 
interviewed at baseline 
(404/414) were randomised 
 
39.7% (79/199) of those 
randomised to the 
intervention group, received 
the intervention, reasons 
were: failed to appear for 
their intervention 
appointment (not further 
specified), unable to attend 
due to institutional lock-
downs, or unexpectedly 
paroled (n/N NR) 
Baseline 
refusal rate 
19% (n/N 
NR) 
 
 
NR 42.5% 
(176/414; 
47.5% in 
intervention 
and 42% in 
control 
group – n/N 
NR) 
NR NR Very low 
Non-
EU/EEA 
Wolitski, 
2006 [130] 
8 state prisons 
in 4 states 
EI: Aged 18-29 years; 
incarcerated ≥90 days; 
94.8% 
(561/592) of 
EI:  Available for 
follow-up 
A total of 91 
optional EI 
NR Very low 
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Region  
Source 
Reference, 
country, 
study 
design 
Prison 
setting, 
sample, time 
period 
Intervention description Eligibility/ access Acceptance Intervention 
adherence 
Attrition Other 
outcomes 
of interest 
Sub-group 
conside-
rations 
Level of 
evidence 
PRL USA 
 
RCT 
n=263 EI vs. 
n=259 SSI 
 
2001 – 2002  
- 2 individual sessions before 
release (60-90 minutes) and 4 
sessions at 1, 3, 6 and 12 
weeks after release (30-60 
minutes) 
- 1st in-prison sessions same as 
SSI session 
- 2nd in-prison session: 
community re-entry needs, 
including referrals 
- Post-release sessions: review 
and update of risk-reduction 
plan 
- Additional sessions if needed 
 
SSI: 
- 60-90 individual session ~2 
weeks before release 
- Based on brief HIV-risk 
assessment and reduction 
planning intervention (Project 
START) 
- Assessment HIV, hepatitis 
and STI knowledge and risk 
behaviour, personal risk-
reduction plan, provision of 
information, skills training and 
referrals 
scheduled for release within 
14-60 days; able to provide 
informed consent and speak 
English; willing to provide 
post-release contact 
information; released to 
unrestricted environment in 
site-specific catchment areas 
 
71.3% (592/830) of men 
selected for recruitment were 
screened and eligible 
 
88.2% (522/592) of eligible 
inmates were released to 
unrestricted environment and 
therefore included 
eligible 
inmates 
provided 
informed 
consent 
- 1st pre-release 
session (=SSI): 
98.5% 
- 2nd pre-release 
session: 88.6% 
- Post-release 
sessions: 79.8%, 
65.8%, 65.8% 
and 74.5% at 
week 1, 3, 6 and 
12 after release 
- 67% ≥5 of the 
6 sessions 
 
SSI: 94.2% 
 
 
after 
release:  
- Week 1: 
87.3% SSI 
and 84.8% 
EI 
- Week 12: 
76.4% SSI 
and 82.1% 
EI 
- Week 24: 
82.2% SSI 
and 83.3% 
EI 
(p=ns) 
sessions 
were 
delivered to 
49 
participants, 
of whom 
61% 
received 1 
additional 
session 
Intervention: pre-release group intervention 
Non-
EU/EEA 
 
PRL 
El-Bassel, 
1995 [124] 
 
USA 
 
RCT 
New York 
City’s Rikers 
Island Jail 
 
n=67 SS vs. 
n=78 AI 
 
NR 
SS:  
- 16 2-hour group sessions 
twice weekly in prison and 6 
group booster sessions 
monthly in the community  
- Group size n=10, led by 2 
group facilitators2 
AI:  
- 3 2-hour group sessions 
- HIV/AIDS information 
primarily focussed on 
NR NR SS: 52.2% 
attended ≥13 
sessions, 28.4% 
4-12 sessions, 
19.4% ≤3 
sessions 
 
AI: 85.9% 
attended all 
sessions 
Lost to 
follow-up 
from pre-
test to post-
test: 
- SS: 26.9% 
(18/67)  
- AI: 33.3% 
(26/78)  
Reasons NR 
NR Study 
focuses 
solely on 
incarcerated 
women with 
recent 
histories of 
significant 
drug abuse  
Very low 
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Region  
Source 
Reference, 
country, 
study 
design 
Prison 
setting, 
sample, time 
period 
Intervention description Eligibility/ access Acceptance Intervention 
adherence 
Attrition Other 
outcomes 
of interest 
Sub-group 
conside-
rations 
Level of 
evidence 
transmission-related issues and 
safer sex and drug alternatives 
Non-
EU/EEA 
 
PRL 
Fogel, 2015 
[125] 
 
USA 
 
RCT 
2 prisons for 
women in 
North Carolina 
(1 is primary 
processing 
facility) 
 
n=265 POWER 
vs. n=256 
control newly 
incarcerated 
inmates 
 
September 
2010 – 
November 
2011 
POWER 
- 8 interactive group sessions 
(1.5 hours) delivered over 4 
weeks provided by nurse and 
social worker3 
- 1 booster session 1 month 
after session 8 and prior to 
release; 3 5-minute booster 
phone calls after release 
 
Control 
- 1 1-h standard-of-care STI 
education session by prison 
nurse, including information on 
STI transmission, sexual 
abstinence, and condom use 
- During 1st 3 months of 
incarceration 
- Provided to all women, also 
POWER participants 
Females; 18-60 years; total 
sentence length ≤12 months; 
speaking English; able to 
provide verbal and written 
consent; planning to live in 
North Carolina during study; 
having had/ expecting to 
have sexual activity with a 
man; HIV-negative; <6 
months left of sentence 
 
Among 820 screened 
women: 
- 12.9% (106/820) were not 
eligible 
- 2.0% (16/820) were 
transferred to non-
participating prisons 
- 0.37% (3/820) initially 
expressed interest but 
dropped out prior to 
randomisation 
- 0.24% (2/820) were 
removed at prison’s request 
21.0% 
(172/820) of 
screened 
women 
refused to 
participate 
The average 
number of 
POWER sessions 
attended was 
5.8; 12.8% 
(34/265) did not 
attend any of the 
intervention 
sessions 
POWER: 
67.5% 
(179/265) 
and 59.6% 
(158/265) 
completed 
the 3-month 
and 6-
month post-
release 
assessments 
 
Control: 
60.5% 
(155/256) 
55.5% 
(142/256) 
completed 
the 3- and 
6-month 
post-release 
assessments 
NR NR Moderate 
Non-
EU/EEA 
 
PRL 
Knudsen, 
2014 & 
Leukefeld, 
2012 
[127,128] 
 
USA 
 
RCT 
4 state prisons 
 
n=378 or 344 
inmates 
 
March 2007 – 
December 
2008 
RRR-HIV: 
- 5 90-minute prison-based 
group sessions starting ~6 
weeks before release 
- 1 telephone/face-to-face 
booster session after release 
- Didactic and interactive skill-
building exercises focused on 7 
relationship thinking myths4 to 
make healthier and safer 
decisions about risky sexual 
behaviour and drug use 
- Receive also control 
intervention in session 1 
 
Control: 
Females; ≥18 years old; 
being scheduled to appear 
before the parole board or 
complete one’s sentence 
within 6 weeks; consenting 
to participate; reporting at 
least weekly substance use 
before incarceration 
 
- 20.7% (124/599) of 
screened women were 
ineligible 
- 0.83% (5/599) of screened 
women discharged before 
intervention start (4 prison 
transfer, 1 mental health 
reasons) 
4.3% 
(26/599) of 
screened 
women 
declined to 
participate 
NR Available at 
3-month 
follow-up 
interview: 
91.0% 
(344/378) 
NR Study 
focuses 
solely on 
inmates with 
at least 
weekly 
substance 
use before 
incarceration 
 
Low 
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Region  
Source 
Reference, 
country, 
study 
design 
Prison 
setting, 
sample, time 
period 
Intervention description Eligibility/ access Acceptance Intervention 
adherence 
Attrition Other 
outcomes 
of interest 
Sub-group 
conside-
rations 
Level of 
evidence 
- 17-minute HIV/AIDS risk 
reduction information and 
awareness video 
- 14.9% (66/444) of 
randomised women were not 
included in the analyses as 
they were not released  
 
Reasons ineligible (n=124): 
- Insufficient pre-
incarceration drug use: 
47.6% 
- Release-related reasons: 
45.2% 
- NR: 7.3% 
Non-
EU/EEA 
 
PRL 
Magura, 
1995 [129] 
 
USA 
 
Comparative 
study 
New York 
City’s central 
jail facility for 
women at 
Rikers Island 
 
n=53 
educations vs. 
n=48 control 
inmates 
 
1991 (not 
further 
specified) 
Health education curriculum: 
- 4 alternate-day, 1-hr small-
group (n=8) educational 
sessions 
- Focusing on drug use, sexual 
behaviour and HIV/AIDS 
knowledge and risk reduction 
and how to seek health and 
social services in the 
community 
- Led by counsellor 
 
Control: 
- No health education, not 
further specified 
- At start study: women who 
were detoxified for heroin or 
were being maintained on 
methadone in jail, and who 
were not in drug dependency 
treatment at arrest 
- Later in study: eligibility 
extended to women who 
were in drug dependency 
treatment at arrest and 
female drug users who were 
not injecting. 
NR NR Follow-up 
interviews 
completed 
with 51.5% 
(53/103) of 
the 
education 
group and 
44.4% 
(48/108) of 
the control 
group. 
NR Study 
focuses 
solely on 
drug users 
Very low 
AI: standard AIDS information intervention, AIDS: acquired immunodeficiency syndrome, EI: enhanced intervention, HIV: human immunodeficiency virus, IDU: injecting drug use, PCM: prevention case management, RCT: randomised 
controlled trial, RRR-HIV: reducing risky relationships for HIV, SS: skills building and social support enhancement intervention, SSI: single-session intervention, STI: sexually transmitted infection, USA: United States of America 
1The initial PCM curriculum in 1996 included 2 mandatory modules (Personalizing HIV/AIDS Risk and Risk Reduction and Transitioning Into the Community) and 5 optional modules (Condoms and Other Devices, Substance Abuse, Self-
Esteem, Relationships, and Employment and Career Goals). In 1998 the Condoms and Substance Abuse modules became mandatory. Additional optional modules have been developed by counsellors to meet client needs, e.g. Personal 
Responsibility, Coping, Communication, and Decision-Making. Methods for each module include activities such as informational lecturing by counsellors; individual or group discussion, according to the format of particular sessions; 
practice exercises and role play; and homework activities to be completed between sessions 
2Aims to bolster participants’ awareness of HIV/AIDS risk behaviours and their ability to anticipate high-risk situations; to enhance their self-efficacy, problem-solving, and coping skills in high-risk and other life problem situations; to enable 
participants to assess their social networks, strengthen ties to drug-free support networks, and use supportive individuals in reducing HIV/AIDS risk behaviour and solving life problems; and to help participants gain access to formal and 
informal help to support their efforts to acquire and sustain protective behaviours 
3 Session 1: purpose intervention, HIV-STIs facts; Session 2: self-protection/individual strength, signs and symptoms of HIV-STIs; Session 3: substance abuse, HIV-STI prevention practices, partner information, condoms, cleaning drug 
paraphernalia; Session 4: female sexuality/ roles, sexual decision-making; Session 5: male-female interaction/relationships, identifying triggers to unsafe sex; Session 6: violence, strategies for decreasing risk; Session 7: preparing for the 
life after release; Session 8: condom negotiation/use, setting goals for oneself, graduation ceremony 
4 7 risky relation thinking myths: 1) Fear of rejection: ‘Having sex without protection will strengthen my relationship’; 2) Self-worth/self-esteem: ‘I only think good things about myself when I am in a relationship, even if it is risky’; 3) Drug 
use: ‘I can use drugs and still make healthy decisions about sex’; 4) Safety: ‘I know my partner is safe by the way my partner looks, talks and/or acts’; 5) Trust: I’ve been with this partner for a long time so there’s no need to practice 
safe sex; 6) Invincibility: I will not get HIV because I’m not really at risk; 7) Strategy/power: ‘I have to use sex to get what I want’ 
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Cost-effectiveness 
No studies were found on cost-effectiveness of interventions to prevent BBVs post-release.  
Guidelines 
No guidelines were found on interventions to prevent BBVs post-release.  
Linkage to care post-release 
Effectiveness 
Region  
Source 
Reference, 
country, 
study 
design 
Prison 
setting, 
time 
period 
Description model 
of care 
Sample, 
eligibility, 
comparator 
Viral load, 
CD4 count 
Treatment 
adherence 
Linkage to HIV care 
post release 
Other outcomes 
of interest 
Sub-group 
considerations 
Level of 
evidenc
e 
HIV treatment in prison – Usual care 
Non-
EU/EEA  
 
PRL 
Beckwith, 
2014 [131] 
 
USA 
 
Longitudinal 
study 
Rhode 
Island Jail 
 
2001 – 2007  
Provision of ART in 
prison or post release 
 
On-site care by HIV 
physicians from 
community hospital, 
which serves as 
primary referral 
centre after release 
n=64 newly 
diagnosed HIV+ 
inmates 
 
All individuals newly 
diagnosed in study 
period (no previous 
HIV diagnosis) 
 
No comparator 
NR NR 57.8% (37/64) 
- 12.5% <90 days 
- 20.3% >90 days 
- 25.0% after subsequent 
incarceration 
 
No significant association 
between length of 
incarceration and linkage 
to care 
NR NR Very low 
Non-
EU/EEA 
 
PRL 
Althoff, 
2013 [137] 
 
USA 
 
Longitudinal 
study 
10 
prisons/jails 
 
January 
2008-March 
2011 
Post-release follow up 
of individuals 
receiving ART during 
detention and 
receiving 
comprehensive jail-
based services 
N=867 included 
participants  
 
6-month follow up 
period 
NR NR 58% (55/867) had a HIV 
visit in the first 3-month; 
47% (406/867) had a HIV 
visit in the second 3-
month period;  
38% had sustained 
retention in care (two HIV 
visits in 6-month) 
Correlates of 
sustained retention 
in care were: being 
male (p<0.01); 
having HIV care 
provider prior to 
incarceration 
(p=0.02); receiving 
pre-release services 
(e.g. disease 
management 
session, discharge 
planning) and post-
release services 
(e.g. needs 
assessment) 
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Region  
Source 
Reference, 
country, 
study 
design 
Prison 
setting, 
time 
period 
Description model 
of care 
Sample, 
eligibility, 
comparator 
Viral load, 
CD4 count 
Treatment 
adherence 
Linkage to HIV care 
post release 
Other outcomes 
of interest 
Sub-group 
considerations 
Level of 
evidenc
e 
HIV treatment in prison – Usual care (partly DOT) 
Non-
EU/EEA 
 
PRL 
White, 2001 
[135] 
 
USA 
 
Cross-
sectional 
study 
San 
Francisco 
City and 
County Jail 
 
January 
1997 – 1 
April 2000 
Provision of ART 
 
Seen by the San 
Francisco Department 
of Public Health, Jail 
Health Services, 
Forensic AIDS Project 
 
If already on 
treatment at entry, 
efforts made to keep 
same medication; if 
not on ART, efforts 
were made to refer 
and facilitate follow-
up with community-
based provider; 3-day 
supply of medication 
upon release 
n=77 inmates on 
ART in jail, who 
were released in 
first quarter of 1997 
 
Receive care if 
tested positive for 
HIV in jail or self-
report a previous 
positive test and 
outside 
documentation is 
available to confirm 
this test result 
 
NR NR 68.6% (24/35) of inmates 
released on ART in jail 
received prescriptions and 
a 3-day supply when they 
left jail; 70.8% (17/24) 
picked up the prescription 
and medicine 
 
Among those who were 
re-jailed, 46.3% (25/54) 
received HIV medications 
in the community 
NR Among those 
re-jailed, 
patients who 
had a pre-
incarceration 
primary health 
care provider in 
the community 
were more likely 
to receive ART 
in the 
community 
before their re-
arrest (63.2%, 
12/19) 
compared with 
those who did 
not (37.1%, 
13/35) 
Very low 
HIV treatment - Different interventions 
Non-
EU/EEA 
 
PRL 
Grinstead 
Reznick, 
2013 [134] 
 
USA 
 
RCT 
California 
jail and 2 
prisons 
 
 
NR 
Ecosystem-focused 
(family, friends, 
drug/sex partners, 
service providers) 
intervention1  
 
Individually focused 
intervention2 
 
Both interventions 
include a 45-minute 
HIV education 
session, 2 pre-release 
and up to 16 post-
release sessions in 4 
months after release, 
ART, and medication 
supply upon release 
n=76 ecosystem vs. 
n=75 individual 
intervention HIV+ 
inmates  
 
Adults within 21-90 
days of release, 
speaking English or 
Spanish, able to 
name ≥1 adult in 
local area to 
participate in 
intervention, willing 
to be contacted 
after release 
 
Ecosystem vs. 
individual 
intervention 
 
NR NR * 4-month post-release 
(92% retention):  
- Both groups: decrease 
taking anti-HIV 
medications and lower 
adherence3 (p<0.01 
ecosystem, p<0.05 
individual) 
- Ecosystem less likely to 
be taking anti-HIV 
medications (OR NR, 
p<0.01) and to be 
adherent (OR NR, 
p<0.05)  
* 8-month (89% 
retention) and 12-month 
(76% retention) post-
release: no significant 
differences in groups and 
between groups (p>0.05) 
No significant 
difference between 
both groups on 
sexual behaviour 
after release 
(p>0.05) 
 
When pooling both 
intervention groups 
significant declines 
of any unprotected 
sex (including 
serodiscordant sex) 
was observed 
across the study 
period post-release 
NR Moderate 
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Region  
Source 
Reference, 
country, 
study 
design 
Prison 
setting, 
time 
period 
Description model 
of care 
Sample, 
eligibility, 
comparator 
Viral load, 
CD4 count 
Treatment 
adherence 
Linkage to HIV care 
post release 
Other outcomes 
of interest 
Sub-group 
considerations 
Level of 
evidenc
e 
 * Averaging across post-
release periods:  
- Both groups: decrease 
taking anti-HIV 
medications and lower 
adherence (both p<0.05) 
-The percentage of 
participants taking anti-
HIV medications 
increased across the post-
release period (OR=1.81, 
95% CI 1.16-2.81, p = 
0.0089) to approximate 
pre-release levels 
- Ecosystem group less 
likely to be taking anti-
HIV medications 
(OR=0.20, 95% CI 0.05-
0.80, p=0.0236) and to 
be adherent (OR=0.35, 
95% CI 0.13-0.95, 
p=0.0408) 
Non-
EU/EEA  
 
PRL 
Jacob 
Arriola, 
2007 [132] 
 
USA 
 
Comparative 
study 
Jails and 
prisons in 5 
states 
 
May 2001 – 
April 2004 
Corrections 
Demonstration 
Project:  
- Individual/group 
HIV prevention & 
disease management 
education, individual 
counselling, and 
discharge planning  
- Collaboration with 
community providers 
- Personal support by 
dedicated staff at the 
gate or soon after 
release 
- Management 
programme starts ~6 
months before 
release (baseline) 
-Follow up six months 
post release 
n=226 HIV+ 
inmates 
 
Receiving case 
management 
services that started 
inside the facility 
and continued after 
release 
 
Being met by a case 
manager upon 
release (i.e. at the 
gate) vs. not being 
met by a case 
manager at the gate 
(although protocol 
is that a case 
manager meets 
inmate soon after 
release, only 46% 
NR NR NR Those being met at 
the gate were since 
release significantly 
more participating 
in drug/alcohol 
treatment (OR 
1.99, 95% CI 1.12-
3.55, p<0.01) and 
significantly less 
engaging in sex 
exchange (OR .014, 
95% CI 0.03-0.71, 
p<0.05) 
Significant 
increase in 
participating in 
drug or alcohol 
treatment 
(p=0.00 33.6% 
vs 60.2%); and 
significant 
decrease in 
reported use of 
street drug 
(p=0.01, 43.8% 
vs. 31.4%) and 
engaging in sex 
exchange 
(p=0.00, 65.9% 
vs. 6.2%) at 6-
month follow up  
Very low 
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Region  
Source 
Reference, 
country, 
study 
design 
Prison 
setting, 
time 
period 
Description model 
of care 
Sample, 
eligibility, 
comparator 
Viral load, 
CD4 count 
Treatment 
adherence 
Linkage to HIV care 
post release 
Other outcomes 
of interest 
Sub-group 
considerations 
Level of 
evidenc
e 
Treatment NR (104/226) were met 
at the gate by a 
case manager) 
Non-
EU/EEA 
 
PRL 
MacGowan, 
2015 [133] 
 
USA 
 
RCT 
California 2 
prisons and 
5 jails 
 
July 2008 – 
July 2009 
POST: individual-level 
educational and skills-
building intervention 
(4 sessions in 2 
weeks before release, 
2 sessions in 2 weeks 
after release)4 
 
TCM: standard of 
care (frequency NR)5 
 
Both: treatment NR 
n=37 POST+TCM 
vs. n=36 TCM only 
HIV+ inmates 
 
Adults incarcerated 
<5 years, scheduled 
for release to local 
bay area counties 
within 60 days and 
before end July 
2009, speaking 
English 
 
POST+TCM vs TCM 
only 
NR Change in 
proportion of 
inmates 
taking HIV 
medications 
at release vs. 
three months 
post-release:  
- 
POST+TCM: 
no significant 
difference 
(p=1.0000) 
- TCM only: 
no significant 
difference 
(p=1.0000) 
- POST+TCM 
vs. TCM: no 
significant 
difference 
(OR 0.86, 
95% CI 0.44-
1.68, 
p=0.6630) 
- Combining 
both groups: 
no significant 
difference 
(OR 0.86, 
95% CI 0.44-
1.68, 
p=0.6630) 
Change in proportion of 
inmates receiving 
healthcare at HIV clinic at 
3 months pre-
incarceration vs. 3 
months post-release: 
- POST+TCM: significant 
increase (OR infinite, 
p=0.0156) 
- TCM only: no significant 
difference (p=0.2266) 
- POST+TCM vs. TCM: no 
significant difference (OR 
1.52, 95% CI 0.43-5.37, 
p=0.5115)  
- Combining both groups: 
significant increase (OR 
5.00, 95% CI 1.54-16.27, 
p=0.01) 
Change from 3 
months pre-
incarceration to 3 
months post-
release not 
significant between 
both groups for:  
- unprotected 
vaginal sex, (OR 
1.85, 95% CI 0.38-
8.95, p=0.4432) 
- unprotected anal 
sex, (OR 0.77, 95% 
CI 0.28-2.09, 
p=0.6016) 
- IDU, (OR 2.25, 
95% CI 0.65-7.76, 
p=0.2003) 
- STI diagnosis (OR 
0.49, 95% CI 0.02-
10.65, p=0.6477) 
Combining the 
two groups, a 
statistically 
significant 
change in IDU 
(39.0% at 
baseline vs. 
23.7% at 
follow-up; OR 
0.18, 95% CI 
0.04-0.79, 
p=0.0225)  
Low 
Non-
EU/EEA 
 
PRL 
Springer, 
2012 [138] 
 
USA 
 
Comparative 
study – 
Connecticut 
Department 
of 
Correction 
 
2004-2009 
94 PWID among 
participants enrolled 
in the CONNECT 
study [144] eligible 
for OST offered 
retention on 
buprenorphine (BPN) 
94 subjects: 50 
(53%) selected 
BPN; 44 (47%) 
selected no BPN 
 
BPN vs no BPN 
 
At 6-month 
post-release 
BPN had 
AOR 5.37 
(p=0.03) of 
achieving 
viral 
  No difference in 
viral suppression 
level with DOT vs 
SAT or with 
methadone 
 Low 
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Region  
Source 
Reference, 
country, 
study 
design 
Prison 
setting, 
time 
period 
Description model 
of care 
Sample, 
eligibility, 
comparator 
Viral load, 
CD4 count 
Treatment 
adherence 
Linkage to HIV care 
post release 
Other outcomes 
of interest 
Sub-group 
considerations 
Level of 
evidenc
e 
nested in 
RCT  
for 6-month after 
release  
 
Participants received 
ART via DOT or SAT 
depending on parent 
study arm 
suppression 
(<50 
copies/ml) 
Non-
EU/EEA 
 
PRL 
Wohl, 2011 
[136] 
 
USA 
 
RCT 
North 
Caroline 
State Prison 
system 
 
NR 
BCM: intensive case 
management 
intervention from 3 
months before 
release to 6 months 
after release 
 
SOC: 3 pre-release 
sessions from 3-6 
months pre-release 
 
ART, 30-day supply 
upon release 
n=52 BCM vs. n=52 
SOC HIV+ inmates 
(consecutive 
sample) 
 
Adults not expected 
to be release during 
4 months following 
study entry, 
receiving ≥3 
antiretrovirals (≥1 
using DOT) for ≥3 
months prior to 
study entry, prison 
within 2h drive from 
the release counties 
 
BCM vs. SOC 
NR NR No significant difference 
between both groups in: 
- % medical care access 
≥once (p=0.2) 
- Median time to clinic 
access (p=0.8) 
- Mean number clinic 
visits (p>0.05) 
- Rate of hospitalisations, 
ER or UCC visits (p=ns) 
 
NR No significant 
difference 
between groups 
in ever receiving 
outpatient care 
for substance 
abuse (p=0.48) 
Low 
Opioid Substitution Treatment in prison  
Non-
EU/EEA 
 
PRL 
Kinlock, 
2009 [139]  
 
USA 
 
RCT 
One 
Baltimore 
pre-release 
facility for 
male 
prisoners  
 
September 
2003 and 
June 2005 
Provision services to 
PWID pre-release: 
1.Counselling and 
recommendation to 
enrol in a community 
OST programme 
2.Counselling and 
passive referral to 
OST community 
programme 
3.Counselling and 
induction on OST 
before release with 
active referral to 
community OST 
programme 
n=204 individuals 
randomised to: 
1.n=70 
2.n=70 
3.n=71 
 
1 vs 2 vs 3 
NR -Group 1: 
0% were on 
OST at 12-
month 
-Group 2: 
17.3% were 
on OST at 
12-month 
-Group 3: 
36.7% were 
on OST at 
12-month 
 
Pairwise 
comparison 
-Group 1:25% enrolled in 
care;  
-Group 2: 53.6% enrolled 
in care;  
-Group 3: 70.4% enrolled 
in care;  
 
Pairwise comparison all 
significant (p<0.01) 
 
 
Positive urine test 
for opioid at 12-
month post-
release: 
-Group 1: 65.6% 
-Group 2: 48.7% 
-Group 3: 25% 
 
Group 3 
significantly less as 
compared to Group 
1 & 2. No 
difference between 
Group 1 & 2 
 
 
NR Low 
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Region  
Source 
Reference, 
country, 
study 
design 
Prison 
setting, 
time 
period 
Description model 
of care 
Sample, 
eligibility, 
comparator 
Viral load, 
CD4 count 
Treatment 
adherence 
Linkage to HIV care 
post release 
Other outcomes 
of interest 
Sub-group 
considerations 
Level of 
evidenc
e 
12-month follow-up all significant 
(p<0.01) 
Non-
EU/EEA 
 
PRL 
Gordon, 
2017 [140] 
 
USA 
 
RCT 
Two 
Baltimore 
pre-release 
prisons (one 
for men; 
one for 
women) 
 
September 
2008 and 
July 2012; 
follow-up 
completed 
in 2014.  
Study design was a 2 
In-Prison Treatment: 
Buprenorphine (BPN) 
Treatment: vs. 
Counselling Only 
 
12-month follow up 
 
Adult pre-release 
prisoners who were 
heroin-dependent 
during the year 
prior to 
incarceration were 
eligible, N=211.  
 
 Participants 
in the in-
prison BPN 
group had a 
higher mean 
number of 
days of 
community 
buprenorphin
e treatment 
vs 
participants 
who initiated 
medication 
after release 
(P=0.005). 
Participants in the in-
prison BPN group were 
significantly more likely 
(p=0.012) of enrolling 
into community OST 
programmes (47.5% vs. 
33.7%). 
No statistically 
significant 
difference for days 
of heroin use and 
crime, and opioid 
and cocaine 
positive urine 
screening test 
results (all 
Ps>0.14)  
No statistically 
significant 
gender effects 
(all Ps>0.18). 
Low 
Non-
EU/EEA 
 
PRL 
McKenzie, 
2013 [141] 
 
USA 
 
RCT 
Rhode 
Island 
Department 
of 
Corrections 
 
October 
2006 - 
February 
2009 
 
 
3 study arms include 
Arm 1—initiation of 
OST pre-release with 
referral post-release 
and short-term 
payment of treatment 
costs;  
Arm 2—referral to 
OST programme upon 
release with provision 
of short-term financial 
assistance;  
Arm 3—referral to 
OST programme upon 
release without 
financial assistance. 
90 participants 
randomised to Arms 
1-3 
 
Arm 1 vs Arm 2 vs 
Arm 3 
  Participants on OST prior 
to release were 
significantly more likely to 
enter treatment 
postrelease (P < .001); 
 
Among participants who 
enrolled in community 
OST, those who received 
OST in prison did so 
within fewer days (P 
= .03).  
Participants on OST 
prior to release 
reported less 
heroin use (P 
= .008), other 
opiate use (P 
= .09), and 
injection drug use 
(P = .06) at 6 
months 
 Very Low 
 
AIDS: autoimmune deficiency syndrome, ART: antiretroviral therapy, BCM: Bridging Case Management, BOP: Bureau of Prisons, CI: confidence interval, DOT: directly observed therapy, ER: emergency room, 
IDOC: Illinois Department of Corrections, IQR: interquartile range, NR: not reported, ns: not significant, OR: odds ratio, POST: Positive Transitions, PRL: peer-reviewed literature, RCT: randomised controlled 
trial, SAT: self-administered therapy, SD: standard deviation, SOC: standard of care, TCM: transitional case management, UCC: urgent care centre, USA: United States of America 
1 3 core activities: 1) assessing membership, functional patterns, and roles in participant’s ecosystems, including his family, friends, sexual and drug using partners, service providers; 2) connecting with 
participant’s ecosystems through joint meetings and other communication; and 3) restructuring interactions and roles through direct interventions, and 3 phases: 1) initiation during which the counsellor built 
the therapeutic alliance and mapped the participant’s ecosystem, and initial joining in which the counsellor established his or her role in the participant’s ecosystem; 2) treatment in which the restructuring 
interventions were conducted through both individual and group counselling sessions and newly acquired interaction patterns within ecosystems were reinforced; and 3) termination in which treatment sessions 
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tapered off and ended. Throughout treatment and at the termination of treatment, counsellors offered facilitated referrals as needed 
2 The participant established goals and objectives in the initial session and worked with the counsellor to achieve and modify the goals as the intervention progressed. Intervention techniques included 
motivational interviewing, facilitated referral and goal setting (based on Project START intervention) 
3 Adherent to HIV medication: those who either did not require HIV medications or who reported taking all prescribed doses in 3-day recall 
4 The first 4 sessions covered the topics: (1) health conditions, medications, skills-building on communicating effectively with providers, assistance with enrolment in AIDS drug assistance programmes, (2) 
sexual risk reduction, (3) substance use and mental health, and (4) planning for transition and access to HIV or other health care provider, HIV medication adherence, and public services after release. Each 
participant set goals and developed an individual action plan to meet during the first 3 months after release. Pre-release sessions included client-centred discussions of motivations, barriers, facilitators, risks, 
and repercussions of risk behaviour. The 2 post-release intervention sessions included discussions of achievement and barriers to reaching individuals goals. These sessions focused on any challenges in 
achieving goals, including determining appropriate health care and prevention services, problem solving to overcome challenges, and discussions about potential repercussions of risk behaviour and any desired 
changes to individual sex and drug use action plan 
5 The TCM programme provided referrals to community-based medical and social services, including assistance with medical appointments, enrolment into AIDS Drug Assistance Programme, housing placement, 
substance abuse treatment, hepatitis testing and vaccination, and provision of food and transportation vouchers (taxi vouchers for 1st visit after release when lack of transportation was reported as barrier to 
accessing services) 
Acceptability/barriers 
Region  
Source 
Reference, 
country, 
study 
design 
Prison 
setting, 
sample, time 
period  
Description model 
of care 
Eligibility/ access Acceptance Treatment 
discontinuation/ 
non-adherence 
Attrition Other outcomes 
of interest 
Sub-group 
conside-
rations 
Level of 
evidence 
HIV treatment in prison – Usual care 
Non-
EU/EEA  
 
PRL 
Beckwith, 
2014 [131] 
 
USA 
 
Longitudinal 
study 
Rhode Island 
Jail 
 
n=64 newly 
diagnosed 
HIV+ inmates 
 
2001 – 2007  
Provision of ART; ART 
provided on-site by 
HIV physicians 
9.4% (6/64) started 
ART during current 
incarceration 
 
Significant factors of 
starting ART: 
- incarcerated for >60 
days more likely to 
start ART (30.0%) 
than incarcerated 
≤60 days (0.0%) 
(p<0.001) 
NR NR NR NR NR Very low 
HIV treatment in prison – Usual care (partly DOT and/or transitional care) 
Non-
EU/EEA 
 
PRL 
White, 2001 
[135] 
 
USA 
 
Cross-
sectional 
study 
San Francisco 
City and 
County Jail 
 
n=77 inmates 
on ART in jail, 
who were 
released in first 
quarter of 1997 
 
Provision of ART 
 
Seen by the San 
Francisco Department 
of Public Health, Jail 
Health Services, 
Forensic AIDS Project 
 
If already on 
treatment at entry, 
National guidelines, 
not further specified 
 
According to 
guidelines available 
during the study 
period, ART was 
indicated for 70.1% 
(54/77) of inmates 
- 58.4% 
(45/77) were 
on ART in jail 
 
Of 54 eligible 
ART inmates:  
- 14.8% (8/54) 
refused 
therapy, 
reasons NR  
NR NR Those who were 
not given a 
prescription at the 
time of release 
(n=11) were either 
released to 
residential drug 
treatment 
programmes that 
provided 
NR Very low 
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Region  
Source 
Reference, 
country, 
study 
design 
Prison 
setting, 
sample, time 
period  
Description model 
of care 
Eligibility/ access Acceptance Treatment 
discontinuation/ 
non-adherence 
Attrition Other outcomes 
of interest 
Sub-group 
conside-
rations 
Level of 
evidence 
January 1997 – 
1 April 2000 
efforts made to keep 
same medication; if 
not already under 
care, efforts were 
made to refer and 
facilitate follow-up 
with community-based 
provider; 3-day supply 
of medication upon 
release 
of whom 72.2% 
(39/54) were on ART 
in jail; 5.6% (3/54) 
scheduled for release 
before therapy could 
be started 
- 7.4% (4/54) 
unknown 
 
An additional 6 
inmates who did not 
fit the criteria, were 
on ART, probably 
therapy started 
before jail 
medications or 
were released 
precipitously from 
court before notice 
could be given to 
the jail medical 
personnel 
Different interventions 
Non-
EU/EEA 
 
PRL 
Grinstead 
Reznick, 2013 
[134] 
 
USA 
 
RCT 
California jail 
and 2 prisons 
 
n=76 
ecosystem vs. 
n=75 individual 
intervention 
 
NR 
Ecosystem-focused 
(family, friends, 
drug/sex partners, 
service providers) 
intervention1  
 
Individually focused 
intervention2 
 
Both interventions 
include a 45-minute 
HIV education 
session, 2 pre-release 
and up to 16 post-
release sessions in 4 
months after release, 
HAART (not further 
specified), and 
medication supply 
upon release  
NR NR Similar median 
(SD) level of 
exposure to 
assigned 
intervention 
(p=ns): 9.5 (5.0) 
sessions in 
ecosystem vs. 9.9 
(5.2) sessions in 
individually 
focussed 
intervention 
92.1% 
(139/151), 
89.4% (135/151) 
and 85.4% 
(129/151) 
completed the 4-
month, 8-month, 
and 12-month 
assessment post-
release, 
respectively 
(p=ns ecosystem 
vs. individual), 
reasons for non-
completion NR 
Ecosystem group: 
28% had no 
ecosystem 
members attend a 
session with them, 
34% only a service 
provider, 24% both 
family and service 
provider, and 11% 
only family 
members, NR of 
remaining 3% 
(n/N NR) 
NR Moderate 
Non-
EU/EEA  
 
PRL 
Jacob Arriola, 
2007 [132] 
 
USA 
 
Jails and 
prisons in 5 
states 
 
n=226 HIV+ 
inmates 
Corrections 
Demonstration 
Project:  
- Individual/ group 
HIV prevention & 
disease management 
NR 
  
NR NR 34.9% (226/647) 
of eligible 
inmates 
completing the 
baseline 
interview had no 
Intervention 
protocol indicate 
that a case 
manager meets the 
inmate soon after 
release, only 
NR Very low 
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Region  
Source 
Reference, 
country, 
study 
design 
Prison 
setting, 
sample, time 
period  
Description model 
of care 
Eligibility/ access Acceptance Treatment 
discontinuation/ 
non-adherence 
Attrition Other outcomes 
of interest 
Sub-group 
conside-
rations 
Level of 
evidence 
Comparative 
study 
 
May 2001 – 
April 2004 
education, individual 
counselling, and 
discharge planning  
- Collaboration with 
community providers 
- Starts in jail shortly 
after intake, in prison 
~6 months before 
release 
 
Treatment NR 
follow-up data – 
reasons were a 
range of logistical 
constraints (e.g. 
released 
unexpectedly, 
released, 
transferred to 
another facility), 
and lost to 
follow-up (% NR) 
46.0% (104/226) 
were met at the 
gate by a case 
manager 
Non-
EU/EEA 
 
PRL 
MacGowan, 
2015 [133] 
 
USA 
 
RCT 
California 2 
prisons and 5 
jails 
 
n=37 POST+ 
TCM vs. n=36 
TCM only 
 
July 2008 – 
July 2009 
POST: individual-level 
educational and skills-
building intervention 
(4 sessions in 2 weeks 
before release, 2 
sessions in 2 weeks 
after release)3 
 
TCM: standard of care 
(frequency NR)4 
 
Both: treatment NR 
NR NR 15.6% (5/32) did 
not complete all 6 
POST+TCM 
intervention 
sessions, reasons 
for non-completion 
NR 
 
 
25.0% (9/36) 
TCM only and 
13.5% (5/37) 
POST+TCM LTFU 
before post-
release 
assessments, 
reasons NR 
During the 6th 
intervention 
session (~2 weeks 
post-release), 
POST+TCM 
participants 
reported achieving 
19 (34%) of the 
personal goals they 
had set overall; 
sexual risk 
behaviours (36% 
of goals), drug-
related risk 
behaviours (45% 
of goals), health 
care at HIV clinic 
(27% of goals), 
adherence to HIV 
medication (27% 
of goals), and use 
of HIV prevention 
resources (36% of 
goals) 
NR Low 
Non-
EU/EEA 
 
PRL 
Wohl, 2011 
[136] 
 
USA 
 
RCT 
North Caroline 
State Prison 
system 
 
n=52 BCM vs. 
n=52 SOC 
 
NR 
BCM: intensive case 
management 
intervention from 3 
months before release 
to 6 months after 
release 
 
NR NR NR 17.3% (9/52) 
BCM and 11.5% 
(6/52) SOC LTFU 
before post-
release 
assessment 
 
NR NR Low 
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Region  
Source 
Reference, 
country, 
study 
design 
Prison 
setting, 
sample, time 
period  
Description model 
of care 
Eligibility/ access Acceptance Treatment 
discontinuation/ 
non-adherence 
Attrition Other outcomes 
of interest 
Sub-group 
conside-
rations 
Level of 
evidence 
SOC: 3 pre-release 
sessions from 3-6 
months pre-release 
 
ART, 30-day supply 
upon release 
27.9% (12/43) 
BCM and 39.1% 
(18/46) SOC did 
not complete 48-
week post-
release visit, 
main reasons 
LTFU and release  
ART: antiretroviral therapy, BCM: Bridging Case Management, CI: confidence interval, DOT: directly observed therapy, HCV: hepatitis C virus, HIV: human immunodeficiency virus, LTFU: lost to follow-up, 
NCDOC: North Carolina Department of Corrections, NGO: non-governmental organisation, NR: not reported, ns: not significant, OR: odds ratio, POST: Positive Transitions, PRL: peer-reviewed literature, RCT: 
randomised controlled trial, RNA: ribonucleic acid, RR: relative risk, SAT: self-administered therapy, SD: standard deviation, SOC: standard of care, TCM: transitional case management, USA: United States of 
America 
1 3 core activities: 1) assessing membership, functional patterns, and roles in participant’s ecosystems, including his family, friends, sexual and drug using partners, service providers; 2) connecting with 
participant’s ecosystems through joint meetings and other communication; and 3) restructuring interactions and roles through direct interventions, and 3 phases: 1) initiation during which the counsellor built 
the therapeutic alliance and mapped the participant’s ecosystem, and initial joining in which the counsellor established his or her role in the participant’s ecosystem; 2) treatment in which the restructuring 
interventions were conducted through both individual and group counselling sessions and newly acquired interaction patterns within ecosystems were reinforced; and 3) termination in which treatment sessions 
tapered off and ended. Throughout treatment and at the termination of treatment, counsellors offered facilitated referrals as needed 
2 The participant established goals and objectives in the initial session and worked with the counsellor to achieve and modify the goals as the intervention progressed. Intervention techniques included 
motivational interviewing, facilitated referral and goal setting (based on Project START intervention) 
3 The first 4 sessions covered the topics: (1) health conditions, medications, skills-building on communicating effectively with providers, assistance with enrolment in AIDS drug assistance programmes, (2) 
sexual risk reduction, (3) substance use and mental health, and (4) planning for transition and access to HIV or other health care provider, HIV medication adherence, and public services after release. Each 
participant set goals and developed an individual action plan to meet during the first 3 months after release. Pre-release sessions included client-centred discussions of motivations, barriers, facilitators, risks, 
and repercussions of risk behaviour. The 2 post-release intervention sessions included discussions of achievement and barriers to reaching individuals goals. These sessions focused on any challenges in 
achieving goals, including determining appropriate health care and prevention services, problem solving to overcome challenges, and discussions about potential repercussions of risk behaviour and any desired 
changes to individual sex and drug use action plan 
4 The TCM programme provided referrals to community-based medical and social services, including assistance with medical appointments, enrolment into AIDS Drug Assistance Programme, housing placement, 
substance abuse treatment, hepatitis testing and vaccination, and provision of food and transportation vouchers (taxi vouchers for 1st visit after release when lack of transportation was reported as barrier to 
accessing services) 
Cost-effectiveness 
No studies were found on cost-effectiveness of interventions to increase linkage to care post-release.  
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Guidelines 
Five guidelines that reported on throughcare were included, of which four were specific to the prison setting (two supranational and two national guidelines) and one was a supranational 
not specific to prison settings. 
Summary of guidelines on throughcare (linkage to care post-release) 
Guideline 
Specific to prison setting – supranational guidelines 
WHO, 2014 
[7] 
For both HIV and hepatitis C, continuity of treatment is essential to ensure the best outcomes and prevent the development of resistance. Health 
programmes in prisons should, therefore, work in close collaboration with the HIV programme in the community to ensure that treatment is not interrupted 
when people enter and leave prison. It is also important to organise this continuity when prisoners are transferred from one prison to another within the 
police/justice system. Before an individual is released from prison, links should be established with a service that will continue treatment. Sometimes it is 
difficult for ex-prisoners to go to these services. This situation should be identified in advance and remedies or support should be provided to ensure that 
contact will be established. The continuity of treatment is best when community services can provide support to a prisoner in prison and after release and 
accompany his/her re-entry into the community. Before release, prisoners undergoing treatment should be provided with a stock of medications for one 
month and a complete copy of their medical files, including the results of all tests conducted during incarceration. When a prisoner is transferred between 
prisons, health professionals should ensure that the medical file follows the prisoner. 
WHO, 2007 
[53] 
 
 
 
Adherence rates in prisons can be as high or higher than among people in the community, but the gains in health status made during the term of 
incarceration may be lost unless careful discharge planning and links to community care are undertaken. 
Ensuring continuity of care from the community to the prison and back to the community as well as continuity of care within the prison system is a 
fundamental component of successful efforts to scale up treatment. Sustainable HIV treatment programmes in prisons, integrated into countries’ general 
HIV treatment programmes or at least linked to them, are needed. 
One serious problem of ART is that any interruption of treatment can lead to resistance to at least some of the drugs used. Health staff should try to 
ensure compliance. In addition, other measures are needed to ensure that interruption of treatment does not occur.  
Specific to prison setting – national guidelines 
SIMIT/ 
Ministero 
della Salute 
(Italy), 
2016 [57] 
 
Assure the linkage of HIV infected prisoners to the local Infectious Diseases (ID) division and arrange a calendar of weekly visits. 
- In order to assure continuity of care, at least 7 days of ART treatment should be given to the prisoner upon release. 
- Transfer of medication (if not available) to the prison of destination if the prisoner is transferred. 
- In order to guarantee continuity of care (50% of prisoners do not show up at the specialist visit after release) the referral ID specialist must be involved 
in outpatients’ networks present in the community. 
SAMHSA, 
2017 [142] 
 
 
Guideline 5: Anticipate that the periods following release (the first hours, days, and weeks) are critical and identify appropriate interventions as part of 
transition planning practices for individuals with mental health and co-occurring substance use disorders leaving correctional settings. 
 
Guideline 6: Develop policies and practices that facilitate continuity of care through the implementation of strategies that promote direct linkages (i.e. 
warm hand-offs) for post-release treatment and supervision agencies. 
Other guidelines – supranational guidelines 
WHO, 2016 
[58] 
If they are being transferred, people in prisons and other closed settings should be given a supply of ART to last until health care can be established at the 
new prison location or, if they are being released, until linkage can be made to community-based HIV care. 
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